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Abstract 
Trypanosoma brucei spp. are protozoan parasites that cause Human African 
Sleeping Sickness and Nagana, a disease of cattle. The diseases have a very high 
mortality rate if untreated and the current drug treatments are inadequate due 
to toxicity and resistance. In order to develop new treatments, potential drug 
targets can be investigated in a candidate approach by genetic validation. In 
trypanosomes this can be performed by using RNA interference (RNAi) 
technology, which is well developed for this organism. One category of potential 
targets are protein kinases; members of this enzyme family have been shown to 
be suitable targets for relatively specific and selective, therapeutic inhibition- 
especially in the field of human oncology. T. brucei possesses 183 eukaryotic 
protein kinases, atypical protein kinase and pseudokinases that may be suitable 
for chemical inhibition. This study intended to genetically validated these 
targets and pursue interesting leads as potential drug targets. 
In order to perform RNAi studies on large numbers of candidate genes an existing 
stem-loop RNAi system was adapted to contain Gateway recombination sites. 
This created a highly efficient system, allowing the rapid generation of RNAi 
plasmids to target the entire complement of the predicted kinome of this 
organism. This collection of plasmids was used to generate a library of RNAi cell 
lines in bloodstream form parasites (BSF) which were screened for growth 
defects using an alamar blue cell viability assay. This identified 53 genes which 
were essential or important for proliferation of the BSF parasites.  
During this screen, a cell line was identified that contained an RNAi construct 
targeting two NEK kinases (NEK12.1: Tb927.8.7110, NEK12.2: Tb927.4.5310) 
which displayed a severe growth defect. This was replicated in a mouse model of 
infection. NEK 12.1 possesses an alanine gatekeeper residue and molecular 
modelling and virtual screening predicted this would allow the accommodation 
of bulky protein kinase inhibitors and therefore was investigated in more detail. 
Expression and purification of NEK12.1 in kinase active and dead forms allowed 
activity assays to be performed; these could be inhibited with the bulky inhibitor 
3-MB-PP1, which also possessed activity against BSF parasites. Experiments to 
confirm the individual essentiality of NEK 12.1 (and its activity) remain to be 
performed, therefore NEK 12.1 has been partially genetically and chemically 
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validated in this study. A unique “Orphan” kinase, containing a putative zinc-
finger domain and a potential homologue of PDK1 were also investigated after 
the pTL RNAi screen. In vivo RNAi studies (using a mouse model) correlated well 
with the in culture RNAi data, demonstrating that these targets are essential in 
mammalian infections. 
During the pTL RNAi screen it was noted that the knockdown of one protein 
kinase, (DFK: Tb11.01.5650) led to a change in the morphology of the cells, yet 
no reduction in the alamar blue ratio was observed. Further investigation 
showed that after 72 h of RNAi induction 17% of cells expressed EP procyclin. 
This was associated with detectable changes in the transcriptome (ascertained 
by RNA -Seq), that were consistent with a BSF-PCF differentiation event. DFK 
was predicted to contain multiple transmembrane domains and features 
suggestive of a receptor kinase. Epitope tagging of DFK followed by cell 
fractionation and immunofluorescence microscopy demonstrated that the 
protein localised to the cell membrane. Transmission immuno-electron 
microscopy confirmed the cell membrane localisation and suggested that the 
protein kinase domain of DFK was intracellular. 
This study reveals several protein kinases as new drug targets, in turn identifying 
one as a key regulator of BSF-PCF differentiation. Due to the tractability of T. 
brucei it also provides a collection of plasmids and cell lines that should further 
the investigation of other key biological processes in this important pathogen. 
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1 General introduction 
 
1.1 African Trypanosomiases caused by Trypanosoma 
brucei spp. 
The Trypanosoma brucei species complex contains three species of 
morphologically indistinguishable, unicellular protozoa that are responsible for a 
large number of deaths of humans and livestock across sub-Saharan Africa. These 
organisms have fascinating, complex biological features and life cycles that belie 
the suffering they continue to impose on those affected. Trypanosoma brucei 
brucei is a pathogen of cattle (causing the disease nagana), T. b. rhodesiense is 
an incidental, zoonotic pathogen of humans and T. b. gambiense is the major 
trypanosomatid pathogen of humans in Africa – all are transmitted by species of 
tsetse flies in the genus Glossina (Figure 1-1). The human disease African 
Sleeping Sickness or Human African Trypanosomiasis (HAT), has historically varied 
in the scale and severity of outbreaks but due to current control techniques is, 
tentatively, on a trajectory for elimination.  
 
Figure 1-1: The overview of the transmission cycle of Human African Trypanosomiasis. 
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Before discussing the biology of Trypanosoma brucei the problem of HAT should 
be reviewed for context.  
HAT has in the past afflicted vast swathes of the African continent and currently 
anyone who lives within the “tsetse belt”, between 14oN and 20oS, is at risk of 
infection (Malvy and Chappuis, 2011). In practice, however, the disease has 
tended to be associated with distinct foci usually based on the ecology of the 
tsetse vector species and where humans contact this range. Currently the 
incidence of HAT cases is at an historic low with only 7139 reported cases in 2010 
(WHO, 2012 - www.who.int/trypanosomiasis_african/en/). A number of factors 
mean this is undoubtedly an underestimate. Despite this, active case finding, 
drug treatment and integrated vector control are controlling the disease. The 
two forms of human disease are geographically segregated (with one exception)– 
the chronic disease caused by T. b. gambiense is confined to West and Central 
Africa and the acute disease caused by T. b. rhodesiense  is found in East Africa. 
Only in Uganda are the two forms found in the same geographic area (Figure 
1-2). 
The history and prehistory of these parasites and disease are reviewed well by 
Steverding, 2008. African trypanosomiases are ancient diseases, with salivarian 
trypanosomes predicted to have evolved 100-300 million years ago with tsetse 
flies predicted to be around 35 million years old. It is likely that early hominids 
were exposed to these parasites and this had an effect on human evolution, 
selecting for trypanotolerance –only two of the African trypanosomes now infect 
humans. This is supported by the fact that local grazing animals are tolerant to 
trypanosomes and domesticated livestock are susceptible to trypanosomiasis 
(Lambrecht, 1985). Reports of diseases resembling nagana and HAT have been 
proposed to exist in records from the ancient Egyptians and the Middle Ages. The 
disease was first documented in early modern Western reports in the 1700’s due 
to investigations of medical officers in slave-trading companies but it was not 
until the 1800s that the association between tsetse flies, trypanosomes and 
(animal) trypanosomiasis was determined. Rigorous investigations into this 
disease were carried out by David Bruce, who in 1895 demonstrated that 
trypanosomes were the causative agent of nagana. Further investigations by 
Robert Forde (1901) and Joseph Dutton (1902) identified trypanosomes in the 
blood of humans; trypanosomes were isolated from cerebrospinal fluid (CSF) by 
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Aldo Castellani. Eventually Bruce was able to demonstrate the complete cyclical 
life cycle of T. brucei through tsetse flies.  
The past century has seen three large-scale epidemics of HAT – the first, 
between 1896 and 1906 killed almost 1 million people and led to major efforts to 
develop therapies. The early treatments were toxic arsenicals (atoxyl, 
tryparsemide) and it was only in 1916 that an effective and (for that time) 
relatively safe drug, suramin, was developed. Incredibly, almost 100 years later, 
this drug is still in use. Between 1920 to 1940 another epidemic raged, leading to 
control by active case finding with drug treatment and vector/reservoir control.  
During this time both pentamidine and DDT were developed which assisted with 
control methods. The drug melarsoprol was discovered in 1949 and became and 
the only treatment for the second stage of T. b. rhodesiense. By the 1960s 
trypanosomiasis was under good control. Between the mid-1960s until the early 
1990s the number of cases rose due to a number of reasons. As African nations 
gained independence from colonial powers many descended into political and 
economic instability and a number experienced internal conflict or war. As HAT 
was at a low prevalence it became a low priority for health services in many 
countries. These factors led to a resurgence of cases across Africa, but with 
particularly in countries experiencing war or civil unrest – which also hampered 
efforts to control the epidemic. A new drug did become available, in the form of 
eflornithine (or DFMO), which was much safer than melarsoprol for treating 
second stage T. b. gambiense disease. A renewed emphasis on HAT control in the 
1990s to 21st century has led to the number of confirmed cases dropping below 
10, 000. With further intense efforts it may be possible to eliminate T. b. 
gambiense disease from large areas or even totally if the status quo remains. 
However, experience shows that if attention is not paid to controlling the 
disease, or if circumstances do not permit effective control, then outbreaks can 
flare rapidly and dramatically (Steverding, 2008).  
19 
 
 
 
Figure 1-2:  Distribution of human African trypanosomiasis with incidences and risk for 
travellers. The black line divides the areas in which Trypanosoma brucei gambiense 
prevails and those in which Trypanosoma brucei rhodesiense predominates – Reproduced 
with permission from (Brun et al., 2010) 
Infection with T. b. gambiense is generally fatal if untreated – until recently 
much of the literature stated it was invariably fatal. However, evidence from a 
long term follow up study of patients refusing treatment for HAT appears to 
show evidence for trypanotolerance and self cure (Jamonneau et al., 2012). 
These findings have implications for control efforts (i.e. detection of silent 
carriers) and statisticians (estimating the amount of under-reporting of cases). 
For most patients though, disease is severe. The typical clinical progression 
recently reviewed in (Brun et al., 2010; Malvy and Chappuis, 2011) states that 
following infection a localised chancre can form, though rarely in T. b. 
gambesiense cases and more often in T. b. rhodesiense cases, this can be 
followed by lymphodenopathy or Winterbottom’s sign. The parasites then 
typically enter the bloodstream and replicate, parasitaemia waves – correlated 
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with VSG switching – leading to waves of fever and malaise. This is the 
haemolymphatic stage (or Stage 1) of the disease. Symptoms are variable with T. 
b. gambiense infection but the general trend is chronic and progressive – with 
typically 1.5 years of Stage 1 disease before entry into Stage 2, the 
menigoencephalitic stage. This stage typically also persists for 1.5 years and 
results from parasites actively penetrating the blood-brain barrier. Here the 
disease exhibits the symptoms for which it is named; major disruption of the 
circadian rhythm can occur, leading to disturbed sleep/wake patterns. Other 
damage can lead to generalised neurological indications including weakness, 
paralysis and movement disorders – a broad range of psychiatric disorders can 
arise. Death typically occurs within 4 years of infection with T. b. gambiense. 
The clinical picture for T. b. rhodesiense is much more severe and acute, with 
disease leading to death in weeks to months, though this only accounts for 
around 2% of HAT cases. 
Due to the non-specific symptoms of Stage 1 disease, diagnosis for T. b. 
gambiense is carried out using the card agglutination test for trypanosomiasis 
(CATT) - this test is practical to use in resource poor settings, fast and relatively 
robust. CATT allows for mass screening to be performed using fingerprick blood 
but a positive result needs to be confirmed by microscopy. The stage of the 
disease must also be determined, so a parasitaemic patient must then have a 
lumbar puncture followed by assessment of CSF for parasites or high levels of 
lymphocytes. Tests may have to be repeated over time to ensure accurate 
diagnosis. 
Treatment of the disease varies with the species and stage of the disease. Four 
main treatments are currently in use. First stage T. b. gambiense is treated with 
pentamidine and the second stage is now treated with eflornithine:nifurtimox 
combination therapy (NECT) – alternatives to this are eflornithine montherapy 
and melarsoprol. T. b. rhodesiense infection can be treated in the first stage 
with suramin and second stage with melarsoprol. Pentamidine is generally well 
tolerated but requires daily dosing for a week by intramuscular injections – it is 
only useful against Stage 1 T. b. gambiense disease. Suramin is effective against 
T. b. gambiense but due to the risk of adverse reactions in patients co-infected 
with Onchocerca spp. is rarely used in West Africa. It does generate frequent 
adverse reactions and the regimen is 30 days long. Melarsoprol is a poorly 
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tolerated drug and it is commonly presented as the proverbial “Catch-22”; Stage 
2 disease must be treated or else prove fatal but between 4-8% of patients 
treated for stage 2 disease with melarsoprol will develop an encephelopathic 
syndrome leading to death in 44-57% of instances. Treatment with eflornithine 
monotherapy is more efficacious than melarsoprol and results in far fewer 
adverse effects however it requires a dosing regimen of four infusions per day 
over two weeks. Dosing kits have been developed by WHO but this is still a 
complex drug to administer in resource-poor settings (Brun et al., 2010). In order 
to reduce the length of time of treatment a combination therapy of eflornithine 
and nifurtimox was developed. This 7 day regime combines eflornithine infusions 
with oral nifurtimox, a drug originally used for the treatment of Chagas Disease 
(caused by T. cruzi). This is now being used as the main treatment against T. b. 
gambiense second stage disease in the countries containing 96% of disease cases. 
More recently Fexinidazole, a new nitroimidazole drug which is orally available 
and can treat both stages of both diseases in mouse models, has passed phase 
one clinical trials and is entering a phase II/III trial in late 2012 (Torreele et al., 
2010; Mäser et al., 2012; Simarro et al., 2012).  
Control of the parasite’s vector is another aspect of successful control 
strategies. T. brucei spp. are transmitted by tsetse flies (both male and female), 
of which there are 3 groups of species – those that inhabit savannah, forest or 
riverine environments. They exhibit differing propensities for human feeding and 
as such vary in their vectoral capacity, though the female flies can feed ever 2-3 
days. The locale that tsetse flies inhabit can provide the foci for transmission of 
HAT, for example watering places, river fords and lakesides. Tsetse flies spend 
most of the day (23 hours) at rest in vegetation, and avoid temperatures over 
36oC. Salivary gland infection rates rarely exceed 0.1%, even in endemic areas. 
The rate of reproduction for tsetse flies is generally low due to their larviparous 
life cycle, where the female fly develops a single larva in her uterus every 9-12 
days. Tsetse flies are still exceptionally sensitive to all classes of insecticide. 
These factors combined mean that effective control of tsetse flies by trapping, 
ultra-low-volume spraying and (in one example) sterile insect technique is 
possible, and can have dramatic effects on the incidence of HAT (Service, 2004). 
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1.2 Trypanosoma brucei life history, cellular and 
molecular biology 
Trypanosoma brucei species fall into the Eukaryotic supergroup Excavata, group 
Discoba (Euglenozoa), subgroup Kinetoplastidae, family Trypanosomatidae 
(Reviewed in (Walker et al., 2011a)). Kinetoplastids are characterised by having 
a single, large mitochondrion containing its mtDNA as a single body, the 
kinetoplast. Trypanosomatids possess a single flagellum and are usually parasitic 
as opposed to Bodonidae (the other order contained within Kinetoplastidae), 
which typically possess two flagella and are usually free living. They are 
considered early branching eukaryotes and have become some of the best 
categorised protozoa due to their amenability for genetic manipulation and in 
vitro culture. 
African trypanosomes have a complex life cycle involving a mammalian host and 
a tsetse fly vector (Figure 1-3 and Figure 1-4). They encounter varied 
environments during their life history and undergo spectacular morphological 
changes accompanied by transcriptomic, proteomic and metabolic changes. They 
exist in the mammalian host as two morphological forms, a replicative, slender 
trypomastigote and a quiescent stumpy trypomastigote and are often termed the 
bloodstream forms (BSF). The stumpy form is preadapted for transmission to a 
tsetse fly (discussed in detail in Chapter 5). Once ingested by a tsetse fly the 
parasites encounter a harsh environment in the digestive tract of the flies and as 
such transform into a procyclic trypomastigote form able to survive there. 
Procyclic forms (PCF) multiply in the midgut and transform into mesocyclic 
trypomastigotes, which migrate to the foregut. Here they transform into 
epimastigotes that divide asymmetrically to form a long and short 
epimastiogote. They then migrate to the salivary glands where the short 
epimastigotes can attach to the lining of the salivary gland using their flagellum 
to form a flagllipodium. The epimastigotes can divide asymmetrically to form 
new epimastigotes and infective metacyclic trypanosomes which are injected 
into a new mammalian host during the tsetse bloodfeeding. This allows tsetse 
flies to remain infective over their relatively long lifespan (Rotureau et al., 
2011, 2012). 
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Figure 1-3: Morphological forms of trypanosomes over the course of the Trypanosoma 
brucei life cycle, determined from electron micrography. Reproduced from (Vickerman, 1985) 
with Permission. 
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Figure 1-4: Overview of the morphological stages of T. brucei development using light and 
fluorescence microscopy (labelling the cytoskeleton) – reproduced from (Rotureau et al., 
2011). Panel a. shows a table listing the localisation of the life cycle stages throughout the 
life cycle. Panel b. shows the forms found in the mammalian host (SL: slender 
trypomastigote, ST: stumpy trypomastigote). Panel c. shows the forms found in the tsetse 
fly. (PC: procyclic trypomastigote, MS: mesocyclic trypomastigote, E: proventricular 
epimastigote, DE: asymmetrically dividing epimastigote, LE: long epimastigote, SE: short 
epimastigote, AE: attached epimastigote, MT: metacyclic trypomastigote). * Denotes 
dividing forms of the parasite. 
The forms of T. brucei amenable to tissue culture are the PCF and BSF. These are 
trypomastigote form parasites, with the kinetoplast posterior to the nucleus. In 
some respects they are an ideal model organism for cell biology due to their 
single-copy-organelle layout (for most organelles). The cells are typically 
elongated in shape and have a highly polarised structure. This structure is 
defined by a sub-pellicular microtubule cytoskeleton (corset), with all the 
microtubules running in an anterior to posterior direction (i.e. the positive end is 
posterior) apart from a specific microtubule quartet which runs in the opposite 
direction. The microtubule corset has a posterior opening to accommodate the 
flagellar pocket and a gap to accommodate the flagellar attachment zone (FAZ) 
filament running beside the microtubule quartet. The flagellum, containing a 
9+2 axoneme and a paraflagellar rod exits the cell from the posterior flagellar 
pocket. The axoneme of the flagellum associates with the basal body which is 
also attached to the kinetoplast via the tripartite attachment complex.  The 
flagellar pocket is the sole point of endo- and exocytosis and is held closely 
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around the flagellum by a collar structure (Matthews, 2005; Farr and Gull, 2012). 
During the cell cycle the basal body duplicates and segregates and this is 
coupled to the division of the kinetoplast. S-Phase in trypanosomes consists of 
first duplicating and segregating the kinetoplast to achieve a 1N2K configuration 
and then replicating and the nucleus. The positioning of these organelles is 
different between the BSF and PCF life cycle stages (Figure 1-5).  In the 
precytokinetic G2 phase, 1N2K cell undergo mitosis and become 2N2K cells 
which are in M Phase. During S-Phase a new flagellum is grown with its anterior 
end attached to the old flagellum. This progresses along the old flagellum until 
the distal, anterior end is reached. Near this point a cleavage plane for 
cytokinesis is initiated, this furrow ingresses until the two daughter cells are 
attached at their posterior ends, which then detach in the process known as 
abscission (Farr and Gull, 2012; Li, 2012).  
 
Figure 1-5: A graphic depicting the cell division cycle of T. brucei. The lower panel 
indicating BSF.   Reproduced from (Bangs, 2011), with permission. 
The T. b. brucei TREU 927 genome strain contains a nuclear and a kinetoplast 
genome totalling 35 megabases (Mb) per haploid genome (Berriman et al., 2005). 
The nucleus contains 11 pairs of megabase chromosomes (0.9-5.7 Mb), 2-4 
intermediate size chromosomes (300-900 kb) and approximately 150 
minichromosomes (50-100 kb) that mainly contain silent VSGs. There is a 500 Mb 
segmental duplication between chromosome 4 and 8 leading to 75 gene 
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duplications unique to T. b. brucei (Jackson, 2007). The total number of genes 
predicted to be encoded in the 11 megabase chromosomes was 9068 (Berriman 
et al., 2005). This has been expanded to 11425 following transcriptomic analyses 
of T. brucei which identified novel transcripts (TriTrypDB) and (Siegel et al., 
2010). T. brucei is predominantly diploid, though meiotic events do occur 
indicating a haploid life stage at some point in the tsetse fly (Peacock et al., 
2009, 2011). The subtelomeric regions contain expression sites for VSG genes 
(Barry et al., 2005, 2012; Berriman et al., 2005). The mitochondrial genome 
(kinetoplast) consists of a complex, concatenated network of DNA consisting of 
minicircles and maxicircles (Liu et al., 2005). The maxicircles encode 
mitochondrial genes, although once transcribed these require modification by 
RNA editing to form complete mRNAs. The guide RNAs required for this process 
are encoded in the minicircles. RNA editing was first described in trypanosomes 
but is now known to occur in other organisms reviewed in (Simpson et al., 2004). 
Loss of the mitochondrial genome can be induced in T. brucei – mimicking 
natural dyskinetoplastic parasites such as T. evansi and T. equiperdum 
(Schnaufer et al., 2002). 
Most genes encoded in the megabase chromosomes are transcribed by RNA 
polymerase II, in polycistrons with apparently little or no transcriptional control 
(Palenchar and Bellofatto, 2006; Günzl, 2010; Rudenko, 2010; Preußer et al., 
2012). Though transcription is polycistronic, genes involved in the same 
biological pathways are not arranged into operons. Transcription initiates 
bidirectionally from strand switch regions – where polycistronic units diverge 
from each other. The pre-mRNAs are then trans-spliced to a 39 nt spliced leader 
RNA which provides the 5’ cap and ribosome binding site – polyadenylation is also 
performed to mature the mRNA (Ullu et al., 1993). Transcription initiation sites 
appear to be regulated by epigenetic modifications such as histone type and 
positioning. Not all of the protein-coding genome is transcribed by RNA Pol II; 
the active variant surface glycoprotein (VSG) expression site is transcribed by 
RNA Pol I, in addition pre-rRNAs being generated by this enzyme.  
The VSG coat is a distinctive feature of trypanosomes and forms a defence 
against the antibody driven immune response at cellular and population level. It 
is transcribed from a single, sub-telomeric expression site – and only a single VSG 
variant is expressed at a time. This protein is a homodimer, anchored into the 
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plasma membrane by covalent linkage to glycosylphosphatidylinositol (GPI) and 
forms a dense monolayer over the surface of the trypanosome. VSG composes 
95% of the external cell surface proteins of BSF trypanosomes – this equates to 
15% of total cellular protein and ~5x106 VSG dimers (Jackson et al., 1985; 
Schwede and Carrington, 2010). During an infection, the host mounts an immune 
response against the predominant VSG variant, however, the antibodies can be 
cleared by the trypanosomes. This occurs by hydrodynamic forces pushing IgG- 
and IgM-VSG complexes to the posterior of the cell, where they can be 
internalised by endocytosis at the flagellar pocket, antibody is removed and 
degraded in the lysosome. The rate of this is higher in stumpy form parasites. 
(Engstler et al., 2007). VSG is recycled back to the plasma membrane and 
trafficked for degradation in the lysosome. This strategy suffices in the short 
term but is not a suitable tactic over the long course of an infection (2-3 years). 
Eventually the antibody titre against a specific VSG variant will rise so high that 
the parasites will be overcome. In order ensure the survival of the population 
parasites will switch the active VSG either by switching the active expression 
site, or by switching the VSG gene transcribed from an expression site. This is 
achieved by homologous recombination targeted to double-stranded breaks 
occurring in 70 bp repeats occurring upstream of an active VSG. VSG genes can 
be recombined from a massive library (~2000) of complete VSGs and 
pseudogenes which can be combined into fully functional mosaic VSGs (Rudenko, 
2011; Barry et al., 2012). 
One of the features unique to trypanosomes (over the mammalian host) is the 
compartmentalisation of glycolysis in BSF parasites into organelles called 
glycosomes. BSF trypanosomes are reliant solely on the constant supply of 
glucose from the host for generating ATP by glycolysis to meet its free-energy 
needs. Glycosomes are single membrane vesicles, similar to peroxisomes. They 
contain nine glycolytic enzymes, 7 of which convert glucose to 3-
phosphoglycerate. This then enters the cytosol for conversion to pyruvate over 
three steps yielding 1 molecule of ATP. The high rate of glycolysis sustained by 
these parasites and the lack of regulation of the activity of hexokinase and 
phosphofructokinase creates a “turbo design” glycolysis. If not 
compartmentalised this becomes toxic to the cell. Glycosomes are turned over 
during differentiation between lifecycle stages. Proteins can be targeted to 
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glycosomes using one of two targeting sequences PTS1 or PTS 2. Due to the 
differences between the regulation of glycolysis in trypanosomes and humans, 
and their importance in linking many metabolic pathways they have been 
examined as drug targets (Michels et al., 2006; Coley et al., 2011; Gualdrón-
López et al., 2012). 
1.3 Protein Kinases 
Protein kinases are enzymes that modify other proteins by the post-translational 
chemical addition of the -phosphate group of ATP. They play regulatory roles in 
almost all cellular process and when disregulated can cause pathologies. They 
have eventually become the targets of many drug development programmes and 
a number of protein kinase inhibitors are now in clinical use. 
Protein kinase activity was first described in 1954 (Burnett and Kennedy, 1954), 
though processes regulated by it had been studied in the 1930s (without the 
investigators understanding). Subsequently the phosphorylation of glycogen 
phosphorylase by phosphorylase kinase was demonstrate by Fischer and Krebs, 
who showed it was dependent on Mg-ATP and that the -phosphate group of ATP 
was transferred to a specific serine residue on phosphorylase (Fischer and Krebs, 
1955; Krebs and Fischer, 1956; Fischer et al., 1959). This discovery won the 
authors a Nobel Prize. Since 1954 the literature has expanded enormously and 
the importance of protein kinases in widespread biological processes has become 
apparent - a search for “protein kinase” in PubMed returns over 41, 000 results. 
A history of key discoveries is provided by Cohen (Cohen, 2002).  
Protein kinases in eukaryotes are almost all contained within the eukaryotic 
protein kinase (ePK) superfamily with a smaller division of atypical protein 
kinases (aPK). The major divisions of ePKs are along substrate specificity at the 
highest order, into tyrosine kinases and serine/threonine kinases (which are 
ubiquitous in eukaryotes). After molecular cloning and sequencing of a number 
of protein kinases, an analysis of the conserved sequences allowed the catalytic 
domain and subdomains to be defined (Hanks et al., 1988). This analysis 
categorised known serine, threonine and tyrosine kinases to determine the core 
features and key residues of protein kinases. The ePKs are defined by a catalytic 
region with 12 subdomains. Knowledge of the conserved sequences of protein 
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kinases combined with genome sequencing has led to the ability to predict the 
protein kinase complement of a given genome. This complement is termed the 
kinome. ePKs are among the most common protein families, composing 1.5-2.5% 
of an organism’s genome (Manning et al., 2002a). Using this type of analysis the 
human genome was predicted to contain over 500 protein kinases, which were 
classified into various families (Manning et al., 2002b). Protein kinases have been 
classified into a number of families, based on the sequence similarities of the 
catalytic domain – 6 major families exist: AGC, CAMK, CMGC, TK, TKL, STE 
(definitions of acronyms in Section 1.5). A category of “Other” ePKs, falling 
outside of these families, exists.  Proteins that have a different domain structure 
to ePKs, but still act as protein kinases are termed atypical protein kinases 
(aPKs) and contain groups such as the PI3-Kinases. The different families share 
substrate preferences and can have similar modes of regulation or function. For 
example, the CMGC family contain many cyclin dependent kinases (CDKs), which 
require the binding of a cyclin partner to become activated. Other CMGCs 
include the mitogen activated protein kinases (MAPKs), which require activation 
by phosphorylation of a TxY motif in the activation loop. Some CMGCs have dual 
specificity for tyrosine as well as serine/threonine (DYRKs). The activators of the 
MAPKs, which often exist in cascades, are contained in the STE group and form a 
hierarchy (e.g. MAPKK, MAPKKK, MAPKKKK). The TK (tyrosine kinases) are often 
receptor kinases and are mostly found in metazoans, mammalian receptor 
kinases are almost all tyrosine kinases. AGC kinases contain several members 
that are activated by cyclic nucleotides; CAMKs are regulated by calcium binding 
(Hanks and Hunter, 1995). Techniques to determine the function and interactions 
of these proteins are now highly advanced for conventional model organisms and 
mammalian cells and tissue and high level of understanding exists for a great 
many protein kinases (Johnson and Hunter, 2005). 
The X-ray crystal structure of a protein kinase was first determined for PKA 
(Protein Kinase A), a cyclic-AMP dependent protein kinase, which began to allow 
the understanding of structure:function relationships for these enzymes 
(Knighton et al., 1991). The structure is bilobed, with a cleft between the lobes 
that is responsible for binding MgATP and the peptide substrate. The conserved 
amino acid sequences could then be mapped to a three dimensional structure 
helping to shed light on their importance in protein kinase activity, these are 
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represented in Figure 1-6 and reviewed in (Hanks et al., 1988; Hanks and Hunter, 
1995; Adams, 2001). The N-terminal lobe consists mostly of -sheets and 
contains domains I-IV, which are involved in binding and orientating the MgATP. 
The C-terminal lobe is larger, consists of mainly -helices, contains domains VIA-
XI and is primarily responsible for binding the peptide substrate and catalysing 
the phosphotransfer reaction. Subdomain V connects the two lobes and acts as a 
hinge region. There are a number of invariant or almost invariant residues and 
motifs spread throughout the subdomains of the kinase domains. These are 
indicated in Figure 1-6b, most are involved in binding ATP into the active site 
and/or catalysing the phosphotransfer reaction. The GxGxxG motif of subdomain 
I interact with the - and - phosphates of the ATP and the invariant lysine of 
subdomain II facilitates the transfer of the phosphoryl group.  The lysine of sub-
domain II is almost always required for protein kinase activity. The glutamic acid 
(E) of subdomain III also stabilises the interaction of the - and - phosphates 
with the invariant lysine. The next conserved motif is DxxxxN occurring in 
subdomain VIB; this is the catalytic loop. The aspartate is extremely important 
for catalytic activity and asparagine helps stabilise the loop and also binds 
magnesium in the active site. Subdomain VII contains the highly conserved DFG 
motif which stabilises another Mg2+, which in turn orients the - and - 
phosphates into the active site – its orientation is crucial for kinase activity. The 
APE motif in subdomain VIII provides stability within the C-terminal lobe by the 
glutamic acid, forming an ion pair with an invariant arginine in subdomain XI. 
Subdomain VIII also contains residues important in peptide substrate recognition 
and contains the activation loop found in many protein kinases, which often 
requires threonine (and a tyrosine in MAPKs) to be phosphorylated to activate 
the protein kinase. Subdomain IX contains a conserved DxxxxG motif that plays a 
role in stabilising the catalytic loop and peptide binding domain.  Subdomain X is 
the least conserved region. It is this conservation in the structural features and 
function of protein kinases that led them to be labelled as “undruggable” for 
many years, as blocking ATP binding in one kinase using an inhibitor would do it 
for all kinases and thus be toxic (Nakano et al., 1987; Fedorov et al., 2010). 
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Figure 1-6: a. Structure of PKA with subdomains mapped – Adapted from (Torkamani and 
Schork, 2008) and b. linear representation of the subdomains with invariant motifs annotated 
(Hanks, 2003). 
1.4 Protein Kinases as Drug Targets 
Even until the late 1990’s the prevailing dogma was that developing a selective 
protein kinase inhibitor would be impossible or very difficult. This dogma was 
broken by the development of Gleevec (Imatinib) for treating chronic myeloid 
leukaemia (CML) during this time researchers at Ciba-Geigy (Novartis) identified 
compounds with activity against the BCR-ABL kinase, reviewed in (Deininger and 
Druker, 2003; Druker, 2004). This is a product of a chimeric gene caused by a 
a.
b.
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chromosome translocation – the protein possesses constitutive tyrosine kinase 
activity and activates various signalling pathways that generate a pathological 
increase in haematopoietic stem cells and myeloid cells. Through high 
throughput screening and analysis of structure:activity relationships the team 
identified a class of 2-phenylaminopyrimidine compounds active against platelet-
derived growth factor receptor (another receptor tyrosine kinase). After various 
modifications to improve potency and selectivity they were also discovered to 
possess activity against BCR-ABL kinase. Further modifications to increase 
solubility generated lead compounds with Imatinib being progressed into Phase I 
clinical trials in 1998. In vitro this could inhibit BCR-ABL with a IC50 of 250 nM. It 
proved to be highly effective against CML in patients, even those who had the 
most severe stage of the disease, and also those resistant to the other therapies 
then in use. It was also extremely well tolerated by patients, and apparently had 
a wide therapeutic window and high bioavailability from oral dosing. Phase II and 
III trials further showed the efficacy of imatinib over the existing treatments. 
Imatinib was once thought to have exquisite sensitivity, due to it binding the 
inactive form of the BCR-ABL kinase and by contacting 21 amino acids. It is a 
Type II protein kinase inhibitor (see below), this also contributes to the low IC50 
as it is not an ATP competitor (Type I inhibitor). This success story broke the 
dogma of protein kinases not being suitable as drug targets. It also provides an 
example of target based drug development – a one gene, one protein one 
inhibitor approach - that was very prevalent during the 1990s and 2000s. 
Due to the clinical success of Imatinib, the demonstration of the possibility to 
achieve selective inhibition of a protein kinase and the increases in the 
understanding of protein kinase involvement in various pathologies there has 
been an explosion in the level of research in this area. There are over 100 
protein kinase inhibitors in either clinical use or trials and many more as 
preclinical candidates (Barouch-Bentov and Sauer, 2011). The range of diseases 
that involve protein kinase dysfunction has now expanded to include various 
cancers, inflammatory/immunological disorders and neurodegenerative diseases 
(Rokosz et al., 2008; Cuny, 2009; Zhang et al., 2009).  
The ability to generate inhibitors specific to a given protein kinase within a 
species has led researchers to reason that selective inhibition of a protein kinase 
in a different species is possible and will allow this strategy to generate new 
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treatments for use against infectious diseases. Currently attempts to achieve 
this are underway for trypanosomatid parasites and apicomplexan parasites 
(Doerig et al., 2005; Naula et al., 2005; Brumlik et al., 2011). It has now become 
acknowledged that the specificity of protein kinase inhibitors can vary greatly, 
ranging from the most “selective” ones such as lapatinib (inhibiting a couple of 
non-targets protein kinases) to staurosporine- which inhibits virtually every 
protein kinase (Karaman et al., 2008). Similarly the strategy of target based drug 
development is also under question – due to the complex nature of many 
diseases. The term polypharmacology (or network pharmacology) has come into 
parlance, and the emphasis with this field is to target multiple proteins in a 
pathway using multiple inhibitors in combination or to use a single inhibitor to 
inhibit multiple targets (Hopkins, 2008). It may be that protein kinase inhibitors 
are ideal for the latter role (Boran and Iyengar, 2010; Knight et al., 2010).  
Protein kinase inhibitors can typically be broken down into three major types. 
Type I inhibitors are typically ATP competitive and bind to a protein kinase in its 
active conformation. Type II inhibitors bind a protein kinase in a region adjacent 
to the ATP binding site, which is exposed when in its inactive conformation, and 
therefore are not competitive with ATP. This conformation is called “DFG out” 
due to the conformation of this conserved motif. These types of inhibitor lock 
the protein kinase in an inactive conformation. Type III and Type IV inhibitors are 
those that bind away from the active site but cause allosteric changes that 
inactivate the protein kinase or prevent it from being activated. Type III 
inhibitors tend to bind closer to the active site than Type IV inhibitors (Knight 
and Shokat, 2005; Liu and Gray, 2006). Inhibitors that do not compete with ATP 
are typically more potent than ATP competitive inhibitors due to the high 
intracellular ATP concentration of 1-10 mM. 
1.5 Protein Kinase of T. brucei 
In 2005 the release of the genomes of three pathogenic trypanosomatids (T. 
brucei, T. cruzi, Leishmania major) allowed for bioinformatics searches to 
examine them for a comprehensive prediction of their protein kinase 
complement (Ivens et al., 2005; Parsons et al., 2005a). This revealed that T. 
brucei had a predicted complement of 156 ePKs and 20 aPKs (as well as 13 ePK 
proteins predicted to be inactive- pseudokinases). These were then compared to 
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kinomes from other organisms and phylogenetic trees were used to group the 
protein kinases into the equivalent families. This analysis, based on sequence 
alignment, showed a number of differences compared with the human kinome 
(Previous Page - Figure 1-7). The protein kinase constitute up to 2% of the T. 
brucei genome, a similar proportion to the human kinome. In relative terms 
some families are expanded or reduced and some unique features also exist.  
Of note is the complete absence of ePKs with sequences corresponding to 
tyrosine kinase or tyrosine kinase-like groups. This is despite the fact that 
tyrosine phosphorylation has been well documented in trypanosomes – with 
localisation and phosphoproteomic studies clearly demonstrating this (Parsons et 
al., 1991; Nett et al., 2009a). Several candidates for conducting tyrosine 
phosphorylation exist in the T. brucei kinome; these include several DYRK, CLK 
and STE7 protein kinases (which can act as atypical tyrosine kinases) as well as 
Wee1, which typically phosphorylates a conserved tyrosine in the ATP binding 
pocket of CDKs. 
The AGC and CAMK families are two groups that are underrepresented in the T. 
brucei kinome. The CAMK family (in other organisms includes 
calcium/calmodulin regulated kinases and AMP-regulated Kinase) is small in T. 
brucei with only 13 members. The AGC kinase family is very small in T. brucei 
consisting of only 12 genes which makes it, proportionally, 50% smaller than the 
family in humans. Of the major families, the overrepresented groups are the 
CMGC kinases (42 genes) and STE kinases (25 genes). The CMGCs contain CRKs, 
11 in total, 10 MAPKs with the remainder falling into smaller families such as the 
DYRKs, CLKs, GSKs, MAPK-like and SRPKs. 
The STE kinases (named after sterile yeast mutants) contain the upstream 
activators of MAPKs. Two STE7 type kinases (which can function as MAPKKs) were 
identified with another 5 being very similar to these, suggesting they may 
function as STE7 kinases. Fourteen STE11 kinases (which can act as MAPKKKs) 
were identified but only 2 STE20 kinases (which in other organisms act as 
MAPKKKKs) were identified. The remainder of the STEs were uncategorised.
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Previous Page - Figure 1-7: The Trypanosome Kinome – a stylised representation of the 
eukaryotic protein kinase complement of Homo sapiens and T. brucei based on the 
depiction of the human kinome by Manning et al. (2002). Protein kinase families are grouped 
together into families defined by amino acid sequence characteristics. In this illustration the 
node arrangements or length of the branches do not have any phylogenetic significance, 
and are purely illustrative. Number of ePKs depicted: H. sapiens N=518, T. brucei = 156. 
The other group of expanded kinases, that actually number more in T. brucei 
than in humans, are the NEK kinases. T. brucei possesses 20 genes for NEK 
kinases compared to 15 in humans. These are discussed in more detail in Chapter 
4.  The study by Parsons et al. (2005) also identified 19 protein kinases that were 
very divergent from known families and thus could not be placed into the 
currently known categories, these have been termed Orphan or unique protein 
kinases. 
During the analysis of the T. brucei phosphoproteome, researchers at the 
University of Dundee used different bioinformatic techniques to define the 
kinome of T. brucei and this led to the expansion of some of the groups by 
placing some of the orphan kinases into groups such as the AGC and STE families 
(Nett et al., 2009b). This analysis also reduced the number of aPKs to 12. 
Many studies have investigated the function of protein kinases in T. brucei using 
reverse genetics. However, none have so far identified the direct 
phosphorylation of a substrate in vivo, this is particularly troublesome in 
trypanosomes as very few reagents exist with which to probe the results of any 
perturbations in signalling pathways. For example, no antibodies exist for 
probing the phosphorylation state of any phosphosite in any T. brucei protein 
kinase and only a few exist for any phosphorylated proteins (phospho-PIP39, 
phospho-GPEET and phospho-PSSA2) (Bütikofer et al., 1999; Fragoso et al., 2009; 
Szöor et al., 2010).  
Other methods of investigating phosphorylation has included phosphoproteomics 
which has shown the relevance of phosphorylation in the both the bloodstream 
and procyclic form of the parasite (Nett et al., 2009a, 2009b). MS analysis of 
phosphotyrosine-containing peptides isolated by immunoprecipitation of proteins 
from PCF whole cell lysates using anti-phosphotyrosine antibody detected 34 
phosphotyrosine containing proteins. This study also localised phosphotyrosine 
using IFA and found the predominant staining to be associated with the flagellar 
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axoneme, basal body and cytoskeleton – this pattern was found in PCF and BSF 
parasites. Of the 34 proteins identified, 19 were protein kinases. Of these all bar 
one were CMGC kinases (the other being a NEK), and included mainly MAPK or 
MAPK like protein kinases. The peptides of 8 MAPKs were fully phosphorylated in 
the TxY motif suggesting the same mode of activation as other canonical MAPK 
systems. The authors also suggested roles for tyrosine phosphorylation in 
regulating the CRKs CRK1, CRK2 and CRK3. A more comprehensive analysis of the 
bloodstream form cytosolic phosphoproteome fraction 1204 phosphopeptides 
across 491 proteins, of these 43 were ePKs (Nett et al., 2009b). The majority of 
these were CMGCs with AGCs, CAMKs, STEs and NEKs composing most of the 
remainder. Several “Other” kinases were detected, as well as the aPK TOR4. 
Serine was the most common residue phosphorylated followed by threonine and 
then tyrosine (63%, 24% and 13% respectively). For non-protein kinase 
phosphosites the ratio was much different at 75%, 21.5% and 3.5% respectively. 
This indicates the importance of tyrosine phosphorylation in regulating protein 
kinases – although most of those detected to contain tyrosine phosphorylation 
were CMGC kinases. The authors compared phosphosite prediction algorithms for 
other eukaryotes against the data set and found 25% of phosphosites were not 
predicted by these algorithms, which appear to indicate that T. brucei possesses 
protein kinases with novel substrate specificity. The results of kinome 
predictions and phosphoproteomics suggest trypanosomes have, to some extent, 
canonical MAPK pathways. However, there are no G-proteins or receptor tyrosine 
kinases in T. brucei, suggesting that the activation of these pathways occurs in a 
non-canonical manner.  
Many of these protein kinases have been investigated at a molecular level 
intrypanosomes but only a few have been thoroughly investigated as drug 
targets. Several of these are conserved protein kinases, found in both the 
parasite and human host but nevertheless have been genetically and chemically 
validated as drug targets. Aurora kinases are conserved regulators of the cell 
cycle and several studies have investigated the biological role of the Aurora 
kinase AUK1 of T. brucei. It has been identified to be inhibited by both 
experimental compounds (hesperaudin, VX-680) and danusertib, a compound in 
phase II clinical trials (Li and Wang, 2006; Jetton et al., 2009). Derivatives of 
danusertib have been shown to exhibit selective toxicity to T. brucei BSF over 
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mammalian cells and this drug is now a proposed lead compound for developing 
trypanosome specific Aurora kinase inhibitors (Ochiana et al., 2012). 
Glycogen synthase kinase 3 is another widely conserved protein kinase, with T. 
brucei  possessing a long and a short homologue. When the short isoform is 
ablated by RNAi in BSF parasites a severe growth defect occurs. Recombinant 
GSK-3 short can be inhibited by inhibitors designed to target human GSK3- and 
their in vitro activity is correlated to their potency against T. brucei in vivo (Ojo 
et al., 2008). Bioinformatic analysis and molecular modelling have suggested 
that there are exploitable structural differences between the parasite and 
human kinases (Osolodkin et al., 2011). The crystal structure of L. major GSK-3 
short has also been determined and allowed modelling and SAR studies of GSK-3 
short of L. major and T. brucei  (Ojo et al., 2010). TbGSK-3 has been used in a 
high throughput screen of a 16,000 compound library to detect inhibitory 
compounds. The hits from this screen were counterscreened against a panel of 
human protein kinases. They were further tested for efficacy against T. brucei 
BSF parasites and toxicity against MRC-5 cells, identifying several attractive lead 
compounds in the process. However, many of the compounds were not selective 
for the T. brucei  GSK3-short over the human homologue (in the enzyme panel 
screen) indicating that selecting conserved protein kinases as drug targets may 
prove problematic when it comes to developing clinically useful inhibitors. 
However, taken together these studies make GSK3-short the most fully validated 
T. brucei protein kinase that has currently been studied. 
The CRK3 protein kinase of Leishmania spp. has been investigated as a drug 
target. It was shown to be essential for proper cell cycle progression in gene 
knockout studies using L. mexicana. LmxCRK3 was epitope tagged, purified from 
L. mexicana promastigotes and used in in vitro kinases assays, where it was 
shown to be inhibited by flavopiridol, a CDK inhibitor. This compound also caused 
cell cycle arrest in L. mexicana promastigotes (Hassan et al., 2001). LmxCRK3 
inhibitors from a 634 compound library were identified in screens performed 
using protein purified from promastigotes. Sixteen of these, from various 
chemical categories, were then shown to have anti-leishmanial activity against 
L. donovani amastigotes (Grant et al., 2004).  Bacterial expression of CRK3 and 
CYCA (the cyclin partner of CRK3) allowed the reconstitution of protein kinase 
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activity in vitro from bacterial expressed protein, allowing functional 
biochemical studies to be performed (Gomes et al., 2010).  This development 
allowed active CRK3:CYCA to be co-expressed and co-purified in large quantities. 
The development of a high-throughput screening assay format allowed large 
chemical libraries to be screened against the L. major CRK3:CYC6 complex. The 
number of compounds in the various libraries was in the region of 30,000 
(Cleghorn et al., 2011; Walker et al., 2011b). The hits generated by these 
screens were investigated against promastigote and amastigote form L. major 
with some of the compounds showing low micromolar IC50 values. However, 
some of the compounds were also toxic towards the Leishmania infected 
macrophages used in these experiments, demonstrating undesirable off target 
effects. The CRK3 protein kinase of Leishmania is a genetically and chemically 
validated drug target highlighting the potential of investigating parasite protein 
kinases in this way. 
1.6 Validating Drug Targets 
The differences between the human and trypanosome kinomes and individual 
protein kinase may make parasite ePKs valuable new drug targets. Protein 
kinases have been demonstrated as druggable targets, with selective inhibition 
of targets being achieved within the human kinome. They are typically 
formulated as orally available treatments, and several, such as gefetinib and 
sorafenib, can cross the blood-brain barrier – these inhibitors can be used to 
treat brain tumours such as glioblastoma (Korfel and Thiel, 2007). This makes T. 
brucei protein kinase potential drug targets, where inhibitors could eventually 
be developed that satisfy the target product profile defined by the DNDi for new 
antitrypansosomal drugs (Table 1-1). In order to pursue a trypanosome protein 
kinase as a drug target, worthy expending cost and effort on, it must be 
validated as one. This involves showing a protein is essential to the parasite and 
can be inhibited using a drug like molecule (Wang, 1997). Similarly, potential 
drug targets can be assessed using a “traffic lights system” to indicate the 
readiness and suitability of a target to move along the drug development 
pipeline. Target product profiles define the desired characteristics of the 
intended product and can help with decision making processes throughout the 
drug development programme by providing criteria to exclude undesirable 
products (Frearson et al., 2007; Wyatt et al., 2011). 
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Essential protein kinases can be validated as essential by genetic and chemical 
methods to prime drug development pipelines with new targets. A target based 
approach typically builds on basic research that has sought to understand the 
biology of potential drug targets; the development of imatinib was a classic 
example of this. Target based approaches can absorb a lot of resources and 
funding, and very many of them fail, thus they can be risky strategies to 
undertake. However, they do generally build a body of knowledge on the target 
and the way the target is inhibited. Approaches to determine if a target is 
essential to an organism can consist of genetic validation or chemical validation, 
though a combination of these is usually required to provide confidence in the 
target for a full drug development programme. Genetic techniques usually used 
in T. brucei are gene knockout (by targeted allelic replacement) and RNA 
interference. Other techniques such as overexpression of a mutant protein to 
achieve dominant negative phenotypes can also be used. Complete gene 
knockout will show that a gene is not essential in the life cycle stage in which it 
is performed under culture conditions (Frearson et al., 2007). If a gene is 
essential a tetracycline inducible version of the gene can be incorporated prior 
to knockout of the endogenous alleles. Removal of tetracycline causes 
expression of the exogenous copy to be stopped, inducing the knockout 
phenotype (Roper et al., 2002). Viability in vivo should be examined using an 
animal model. RNAi is easy to perform but if no phenotype is observed it does 
not exclude the target from being essential, as RNAi can have varying 
penetrance depending on the system used and the stability of the protein 
encoded by the target mRNA (Kolev et al., 2011). Both techniques ultimately 
either remove or radically deplete a protein from the parasite and any 
phenotype observed may be due to disruption of protein complexes or other 
structural requirements. Thus other techniques are required to identify whether 
enzymatic activity is required for a given targets essentiality. This can be 
achieved in knockout parasites by re-expressing a non-active version of the 
protein. Expression of re-coded RNAi refractory mutants in RNAi cell lines is also 
feasible (Szöor et al., 2006).  
Chemical validation of a target uses a drug or experimental inhibitor to show 
that specific inhibition of a target is lethal or detrimental to a pathogen (Cong 
et al., 2012). If this can be carried out in the appropriate life cycle stage or in a 
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model infection it increases the strength of the validation. It further strengthens 
the case for a target being druggable, by showing inhibitory compounds can 
enter the cell and can be used in counter screens against host cells. However, 
this strategy is not without its difficulties and very often a specific inhibitor will 
not exist for a target during the early stages of target validation/drug discovery. 
The problem of off-target effects can be difficult to establish and identifying 
compounds acting on a specific target can be challenging to achieve using a 
phenotypic screen. However, chemical-genetic approaches such as generating 
analogue sensitive kinase alleles (ASKA) can be used to generate mutant proteins 
that are highly sensitive to specific experimental compounds. 
The drugs melarsoprol, suramin and pentamidine were developed using 
phenotypic screens in that they were detected to be effective at killing T. 
brucei.  Eflornithine arose from studies to develop anti-cancer treatments and 
was eventually found to be effective against T. brucei. Eflornithine was 
rationally designed to inhibit ornithine decarboxylase, though the turnover of 
this enzyme in mammalian cells is so rapid that it is ineffective. The rate of 
turnover in T. b. gambiense is low enough that a selective toxicity is achieved. 
Eflornithine is the only anti-trypanosomal drug with a well understood mode of 
action and selectivity (Burri and Brun, 2003; Steverding, 2010). Phenotypic 
screens are making something of a resurgence due to, in some quarters, the 
perceived failure of the target based approach and the ability to use high-
content screening to detect very detailed and specific phenotypic information. 
Other techniques such as chemical proteomics can be used to identify the target 
of compounds detected in phenotypic screens. 
Several studies have attempted to chemically validate protein kinases as drug 
targets in T. brucei, in particular using chemical proteomics. These methods are 
becoming more informative due to improvements in mass spectrometry 
technology (Cong et al., 2012). Chemical proteomics has been used to identify 
the targets of several trypanocidal 2,4-diaminopyrimidines that were identified 
in high-throughput screens (HTS) against whole parasites (Mercer et al., 2011). 
This compound family was known to possess activity against human CDKs and 
MAPKs, but the hits identified in the HTS had much lower IC50s against T. brucei 
and Leishmania spp. than against L929 fibroblasts. One of the hits, SCYX-5070 
was also used to cure experimental T. brucei infections in a mouse model, with 
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no apparent acute toxicity in this system. In order to determine the targets of 
the compound the inhibitor was coupled to resin beads and mixed with cell 
lysates; free inhibitor and ATP was then used to elute interacting proteins. 
Proteomic analysis of these proteins identified a number of MAPKs and CRKs. 
This analysis used MALDI-MS and the data generated was non-quantitative. 
Advances in MS technology, combined with targeted enrichment strategies have 
allowed this type of analysis to go much further, and identify the potencies with 
which a given protein kinase inhibitor binds to an individual protein kinase. By 
pulling down protein kinases using beads coated with a broad spectrum of 
inhibitors (KinoBeads) in the presence of varying quantities of a single, free 
inhibitor the amount of each protein kinase can be determined using 
quantitative mass spectrometry (in this case ITRAQ). This allows the IC50 of an 
inhibitor to be calculated for any protein kinases detectable in the assay. This, in 
theory, allows kinome-wide determination of inhibitor potency in the absence of 
enzyme panels that are often used to profile inhibitors to determine their target 
specificity. This was recently applied to the trypanosome kinome allowing the 
profiling of inhibitors of GSK3, PK50 and PK53. This also allowed the 
counterscreening of the human kinome from MRC5 cells to identify potential 
anti-targets (Urbaniak et al., 2012b). However, it does not detect any protein 
kinase (or other protein) that does not bind to the Kinobeads – in this case the 
inhibition of PK50/PK53 could not be determined as these and other human NDR 
kinases were not bound by the Kinobeads. This study showed that it was possible 
to achieve different inhibition profiles in the trypanosome kinome compared to 
the human kinome, suggesting that the differences between the host/pathogen 
kinomes could be enough to allow the development of a usable, therapeutic 
protein kinase inhibitor. 
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Table 1-1: Target-product profile for next generation antitrypanosomals as determined by 
DNDi (http://www.dndi.org/diseases/hat/target-product-profile.html) highlighting the ideal 
scenario, an acceptable scenario and the current first line therapy.
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1.7 Research Aims 
The work presented in this thesis aimed to genetically validate the protein 
kinase complement of T. brucei as drug targets, generating a library of RNAi cell 
lines for use in further studies. Several protein kinases were investigated in 
greater detail due to their potential amenability for rational drug design or their 
specific phenotype when ablated by RNAi. Due to the range of subjects covered 
in the course of these studies each results chapter contains a specific 
introduction and discussion in order to put the results in proper context. The 
generation of a kinome-wide library of RNAi plasmids and cell lines is presented 
first, second the examples of protein kinases interesting as drug targets and 
third the observations on a protein kinase involved in regulating bloodstream to 
procyclic form differentiation.
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2 Materials and Methods 
2.1 Bioinformatics 
2.1.1 Sequence Retrieval 
DNA and amino acid sequences for genes of interest were retrieved from 
TriTrypDB in FASTA format (http://tritrypdb.org/tritrypdb/). In certain instances 
annotated amino acid sequences were obtained from Genbank in GenPept 
format (http://www.ncbi.nlm.nih.gov/genbank/). TriTrypDB was also used to 
view collated data available for genes of interest including protein domain 
architecture, transcriptomic and proteomic evidence and other post-
translational modifications. 
2.1.2 Sequence Manipulation 
In silico manipulation of DNA and amino acid sequences was conducted using CLC 
Genomics Workbench (CLC Bio). Features of this software allowed the design of 
oligonucleotide primers, sequence alignment, in silico cloning, restriction digest 
mapping and reverse translation/recoding of proteins. This software allows PFAM 
searches to identify protein domains to be carried out within it 
(http://pfam.sanger.ac.uk/). Sequences were analysed using the full PFAM 
library downloaded as an add-on from CLC Genomics plugins 
(http://www.clcbio.com/products/clc-genomics-workbench/). 
2.1.3 Molecular Modelling 
Homology models of the NEK 12 kinases were constructed using Molecular 
Operating Environment. Molecular Operating Environment (MOE), 2011.10; 
Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, 
QC, Canada, H3A 2R7, 2011. Access to this software and training in its use was 
kindly provided by Dr Paul Selzer and colleagues (Intervet) at the COST Action 
CM0081 Training School – In Silico Tools for Drug Target Prioritisation (University 
of Siena, 2011). 
For each NEK12 isoform (Tb927.8.7110, Tb927.4.5310) the amino acid sequence 
was used to search the MOE inbuilt PDB database for templates then aligned 
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using MOE’s search and alignment function. Alignment was manually checked to 
ensure key residues were correctly aligned. Modelling was carried out using 10 
stochastic iterations using the forcefield AMBER99 R-Field (used for amino acids 
and to include the effect of solvation in water on the model) with the lowest 
energy model being selected. MOE models the backbone, followed by loops and 
sidechains, and chooses the optimum model. Each optimum model was validated 
by viewing the Ramachandran plot for all residues and any amino acid lying 
outside the optimal areas was selected and energy minimised to make the model 
more energetically favourable before exporting it as a .PDB file for further use. 
 
Table 2-1: Template PDB structures used for homology modelling of T. brucei NEK 12.1 and 
NEK12.2 
Template PDB ID Description Pubmed ID 
2JAV HsNEK2 PI Ligand 17197699 
2W5H HSsNEK2 Apo 19124027 
2WQM HsNEK7 Apo 19941817 
 
2.1.4 Data Mining for Potential NEK 12 Inhibitors 
To identify ligands with the potential to bind into the NEK 12 models, the two 
models were screened using Ligand Discover at Edinburgh University (LIDAEUS) 
Models containing a pyrrole-indolinone ligand were used to define the binding 
site that was then screened against the CAMLESICK 2 library, this contains 4.3 
million commercially available compounds that fit the Lipinski Rules, and 3.2 of 
these meet Oprea guidelines for lead-likeliness (Hann and Oprea, 2004; Taylor et 
al., 2008). Sitepoint matching tolerance was set to 0.04 Å (from 0.02 Å), which 
provides lower stringency but increases the number of returned compounds. The 
top 100, 000 compounds were returned as a .SDF file.  
2.1.5 Virtual Screening  
Compounds returned from LIDAEUS screening were docked into the NEK 12 
models using Autodock (rigid docking) and Vina (flexible sidechain docking) using 
a PyMOL plugin under the supervision of Dr D. Houston, University of Edinburgh 
(Seeliger and De Groot, 2010). Proteins and ligands were visualized using the 
PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC. The ligand 
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from the model template 2JAV was again used to define the centre of the active 
site box for virtual screening (the volume of the molecule where the software 
will attempt to dock the compounds). The top 500 compounds were ranked 
based on their binding energy and the top 100 manually validated. Compounds 
ranking in the top 100 that exhibited a posematch (when both docking 
techniques predict the same binding conformation) were classed as being 
interesting targets for inhibitor studies and the top 10 for each were 
investigated for purchase. 
2.2 Molecular Biology 
2.2.1 DNA Sequencing 
DNA sequencing was performed by DNA Sequencing & Services (MRCPPU, College 
of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using 
Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 
3730 automated capillary DNA sequencer. 
2.2.2 Polymerase Chain Reaction 
Oligonucleotide primers were designed using CLC Genomics Workbench and 
synthesised by Eurofins MWG Operon (Ebersber, Germany). 
Standard PCRs (e.g. colony PCR): template DNA (100 ng genomic DNA, 100pg 
plasmid DNA or bacterial inoculation), 2.5 µl of 10 x PCR mix (1.13 mg ml-1 BSA, 
450 mM Tris pH 8.8, 110 mM ammonium sulphate, 45 mM MgCl2, 68.3 mM β-
mercaptoethanol, 44 µM EDTA pH 8.0, 10 mM dCTP, 10 mM dATP, 10 mM dGTP, 10 
mM dTTP), 5 pmol of each primer, 1 unit of Taq polymerase and sterile distilled 
deionised water to a final volume of 25 µl.  Thermocycling was programmed for 
an initial denaturation step of 96°C for 5 minutes, followed by 30 cycles of: 
denaturation 96°C for 30 seconds; annealing at [primer specific Tm]  for 30 
seconds; extension at 72°C for Taq polymerase, 30 seconds per 0.5 kb of 
sequence. PCR conditions were subject to optimisation for specific primer 
pairs/templates and primer annealing temperature and elongation time were 
adjusted as required.  
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For generating PCR products for RNAi inserts or molecular cloning a proofreading 
enzyme was used, in this study Phusion (New England Biolabs) was used 
exclusively due to its robustness and reliability. Phusion reactions were set up as 
follows; Phusion HF buffer at 1x (stock at 5x), each dNTP at 200 M, primers at 
0.5 M each, template DNA and Phusion polymerase at 0.02 U/l. Reactions were 
usually set up to 50 l. 
2.2.3 Restriction Enzyme Digests 
All restriction endonucleases used in this study were sourced from New England 
Biolabs (NEB) and used according to the manufacturer’s instructions and buffers. 
For restriction mapping of plasmids or generating fragments/backbones for 
cloning reactions were allowed to proceed for 1 hour before agarose gel 
electrophoresis. Plasmids that were being linearized in 5 g amounts prior to 
transfection were generally digested overnight to ensure complete digestion. 
2.2.4 Agarose Gel Electrophoresis 
DNA sequences in this study were analysed by agarose gel electrophoresis which 
also serves as a method for purifying DNA fragments by size. UltraPure agarose 
(Invitrogen) was dissolved in 0.5 x TBE buffer (20mM Tris, 20 mM boric acid, 
0.5mM EDTA, pH 7.2) at 1% w/v. For resolving larger fragments this was reduced 
to 0.8% w/v. After allowing the gel to cool SYBR-safe DNA stain (Invitrogen) was 
added to allow the visualization of DNA. Gels were then cast in the required size 
of gel support. DNA was prepared by addition of 6x Loading Buffer (0.25 % (w/v) 
bromophenol blue, 0.25 % (w/v) xylene cyanol FF, 30 % (v/v) glycerol, in H2O) 
and loaded into wells. Gels were run at 120 V for 60 min depending on expected 
fragment sizes. Gels were imaged using a GelDoc (BioRad) and the associated 
Quantity One Software (BioRad). 
In order to purify DNA fragments from agarose gels the DNA was visualised using 
a DarkReader blue light transilluminator, the band excised using a sterile scalpel 
blade and extracted from the agarose gel with a Gel Extraction kit (Qiagen) for 
general purposes, or a MinElute Kit (Qiagen) for more sensitive applications such 
as Gateway cloning. This was performed on a Qiacube (Qiagen) according to the 
manufacturer’s instructions. 
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2.2.5 Ligations 
When cloning constructs by the cohesive end technique compatible DNA 
fragments were ligated together using T4 DNA ligase (NEB) and the 10x Ligase 
Buffer supplied with it. Insert and plasmid backbone DNA fragments were mixed 
in equimolar amounts in a 10 l volume of 1xLigase buffer plus T4 DNA Ligase. 
These were incubated overnight at 16 oC. Some inserts were first subcloned into 
p-GEMT Easy (Promega) or PCR-Script (Stratagene) depending on the size of the 
insert. PCR-Script was typically used for inserts over 2 Kb due to its greater 
efficiency for larger inserts. 
2.2.6 Gateway Cloning of RNAi Constructs 
To recombine RNAi target sequences into the RNAi vector (pGL2084), 50 ng of 
purified, attB-tagged PCR product was mixed with 150 ng pGL2084 and adjusted 
to 8.75 l using TE buffer (pH 8.0) then mixed with 0.25 l of BP Clonase II 
enzyme (Invitrogen). Reactions were incubated at room temperature for 40 – 60 
min and terminated by the addition of 1 l proteinase K solution (Ambion). A 1 l 
aliquot of the BP reaction mix was added to 50 l of Max Efficiency DH5 E. coli 
(Invitrogen) which were incubated on ice for 30 min followed by 42oC heat shock 
for 30 seconds and recovery in SOC media for 1 hour at 37oC. The full 
transformation was plated onto agar plates containing 100 g ml-1 Ampicillin 
(Sigma) and incubated overnight at 37oC. A colony was picked for overnight 
culture and plasmid DNA was extracted by Qiaquick Miniprep (Qiagen). 
Completed vectors were termed PTL##. An aliquot of 5g of plasmid DNA was 
digested overnight with AscI, ethanol precipitated and used to transfect T. b. 
brucei 2T1 BSF cells. Details of the RNAi library oligonucleotide, plasmid and cell 
line identification numbers are contained in supplemental data file S1 on the 
appended CD-ROM. 
 
2.2.7 Ligation Independent Cloning of Kinase CDS for Protein 
Expression 
PCR fragments containing full CDS for kinase genes or fragments thereof were 
cloned into the commercial pET-30Xa/LIC or pET-32Xa/LIC (Novagen) vectors 
following the manufacturer’s instructions. pET-30Xa/LIC encodes an N-terminal 
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6xHis tag which can be cleaved from the protein of interest using activated 
Factor X. pET-32Xa/LIC encodes a N-terminal thioredoxin tag prior to the 6xHis 
tag that is intended to increase the solubility of the endogenous protein it is 
fused to. Expression of cloned genes is driven by the strong T7 promoter and the 
plasmids are for use with bacteria containing the DE3 lysogen.  Oligonucleotides 
for amplifying the CDS of interest contained 20 nt specific to the gene and 5’ of 
this sequence contained a 15 nt (GGTATTGAGGGTCGC-GOI) or 17 nt 
(AGAGGAGAGTTAGAGCC-GOI) vector specific sequence on the forward and 
reverse primers respectively. The purified PCR products were then treated with 
T4 DNA polymerase to remove 12 or 15 nt in a 3’ to 5’ direction leaving single-
stranded overhangs allowing it to be annealed to the pre-treated vector and 
remain in frame. This annealed plasmid was then transformed into Gigasingle 
Competent Cells where the DNA was covalently bound and replicated.  
A number of protein kinase sequences were analysed at the University of 
Edinburgh to define regions around the protein kinase domain optimised for 
protein expression and solubility (J. Cowman). This information allowed them to 
be cloned as kinase domain fragments for expression testing.  
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Table 2-2: List of oligonucleotides used to generate RNAi constructs prior to the establishment of a Gateway adapted cloning system.  
OL number Gene ID Gene Sequence Restriction Sites 
OL 3328 Tb927.7.3580 NEK11 GATCCTCGAGGGTACCCCTGAAGCTGGGAGAGCTTTG XhoI, KpnI 
OL 3329 Tb927.7.3580 NEK11 GATCTCTAGACTTAAGTTTTGTTATTACCTCGGGCG XbaI, AflII 
OL 3332 Tb10.70.2210 CRK3 GATCGGGCCCGGTACCAAAGGCTCTCGAGAAGAGGG ApaI, KpnI 
OL 3333 Tb10.70.2210 CRK3 GATCAAGCTTCTTAAGAGCGCTGGTAACACCTGAGT HindIII, AflII 
OL 3463 Tb10.61.0100 Orphan GATCCTCGAGCCCGGGAAATGGACTTTACCCTCCGC XhoI, XmaI 
OL 3464 Tb10.61.0100 Orphan GATCTCTAGAGGATCCCTGCCTCGGCTAATTCTGAC XbaI, BamHI 
OL 3465 Tb927.3.3290 Orphan GATCCTCGAGCCCGGGTGTATTGCATGTGGGAGGAA XhoI, XmaI 
OL 3466 Tb927.3.3290 Orphan GATCTCTAGAGGATCCGGCACTTGTATACCACGCCT XbaI, BamHI 
OL 3467 Tb11.02.4530 Orphan GATCCTCGAGCCCGGGATCTCCAGACCCACTGATGG XhoI, XmaI 
OL 3468 Tb11.02.4530 Orphan GATCTCTAGAGGATCCAGGCAAGGGCACATACAATC XbaI, BamHI 
OL 3598 Tb927.8.7110 NEK12.1 GGGGACAAGTTTGTACAAAAAAGCAGGCTCTCGAGGGTACCTTGGGTCAAGGAAGTTTTGGAAGCG XhoI, KpnI sites (+AttB1) 
OL 3599 Tb927.8.7110 NEK12.1 GGGGACCACTTTGTACAAGAAAGCTGGGTTCTAGAGGATCCACCAAGAGCCCACATTTCACTCTTT XbaI, BamHI sites (+AttB2) 
OL 3606 Tb927.3.3080 NEK6 GATCCTCGAGGTACCGAAGAAGTTGCAGGTCAGGC XhoI, KpnI sites  
OL 3607 Tb927.3.3080 NEK6 GATCTCTAGAGGATCCTCATCAAGGAAACTCGACCC XbaI, BamHI sites  
OL 3608 Tb927.3.3190 NEK7 GATCCTCGAGGGTACCGCCCTCGGTGTCATTCTTTA XhoI, KpnI sites  
OL 3609 Tb927.3.3190 NEK7 GATCTCTAGAGGATCCTATGCTCTCCCGATTCATCC XbaI, BamHI sites  
OL 3610 Tb927.8.1670 NEK13 GATCCTCGAGGGTACCCACGTGAAGAGAAGCAGCAG XhoI, KpnI sites  
OL 3611 Tb927.8.1670 NEK13 GATCTCTAGAGGATCCAATTTCGACTGAAACGTCCG  XbaI, BamHI sites  
OL 3612 Tb09.160.3480 TbPDK1 ATCCTCGAGGGTACCGGTCCGCAGGACCTTATGTA XhoI, KpnI sites  
OL 3613 Tb09.160.3480 TbPDK1 GATCTCTAGAGGATCCACCACAGGCCCAGTAATCAG XbaI, BamHI sites  
OL 3614 Tb927.3.2240 AGC GATCGGGCCCCCCGGGGGCGAACTCATTTGTTGGTT ApaI, XmaI 
OL 3615 Tb927.3.2240 AGC GATCTCTAGAGGATCCTTGTTTCCACTTTGTGCAGC XbaI, BamHI 
OL 3730 Tb927.6.2250 TbRAC GATCTCTAGAGGATCCCTCCAGAGTTTCTGCTTGGG XbaI, BamHI 
OL 3731 Tb927.6.2250 TbRAC GATCCTCGAGCCCGGGCCACTACTTCATCGTCCGGT XhoI, XmaI 
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Table 2-3: List of RNAi plasmids generated prior to the generation of a Gateway adapted vector system. 
Plasmid Gene ID Gene Name Backbone Description 
PGL 1987 Tb10.70.2210 TbCRK3 pGL 1875 Stem loop RNAi Vector AmpR 
PGL 1988 Tb11.01.8460 TbCYC6 pGL 1875 Stem loop RNAi Vector AmpR 
PGL 1989 Tb927.7.3580 NEK 11 pGL 1875 Stem loop RNAi Vector AmpR 
pGL 2028 Tb10.61.0100 Orphan 0100 pGL 1875 Stem loop RNAi Vector AmpR 
pGL 2029 Tb927.3.3290 Orphan 3290 pGL 1875 Stem loop RNAi Vector AmpR 
pGl 2030 Tb11.02.4530 Orphan 4530 pGL 1875 Stem loop RNAi Vector AmpR 
pGL 2051 Tb927.3.3080 NEK 6 pGL 1875 Stem loop RNAi Vector AmpR 
pGL 2052 Tb927.8.1670 NEK 13 pGL 1875 Stem loop RNAi Vector AmpR 
pGL 2053 Tb09.160.3480 TbPDK1 pGL 1875 Stem loop RNAi Vector AmpR 
pGL 2064 Tb927.8.7110 NEK 12 pGL 1875 Stem loop RNAi Vector AmpR 
pGL2068 Tb927.3.2440 AGC pGL 1875 Stem loop RNAi Vector AmpR 
pGL 2093 Tb927.3.3190 NEK7 pGL 1875 Stem loop RNAi Vector AmpR 
pGL2084 N/A N/A pGL1875 Gateway adapted stem-loop RNAi plasmid backbone AmpR 
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Table 2-4: List of oligonucleotide primers generated in this study for the purposes of ligation independent cloning into the pET-30/32 Xa/LIC systems.  
Oligo Gene ID Gene Sequence Region of Gene 
OL 3158 Tb927.5.3210 Orphan GGTATTGAGGGTCGCATGGAATGCGCAATGTTTCTTCCCT  CDS 
OL 3159 Tb927.5.3210 Orphan AGAGGAGAGTTAGAGCCTCAAGTCATGCATCAACGGCAAC  CDS 
OL 3160 Tb927.7.3580 NEK 11  GGTATTGAGGGTCGCATGGATAGGTTTACTAAGGTCCGT  CDS 
OL 3161 Tb927.7.3580 NEK 11  AGAGGAGAGTTAGAGCCTCAAGTAGCATTCCGCCTT  CDS 
OL 3269 Tb11.02.4530 Orphan GGTATTGAGGGTCGCATGGAACGAGACGATGGTG  CDS 
OL 3270 Tb11.02.4530 Orphan AGAGGAGAGTTAGAGCCCTAAGCATTCGCTCCTGATAGA  CDS 
OL 3271 Tb927.3.1570 Orphan GGTATTGAGGGTCGCATGAGTGGCCATTGGGAGGG  CDS 
OL 3272 Tb927.3.1570 Orphan AGAGGAGAGTTAGAGCCTCACTCGTACACAATCTTTA  CDS 
OL 3273 Tb927.3.3290 Orphan GGTATTGAGGGTCGCATGTTCACGACAATGGAGAG  CDS 
OL 3274 Tb927.3.3290 Orphan AGAGGAGAGTTAGAGCCTCACTTCTTCTTCAGAAGTA  CDS 
OL 3282 Tb09.160.0450 NEK 15 GGTATTGAGGGTCGCATGGATGGCGTGTGCG  CDS 
OL 3283 Tb09.160.0450 NEK 15 AGAGGAGAGTTAGAGCCTCACTTGACAATCTTCTGCGA  CDS 
OL 3284 Tb11.01.6650 NEK 21 GGTATTGAGGGTCGCATGGGAAACGGTGTTGTGA  CDS 
OL 3285 Tb11.01.6650 NEK 21 AGAGGAGAGTTAGAGCCCTACCCCATGTCAAGAGTAAACA  CDS 
OL 3286 Tb927.3.3190 NEK 7 GGTATTGAGGGTCGCATGGCGCAGGTTGCAGAT  CDS 
OL 3287 Tb927.3.3190 NEK 7 AGAGGAGAGTTAGAGCCCTACATCTTCTTCCCCTCGTACA  CDS 
OL 3288 Tb11.01.2900 NEK 20 GGTATTGAGGGTCGCATGCACCGGGGGAGC  CDS 
OL 3289 Tb11.01.2900 NEK 20 AGAGGAGAGTTAGAGCCTCACTCTAGGGACGAAATCGG  CDS 
OL 3290 Tb10.70.0960 NEK 17 GGTATTGAGGGTCGCATGTCGTCAACGGATGCAA  CDS 
OL 3291 Tb10.70.0960 NEK 17 AGAGGAGAGTTAGAGCCTCACTCAGCATCACCAATGC  CDS 
OL 3292 Tb927.2.2120 NEK 22 GGTATTGAGGGTCGCATGGCTGATCTCCTTGAGCTTC  CDS 
OL 3293 Tb927.2.2120 NEK 22 AGAGGAGAGTTAGAGCCTTAATTACTGCTGCCGCTGCT  CDS 
OL 3294 Tb927.8.1670 NEK 13 GGTATTGAGGGTCGCATGGGGATGGATCACTACACCG  CDS 
OL 3295 Tb927.8.1670 NEK 13 AGAGGAGAGTTAGAGCCTCACTGCACAGCAGGTGCGA  CDS 
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OL 3296 Tb927.8.7110 NEK 12.1 GGTATTGAGGGTCGCATGACCGCGCACAAACG  CDS 
OL 3297 Tb927.8.7110 NEK 12.1 AGAGGAGAGTTAGAGCCTCAATGCGATATGGCTTTCTG  CDS 
OL 3393 Tb927.3.3190 NEK 6 GGTATTGAGGGTCGCGGATCCATGAAGCCGCGGGATATTT  CDS 
OL 3394 Tb927.3.3190 NEK 6 AGAGGAGAGTTAGAGCCGTCGACTCAACACAACCCATAATTTGTAACC  CDS 
OL 3395 Tb10.61.0100 Orphan GGTATTGAGGGTCGCGGATCCGCGTGCAGACTTGCAATGAGCGACA  CDS 
OL 3396 Tb10.61.0100 Orphan AGAGGAGAGTTAGAGCCGTCGACTTAACTTCTCAGACTACAATGC  CDS 
OL3552 Tb09.160.3480 TbPDK1 GGTATTGAGGGTCGCGAATTCATGTCAGCGTCCCGGATGGTGCCGG  CDS 
OL3553 Tb09.160.3480 TbPDK1 AGAGGAGAGTTAGAGCCGTCGACTCAATCCCCCCTAATCTTGCCAAG  CDS 
OL 3695 Tb927.3.2440 AGC GGTATTGAGGGTCGCATGCTCAATAGAGACTA  CDS 
OL 3696 Tb927.3.2440 AGC AGAGGAGAGTTAGAGCCCTAACTACCACCACC  CDS 
OL 3697 Tb927.6.2250 TbRAC GGTATTGAGGGTCGCATGACCATCGATTAC  CDS 
OL 3698 Tb927.6.2250 TbRAC AGAGGAGAGTTAGAGCCCCTATGTAGGTCTTGA  CDS 
OL 3746 Tb927.4.5310 NEK12.2 GGTATTGAGGGTCGCATGACGGAACATAAGCGTCC  CDS 
OL3747 Tb927.4.5310 NEK12.2 AGAGGAGAGTTAGAGCTCAACGAGGCACGGCATTCT  CDS 
OL3916 Tb11.01.5650 DFK GGTATTGAGGGTCGCTCTAGTGATTGTAAACCTGA Kinase Domain 
OL3917 Tb11.01.5650 DFK AGAGGAGAGTTAGAGCCTCACAACAAAAATGCATATG Kinase Domain 
OL3918 Tb11.01.5650 DFK GGTATTGAGGGTCGCCTTTTTCTAACCGATTCCAA Kinase Domain 
OL3919 Tb09.211.2260 ZFO GGTATTGAGGGTCGCTTATCCCTGGAGGCGTGCGA Kinase Domain 
OL3920 Tb09.211.2260 ZFO AGAGGAGAGTTAGAGCCTTAGCGCCTATCGCCCCATTCCG Kinase Domain 
OL3921 Tb11.02.2050 ULK GGTATTGAGGGTCGCCCGAAAATTCGGAATATGGA Kinase Domain 
OL3922 Tb11.02.2050 ULK AGAGGAGAGTTAGAGCCTTATACCGCCATCAACCACTTCT Kinase Domain 
OL3923 Tb927.4.3420 Wee1 GGTATTGAGGGTCGCCGTCGCATTCTGACTGACTA Kinase Domain 
OL3924 Tb927.4.3420 Wee1 AGAGGAGAGTTAGAGCCTTATACAACCCACTGCGACATAA Kinase Domain 
OL3925 Tb11.46.0003 STE GGTATTGAGGGTCGCGCGTGCAACTTTAAGTTCAA Kinase Domain 
OL3926 Tb11.46.0003 STE AGAGGAGAGTTAGAGCCTTAGGAATAGCTTTGCGAAAAGA Kinase Domain 
OL3927 Tb927.10.2040 STE GGTATTGAGGGTCGCAGATATTCCACATATCAGTT Kinase Domain 
OL3928 Tb927.10.2040 STE AGAGGAGAGTTAGAGCCTTATACAATGTTCTCCGCAAGGA Kinase Domain 
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OL3929 Tb927.10.5140 MAPK2 GGTATTGAGGGTCGCCCACATATCCTCCGGAAATA Kinase Domain 
OL3930 Tb927.10.5140 MAPK2 AGAGGAGAGTTAGAGCCTTAGTGGAAAGCCGCCACATACG Kinase Domain 
OL3931 Tb09.160.0570 Aur GGTATTGAGGGTCGCATGTGGTCTTTGGACGATTT Kinase Domain 
OL3932 Tb09.160.0570 Aur AGAGGAGAGTTAGAGCCTTAGTAACGGTTGCTTATGCGAC Kinase Domain 
OL3933 Tb927.6.4970 SRPK GGTATTGAGGGTCGCGGCTACCACCCAGTCGTGGT Kinase Domain 
OL3934 Tb927.6.4970 SRPK AGAGGAGAGTTAGAGCCTTAAAAAAAGTGCTGAAAATTAT Kinase Domain 
OL3935 Tb11.02.3010 CMGC GGTATTGAGGGTCGCGAGTTCAATTATGAGATTAG Kinase Domain 
OL3936 Tb11.02.3010 CMGC AGAGGAGAGTTAGAGCCTTAACATCCCTGATGAATGGAAC Kinase Domain 
OL3937 Tb927.8.7110 NEK12.1 GGTATTGAGGGTCGCTGCAGGTATGTCAAAAAAAAG Kinase Domain 
OL3938 Tb927.8.7110 NEK12.1 AGAGGAGAGTTAGAGCCTTAGTCTAAGCCACGGCGAATGA Kinase Domain 
OL3939 Tb927.4.5310 NEk12.2 GGTATTGAGGGTCGCTGCAAATATGTTAAGAAGAA Kinase Domain 
OL3940 Tb927.4.5310 NEk12.2 AGAGGAGAGTTAGAGCCTTATTCTAAGCCACGGCGAATGA Kinase Domain 
OL3941 Tb09.160.3480 TbPDK1 GGTATTGAGGGTCGCGTGCCGGCCGATTTTGAGCT Kinase Domain 
OL3942 Tb09.160.3480 TbPDK1 AGAGGAGAGTTAGAGCCTTATGCGAGACCATCAAAATCAA Kinase Domain 
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Table 2-5: List of oligonucleotides generated for site directed mutagenesis of catalytic lysine residues in various protein kinases. 
Oligo Gene ID Gene Sequence Mutation 
OL3954 Tb927.8.7110 NEK 12.1 CGATCTTTGCAGCAATGGTGATGGATACAAACAATATGAGC K70M 
OL3955 Tb927.8.7110 NEK 12.1 GCTCATATTGTTTGTATCCATCACCATTGCTGCAAAGATCG K70M 
OL3956 Tb9274.5310 NEK 12.2 GCTAATTTTTGCAGCAATGGTGATGGACACAAACAATATGAGC K70M 
OL3957 Tb9274.5310 NEK 12.2 GCTCATATTGTTTGTGTCCATCACCATTGCTGCAAAAATTAGC K70M 
OL4057 Tb11.01.5650 DFK  CTCAGGTCGCCATCATGTGCATTCCGCGGTTG K950M 
OL4058 Tb11.01.5650 DFK  CAACCGCGGAATGCACATGATGGCGACCTGAG K950M 
OL4059 pGL2218 NEK12.1recoded GTATTTTTGCCGCCATGGTAATGGACACTAAC K70M 
OL4060 pGL2218 NEK12.1recoded GTTAGTGTCCATTACCATGGCGGCAAAAATAC K70M 
OL4061 pGL2222 NEK12.2recoded GGACTTATATTTGCAGCGATGGTAATGGATACGAACAAC K70M 
OL4062 pGL2222 NEK12.2recoded GTTGTTCGTATCCATTACCATCGCTGCAAATATAAGTCC K70M 
 
Table 2-6: List of plasmids generated for the purpose of protein expression in E. coli DE3 lysogen cell lines. 
Plasmid Gene ID Gene Name Backbone Description Region of Gene 
PGL 1990 Tb927.3.3080 NEK 6 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1991 Tb927.3.3190 NEK 7 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1992 Tb927.7.3580 NEK 11 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1993 Tb927.8.7110 NEK 12.1 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1994 Tb927.8.1670 NEK 13 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1995 Tb09.160.0450 NEK 15 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1996 Tb10.70.0960 NEK 17 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1997 Tb11.01.2900 NEK 20 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1998 Tb11.01.6650 NEK 21 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 1999 Tb927.2.2120 NEK 22 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
  
5
7 
PGL 2000 Tb10.61.0100 Orphan 0100 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 2001 Tb927.3.3290 Orphan 3290 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
PGL 2002 Tb11.02.4530 Orphan 4530 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
pGL 2023 Tb09.160.3480 TbPDK1 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
pGL 2099 Tb927.8.7110 NEK12.2 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS 
pGL 2181 Tb09.211.2260 ZFO pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2182 Tb11.02.2050 ULK pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2183 Tb927.4.3420 Wee1 pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2184 Tb11.46.0003 STE pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2185 Tb927.10.2040 STE pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2186 Tb927.10.5140 MAPK pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2187 Tb09.160.0570 Aur pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2188 Tb927.6.4970 SRPK pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2189 Tb11.02.3010 CMGC pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2190 Tb927.8.7110 NEK12.1 pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2191 Tb927.4.5310 NEK12.2 pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL 2192 Tb09.160.3480 TbPDK1 pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL2197 Tb11.01.5650 STE -Differentiation  Kinase pET-30 Xa/LIC N terminal, S, His tags. KanR Kinase Domain 
pGL2198 Tb11.01.5650 STE -Differentiation  Kinase pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR Kinase Domain 
pGL2199 Tb11.01.5650 STE -Differentiation  Kinase pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR Kinase Domain 
pGL2200 Tb927.8.7110 NEK12.1 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR Kinase Domain 
pGL2201 Tb927.4.5310 NEK12.2 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR Kinase Domain 
pGL2202 Tb09.211.2260 ZFO pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR Kinase Domain 
pGL 2214 Tb927.8.7110 NEK 12.1 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS K70M  
pGL 2215 Tb927.4.5310 NEK12.2 pET-32 Xa/LIC N terminal TRX, S, His tags. AmpR CDS K70M  
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Table 2-7: List of oligonucleotides used to generated fragments for cloning of endogenous tagging vectors. 
Oligo Gene ID Gene Cloning into Description Sequence Restriction Sites 
OL 3774 Tb927.8.7110 NEK12.1 pGL1796 NEK12.1 Endogenous Tagging  CATGTCTAGAATGACCGCGCACAAACGTGC XbaI 
OL 3775 Tb927.8.7110 NEK12.1 pGL1796 NEK12.1 Endogenous Tagging  CATGGGATCCTCAATGCGATATGGCTTTCT BamHI 
OL3869 Tb09.211.2260 ZFO 5' UTR pHG80 ZFO eGFP HA N-Ter Endogenous Tagging GATCGGCGCGCCAATTTATCTGTGCAGCAGCG AscI 
OL3870 Tb09.211.2260 ZFO 5' UTR pHG80 ZFO eGFP HA N-Ter Endogenous Tagging GATCGGATCCATCCAAAAAATGCAAGTGT BamHI 
OL3871 Tb09.211.2260 ZFO CDS pHG80 ZFO eGFP HA N-Ter Endogenous Tagging GATCTCTAGAATTGGCACAGTAGAACAAAT XbaI 
OL3872 Tb09.211.2260 ZFO CDS pHG80 ZFO eGFP HA N-Ter Endogenous Tagging GATCGGCGCGCCCCATCCAAATCGAAGACAAA AscI 
OL3914 Tb11.01.5650 DFK 3' CDS pGL2178 DFK 12Myc Endogenous tagging GATCTCTAGACAACAAAAATGCATATGAAA XbaI 
OL3915 Tb11.01.5650 DFK 3' CDS pGL2178 DFK 12Myc Endogenous tagging GATCAAGCTTACGACGTCCGGATGGGGAGG HinDIII 
 
Table 2-8: List of plasmids generated for endogenous tagging of genes in this study. 
Plasmid Gene ID Gene Name Backbone Description 
pGL2111 Tb927.8.7110 NEK 12.1  pGL1796 pEnT6BG, AmpR. N-Ter GFP-TY-NEK 12.1. Linearise with AgeI. 
pGL2167 Tb09.211.2260 ZFO pHG 80 pEnT6BG derivative. AmpR. N-ter GFP 3HA ZFO UTR/CDS for endogenous taging Linearise with AscI. 
pGL2203 Tb11.01.5650 Diff STE pGL2178 pNAT BSD AmpR 3' CDS of DFK for endogenous C-ter 12Myc tagging. Linearise with PstI. 
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2.2.8 Site Directed Mutagenesis 
Mutations of single bases and deletions of multiple bases were attempted using 
the Quikchange Mutagenesis kit (Stratagene) according to manufacturer’s 
instructions. In the Case of NEK12.1 and NEK12.2 the gene could not be mutated 
in this manner and a gene sewing approach was undertaken using a combination 
of the Quikchange mutagenesis primers and the pET-32 LIC primers. Mutations 
were carried out to change the catalytic lysine of kinase domains. This was 
determined in individual cases by sequence alignment prior to designing oligos to 
replace the endogenous lysine codon to a methionine codon. 
2.2.9 Transformation of Bacteria 
Chemically competent E. coli cells were transformed by heat shock. Plasmid DNA 
was added to 50 l competent cells and incubated on ice for 5 minutes before a 
45 second heat shock at 42oC. Reactions were returned to ice for 2 minutes 
before cells were plated directly onto selective LB agar plates. Ligations and 
recombination reactions were incubated longer (60 min) prior to heat shock and 
reactions were recovered in 200 l of SOC medium for 60 min at 37oC with 
shaking prior to plating.  When transforming with a plasmid carrying kanamycin 
resistance, cells were also recovered for 1 hour prior to plating. 
2.2.10 Genomic DNA Extractions 
Genomic DNA was prepared from cultured T. brucei brucei TREU 927 PCF forms 
using the DNeasy Blood and Tissue kit (Qiagen), following the Cultured Animal 
Cell protocol outlined in the manufacturer’s instructions.  
2.2.11 Preparation of DNA for Trypanosome Transfection 
Five micrograms of a purified plasmid were digested with restriction 
endonucleases appropriate for linearising the plasmid, e.g. the pTL vectors were 
linearised with AscI. Reactions were cleaned up by the addition of 0.1 volume of 
3M sodium acetate pH 5.5 followed by 0.7 volumes of isopropanol then 
centrifugation at 13 000g x 20 min to precipitate and pellet DNA. DNA pellets 
were washed with 70% ethanol and dissolved in 10 l molecular biology grade 
H2O under sterile conditions. 
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2.2.12 RNA Extraction, cDNA Preparation, and qPCR 
For qPCR analysis of RNAi lines a total of 2x107 cells for induced and uninduced 
cultures were harvested at 24h post induction. Total RNA was isolated from the 
cell pellets using the Qiagen RNeasy Kit on the Qiacube (with on column DNaseI 
digest) to minimize RNase contamination.  Samples were then treated again with 
RQ1 RNase-free DNaseI (Promega) to ensure gDNA was totally degraded. All 
pipetting equipment and gloves were cleaned with RNase-ZAP (Sigma Aldrich) 
prior to manipulating RNA samples. Sample concentration and purity were 
estimated using a NanoDrop UV Spectrometer.  
To prepare cDNA, 2 g of total RNA was used as a template in a reverse 
transcriptase reaction using the SuperScript Reverse Transcriptase III system 
(Invitrogen). RT-PCRs were primed with random hexamers (Invitrogen). 
RNaseOUT RNase inhibitor (Invitrogen) was included to reduce sample 
degradation. Following cDNA synthesis E. coli RNase H (Invitrogen) was added to 
degrade the template RNA. Samples were also processed that did not contain 
reverse-transcriptase to monitor for gDNA contamination in the qPCR template. 
qPCR reactions were set up using Applied Biosystems SYBR Green PCR master 
mix, each reaction was performed in quadruplicate and contained 12.5 l 
Mastermix, 2.5 l of each primer (3 M), 5.5 l H20 and 2 l of the template 
cDNA. Reactions were set up in MicroAmp® Optical 96-Well Reaction Plate 
(Applied Biosystems) and sealed with MicroAmp® Optical Adhesive Film (Applied 
Biosystems). Samples were analysed in an Applied Biosystems Prism 7500 using 
the default thermocycling settings with the reaction volume set to 25 l. A 
denaturation step was added to check that only a single product was being 
formed by each primer pair. 
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Table 2-9: List of oligonucleotides used to prime qPCR reactions. 
Oligo Gene ID Gene Sequence 
OL 3701 Tb09.160.3480 TbPDK1 GCTCCGCGAATCATATTACCA 
OL 3702 Tb09.160.3480 TbPDK1 AGCAAGAATCACAAACCCTCTCA 
OL 3703 Tb927.3.3080 NEK6 AAGCCGCGGGATATTTCC 
OL 3704 Tb927.3.3080 NEK6 GTTACCTAAAAACAAGGCCTTCTCA 
OL 3705 Tb927.8.1670 NEK13 AATTCATTGAGTCTTACCTGCAAAAG 
OL 3706 Tb927.8.1670 NEK13 AGGTCCCTCCGCGATTAAAA 
OL 3707 TbCRK3 CRK3 AAACAGCTCTTCGGGAGGTATCT 
OL 3708 TbCRK3 CRK3 CCATCGGCACATATAACATCTAGAA 
OL 3756   Tb927.8.7110 NEK12.1 TGGCGTTGAAACGGTGAAT 
OL 3757 Tb927.8.7110 NEK12.1 GCGGTTGCCGCGTCTA 
OL 3758 Tb927.8.7110 NEK12.1 GGAGTAGTGTAACGCCTCATCGT 
OL 3759 Tb927.8.7110 NEK12.1 CTCGCAATCCTTCCAACCA 
OL3896 Tb11.01.5650 DFK CTCCATCTTCCTCATCCTC 
OL3897 Tb11.01.5650 DFK CACCTCCATCTCCTTCTC 
OL3898 Tb09.211.2260 ZFO CCGAAGGAAAACGCTGAGTT 
OL3899 Tb09.211.2260 ZFO CCACTAGGCCACGACCATTC 
OL3900 Tb927.3.4860 MKK1 GGGAGGAAAATACTTGGGAGTGT 
OL3901 Tb927.3.4860 MKK1 CGCCCCGGCCAATAAT 
OL3902 Tb927.10.5270 MKK5 TCACGACGTGCATTCAAAGG 
OL3903 Tb927.10.5270 MKK5 TGCCGCCGGAGTTCAT 
OL3904 Tb927.4.3420 Wee1 TGACCGGCGCTGTAACTTG 
OL3905 Tb927.4.3420 Wee1 GTGCGCTGAACTGTGAAAGC 
OL3906 Tb927.4.2500 PERK EIF TGACGCGCCGCTCACT 
OL3907 Tb927.4.2500 PERK EIF GCCGACGGCGAATAAGC 
OL3908 Tb11.02.2050 ULK1 TGTTTCCGGAGGGTAATGCT 
OL3909 Tb11.02.2050 ULK1 CGGTGATGCATCTATTGTTTCTTG 
 
2.3 Protein Production and Biochemistry 
2.3.1  Bacterial Cell Lines 
Single colonies of the respective E. coli strain were used to inoculate 2 ml of LB 
medium and incubated overnight at 37 °C. 0.5 ml of this culture was used to 
inoculate 100 ml LB broth which was cultured for several hours until an OD600 of 
0.4 – 0.6 was reached. The culture was chilled on ice for 10 mins, then 
centrifuged at 1000 x g for 15 mins at 4 °C in 50 ml conical flasks (Falcon). The 
cell pellet was resuspended in 33 ml cold RF1 buffer (100 mM RbCl, 50 mM MnCl2 
· 4H2O, 30 mM potassium acetate pH 7.5, 10 mM CaCl2 (dihydrate), 15 % (w/v) 
glycerol, pH adjusted to 5.8 with 0.2 M acetic acid, filter-sterilised), incubated 
for 15 mins on ice and centrifuged again. The pellet was resuspended in 8 ml 
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cold RF2 buffer (10 mM MOPS pH 6.8, 10 mM RbCl, 75 mM CaCl2.2H20, 15 % (w/v) 
glycerol, pH adjusted to 6.8 with NaOH, filter-sterilised) and incubated on ice 
for one hour. The suspension was divided into 50 l single-use aliquots and flash-
frozen in ethanol:dry-ice slurry or liquid nitrogen; aliquots were stored at –80°C. 
Cell lines tested during the optimisation of protein expression included BL21 
(DE3), BL21 (DE3) pLysS, and BL21 (DE3) Rosetta pLysS (Novagen). C41 (DE3) and 
C43 (DE3) were also tested (Dumon-Seignovert et al., 2004).  
2.3.2 Protein Expression 
The proteins examined in detail in this project were the NEK 12 kinases. The 
expression and purification for these was as follows. Rosetta pLysS cells were 
transformed with the appropriate plasmid and plated to yield single colonies. 
Single colonies were used to inoculate 50 ml starter cultures that were grown 
overnight until stationary. These were used to inoculate 1 litre main cultures 
(divided up into 200 ml aliquots in 1.5 litre conical flasks) that were grown at 
37oC with shaking until an OD600 of 0.6 was reached. Cultures were then cooled 
to 15 oC and then induced with 1 mM IPTG. Protein expression was allowed to 
continue overnight at 15 oC with shaking. Cells were harvested by centrifugation 
at 10 000 g for 15 min at 4 oC. Cell pellets were then lysed using BPER (Pierce) 
supplemented with Complete EDTA-Free protease inhibitors (Roche) and clarified 
by centrifugation at 50 000 g for 20 min at 4 oC. 
Large-scale native purifications were performed using an IMAC (immobilised 
metal-ion affinity) column packed with MC-20 matrix (Poros) on an ÄKTA Purifier 
(GE Healthcare). The column was equilibrated with equilibration buffer (50 mM 
NaH2PO4, 300 mM NaCl, 0.5 mM imidazole, pH 8.0), the filtered soluble fraction 
of a bacterial extract was loaded onto the column, washed with 10 column 
volumes of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 50 mM imidazole, pH 8.0) 
and eluted into several fractions with elution buffer (50 mM NaH2PO4, 300 mM 
NaCl, 500 mM imidazole, pH 8.0). Prior to kinase assays the eluted protein was 
buffer exchanged into 50 mM NaH2PO4, 300 mM NaCl, pH 8.0 using a PD-10 
desalting column. 
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2.3.3 SDS-PAGE 
Cell lysates and purified recombinant proteins were size-separated by SDS-PAGE 
(sodium dodecyl phosphate polyacrylamide gel electrophoresis).  For general 
uses 12 % (w/v) polyacrylamide gels were used (or 8 % in the case of DFK 
analyses), with a layer of 5 % stacking gel to focus samples before separation in 
the resolving gel.  Samples were prepared by addition of 2 x SDS-PAGE loading 
buffer (20 % (v/v) glycerol, 2.5 % (w/v) SDS, 0.05 % (w/v) bromophenol blue, 0.2 
M Tris-HCl pH 6.8, 20 mM DTT) and denatured by boiling for 4 minutes.  
Electrophoresis was performed in XCell SureLock Mini Cell chambers (Invitrogen) 
with SDS-PAGE running buffer (2.5 mM Tris, 19.2 mM glycine and 0.01 % (w/v) 
SDS).  The voltage was set at 100 V while samples were in the stacking gel, then 
increased to 180 V as samples progressed through the resolving gel.  With each 
gel, 2 μg of protein marker (Pre-stained Protein Marker Broad Range, New 
England Biolabs or Precision Plus Dual Extra, BioRad) was run as a reference to 
estimated molecular weight of protein samples.   
2.3.4 Coomassie Staining of SDS-PAGE Gels 
SDS-PAGE gels were stained by immersion in Coomassie stain solution (2.5 % 
(w/v) Coomassie Brilliant Blue R-250, 45 % (v/v) methanol, 10 % acetic acid) for 
1 hour at room temperature.  Gels were destained with several changes of 
destain solution (10 % (v/v) methanol, 10% (v/v) acetic acid) overnight at room 
temperature with inclusion of tissue paper to adsorb free dye, following which 
they were equilibrated in distilled water and photographed on the Gel-Doc 2000 
(Biorad) or dried for further analysis e.g. autoradiography. 
2.3.5 Western Blotting  
To analyse by Western blot, samples were separated by SDS-PAGE and 
transferred by ‘wet’ transfer to PVDF Biotrace membrane (Pall) in an X-Cell II 
Blot Module (Invitrogen). PVDF membrane was activated in methanol for 30 s, 
rinsed in ddH2O then equilibrated in transfer buffer (20 % (v/v) methanol, 20 mM 
Tris, 15 mM glycine). The transfer chamber was assembled with all pads and 
filter papers soaked in transfer buffer, then filled with transfer buffer. Transfer 
was performed at 30 volts for 2 hours with the outer chamber filled with water 
to provide a coolant.  After transfer the membrane was blocked with 5 % 
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powdered milk (Marvel) in TBST buffer (25 mM Tris-HCl pH 8, 120 mM NaCl, 0.1 % 
Tween-20) for at least 1 hour (often overnight at 4oC) followed by incubation 
with the appropriate antibodies diluted in blocking solution. Primary antibodies 
diluted in blocking solution were applied to the blot for 1 hour at room 
temperature then washed 3x 10 minutes in TBST.  Secondary antibodies were 
applied in blocking buffer for 1 hour at room temperature. All secondary 
antibodies used were conjugated to horseradish peroxidase (HRP) and antibody 
labelling of protein was revealed by applying an ECL (enhanced 
chemiluminescence) substrate (ECL prime, Amersham; Illuminati Classico or 
Crescendo, Millipore) to the membrane according to manufacturer’s instructions.  
Chemiluminescence was visualised by exposing X-Ray film to the blot and 
developing this in a Kodak Xomat film processor.  
Blots were stripped with by incubation in stripping buffer (glycine 15 g/L, SDS 
1g/L, 1% Tween 20, pH 2.2) twice for 10 min, washing twice in PBS for 10 min 
and washing in TBST twice for 5 min. Blots were then reblocked and reprobed.  
2.3.6 Protein Kinase Assays 
Purified, recombinant NEK 12 proteins (active and dead mutants) were adjusted 
to 100 g/ml in 20 l of KAB (50 mM MOPS, 20 mM MgCl2, 10 mM DTT, 10 mM 
EGTA). A mastermix of KAM was prepared (50 g/ml) containing 100 M ATP (-
32P). Reactions were incubated at 30oC for 30 min with shaking and stopped by 
the addition of 40 l 2x SDS-PAGE buffer and boiling for 3 min. Twenty 
microlitres of this was separated by SDS-PAGE, the gel was dried and placed into 
a cassette with a phosphor-storage screen (Molecular Dynamics) for 4 h to 24 h 
before visualising the screen in a Typhoon 9400 imager (GE Healthcare). 
2.4 Trypanosome Cell Culture 
2.4.1 Cell Lines and General Culturing Techniques. 
The predominant cell line used in this study was Trypanosoma brucei brucei 2T1 
which was gifted by Dr. David Horn. T. b. brucei 427 was occasionally used as a 
wild type control.  
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Trypanosomes were maintained in HMI-11 (HMI-9 (GIBCO), 10% v/v FCS (GIBCO 
10270), Pen/Strep (SIGMA) (penicillin 20 U/ml, streptomycin 20 g/ml)), at 37oC, 
5% CO2 in vented flasks. (Hirumi, H. Hirumi, 1989). When harvesting the cells for 
microscopy they were centrifuged at 800g for 10 mins. For other applications 
they were harvested at 1500g for 5 min (10 min for large volumes). Cells were 
maintained at densities below 2x106 cells/ml. 
Drug concentrations used for BSF T. brucei 2T1 (and derivatives): 5 μg/ml 
hygromycin B (Calbiochem), 2 μg/ml Puromycin, 2.5 μg/ml phleomycin 
(InvivoGen) and 10 μg/ml blasticidin (InvivoGen). Puromycin and phleomycin 
were used in the maintenance of untransfected 2T1s, switching to phleomycin 
and hygromycin after pTL transfection. Blasticidin was used to select for 
transfectants carrying tagging constructs. 
When stabilating a cell line, 10 ml of mid-log cells were pelleted by 
centrifugation at 1500 g x 10 min and resuspended in 4ml HMI-11 + 10% glycerol 
v/v as a cryoprotectant. Aliquots of 1 ml were placed in cryovials 
(AlphaLaboratories, Feel the Seal 1 ml tubes) and placed at -80oC overnight then 
stored long-term under liquid nitrogen.  
2.4.2 Genetic Modification of Trypanosomes 
Bloodstream form parasites were grown to a density of 1x106 cells/ml and 1x107 
cells were gathered for each transfection. Cells were collected by centrifugation 
at 1500 g for 10 minutes. Cells were resuspended in 100 l of Amaxa T-Cell 
transfection buffer (Lonza). Five micrograms of linearised plasmid in 10 l of 
water was added to this mix. Electroporation was conducted using an Amaxa 
Nucleofector 2 (Lonza) set to programme X-001. The transfected cells were 
placed into a 30 ml volume of HMI-11 and then diluted 1:20 and 1:40 in the case 
of RNAi plasmids and 1:10, 1:100 and 1:1000 in the case of vectors with unknown 
transfection efficiency. Selective drugs were added 6 hours after transfection. 
Clones were selected from the plates with the lowest number of positive wells. 
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2.4.3 Growth Curves 
Thirty millilitres of HMI-11 was seeded to a density of 105 cells/ml and divided in 
5 ml aliquots into a 6 well plate (Corning). Three wells were induced with 
tetracycline. Stock tetracycline (Sigma) was made in 70% ethanol at 1 mg/ml 
and added to cultures at 1 g/ml. Negative controls used the same volume of 
70% ethanol. Cells were counted at 24 hour timepoints and cultures maintained 
below 1x106 cells/ml. Cell densities were calculated and dilution factors 
accounted for, allowing a cumulative growth curve to be generated. 
2.4.4 Mouse Infections 
ICR mice were inoculated with varying parasite numbers and RNAi induced at 
varying times depending on the severity of the in culture phenotype (detailed 
below). Inoculum volume was adjusted to 500 l in TDB. The concentration of 
the inoculum varied depending on the expected severity of the phenotype. For 
CRK3 in vivo RNAi mice were inoculated with 5x105 parasites and RNAi was 
induced 48 h post infection. For PDK1, ZFO and NEK 12.1 mice were inoculated 
with 5x104 parasites and RNAi induced 24h post infection. RNAi was induced by 
offering Doxycycline hyclate-laced (Sigma Aldrich D9891-5g), sugar water to 
mice (0.2 g/L plus 50 g/L sucrose). Mice with parasitaemia above 1x108 cells per 
ml were humanely culled. Parasitaemia was monitored using a haemocytometer. 
All animal work was conducted in accordance with Home Office regulations by 
licensed animal handlers. 
2.4.5 Alamar Blue Screening for RNAi Phenotypes 
Cell cultures were adjusted to 2x104 cells per ml and divided into two pools. One 
had RNAi induced by the addition of tetracycline (Sigma) in 70% ethanol to a 
final concentration of 1 g/ml the other treated with an equivalent volume of 
70% ethanol, 200 l of each culture was then plated in triplicate into wells of a 
96 well plate (Corning) and incubated for 48 h. Alamar blue (Resazurin 0.49 mM 
in PBS, 20 l) was added and the plates incubated for a further 24 h. The plate 
was then read at excitation 530 nm and emission 590 nm in an Envision Plate Reader 
(Perkin Elmer). The ratio of the values for induced wells over uninduced wells 
was calculated and used to derive a mean and standard deviation. A value of 1 
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indicated there was no effect of the RNAi on cell proliferation, <1 shows a 
decrease in proliferation and decreases further dependent on the severity of the 
growth defect. 
2.5 Further Analyses 
2.5.1 Flow Cytometry for DNA Content and EP Procyclin 
Pellets of were made from trypanosome cultures (containing 3x106 cells) and 
were washed in Trypanosome Dilution Buffer (TDB; 20 mM Na2HPO4, 2 mM 
NaH2PO4, 80 mM NaCl, 5 mM KCl, 1 mM MgSO4, 20 mM glucose, pH 7.4).  
To determine DNA content of cells by flow cytometry cells were fixed in 70% 
methanol 30%:PBS overnight at 4 oC. Cells were washed in PBS then resuspended 
in PBS + 10 g/ml propidium iodide, 10 g/ml RNase A at 37oC for 45 min. Cell 
fluorescence and scattering parameters were measured on a FACS-Calibur Flow 
Cytometer (Becton Dickinson) using the FL-2A channel.  Data analysis was 
performed using FlowJo software (Tree Star Inc.). 
For the analysis of BSF to PCF differentiation the cells were fixed in 2% 
formaldehyde v/v, 0.05% glutaraldehyde v/v at 4oC for 1 hour, cells were stable 
in this buffer for several weeks but routinely analysed sooner. After washing in 
PBS once, the cells were labelled with FITC-conjugated anti-EP procyclin mouse 
monoclonal IgG1 (CLP001F, clone TBRP1/247, Cedarlane Laboratories, Ontario) at 
a dilution of 1/100 in PBS for 1 hour on ice. Cells were washed once in PBS 
before being resuspended in 1 ml of PBS and filtered through a 40 m Nitex 
mesh to remove aggregates. Cell fluorescence and scattering parameters were 
measured on a FACS-Calibur Flow Cytometer (Becton Dickinson) using the FL-1H 
channel.  Data analysis was performed using FlowJo software (Tree Star Inc.). 
2.5.2 Immunofluorescence for Epitope Tagged DFK 
IFA protocols were provided by Dr Tansy Hammarton, University of Glasgow. 
BSF cells (106) containing an endogenously tagged 12Myc-DFK fusin protein (cell 
line STL2378/STL2379) were pelleted at 800 x g for 10 min. Cells were washed in 
TDB and then resuspended in 100 l PBS before 10 l aliquots were spotted onto 
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poly-l-lysine coated microscope slides (Hendley, Essex) with wells divided by a 
PAP pen (Invitrogen). Cells were allowed to dry onto slides before being place 4% 
formaldehyde (Pierce) in PBS was placed on the wells for 5 minutes then washed 
twice in PBS for 5min per wash. Wells were blocked using PBS/1%BSA for 1 hour. 
This step included 0.1% Triton X100 if a permeabilization step was required. 
Primary antibody was added in PBS for 1 h at room temperature in a humid box. 
The primary was removed and the wells washed twice with 50 l PBS. An 
appropriate secondary antibody was added at 1/200 dilution in PBS and incubate 
for 1 h in a dark humidified box. The secondary antibody was removed and the 
slide washed four times with 100 mM HEPES pH7.5 for 5 minutes before the 
addition of a small drop of VECTASHIELD + DAPI (Vector Laboratories). A cover 
slip was placed on the slide and sealed with nail varnish (Superdrug). 
2.5.2.1 Microscopy 
Routine microscopy was carried out on a Zeiss Axioskop UV microscope equipped 
with an Orca-ER camera (Hammamatsu) and Openlab software (Improvision). 
Images of two or more fluorescence channels and / or brightfield were merged 
using Photoshop CS (Adobe). Some images were obtained from an IN-Cell 
Analyzer 2 (GE Healthcare) and merged using ImageJ (NIH).  
2.5.3 Cell Fractionation 
Crude cell fractionation experiments were conducted by lysing pellets of 2x107 
BSF trypanosomes under different buffer conditions. Pellets were washed in TDB. 
For hypotonic lysis cells were suspended in 500 l of 10 mM Tris-HCl, pH 7.4 and 
lysed with 4 x 15 s bursts of sonication in Fisher FB15047 water bath filled with 
ice-cold water. Detergent lysis was conducted by resuspending cell pellets in 500 
l of 1% Triton X-100, 25 mM HEPES, 1 mM EDTA, pH 7.4 for 30 min on ice. The 
lysates were clarified by centrifugation at 14 000 g for 5 min. In both cases the 
supernatant was mixed with 125 l of 4x SDS-PAGE buffer with boiling for 5 min 
and the pellet was solubilised in 625l of 1x SDS-PAGE buffer with boiling for 5 
min. The fractions were analysed by SDS-PAGE where the equivalent of 1x106 
cells was loaded per sample.  
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2.5.4 Transmission Immuno-Electron Microscopy 
A pellet of 2x107 BSF trypanosomes expressing C-terminally 12xMyc tagged DFK 
(STL2378) was chemically fixed in 0.2% v/v glutaraldehyde, 2% formaldehyde 
w/v in PBS pH7.4 at room temperature for 10 min followed by 1 h on ice. Fixed 
pellets were transferred to the Integrated Microscopy Facility at the University 
of Glasgow, with procedures conducted by Ms Margaret Mullin. The pellets were 
prepared for transmission electron microscopy by the low temperature 
dehydration embedding protocol as follows. 
The fixed cells were rinsed 3x5 min with PBS on ice, dehydrated through ethanol 
series as follows: 
50% Ethanol - 2x5 min on ice. 
70% Ethanol - 3x10min at -40oC. 
90% Ethanol - 3x10 min at -40oC. 
100% Ethanol - 3x10 min at -40oC. 
 
2:1  Absolute Ethanol:HM20 resin – 30 min at -40oC. 
1:1  Absolute Ethanol:HM20 resin – 30 min at -40oC. 
1:2  Absolute Ethanol:HM20 resin – 1 h at -40oC. 
Pure HM20 resin overnight at -40oC 
Several changes of Pure HM20 resin next day (x3) -40oC. 
Cell pellets were embedded in gelatine capsules excluding air with cover slips 
and UV polymerised at -40oC for 24 h. 60-70 nm sections were cut using a Leica 
Ultracut UCT and picked up on 300mesh formvar coated Nickel grids. The sample 
sections were immuno labelled using Mouse Anti-Myc4A6 (Millipore) 1/10 or 
1/100 for 1 h RT and Gold Anti-Mouse 1/20 for 1 h at  room temperature. The 
samples were contrast stained with 0.5% aqueous Uranyl Acetate - 10mins and 
Reynolds Lead Citrate - 5mins before viewing on the TEM Leo 912AB OMEGA. 
Images were captured using Olympus iTEM soft imaging system. 
2.5.5 Immunoprecipitation of DFK 
Cultures of STL2378 BSF trypanosomes containing DFK-12Myc, and T. b. brucei 
2T1 as a negative control, were scaled up to 500 ml to allow the harvesting of 
5x108 – 1x109 parasites. These were pelleted by batch centrifugation at 1500 g 
for 10 min then combined into large pellets that were stored at -80oC until lysis. 
Pellets were lysed in 0.85 ml of lysis buffer (50 mM Tris, 50 mM NaCl, 1% v/v NP-
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40, Complete EDTA-free protease inhibitors (Roche), Phosphatase Inhibitor 
Cocktail II (Merck) – which was also added to all further buffers) on ice for 10 
min with pipetting and then clarified by centrifugation at 10, 000 g for 10 min at 
4oC. These lysates were applied to columns from the c-Myc Tag IP/Co-IP Kit 
(Pierce) – containing mouse anti-cMyc conjugated to agarose beads- and 
incubated at 4oC for 1 h with rotation. The beads were washed three times using 
the TBS buffer supplied with the kit (25 mM Tris, 0.15 M NaCl, pH 7.2) then 
eluted using  the included non-reducing elution buffer (0.3 M Tris•HCl, pH 6.8, 
5% SDS, 50% glycerol). 
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3 Generation and Analysis of a Kinome-Wide RNAi 
Library in Trypanosoma brucei 
3.1 Introduction 
3.1.1 RNA Interference in T. brucei 
Trypanosoma brucei was one of the first organisms in which RNA interference 
was discovered to function and this biological process has been exploited to 
allow functional genetics to probe this organism’s biology. RNAi is a process 
where double stranded RNA is cleaved, processed to form siRNAs which are used 
to direct endonucleases to cleave target RNAs and is an essential part of post-
transcriptional gene regulation and defence against dsRNA viruses and 
transposable elements.  
In a landmark study, Fire and Mello (1998) demonstrated that double-stranded 
RNA could dramatically downregulate the expression of genes in C. elegans when 
present at only a few molecules per cell, at much lower concentrations than 
single stranded anti-sense RNA (Fire et al., 1998). Following shortly from this 
study it was discovered that the introduction of double stranded RNA targeting 
-tubulin caused trypanosomes to round up and become “fat”. Reduction of 
tubulin mRNA and protein expression resulting in disruption of microtubules, 
causing a cytokinetic defect, was found to be the cause (Ngô et al., 1998). 
Further analyses have allowed the identification of much of the RNAi machinery. 
Reviewed recently the process of RNAi is fairly well understood (Atayde et al., 
2011; Kolev et al., 2011). T. brucei possesses two Dicer-like proteins (DCL1 and 
2), one Argonaut (AGO) protein and two RNA interference factors (RIFs) that 
participate in generating the RNAi response. DCL1 is localised in the cytoplasm 
whereas DCL2 is nuclear. These each possess two RNase III motifs (RNase IIIa and 
b), bind dsRNA and cleave it into siRNA duplexes of 24-26nt (Shi et al., 2006). 
These are assisted into TbAGO by TbRIF4 and TbRIF5 leading to the formation of 
the RNA-induced silencing complex (RISC) which separates the passenger strand 
from the duplex (Barnes et al., 2012). This leaves the guide strand in RISC 
allowing it to bind to the complementary target mRNA, which is then cleaved. 
Unlike the RNAi machinery in higher eukaryotes, T. brucei does not appear to 
possess RdRp (RNA dependent RNA polymerase), which allows the amplification 
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of the RNAi response (Kolev et al., 2011). Gene silencing by transfection of 
dsRNA is therefore transient and limited to one cell division cycle (Ngô et al., 
1998). Thus in order to utilise RNAi as a tool for genetic analysis systems had to 
be developed to allow stable transfectants carrying an inducible dsRNA 
expression system to be generated. Trypanosoma brucei is not unique amongst 
the kinetoplastids in possessing the RNAi pathway; T. congolense and Leishmania 
braziliensis both possess functional RNAi and systems have been developed to 
exploit this for functional genetics. However, T. brucei is the most amenable 
organism to work with (Kolev et al., 2011).  
3.1.2 RNAi as a Tool for Investigating Trypanosome Biology 
The implications of being able to selectively inhibit expression of a protein by 
reducing its parent mRNA levels soon led to the development of RNAi as a tool 
for functional genetics. This led to a burgeoning of systems to perform RNAi in 
trypanosomes. The early work to generate stable transfectants carrying 
inducible systems for expressing exogenous or toxic genes was pioneered in the 
laboratories of Christine Clayton (Biebinger et al., 1997) and George Cross (Wirtz 
et al., 1999). These systems were then used to develop systems for expressing 
stem-loop and opposing promoter RNAi fragments (Shi et al., 2000; Wang et al., 
2000). The differing systems have been compared and demonstrate that stem-
loop RNAi, where the sense and anti-sense RNA strands are covalently bound by a 
linker sequence, demonstrate a more potent silencing of the target mRNA 
(Durand-Dubief et al., 2003). A large number of systems have been developed 
since in order to meet particular needs, for example some constructs work more 
effectively in PCF parasites than BSF cells due to the use of the PARP promoter 
to drive transcription. Vectors for use in BSF cells typically rely on the T7 
promoter using cells modified to express T7 RNA polymerase (Shi et al., 2000; 
Alibu et al., 2005). Inducible RNAi constructs that contain deleterious inserts 
must be placed in a transcriptionally inactive region of the genome to ensure 
stable transfection. Vectors that randomly integrate into the ribosomal RNA 
(rRNA) spacer regions are plagued by the problem of inter-clone variability as T. 
brucei possesses 9 rRNA spacer regions in the haploid genome. Some of these are 
more transcriptionally-“silent” than others and the variation in the levels of 
transcription in these regions leads to variability in the expression of any 
cassette entering them (Biebinger et al., 1996). Both the problems of T7 RNA pol 
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toxicity and clonal variability were simultaneously resolved by tagging a single 
rRNA spacer locus and utilising expression vectors with an endogenous rRNA 
promoter (Alsford et al., 2005; Alsford and Horn, 2008). Alsford and co-workers 
modified BSF T. b. brucei Lister 427 to express the tet repressor, then an 
inducible, GFP expressing plasmid (hygR) was transfected in, and resulting cell 
lines were screened for robust expression that was not leaky in un-induced cells. 
After choosing a cell line, the reporter construct was replaced in a manner that 
removed the 5’ region of the hygromycin resistance gene, this cell line was 
termed T. b. brucei 2T1. This could be re-constituted with appropriate plasmids 
containing the 5’ of the hyg gene and an expression cassette under the control 
of a rRNA promoter and a tet operator. The tagged locus is located on 
chromosome 2a and actually resulted in increased transfection efficiency over 
untagged cell lines. Though the cell line only allows the analysis of BSF parasites 
the combination of an endogenous promoter, very low clonal variability and the 
efficacy of the stem-loop RNA produced make it a very reliable system for BSF 
RNAi cell lines. The negatives aspect of the pRPaISL stem-loop RNAi constructs is 
the necessity to clone two inserts in opposing directions using different 
restriction enzymes. This can limit the target sequence selection and requires 
several sub-cloning steps. Our experience of the system was that of a low 
cloning efficiency, making this unsuitable for analysing large cohorts of genes.  
3.1.3 RNAi Screens in T. brucei 
Following the discovery of RNAi in trypanosomes and the generation of the early 
tools for conducting inducible RNAi, a number of studies worked to characterise 
individual genes of interest. As the tools for RNAi in trypanosomes became 
established, efforts began to intensify their use from a mix of candidate studies 
towards systematic interrogation of large numbers of genes or genome-wide 
screens.  
Studies using RNAi on a candidate gene often then followed up initial 
phenotyping with highly detailed experiments to try and ascribe function to the 
target e.g. growth defects can be investigated for cell cycle effects. This can be 
intensive work and is not amenable to high-throughput screening. However, in 
2006 the results of a multi-centre collaboration to perform RNAi studies against 
ORFs on chromosome 1 of were published (Subramaniam et al., 2006). The 
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TrypanoFAN project sought to expand the scale of reverse-genetic studies to at 
least a medium-throughput and targeted 197 of the 369 predicted ORFs on 
chromosome 1 (210 total after inclusion of other genes). VSG genes and 
pseudogenes were excluded, as well as those where RNAi could not be 
guaranteed to be specific (as assessed by the RNAit Software) (Redmond et al., 
2003). The study was a huge task; analysing growth, motility, morphology, cell 
cycle, and the integrity of cellular processes and organelles of bloodstream form 
trypanosomes. Of the 210 knockdowns analysed 33% generated a significant 
phenotype (12% being lethal). The next largest systematic RNAi screen was 
undertaken in the laboratory of Christine Clayton; it targeted 37 genes (the 
products of which were predicted to contain RNA binding motifs) in both BSF and 
PFC trypanosomes and also attempted to localise some of the proteins (Wurst et 
al., 2009). Twenty-five of these genes generated RNAi phenotypes: 8 strong 
defects in BSF, 9 mild defects in BSF and 7 weak defects in PCF. The number of 
contributing workers in both the Wurst and Subramaniam studies highlights how 
labour intensive this type of candidate driven research is. Another, smaller 
screen targeted 30 protein kinase genes by RNAi, but appeared to be limited in 
its success and is discussed below (Mackey et al., 2011). 
In stark contrast to the candidate approach is the genome-wide library 
approach, a technique which allows the response of a huge pool of parasites, 
carrying random RNAi target sequences, to a specific selection pressure or 
method. In 2002 the first ever example of a genome-wide RNAi screen (in any 
organism) was performed in the laboratory of Paul Englund (Morris et al., 2002). 
Genomic DNA was sheared by sonication into target sequences with a mean 
length of 600bp. These were blunt-end ligated into the pZJM vector and used to 
transfect procyclic form trypanosome. Enough trypanosomes were transfected to 
theoretically target the genome 5 times over. As individual, clonal cell lines can 
not be analysed using this technique a selection process is needed to generate 
meaningful data. In this study RNAi was induced and cells were passed over 
concanavalin A sepharose to bind cells that expressed EP procyclin. Cells that 
expressed RNAi targets against genes involved in controlling EP procyclin 
expression would not be bound to the column. Cells that did not bind to the 
column were further purified by FACS sorting and these were cloned out and the 
cultures expanded. The clones were then analysed by sequencing the RNAi 
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plasmid they carried allowing the identification of the target gene; in this case 
the clones that were identified had RNAi targets against the hexokinase gene 
showing that changes in the surface coat could be linked to changes in 
glycolysis. 
This library was used in conjunction with other selection strategies to further 
probe trypanosome biology. One study used the compound tubercidin to select 
for drug resistance phenotypes in RNAi induced procyclic cultures and identified 
hexose transporters as being silenced (Drew et al., 2003). The authors also 
showed that silencing hexokinase also yielded tubercidin resistant parasites, 
implicating glycolysis as being the target pathway for tubercidin (and highlighted 
phosphoglycerate kinase as being the major target of the compound). This type 
of approach has since been used with other RNAi library systems to elucidate 
mechanisms of drug action and resistance of BSF trypanosomes to trypanocidal 
drugs (discussed below). 
Using this type of library without selection, and instead cloning the parasites by 
dilution after transfection of the library, allowed individual cell lines to be 
screened for kDNA defects in another study, however this is a difficult way to 
maximise the returns from this type of library (Zhao et al., 2008). Another study 
utilising this type of approach identified cell cycle regulators including TOR1 and 
TOR2 kinases, but again highlighted the limitations of this type of approach 
(Monnerat et al., 2009). More recently two separate studies used RNAi libraries 
of differing construction to identify the transporters responsible for the uptake 
of melarsoprol and eflornithine and the activator of the nifurtimox pro-drug 
(nitroreductase enzyme) (Baker et al., 2011; Schumann Burkard et al., 2011). 
In a paradigm shift of how genome-wide RNAi libraries are analysed, Alsford and 
colleagues used Illumina Sequencing to analyse in parallel the effect of the 
Englund genome -wide RNAi library, in various life-cycle stages and under various 
conditions (Alsford et al., 2011). The technique, known as RIT-seq (RNA 
interference target sequencing) was made possible due to the development of 
2nd generation sequencing technologies and their subsequent ubiquity in modern 
molecular biology as well as developments to improve the transfection efficiency 
of T. brucei.  
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In order to achieve this increase in transfection efficiency a cell line termed Sce* 
was generated to allow transfection with the Englund RNAi library. This cell line 
inducibly expresses a homing endonucleases I-SceI from a cassette in the rRNA 
spacer region on chromosome 2, a region shown to give high levels of expression 
(Alsford et al., 2005; Glover and Horn, 2009). Tetracycline can be used to induce 
this enzyme several hours before transfection of the RNAi library. The I-SceI 
enzyme then induces double stranded breaks at sites flanking the expression 
cassette in the RRNA spacer region allowing it to be replaced by the RNAi 
cassettes. Transfected cells were drug selected and then RNAi was induced 
under various conditions (BSF, PCF and differentiating cells), DNA was then 
extracted and prepared for Illumina sequencing. Semi-specific PCR and size 
selection were used to enrich the sample for DNA containing part of the RNAi 
vector and an RNAi insert. Following sequencing these were mapped onto the 
genome sequence of T. brucei 927 and allowed the identification of “cold-
spots”. These cold-spots correspond to genes that have been lost from the 
population, indicating that induction or RNAi for that sequence was lethal or 
reduced the parasites growth in the population and allowed identification of 
genes responsible for loss of fitness when silenced. The analysis was estimated 
to cover over 99% of non-redundant protein coding sequences in the genome 
(7435 ORFs) and to target each ORF five-fold. Significant loss of fitness 
phenotypes were reported for 1908 and 2724 CDS in BSF sample induced for 3 
days and 6 days respectively, 1972 in PCF cells and 2677 in differentiating cells.  
The RIT-seq approach has since been applied to other scenarios, which instead 
of looking for loss of fitness phenotypes look for genes which are not essential to 
the parasite and provide a selective advantage in response to certain pressures 
when silenced. In order to identify genes and pathways associated with drug 
action and resistance cultures of RNAi induced cell lines were exposed to lethal 
doses of various trypanocides. Surviving cells were analysed by RIT-seq and 
genes for which RNAi fragments were present were presented as “hot-spots” in 
the analysis, thus linking them to resistance to the individual trypanocidal drugs 
(Alsford et al., 2012). RIT-seq is a powerful technique but is not without is 
downsides. It still relies on having some form of assay that selects for a certain 
phenotype. The technique also relies on a vector containing opposing T7 
promoters. These can be leaky, and T7 RNA polymerase itself is toxic to the 
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trypanosome. The sense and antisense RNA generated is not covalently bound so 
the penetrance of the RNAi effect may be lower than that from an equivalent 
stem-loop vector. Despite the power of genome-wide libraries it is in many cases 
advantageous to generate individual RNAi cell lines to study candidate genes in 
detail. 
3.2 Research Aims 
The aim of this part of the study was to improve the T. brucei 2T1 and pRPaISL 
system to allow RNAi of candidate genes to be performed in larger cohorts than 
previous techniques allowed. The aim was to make a system that would allow 
the screening of the kinome of Trypanosoma brucei brucei.  The RNAi lines would 
be assessed for growth phenotypes and protein kinases considered to be good 
drug targets investigated further. Levels of target gene knockdown would be 
assessed by qPCR. 
3.3 Results 
3.3.1 Generation and Validation of the pTL System 
Cloning of several RNAi constructs was undertaken using the pRPaISL (MCS1) 
vector as a backbone (Alsford and Horn, 2008). In an attempt to generate large 
numbers of RNAi constructs rapidly, a ligation independent cloning strategy 
(Clontech) was attempted, though no success was ever achieved using this 
system (Novy and Yaeger, 1996). Reverting to restriction enzyme cloning proved 
successful but very slow, so alternative methods were sought. It was noted that 
RNAi vectors for use in Arabidopsis thaliana had been developed that used 
Gateway technology to allow high-throughput cloning of constructs (Helliwell et 
al., 2002).   
It was decided to modify the pRPaISL vector to contain repeated, inverted AttP 
sites from the Gateway system (Invitrogen), allowing one step-cloning of a single 
AttB-tagged PCR product into the vector, thus generating stem-loop RNAi 
constructs. The modification was synthesised as a cassette and inserted between 
the BamHI and XbaI sites of the vector backbone by Blue Heron (Bothwell, WA). 
This insert consisted of AttP1-ccdB-AttP2-Stuffer-AttP2-ccdB-AttP1 (Figure 3-1). 
Restriction enzyme sites for ClaI and StuI were inserted to allow digests of sense 
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and anti-sense inserts to assist in confirmation of correct integration of inserts. 
The stuffer-fragment was reduced from a 468bp fragment of the lacz gene to a 
150bp of the same gene to reduce the size of the synthesis and thus reduce the 
cost of the project. Predictions of RNA folding suggested this stuffer would still 
allow hairpin formation (Figure 3-2). Following recombination of an insert the 
RNAi fragment is flanked by 100 nt attL sites, these are also transcribed to dsRNA 
so the sequence was analysed to ensure it would not target part of the 
trypanosome genome. This was not the case and it was not anticipated that non-
specific RNAi phenotypes would be generated.  
Upon delivery of the plasmid a large batch was prepared and tested for purity by 
restriction enzyme digest (Figure 3-3). It was found that due to the inverted 
repeats and double complement of toxic ccdB genes the plasmid was unstable 
when grown at 37oC and was subsequently produced at 25oC.It was dubbed 
pGL2084 in our laboratory’s plasmid database. Derivatives from this plasmid 
were termed pTLs (plasmid-Trypanosome Library), and oligos used to generate 
the RNAi inserts for a gene of interest were called TLO (Trypanosome Library 
Oligo). Collectively this was called the pTL System.  
Figure 3-3 also shows the results of a restriction enzyme digest to validate a 
completed pTL plasmid targeting TbNEK 9 (Tb927.5.2820). pTL2 yields a simple 
digest pattern for exemplifying the mode of verification that was used for 
validating these plasmids. Restriction sites specific to the RNAi target sequence 
can allow additional verification. 
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Figure 3-1: Schematic depicting Gateway cloning of inserts into pGL2084. Panel a. depicts 
main features of the plasmid required for cloning of inserts, integration into the T. b. brucei 
2T1 cell line, and control of RNAi expression. After transfection the expression of the 
complete hyg  gene is controlled by the EP procyclin promoter (PEP) and the RNAi sequence 
by the ribosomal RNA promoter (PRRNA). Panel b. depicts the cloning of an insert into the 
vector and the excision of the ccdB counter selectable marker.  
 
Figure 3-2: Prediction of hairpin folding from the redesigned, 150 nt stuffer fragment of 
pGL2084. RNA structure was predicted using CLC Genomic Workbench to assess whether 
the stuffer fragment would form a loop. 
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 b. Fragment Sizes bp 
  pGL2084 pTL vector   
Enzyme Insert Backbone Insert Backbone 
StuI 1577 6754 ~600 (insert dependent) 5788 
ClaI 1579 6756 ~600 (insert dependent) 5790 
AscI 5729 2610 ~3797 (insert dependent) 2610 
BamHI+XbaI 3337 5002 
1300-1600 (insert 
dependent) 5013 
 
Figure 3-3: Validation of correct cloning by restriction endonucleases digest of pGL2084 
and a correctly recombined plasmid (pTL2). Upper panel contains an example of the 
analysis for the pGL2084 vector and the pTL2 plasmid. Panel b. contains the expected 
fragment sizes for the various digest conditions. 
3.3.2 Validation of the System 
In order to validate this system a construct targeting TbCRK3 was generated and 
transfected into T.b.brucei 2T1. CRK3 is a positive control for an essential gene 
in trypanosomes and Leishmania and was used to prove the modified RNAi 
system could still function. Ablation of this gene by RNAi in trypanosomes rapidly 
results in cell cycle block at the G2/M boundary causing an increase in cells with 
multiple nuclei and kinetoplasts(Hassan et al., 2001; Tu and Wang, 2004). RNAi 
was induced in the cell line STL103 (containing the pTL21 plasmid to target 
CRK3) by addition of tetracycline and cell growth monitored over the following 
72 hours. They were compared to an RNAi line (14006) generated with pGL1987 
(this is derived from the original pRPaISL plasmid), which contains the same 
target sequence against CRK3 but was generated using conventional molecular 
cloning. It lacks the attL sequences found in pTL vectors and the stuffer 
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fragment is also longer, at 500 nt. However, the phenotype was indistinguishable 
between each cell line in terms of the growth defect (Figure 3-4). CRK3 mRNA 
levels were measured by qPCR and showed that both cell lines exhibited 
comparable reduction in target RNA (Figure 3-7).  
 
Figure 3-4: Growth curves of two cell lines targeting CRK3 using different RNAi systems. 
Cell line STL103 was generated using the pTL system and exhibits the same growth defect 
as cell line 14006 which was generated using pGL1875. The RNAi targeting sequence was 
the same in both plasmids. Cell line 14006 was created under an old system of stabilate 
numbering, STL represents the cell lines generated as part of the kinome-wide RNAi screen. 
 
3.3.3 Generation of kinome-wide RNAi plasmid library 
Following validation of the functionality of pGL2084, RNAi inserts were designed 
for the all the protein kinases in the kinome by using RNAit to assess the CDS of 
each gene for suitable target regions. AttB sites were added to the 5’ of each 
gene specific primer sequence and these oligos were used to generate PCR 
inserts. These were purified by gel electrophoresis followed by gel extraction. 
Inserts were cloned into pGL2084 and transformed into DH5MaxEfficiency cells 
due to their high transformation efficiency and their almost total inability to 
propagate ccdB-containing plasmids. After an initial period of optimisation, the 
process was carried out in batches. A QiaCube robot (Qiagen) allowed 
automation of purification steps leading to high quality DNA for Clonase 
reactions, such was the efficiency of these reactions that an average of 12 RNAi 
Time (Hours)
0 24 48 72
C
u
m
u
la
ti
ve
 c
e
ll 
n
u
m
b
e
r 
p
e
r 
m
l
1
110
210
310
410
510
610
710
810
910
14006
14006 +Tet
STL103
STL103 +Tet
82 
 
8
2
 
constructs could be generated per week. The extremely high cloning efficiency 
of the Gateway system allowed the rapid generation of plasmids targeting all the 
genes in the kinome. Due to the inverted, repetitive nature of the DNA in this 
plasmid it proved difficult to sequence for confirmation of correct cloning. The 
AscI digest used to linearise the plasmid appeared to give obvious differences 
between correct and incorrect plasmids so this digest was used to validate the 
plasmids to ensure proper recombination events. 
Since implementing the pTL system we have generated over 250 plasmids for 
various gene families, including a set targeting 190 eukaryotic protein kinases 
(ePKs), atypical protein kinases (aPKs) and pseudokinase genes in Trypanosoma 
brucei. These plasmids were numbered PTL### and the library is named the PTL 
library (Plasmids, Trypanosome Library) 
3.3.4 Generation of RNAi-cell lines 
RNAi plasmids pTLs were purified from E. coli DH5 and linearised using AscI. 
Following ethanol precipitation this DNA was rehydrated and used to transfect 
bloodstream form T.b.brucei 2T1. After cloning by limiting dilution the lines 
were tested for loss of puromycin resistance, with puromycin sensitive clones 
being preferentially selected for analysis. These clones appeared to give more 
consistent and stable RNAi phenotypes. Cell lines were designated with an 
STL###, cryo-stabilated and screened for RNAi growth phenotypes. At least two 
independent clones were generated for each plasmid. 
3.3.5 Alamar blue screening for growth defects under RNAi 
induction 
In order to assess the growth phenotype of a limited number of RNAi clones, the 
gold standard is by counting cells in a Neubauer Improved Haemocytometer. This 
allows the cells to be counted accurately and sick or dead trypanosomes can 
easily be identified. However, this method is time consuming and is totally 
unsuitable for the medium-throughput size of the screen envisaged here. Other 
methods of counting cells were tested, including the Coulter Counter Z2, 
Millipore Sceptre and Invitrogen Countess but all were deemed unsuitable for 
various reasons. Methods of determining cell viability such as the MTT assay and 
alamar blue have been used to measure trypanosome viability and the alamar 
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blue assay has been well optimised for use in T. brucei 427 (Räz et al., 1997). 
This assay was tested against various RNAi lines and was found to be an accurate 
way of detecting growth defects over a range of scenarios, from very weak 
growth defects (NEK 16) to very severe growth defects such as CRK3 and those 
falling in between (PDK1) (Figure 3-5). 
 
Figure 3-5: Growth curves for selected induced RNAi cell lines and a 2T1 control, with the 
corresponding values of the alamar blue assay which measures cell viability at 72h.  
 
RNAi cell lines were assessed using the alamar blue cell viability assay. Induced 
and un-induced cultures were grown for 48h at which time alamar blue was 
added, 24 h after this addition the fluorescence of alamar blue at 590 nm was 
measured after excitation of 530 nm. The fluorescence value ratio for 
induced:un-induced was calculated and a mean of triplicate values generated. 
This value was thus calculated at 72 h after induction of RNA interference. This 
is the standard endpoint in an alamar blue assay and it was deemed to be 
suitable for the needs of this study as the aim was to detect strong phenotypes 
of essential protein kinases. It also allowed for rapid screening of the library to 
allow time for more detailed characterisation of essential/interesting 
phenotypes. Arbitrarily, cell lines showing a reduction in the ratio from 1 to 0.9 
were classified as not showing a loss of fitness phenotype, those <0.9 - 0.5 were 
intermediate and those showing under 0.5 a severe loss of fitness phenotype. 
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Cell morphology was also observed during the course of the screening and very 
obvious phenotypes noted. 
3.3.6 Results of a Kinome-Wide RNAi Screen 
Following the transfection of the pTL RNAi library of plasmids to create 
individual cell lines targeting each protein kinase, two clones were assayed by 
the alamar blue method to detect growth defect phenotypes at 72 hours. This 
allowed the assessment of 190 genes for essentiality either individually or for a 
small subset of closely related genes, in double-knockdowns. Of the 190 genes 
targeted by RNAi constructs, 53 generated loss of fitness phenotypes detectable 
by alamar blue assay in the bloodstream form of the 2T1 strain of Trypanosoma 
brucei brucei (Figure 3-6). Twenty-six of these generated strong growth defects 
(<0.5 AB) (Table 3-1) and 27 generated milder loss of fitness phenotypes (0.5-0.9 
AB) (Table 3-2). The remainder displayed no detectable growth defect by alamar 
blue (Table 3-3). Several of the identified genes resulted from double RNAi 
knockdowns but are known to be non-essential to trypanosomes (discussed 
below). 
These data showed that all families of kinase in Trypanosoma brucei contained 
genes essential to the growth of bloodstream form cells, and that almost all 
contained genes that led to severe growth defects when ablated by RNAi. The 
protein kinases identified here are potential drug targets due to their essential 
role in BSF biology. 
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Table 3-1: Protein kinases determined to have a severe RNAi loss of fitness phenotype as determined by alamar blue ratio. * indicates an RNAi fragment that 
targets more than one gene. Rit-Seq Column denotes the phenotype detected by Alsford et. al. 2011 – LOF; loss of fitness. Whether a clone lost puromycin 
resistance is denoted in the Puro R/S column. If a protein was detected as phosphorylated by Nett et al. 2009 this is denoted in the column BSF Phos. 
Family Name Gene ID RIT-Seq 
Screen 
Clone 1 Puro 
R/S 
Alamar Blue 
Ratio 
Clone 2 Puro 
R/S 
Alamar Blue 
Ratio 
BSF Phos Nett 
et al. 
Ref. 
AGC/NDR PK50 Tb927.10.4940 No LOF Sensitive 0.21 Sensitive 0.86 Y  (Ma et al., 2010) 
aPK-
PIKK/ATR 
ATR Tb11.01.6300 No LOF Sensitive 0.43 Sensitive 0.82     
CK1/CK1* CK1.1 Tb927.5.790 Day 3 BSF Sensitive 0.16 Sensitive 0.16    (Urbaniak, 2009) 
CK1/CK1* CK1.2 Tb927.5.800 Day 6 BSF Sensitive 0.16 Sensitive 0.16 Y  (Urbaniak, 2009) 
CMGC   Tb11.02.3010 No LOF   0.30   0.37     
CMGC/CDK CRK9 Tb927.2.4510 Day 3 BSF Sensitive 0.17 Sensitive 0.18 Y   
CMGC/CDK CRK12 Tb11.01.4130 Day 3 BSF Sensitive 0.20 Sensitive 0.20    (Mackey et al., 2011) 
CMGC/CDK CRK3 Tb927.10.4990 Day 3 BSF Sensitive 0.32 Sensitive 0.27 Y  (Tu and Wang, 2004, 
2005) 
CMGC/CDK CRK2 Tb927.7.7360  No LOF Resistant 0.47 Sensitive 0.29 Y (Tu and Wang, 2004, 
2005) 
CMGC/CLK   Tb11.01.4250 Day 3 BSF Resistant 0.18 Sensitive 0.19     
CMGC/CLK   Tb11.01.4230 Day 3 BSF Sensitive 0.21 Sensitive 0.26 Y   
CMGC/GSK GSK3-
short 
Tb927.10.13780 Day 3 BSF Sensitive 0.46 Resistant 0.61 Y  (Ojo et al., 2008) 
CMGC/MA
PK 
  Tb927.10.5140 Day 3 BSF Sensitive 0.21 Sensitive 0.22     
CMGC/MA
PK 
KFR1 Tb927.10.7780 No LOF Resistant 0.42 Sensitive 0.55    (Hua and Wang, 1994, 
1997) 
CMGC/RCK   Tb927.3.690 Day 6 BSF Resistant 0.23 Resistant 0.18     
NEK* NEK12.2  Tb927.4.5310 Day 6 BSF Sensitive 0.19 Sensitive Growth Curves Y   
NEK* NEK12.1 Tb927.8.7110 No LOF Sensitive 0.19 Sensitive Growth Curves Y   
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Orphan PK6 Tb09.211.2260 Day 3 BSF Sensitive 0.24 Sensitive 0.23 Y   
Other/AUR AUK1 Tb11.01.0330 Day 3 BSF Sensitive 0.19 Resistant 0.19     
Other/AUR   Tb09.160.0570 Day 6 BSF Sensitive 0.35 Resistant 0.46     
Other/TLK* TLK2 Tb927.8.7220 Day 6 BSF Sensitive 0.21 Resistant 0.22    (Li et al., 2007b) 
Other/TLK* TLK1 Tb927.4.5180 No LOF Sensitive 0.21 Resistant 0.22   (Li et al., 2007b)  
STE   Tb927.10.2040 No LOF Sensitive 0.32 Sensitive 0.26     
STE/STE11   Tb11.46.0003 No LOF Sensitive 0.20 Resistant 0.20     
STE/STE20 SLK2 Tb09.211.3820 No LOF Resistant 0.32 Resistant 0.78 Y   
STE/STE20 SLK1 Tb927.8.5730 No LOF Resistant 0.46 Sensitive 0.21 Y   
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Table 3-2: Protein kinases detected to have an RNAi loss of fitness phenotype as determined by an alamar blue assay ration between 0.5 and 0.9. * indicates a 
RNAi targeted more than 1 gene. # indicates a morphological phenotype was detected despite no change in alamar blue value. Rit-Seq Column denotes the 
phenotype detected by Alsford et. al. 2011 – LOF; loss of fitness. Whether a clone lost puromycin resistance is denoted in the Puro R/S column. If a protein 
was detected as phosphorylated by Nett et al. 2009 this is denoted in the column BSF Phos. 
 
Family Name Gene ID RIT-Seq 
Screen 
Clone 1 Puro 
R/S 
Alamar Blue 
Ratio 
Clone 2 Puro 
R/S 
Alamar Blue 
Ratio 
BSF 
Phosphorylation 
Nett et al. 
Ref. 
AGC   Tb927.3.2440  Day 6 
BSF 
Sensitive 0.69 Sensitive 0.62 Y   
AGC TbPDK1 Tb09.160.3480 No LOF Sensitive 0.80 Sensitive  Two identical 
growth curves  
    
AGC/NDR PK53 Tb927.7.5770 No LOF Sensitive 0.84 Sensitive 1.00 Y  (Ma et al., 2010) 
AGC/PKA* PKAC1 Tb09.211.2410 Day 3 
BSF 
Sensitive 0.53 Sensitive 0.50 Y   
AGC/PKA* PKAC2 Tb09.211.2360  Day 6 
BSF 
Sensitive 0.53 Sensitive 0.50     
aPK-ABC1  Tb927.10.9900 No LOF Resistant 0.70 Sensitive 0.88     
aPK-
PIKK/FRAP 
TOR 1 Tb927.10.8420 No LOF Sensitive 0.56 Sensitive 0.62     
aPK-
PIKK/FRAP 
Tor 4 Tb927.1.1930 Day 3 
BSF 
Sensitive 0.71 Sensitive 0.92 Y   
aPK-RIO RIO2 Tb927.6.2840 No LOF Resistant 0.72 Resistant 0.70     
aPK-RIO RIO1 Tb927.3.5400 No LOF Sensitive 0.84 Sensitive 0.98     
CAMK   Tb927.7.6220 No LOF Sensitive 0.77 Sensitive 0.84     
CAMK LDK Tb11.01.0670 No LOF Sensitive 0.81 Sensitive 0.78    (Flaspohler et al., 
2010) 
CAMK   Tb927.7.2750 No LOF Sensitive 0.83 Sensitive 0.75     
CAMK/CAM
KL 
  Tb927.8.870 No LOF Sensitive 0.87 Sensitive 0.87     
CK1/CK1 CK1 Tb927.3.1630 No LOF Sensitive 0.87 Sensitive 1.02     
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CMGC/CDK CRK6 Tb11.47.0031 No LOF Sensitive 0.76 Sensitive 0.76    (Tu and Wang, 2004, 
2005) 
CMGC/CDK CRK1 Tb927.10.1070 Day 3 
BSF 
Resistant 0.81 Resistant 0.76   (Tu and Wang, 2004, 
2005)  
CMGC/DYRK   Tb927.10.9600 No LOF Resistant 0.85 Resistant 0.81     
CMGC/SRPK   Tb927.6.4970 No LOF Sensitive 0.68 Resistant 0.78     
Other/CAM
KK 
  Tb927.10.15300 No LOF Resistant 0.79 Resistant 0.77 Y   
Other/CK2 CK2A1 Tb09.211.4890 No LOF Sensitive 0.63 Sensitive 0.65 Y   
Other/NEK NEK16 Tb927.10.14420 Day 3 
BSF 
Sensitive 0.88 Sensitive 0.86     
Other/ULK   Tb11.02.2050 Day 3 
BSF 
Sensitive 0.70 Resistant 0.87     
pseudo 
Other/NAK 
  Tb09.160.4770 Day 3 
BSF 
Sensitive 0.57 Sensitive 0.71 Y   
pseudo 
Other/ULK 
  Tb11.01.0400 No LOF Resistant 0.83 Resistant 0.77     
Pseudo-
Orphan 
  Tb927.7.3210 Day 6 
BSF 
Sensitive 0.89 Resistant 0.75     
STE/STE11   Tb927.8.1100 No LOF Sensitive 0.84 Sensitive 0.83     
 
 
 
 
  
8
9
 
Table 3-3: Protein kinases for which no loss of fitness phenotype was detected by alamar blue assay. Those marked with an asterisk had a visible 
morphological defect. Rit-Seq Column denotes the phenotype detected by Alsford et. al. 2011 – LOF; loss of fitness. Whether a clone lost puromycin 
resistance is denoted in the Puro R/S column. If a protein was detected as phosphorylated by Nett et al. 2009 this is denoted in the column BSF Phos. 
 
Family Name Gene ID 
RIT-Seq 
Screen 
Clone 1 Puro 
R/S 
Alamar Blue 
Ratio 
Clone 2 Puro 
R/S 
Alamar Blue 
Ratio 
BSF 
Phosphorylation 
Nett et al. 
Ref. 
AGC ZFK Tb11.01.1030 No LOF Resistant 1.00 Sensitive 0.99 Y 
(Vassella et al., 
2001) 
AGC RAC Tb927.6.2250 No LOF Resistant 1.01 Resistant 0.99 
  
AGC 
putative 
PKB 
Tb927.6.2450 Day 3 BSF Sensitive 1.01 Sensitive 0.98 
  
AGC 
 
Tb927.4.4590 No LOF Sensitive 1.04 Sensitive 1.01 
  
AGC/PKA PKAC3 Tb927.10.13010 No LOF Sensitive 1.00 Sensitive 0.99 Y 
 
AGC/RSK 
 
Tb927.3.2690 No LOF Sensitive 0.97 Sensitive 1.01 
  
aPK 
 
Tb927.1.1000 No LOF Sensitive 1.02 Sensitive 1.03 
  
aPK 
 
Tb927.8.7450 
 
Sensitive 1.04 Sensitive 1.02 
  
aPK-A6 
 
Tb927.3.5180 No LOF Sensitive 0.97 Sensitive 1.05 
  
aPK-ABC1 
 
Tb927.10.8730 No LOF Sensitive 0.92 Sensitive 0.93 
  
aPK-ABC1 
 
Tb927.8.4000 No LOF Sensitive 1.01 Sensitive 0.98 
  
aPK-ABC1 
 
Tb927.5.3420 No LOF Sensitive 1.02 Sensitive 1.02 
  
aPK-ABC1 
 
Tb927.10.11940 No LOF Sensitive 1.04 Resistant 1.02 
  
aPK-Bud32 
 
Tb11.03.0290 No LOF Sensitive 0.95 Sensitive 1.00 
  
aPK-PDK 
 
Tb11.02.2390 No LOF Sensitive 1.01 Sensitive 1.02 
  
aPK-PDK 
 
Tb927.4.840 No LOF Sensitive 1.03 Sensitive 1.03 
  
aPK-
PIKK/ATM 
ATM Tb927.2.2260 No LOF Sensitive 0.99 Sensitive 0.98 
  
aPK-
PIKK/FRAP 
TOR 2 Tb927.4.420 No LOF Sensitive 1.00 Sensitive 0.92 
  
aPK- TOR- Tb927.4.800 No LOF Sensitive 1.00 Sensitive 1.03 Y 
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PIKK/FRAP LIKE1 
aPKS 
 
Tb927.4.4970 No LOF Resistant 1.01 ND ND 
  
CAMK 
 
Tb09.160.0500 Day 6 BSF Sensitive 0.98 Resistant 0.95 
  
CAMK 
 
Tb927.5.4430 No LOF Sensitive 0.98 Sensitive 1.00 
  
CAMK 
 
Tb927.4.3770 No LOF Sensitive 0.98 Resistant 1.03 
  
CAMK 
 
Tb927.10.14770 No LOF Sensitive 1.04 Resistant 1.11 
  
CAMK/CAM
KL  
Tb927.2.1820 Day 6 BSF Sensitive 0.92 Sensitive 1.07 Y 
 
CAMK/CAM
KL  
Tb927.10.3900 No LOF Resistant 0.97 Sensitive 1.09 Y 
 
CAMK/CAM
KL  
Tb927.10.5310 No LOF Sensitive 1.01 Resistant 1.01 
  
CAMK/CAM
KL  
Tb927.10.13480 Day 6 BSF Sensitive 1.05 Sensitive 1.06 Y 
 
CAMK/CAM
KL  
Tb927.10.13490 Day 6 BSF Sensitive 1.05 Sensitive 1.06 
  
CAMK/CAM
KL  
Tb927.3.4560 No LOF Sensitive 1.13 Sensitive 1.14 Y 
 
CK1/CK1 
 
Tb927.10.2390 Day 3 BSF Sensitive 1.01 Resistant 0.98 
  
CK1/TTBK 
 
Tb927.4.1700 No LOF Sensitive 1.06 Resistant 1.05 
  
CMGC 
 
Tb927.10.10870 No LOF Sensitive 1.01 Sensitive 1.01 
  
CMGC/CDK CRK4 
(Tu and Wang, 
2004, 2005) 
No LOF Sensitive 0.99 Sensitive 1.01 
  
CMGC/CDK CRK11 Tb927.6.3110 No LOF Resistant 0.99 Resistant 0.98 
  
CMGC/CDK CRK8 Tb11.02.5010 No LOF Sensitive 1.00 Sensitive 1.01 
  
CMGC/CDK CRK7 Tb927.7.1900 Day 6 BSF Sensitive 1.01 Sensitive 1.00 
  
CMGC/CDK CRK10 Tb927.3.4670 Day 6 BSF Sensitive 1.03 Sensitive 1.03 
  
CMGC/CDKL 
 
Tb11.01.0380 No LOF Resistant 1.01 Sensitive 0.95 
  
CMGC/CDKL ECK1 Tb11.01.8550 Day 6 BSF Sensitive 1.02 Sensitive 1.00 Y (Ellis et al., 2004) 
CMGC/CLK 
 
Tb927.2.4200 No LOF Sensitive 1.00 Sensitive 1.01 
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CMGC/CLK 
 
Tb927.3.1610 No LOF Resistant 1.00 Sensitive 1.04 
  
CMGC/DYRK 
 
Tb927.7.3880 Day 6 BSF Sensitive 0.97 Resistant 0.97 
  
CMGC/DYRK 
 
Tb927.7.4090 No LOF Sensitive 0.99 Sensitive 0.98 
  
CMGC/DYRK 
TbDYRK
2 
Tb11.02.0640 Day 3 BSF Sensitive 1.01 Sensitive 1.01 Y 
 
CMGC/DYRK 
 
Tb927.10.15020 No LOF Sensitive 1.01 Sensitive 1.01 Y 
 
CMGC/DYRK 
 
Tb927.5.1650 No LOF Resistant 1.02 Sensitive 1.01 
  
CMGC/DYRK PK4 Tb927.10.350 No LOF Resistant 1.03 Resistant 1.02 Y 
 
CMGC/GSK 
GSK3-
long 
Tb927.7.2420 No LOF Sensitive 0.92 Sensitive 1.07 
 
(Ojo et al., 2008) 
CMGC/MAP
K 
mapk3 Tb927.8.3550 No LOF Sensitive 0.95 Resistant 1.01 
  
CMGC/MAP
K 
mapk Tb927.8.3770 No LOF Resistant 0.97 Resistant 0.98 Y 
 
CMGC/MAP
K  
Tb927.10.12040 No LOF Resistant 0.97 Resistant 1.00 
  
CMGC/MAP
K 
MAPK4 Tb927.6.1780 No LOF Resistant 1.00 Resistant 0.95 Y 
(Güttinger et al., 
2007) 
CMGC/MAP
K 
MAPK2 Tb927.10.16030 No LOF Resistant 1.00 Sensitive 0.97 Y 
(Müller et al., 
2002a) 
CMGC/MAP
K 
MAPK5 Tb927.6.4220 Day 6 BSF Sensitive 1.01 Sensitive 1.01 Y 
(Domenicali Pfister 
et al., 2006a) 
CMGC/MAP
K  
Tb927.10.3230 No LOF Sensitive 1.02 Resistant 1.03 Y 
 
CMGC/RCK MAPK9 Tb927.10.14800 No LOF Sensitive 1.01 Sensitive 1.02 Y 
 
CMGC/RCK-
MAPK 
MOK Tb09.211.0960 No LOF Sensitive 0.93 Sensitive 0.94 Y 
 
CMGC/SRPK 
 
Tb927.7.960 No LOF Sensitive 1.00 Sensitive 1.01 
  
NEK NEK6 Tb927.3.3080 No LOF Sensitive 0.94 Sensitive 0.99 
  
NEK NEK-19 Tb927.10.1380 No LOF Resistant 0.98 Sensitive 0.98 
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NEK NEK-22 Tb927.2.2120 No LOF Resistant 0.98 Resistant 1.01 
  
NEK NEK-10 Tb927.6.3430 No LOF Sensitive 0.99 Resistant 0.95 
  
NEK NEK-21 Tb11.01.6650 No LOF Sensitive 0.99 Sensitive 0.99 
  
NEK NEK-15 Tb09.160.0450 No LOF Sensitive 0.99 Sensitive 1.01 
  
NEK NEK-9 Tb927.5.2820 No LOF Sensitive 1.00 Sensitive 1.01 
  
NEK NRKA Tb927.4.5390 No LOF Resistant 1.00 Resistant 0.99 
  
NEK NRKB Tb927.8.6930 No LOF Resistant 1.00 Resistant 0.99 
  
NEK NEK20 Tb11.01.2900 Day 6 BSF Resistant 1.01 Sensitive 1.01 
  
NEK NRKC Tb927.10.460 No LOF Resistant 1.02 ND ND Y 
 
NEK NEK11 Tb927.7.3580 No LOF Sensitive 1.03 Sensitive 1.01 
  
NEK NEK7 Tb927.3.3190 No LOF Sensitive 1.03 Sensitive 1.04 
  
NEK* NEK-14 Tb927.8.1670 No LOF Sensitive 0.96 Resistant 0.97 
  
NEK* NEK-14 Tb927.8.1690 No LOF Sensitive 0.96 Resistant 0.97 
  
NEK* NEK-17 Tb927.10.5950 No LOF Resistant 0.99 Resistant 1.02 Y 
 
NEK* 
 
Tb927.10.5940 No LOF Resistant 0.99 Resistant 1.02 Y 
 
NEK* 
 
Tb927.10.5930 No LOF Resistant 0.99 Resistant 1.02 
  
Orphan 
 
Tb927.10.3340 No LOF Sensitive 0.99 
 
1.01 Y 
 
Orphan 
 
Tb927.3.3290 No LOF Sensitive 1.00 
ND-growth 
curves I think 
n/a 
  
Orphan 
 
Tb11.03.0340 No LOF Sensitive 1.00 Sensitive 1.01 Y 
 
Orphan 
 
Tb11.01.2290 Day 3 BSF Sensitive 1.01 Sensitive 0.98 
  
Orphan 
 
Tb11.02.3640 No LOF Resistant 1.01 Resistant 1.03 
  
Orphan KinER5 Tb927.5.3150 No LOF Sensitive 1.01 Sensitive 1.01 
  
Orphan 
 
Tb09.160.0930 No LOF Sensitive 1.02 Sensitive 1.05 
  
Orphan 
 
Tb927.8.5500 No LOF Sensitive 1.02 Sensitive 1.00 
  
Orphan 
 
Tb927.10.1460 No LOF Resistant 1.02 Sensitive 1.01 
  
Orphan 
 
Tb927.5.3160 No LOF Sensitive 1.03 ND n/a 
  
Orphan 
 
Tb11.02.4530 No LOF Sensitive 1.03 Sensitive 1.02 
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Orphan 
 
Tb927.3.1850 No LOF Sensitive 1.03 Sensitive 1.01 Y 
 
Orphan 
 
Tb927.3.1570 No LOF Resistant 1.03 Resistant 1.07 
  
Orphan 
 
Tb927.10.15880 No LOF Resistant 1.04 Resistant 1.01 
  
Orphan 
 
Tb927.10.16160 No LOF Sensitive 1.05 Sensitive 1.04 
  
Orphan FlaK Tb927.2.2720 No LOF Sensitive 1.05 Sensitive 1.02 
  
Orphan 
 
Tb927.1.3130 No LOF Sensitive 1.06 Sensitive 1.01 
  
Orphan 
 
Tb927.8.4260 No LOF Resistant 1.06 NA NA 
  
Orphan 
 
Tb09.160.1090 No LOF Resistant 1.08 Resistant 1.07 
  
Other/AUR 
 
Tb927.3.3920 Day 3 BSF Sensitive 1.00 Sensitive 1.01 
  
Other/CAM
KK  
Tb11.02.4860 No LOF Sensitive 1.02 Resistant 1.04 Y 
 
Other/CAM
KK  
Tb11.02.4830 Day 3 BSF Resistant 1.04 Resistant 1.06 
  
Other/CAM
KK  
Tb927.8.6490 No LOF Sensitive 1.06 Resistant 1.05 
  
Other/CK2 CK2A2 Tb927.2.2430 No LOF Sensitive 1.04 Sensitive 1.01 
  
Other/PEK TbEIFK1 Tb11.02.5050 No LOF Sensitive 1.01 Sensitive 1.01 
  
Other/PEK TbEIFK3 Tb927.6.2980 No LOF Sensitive 1.04 Resistant 1.03 
  
Other/PEK EIF2K2 Tb927.4.2500 No LOF Sensitive 1.05 Sensitive 1.03 
  
Other/PLK PLK Tb927.7.6310 Day 3 BSF Sensitive 0.93 Sensitive 0.93 Y 
(Li et al.; 
Hammarton et al., 
2007; de 
Graffenried et al., 
2008; Umeyama 
and Wang, 2008; 
Sun and Wang, 
2011; Ikeda, 2012) 
 
Other/PLK 
 
Tb927.6.5100 No LOF Sensitive 1.01 Sensitive 0.97 
  
Other/VPS1
 
Tb11.01.0930 No LOF Sensitive 1.03 Resistant 0.91 
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5 
Other/WEE Wee1 Tb927.4.3420 No LOF Sensitive 0.98 Resistant 0.99 
  
pseudo 
CAMK  
Tb927.2.5230 Day 3 BSF Sensitive 1.03 Resistant 1.02 
  
Pseudo-
CAMK/CAM
KL 
 
Tb927.10.1940 No LOF Sensitive 1.03 Resistant 1.02 
  
Pseudo-
Orphan  
Tb11.01.1050 No LOF Resistant 0.91 Resistant 1.00 Y 
 
Pseudo-
Orphan  
Tb927.5.3320 No LOF Sensitive 1.00 Resistant 0.97 
  
Pseudo-
Orphan  
Tb927.7.3190 No LOF Sensitive 1.01 Sensitive 1.00 
  
Pseudo-
Orphan  
Tb927.4.2460 No LOF Resistant 1.01 Resistant 1.00 
  
Pseudo-
Orphan  
Tb09.211.1570 No LOF Resistant 1.02 Resistant 1.01 
  
Pseudo-
Orphan  
Tb09.160.0990 No LOF Resistant 1.04 Resistant 1.00 
  
Pseudo-
Orphan  
Tb11.01.6100 No LOF Resistant 1.07 ND n/a 
  
STE 
 
Tb927.8.5950 No LOF Sensitive 0.97 Resistant 0.96 Y 
 
STE 
 
Tb927.3.2060 No LOF Sensitive 0.97 Sensitive 1.00 Y 
 
STE 
 
Tb927.1.1530 No LOF Sensitive 0.99 Sensitive 1.04 Y 
 
STE kinER4 Tb927.3.5650 No LOF Sensitive 1.00 Resistant 0.99 
  
STE 
 
Tb11.01.5880 No LOF Sensitive 1.00 Sensitive 1.03 Y 
 
STE MKK1 Tb927.3.4860 No LOF Resistant 1.02 Resistant 1.00 
 
(Jensen et al., 2011) 
STE/STE11 
 
Tb927.7.6680 No LOF Sensitive 0.96 Sensitive 0.95 
  
STE/STE11 KinER3 Tb09.211.3410 No LOF Sensitive 0.98 Sensitive 0.97 
  
STE/STE11 
 
Tb927.6.2030 No LOF Sensitive 0.98 Sensitive 0.97 Y 
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STE/STE11 
Forkhea
d Kinase 
Tb927.7.5220 No LOF Resistant 0.99 Sensitive 1.14 
  
STE/STE11 
 
Tb927.10.10350 No LOF Sensitive 0.99 Resistant 1.01 
  
STE/STE11 
 
Tb927.8.6810 No LOF Sensitive 1.00 Sensitive 1.08 
  
STE/STE11 
 
Tb927.10.14300 Day 6 BSF Sensitive 1.00 Sensitive 1.00 Y 
 
STE/STE11 KinER2 Tb09.160.1780 No LOF Resistant 1.00 Resistant 1.01 
  
STE/STE11 
 
Tb927.10.14780 Day 6 BSF Sensitive 1.03 Sensitive 1.00 
  
STE/STE11 
 
Tb927.10.1910 No LOF Sensitive 1.04 Sensitive 1.01 
  
STE/STE11 
 
Tb927.7.3650 No LOF Sensitive 1.09 Sensitive 1.00 
  
STE/STE11# 
DFK/Kin
ER1 
Tb11.01.5650 No LOF Sensitive 0.96 Sensitive Growth Curves 
  
STE/STE7 
 
Tb927.8.1780 No LOF Resistant 1.00 Sensitive 1.00 
  
STE/STE7 MKK5 Tb927.10.5270 No LOF Resistant 1.02 Sensitive 1.02 
 
(Jensen et al., 2011) 
 
  
9
6
 
 
Figure 3-6: Results of a kinome-wide RNAi screen. The kinome has been divided into the major families and broken down by RNAi alamar blue phenotype, Red 
bars depict strong RNAi phenotypes (alamar blue value <0.5) and Orange bars denote moderate phenotype (0.5-0.9 alamar blue value).
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Some RNAi constructs targeted multiple genes (for example TLK1/TLK2 and 
CK1.1/CK1.2), due to the similarity of the CDS regions used to design the RNAi 
inserts (listed in Table 3-4). Several of these have been the subject of more 
detailed, published studies. The RNAi target sequences used in this study were 
designed against the CDS of the genes and did not include UTRs, which may have 
limited the level of specificity achieved. TLK2 was shown not to be essential in 
PCF trypanosomes while TLK1 was essential, specificity being achieved by 
targeting the 3’ UTR (Li et al., 2007b). TLK1 was later shown to be essential for 
BSF forms by RNAi, but no work to characterise TLK2 was shown for BSF parasites 
(Li et al., 2008). CK1.1 and CK1.2 have unambiguous evidence to define their 
essentiality in BSF parasites as CK1.1 has been knocked-out in BSF parasites with 
no detectable growth defect in culture.CK1.2 was shown to be essential in BSF 
by RNAi which targeted a region of the 5’ UTR and the CDS unique to CK1.2. 
Other genes targeted by dual RNAi have suggestions of essentiality by RIT-Seq 
analysis, though during this analysis redundant reads were discarded which may 
impact on the detection of loss of fitness phenotypes on highly similar genes 
(Alsford et al., 2011). The two CLKs (Tb11.01.4230 and Tb11.01.4250) are dually 
targeted by two plasmids (pTL81/82); this seemed to be due to an error in RNAit 
where it did not identify them as paralogues. These have been re-designed to 
produce individual RNAi plasmids but remain to be tested. 
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Table 3-4: List of RNAi plasmids targeting multiple genes. The pTL screen phenotypes are 
depicted by colour (red: strong, orange: intermediate, grey: not detected) and the published 
phenotype and reference included for comparison. Note that by the RIT-Seq technique the 
phenotype is difficult to determine due to high sequence homology between the genes in 
this table.  
Plasmid Family 
Genes 
Targeted 
Name  Published Phenotype Reference 
pTL 46 
AGC/PKA Tb09.211.2410 PKAC1 LOF phenotype BSF by RIT-Seq (Alsford 
et al., 
2011) AGC/PKA Tb09.211.2360  PKAC2 No LOF Phenotype by RIT-Seq 
            
pTL 204 
CK1/CK1 Tb927.5.790 CK1.1 Not essential by double knockout (Urbaniak, 
2009) CK1/CK1 Tb927.5.800 CK1.2 Essential by RNAi 
            
pTL 167 
Other/TLK Tb927.8.7220 TLK2 Not essential by RNAi (PCF) (Li et al., 
2007b) Other/TLK Tb927.4.5180 TLK1 Essential by RNAi (BSF/PCF) 
            
pGL 
2064 
Other/NEK Tb927.4.5310 NEK12.2  LOF phenotype BSF by RIT-Seq (Alsford 
et al., 
2011) Other/NEK Tb927.8.7110 NEK12.1 No LOF Phenotypes by RIT-Seq 
            
pTL81 CMGC/CLK Tb11.01.4230 
Tb11.01.4250 
 
LOF phenotype BSF by RIT-Seq (Alsford 
et al., 
2011) pTL82 CMGC/CLK  
LOF phenotype BSF by RIT-Seq 
      
pTL 7 
Other/NEK Tb927.10.5950 NEK-17 No LOF detected by RIT-Seq (Alsford 
et al., 
2011) 
Other/NEK Tb927.10.5940   No LOF detected by RIT-Seq 
Other/NEK Tb927.10.5930   Possible LOF BSF Day 6 
            
pTL 4 
Other/NEK Tb927.8.1670 NEK-14 No LOF detected by RIT-Seq (Alsford 
et al., 
2011) Other/NEK Tb927.8.1690   No LOF detected by RIT-Seq 
 
The expanded family of NEK kinases did not demonstrate a high number of hits 
during this screen. A severe growth phenotype was detected when two closely 
related NEK kinases, NEK12.1 and NEK 12.2 (Tb927.8.7110 and Tb924.4.5310), 
were jointly targeted by one RNAi fragment. Another NEK kinase, 
Tb927.10.14420, produced a very small reduction in growth when ablated by 
RNAi. The family of diverged, Orphan kinases appeared to be a poor family for 
providing new drug targets; only one, Tb09.211.2260, generated a loss of fitness 
phenotype of any note, though this was a strong phenotype and as such was 
investigated further. 
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The AGC family generated 6 hits, including PK50, a gene known to be essential in 
BSF parasites(Ma et al., 2010). For PK53, another essential AGC family protein 
kinase (Ma et al., 2010), knockdown generated an inconsistent phenotype with 
one cell line indicating a mild growth defect and another not.  The CAMK 
(calmodulin –dependent protein kinase) family generated 4 hits, showing 
moderate growth defects. This included the lipid-droplet kinase known to 
generate an RNAi growth defect in BSF parasites (Flaspohler et al., 2010).The 
CMGC family contained a large number of protein kinases that generate severe 
phenotypes under RNAi induction. This included many of the CRKs that have 
been previously studied by RNAi. We detected CRK1 and CRK3 and CRK12 as 
generating an RNAi phenotype, similar to previous work (Tu and Wang, 2004; 
Mackey et al., 2011). The pTL analysis also detected CRK2, CRK6 and CRK 9 as 
having growth defects under RNAi induction. GSK3-short was detected as 
generating a strong phenotype (Ojo et al., 2008). Several of the MAPK family and 
related RCK group were identified as generating a severe growth defect 
(Tb927.10.5140, Tb927.10.7880, Tb927.3.690). In the smaller subfamilies of the 
CMGC group a dual-specificity protein kinase (Tb927.10.9600) as well as a serine-
arginine rich protein kinase (Tb927.6.4970) was detected as generating 
intermediate growth defects.  
The potential upstream activators of the MAPKs are typically found in the STE 
family and this provided several hits generating severe and intermediate growth 
defects. Tb927.10.2040, Tb11.46.0003, Tb09.211.3820, Tb927.8.5730 generated 
severe growth defects with Tb927.8.1100 generating an intermediate growth 
defect. Tb09.211.3820 and Tb927.8.5730 are STE20 family protein kinases (SLK1 
and SLK2) which may represent the top of MAPK cascades (MAPKKKK).  
Tb11.46.0003 and Tb927.8.1100 are STE11 type protein kinases which may act as 
MAPKKKs. Tb927.10.2040 is an undefined STE type kinase. The STE11 protein 
kinase Tb11.01.5650 did not generate an alamar blue value but displayed 
interesting morphological changes which are discussed in Chapter 5. 
In the “Other” group of protein kinases the pTL screen identified two of the 
three Aurora kinases, Tb11.01.0330 (TbAuk1), Tb09.160.0570 (TbAuk3). CK2A1 
(Tb09.211.4890) was also identified as generating an RNAi phenotype. RNAi of 
the predicted CAMKK (calmodulin–dependent protein kinase kinase) 
Tb927.10.15300 also generated a mild growth defect. The ULK homologue, and 
100 
 
1
0
0
 
potential regulator of autophagy Tb11.02.2050, was observed to cause a growth 
defect under RNAi ablation. 
Several members of the pseudokinase family also showed loss of fitness 
phenotypes hinting at a regulatory role for these non-catalytic relatives of 
protein kinases. However, as they are predicted to be inactive they would make 
poor drug targets. The pTL screen of atypical protein kinases also yielded known 
essential genes such TOR1 and TOR4 (Barquilla et al., 2008, 2012). 
3.3.7 Validation of mRNA Knockdown by qPCR 
In order to assess the level of mRNA knockdown of the target gene a number of 
cell lines were assessed by quantitative PCR using the/Ct method (to achieve 
relative quantitation). For any given target gene, primer pairs were designed for 
regions not targeted by the RNAi cassettes. These primer pairs were tested for 
efficiency using a titration of genomic DNA from 2 ng to 0.125 ng. Primers that 
exhibited efficiency significantly different to that of the endogenous control 
(which was approximately 100%) were redesigned to allow accurate comparison 
by the/Ct method. Primers were also assessed by dissociation curve analysis 
to ensure only 1 PCR product was generated. 
Total RNA was extracted from induced and uninduced cultures, treated with 
DNaseI to remove genomic DNA and then converted to cDNA using reverse 
transcriptase with random hexamer primers. Control reactions lacking reverse 
transcriptase were included to allow detection of gDNA contamination in the 
samples. cDNA reactions were used as templates in qPCR reactions. GPI8 primers 
were used in endogenous control reactions and relative mRNA values were 
determined using the /Ct method using the uninduced, reverse transcribed 
templates as the reference sample. 
Transcripts were significantly reduced for 8 of the 9 genes studied by qPCR 
(Figure 3-7). mRNAs for target genes were typically reduced by 40-60%. RNAi of 
CRK3 using the original pRPAISL/pGL1875 and the pTL-based vector were not 
significantly different. RNAi of MKK5 did not lead to a significant reduction in 
mRNA levels, though a downward trend was observed. Further validation of 
knockdown for a NEK12.1, ZFO, and DFK genes was carried out using western 
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blotting to assess protein levels of endogenously tagged alleles (see following 
chapters). 
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Figure 3-7: Bar chart showing the mean relative quantification of mRNA in induced and 
uninduced RNAi cell lines. Error bars represent the standard deviation of RQ values from 
the 4 technical replicates used to generate the mean. Significance of the result (as derived 
from unpaired t-test) is indicated above bars for each gene (*: p  0.01 to 0.05, **: p0.001 to 
0.01, *** : p< 0.001). Identifiers for genes can be found in Table 3-1, Table 3-2 and Table 3-3.  
 
3.4 Discussion 
3.4.1 Comparison of pTL Screen to Candidate Studies 
The pTL RNAi libraries efficacy was validated by its ability to rediscover 
previously confirmed phenotypes (Table 3-5). The initial validation of the system 
was performed against CRK3, a known essential gene in trypanosomes (Tu and 
Wang, 2004). Other candidate genes such as TLK1 and CK1.2 were detected as 
essential (though the pTL RNAi also co-targeted their related genes TLK2 and 
CK1.1 respectively.) Detailed studies have determined the importance of TLK1 
and CK1.2 individually, so pTL RNAi constructs targeting them individually were 
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not developed (Li et al., 2007a; Urbaniak, 2009). Several genes which have been 
knocked out of monomorphic BSF parasites did not generate growth defects 
when targeted in RNAi lines; these include ZFO, MKK1, MKK5, MAPK 2, MAPK 4 
and MAPK 5 (although for MKK5 mRNA levels were not detected as significantly 
reduced by qPCR). This confirmed the prediction that double stranded RNAi 
coming from the transcribed attL sites had no disruptive effect on trypanosome 
biology. These data combined with the qPCR validation suggest that the pTL RNAi 
is operating effectively and reliably, allowing confidence to be placed in the 
accuracy of this screen. 
Table 3-5: Table of pTL phenotypes confirming previously published work on BSF 
trypanosomes. 
Kinase 
pTL 
Phenotype Published BSF Phenotype Ref. 
CRK3 
 
Essential by RNAi (Tu and Wang, 2004) 
Auk1 
 
Essential by RNAi (Li and Wang, 2006)  
TLK1 
 
Essential by RNAi (Li et al., 2007b) 
CK1.2 
 
Essential by RNAi (Urbaniak, 2009) 
GSK3-s 
 
Essential by RNAi (Ojo et al., 2008) 
PK50 
 
Essential by RNAi (Ma et al., 2010) 
PK53 
 
Essential by RNAi (Ma et al., 2010) 
LDK 
 
Mild growth defect RNAi (Flaspohler et al., 2010) 
TOR1 
 
Essential by RNAi (Barquilla et al., 2008) 
MKK1 
 
Non-essential by double 
knockout (Jensen et al., 2011) 
MKK5 
 
Non-essential by double 
knockout (Jensen et al., 2011) 
MAPK
2 
 
Non-essential by double 
knockout (Müller et al., 2002b) 
MAPK
4 
 
Non-essential by double 
knockout (Güttinger et al., 2007) 
MAPK
5 
 
Non-essential by double 
knockout 
(Domenicali Pfister et al., 
2006a) 
ZFK 
 
Non-essential by double 
knockout (Vassella et al., 2001) 
 
It should be noted that in some instances (notably for the several metacaspases) 
performing a gene knockout can show a gene is not essential whereas RNAi can 
generate a strong phenotype; however, this was not observed in this study for 
protein kinases that have been knocked out in previous works (Helms et al., 
2006; Proto et al., 2011). Also the strain of trypanosomes can have an effect on 
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the observed phenotype. Pleiomorphic trypanosome lines (capable of efficient 
tsetse fly transmission) can show deleterious effects of genetic interference 
whilst monomorphic lines do not (Vassella et al., 2001). Deletion of ZFK causes 
no defect in the proliferation of monomorphic MITat 1.4 cell line but leads to a 
growth defect in AnTat 1.1 after about 4 days in culture.  The 2T1 strain is 
considered monomorphic and may give an underrepresentation of genes that 
may be essential to pleiomorphic cell lines.  
The study by Mackey et al. generated an RNAi library targeting 30 genes in the 
BSF trypanosome kinome and analysed the cell lines using a luciferase based HTS 
assay (Mackey et al., 2011). However, the results correlated poorly with the pTL 
Screen data and the RIT-seq data. mRNA downregulation was only confirmed for 
2 genes and the study was conducted using the pZJM system which is now 
considered a less  reliable method for performing RNAi in BSF trypanosomes due 
to the range of sites it can integrate into the genome (Mackey et al., 2011).  
3.4.2 Comparison to RIT-Seq Data 
The genome-wide study for loss of fitness phenotpyes by Alsford et al. has 
provided a large data set against which to compare our kinome-wide RNAi. For 
the majority of the genes studied the same phenotype was found. To simplify the 
analysis, RNAi targets against multiple genes were ignored. For the remaining 
177 genes agreement on phenotype was found for 129. RIT-Seq did not identify a 
phenotype in a group of 27 genes for which the pTL screen generated a loss of 
fitness phenotype. This may be due to the RIT-seq approach lacking the 
resolution to detect some RNAi phenotypes if that region of the genome is 
under-represented in the RNAi library. Differences in the strain of parasite used 
and the RNAi system (with the stem-loop being more effective in the pTL screen) 
may account for the observed differences.  
Twelve genes identified in the RIT-Seq data as generating loss of fitness 
phenotypes at Day 6 were not identified in the pTL screen. The pTL screen 
analysed cell lines at 72 hours, as we were aiming to detect strong phenotypes 
that may be more attractive drug targets. Thus we may have not detected these 
more subtle phenotypes that only become apparent after 72 hour. RNAi 
phenotypes requiring longer to appear may indicate that the kinase in question 
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is not an ideal drug target. The alamar blue assay required cells to be seeded at 
2x104 cells per ml and for 72 h- this may have masked very minor phenotypes. 
Performing growth curves of these cell lines only identified one that generated a 
growth defect after 6 days, Tb927.2.1820 (M Saldivia, Unpublished). 
Possibly the most relevant cohort for scrutiny is the 9 genes for which RIT-seq 
generates a strong phenotype but the pTL screen does not. These may represent 
false negatives in the pTL screen or false positives in the RIT-seq screen.  One 
example is the well characterised gene PLK (see below).  
3.4.3 False Negatives 
As with any large-scale screen, we expected some false negatives. This was 
clearly demonstrated by our inability to generate an RNAi phenotype for PLK, 
where RNAi should lead to cytokinetic defects and growth arrest within 8 hours  
(Hammarton et al., 2007). This was despite targeting the gene with two separate 
RNAi fragments in multiple different transfections. Initially it was assumed that 
the RNAi could be “leaky” while selecting for transfectants, however, we could 
still generate RNAi lines for other critically essential genes. The same batch of 
serum was used for all transfections (Gibco 10270), is marketed as tetracycline 
free and transfections for other essential genes proceeded unhindered; so this 
was not believed to be causing expression of the RNAi cassette.  Quantification 
of PLK mRNA knockdown has not yet been performed and as such there is no 
data to show whether the RNAi is actually downregulating the gene.  
A small cohort of 9 genes were detected by Alsford et al. as having a loss of 
fitness phenotype after 3 day RNAi in BSF parasites and were not detected in the 
pTL screen. These genes have not been independently validated but the RIT-seq 
data suggest that these may be false negatives in our screen. However, these 
could also be false positives in the RIT-seq data due to low sequence coverage 
over that particular gene; for example, cell density at time of induction may 
also play a role in the detected phenotype. TOR 2 RNAi did not produce a growth 
defect by alamar blue assay or RIT-seq but when growth curves were performed 
after seeding the cells at 104 per ml a growth defect replicating the published 
phenotype was observed (W. Proto, Unpublished) (Barquilla et al., 2008). 
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The 9 genes in question have not been investigated further; however, it would be 
prudent to check whether mRNA is being degraded in these cell lines to begin to 
establish why the RNAi is not effective. 
3.4.4 Other high-throughput cloning systems 
Recently, during the course of this research, other systems have been generated 
to increase the efficiency of cloning stem-loop RNAi vectors. A Gateway ® 
system named pTrypRNAiGate has been utilised to facilitate this (Kalidas et al., 
2011). The Gateway system from Invitrogen uses an Integrase from  phage to 
catalyse the recombination of specific DNA sequences termed att sites. It is not 
dependent on restriction enzymes sites and uses counter selectable markers to 
ensure very high cloning efficiencies (Fu et al., 2008). However pTrypRNAiGate 
first requires the cloning of a PCR product into a donor vector and then a second 
recombination reaction to clone the insert into the RNAi expression vector and 
does not bring any reduction in the number of sub-cloning steps over the 
restriction enzyme method. This vector randomly integrates into the rRNA spacer 
regions of the parasite and does nothing to resolve the problem of inter-clonal 
variation. Another recent method utilised complementary restriction sites and 
oligos that include random sequence to introduce the loop into the stem-loop 
construct (Atayde et al., 2012). This approach is a valid one for all stem-loop 
RNAi constructs and requires only one PCR product to be generated and one 
cloning step to take place but still relies on restriction enzymes and is affected 
by their associated limitations such as reduced cloning efficiency. 
3.4.5 Further Utilities of the RNAi Library 
The pTL library has been used for a relatively simple screen, generating 
information only for cell viability phenotypes. This is due to the recurring 
problem that phenotyping large numbers of cell lines by multiple techniques is 
very labour intensive. New technologies may allow an increase in the throughput 
of phenotypic analysis of libraries like this. High-content imaging systems should 
allow multiple phenotypic characterisation of large number of cell lines 
subjected to multiple variables. This is termed High-Content Screening (HCS). At 
a simple level, HCS can be used to look for changes in fluorescence whether this 
is from a probe or from a fluorescent reporter gene. Increasing the complexity of 
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analysis can allow the counting of organelles within a cell, the infection 
efficiency and intensity of an intracellular parasite or even morphological 
changes of cells and organelles. Using computational machine learning or writing 
scoring algorithms is a crucial part of the analysis. The ability to prepare 
samples consistently, on a large scale, and to image the results of an assay 
require appropriate robotic systems in aseptic conditions (Conrad and Gerlich, 
2010). The installation of the Scottish Bioscreening Facility (SBF) at the 
University of Glasgow provides all of this and presents an ideal opportunity for 
implementing the pTL library into HCS assays. The SBF contains a GE Healthcare 
IN Cell 2000 automated microscope system, Beckman BioMek liquid handling 
robotics and various peripherals for dispensing medium, cell cultures and 
compound libraries. An example is presented in Chapter 5 about how this can 
system can be used for dissecting BSF to PCF differentiation of African 
trypanosomes. 
Trypanosomes have a carefully choreographed cell division cycle, and multiple 
protein kinases have already been implicated in regulating it in both PCF and BSF 
parasites. Screening the pTL library for cell cycle defects could uncover novel 
regulators of the BSF cell division cycle that are not conserved in other 
organisms. RNAi could be induced in the pTL cell lines and these then subjected 
to cell cycle analysis by DAPI counting. This is time consuming, tedious and has 
potential for investigator bias to creep in; thus it is an ideal target for 
automation. It has already been automated using conventional microscopy and 
ImageJ scripting (Wheeler et al., 2012). Thus, it is not unreasonable to imagine 
this being translated into a HCS workflow allowing large-scale cell cycle analysis 
to be possible.  
HCS assays can be performed for any phenotype that can be assayed using a 
fluorescent reporter. The CRK12 kinase has been shown to play some role in 
endocytosis as when ablated by RNAi cells exhibit accumulation of material in 
the flagellar pocket, showing a “big-eye” phenotype (C. Costa, pers. comm.). 
This is assessed by using fluorescently labelled ConA or FM4-64 followed by 
microscopy (Field et al., 2004). Other RNAi lines could be screened for this 
defect using HCS microscopy to identify other kinases acting on this process, and 
that could be part of a pathway regulating or being regulated by CRK12. 
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Treating cells with fluorescent probes (for example a fluorescently-labelled 
antibody) can add complexity to the sample preparation in a HCS. Reporter cell 
lines can relieve this to some extent, by generating a fluorescent readout from 
reporter genes or fluorescently labelled fusion proteins. One investigation, 
which is being used in complementation with the pTL library, is looking into the 
process of autophagy in trypanosomes. Autophagy is a process undertaken by 
cells, often during differentiation or when under nutrient stress, where a double 
membrane vesicle is constructed around a substrate or organelle that is then 
targeted for degradation in the lysosome (Brennand et al., 2011; Duszenko et 
al., 2011). A marker for mature autophagosomes is the ATG8 protein, of which T. 
brucei contains two forms. Fusion proteins of YFP-ATG8.1 and YFP-ATG8.2 have 
been created and expressed in BSF form trypanosomes. The aim is now to screen 
the trypanosome kinome for protein kinases that can induce or suppress 
autophagy. The ATG8 reporter genes are compatible with the pTL system and 
have been transfected into several cell lines for validation. Normal BSF cells very 
rarely possess autophagosomes but when TOR1 is depleted by RNAi the number 
increases, as has been shown by electron microscopy. In a cell line containing 
the ATG8.2 reporter cell line and the pTL149 which targets TOR1, the number of 
autophagosomes was observed to increase (W. Proto, Unpublished). This appears 
to validate the work by Barquilla et al. (2008) and also the feasibility of using 
the pTL system along with this reporter, although large numbers of transfections 
would be required to combine the reporter plasmid with the pTL library. It does 
appear that this methodology would be compatible with a HCS study. 
More speculatively, the system could be used alongside protein kinase inhibitors 
to look for synthetic-lethal phenotypes. The concept of an essential gene is 
important. Many genes are not individually essential, in brewer’s yeast for 
example, in a rich growth medium only 17% of genes were essential for viability, 
though cumulatively, 40% did give a detectable loss of fitness in either rich or 
minimal media (Giaever et al., 2002). In the RIT-seq analysis of T. brucei only 
10% of genes were essential in all conditions tested, and 43% of knockdowns did 
not give a loss of fitness under any conditions tested (Alsford et al., 2011). In the 
analysis of Chromosome 1 by RNAi only 23% of genes gave growth defects 
(Subramaniam et al., 2006). The pTL analysis gives an essential or important role 
for 27% of the kinome. Aside from any experimental problems the reason for 
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some of the “non-essential” genes being non-essential is potentially due to 
either direct redundancy of the gene product or the ability of other biological 
pathways to accommodate its absence. Cell signalling is probably not best 
viewed as a linear pathway, but a complex network. Removal of one of the nodes 
in a pathway or network may shift signalling in an alternative route to ensure 
the survival of the organism (D’Elia et al., 2009; Brognard and Hunter, 2011). A 
potential way of probing these networks is through synthetic-lethal studies. By 
perturbing two genes which are not individually essential a lethal phenotype can 
be achieved due to an inability to compensate for the double perturbation. By 
taking the STL lines for which RNAi did not generate a growth defect and then 
inhibiting another gene either by double RNAi or by adding inhibitors one can 
begin to probe for association between genes that are not individually essential. 
Another strategy could be to knock a non-essential gene of interest out of the 
2T1 parental cell then transfect the pTL plasmids for non-essential protein 
kinases and screen for defects (sufficient drug selectable markers do exist to do 
this). In doing so, one can begin to identify signalling networks essential to an 
organism or disease. The concept of synthetic lethality is being increasingly 
investigated as a possibility of designing effective combination therapies to 
improve the treatment of various cancers. 
The use of the pTL system is ideal for exploring the biology of BSF trypanosomes 
but due to the characteristics of the 2T1 cell line the study of differentiation 
and procyclic trypanosomes is complicated. The 2T1 cell line will not 
differentiate into a viable PCF line and will not transmit through tsetse flies. The 
library is therefore unsuitable for studying the role of protein kinases in the 
progress of the parasite through the tsetse fly. Although not relevant for drug 
target validation, a study of the role of protein kinases may assign a role to some 
of the protein kinases that were shown not to be essential in BSF. This type of 
systematic study of the role of kinases in life cycle progression has been carried 
out in the rodent parasite Plasmodium berghei (Tewari et al., 2010). Modifying a 
pleiomorphic strain (such as Antat 1.1) to be compatible with the pTL RNAi 
library might allow such a study. 
In summary the pTL RNAi screen has genetically validated a cohort of protein 
kinases as potential drug targets. Further validation of each of these is necessary 
to classify them as a true drug target, for example testing the essentiality of 
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kinase activity of each enzyme. The library provides a resource for future studies 
into the biology of Trypanosoma brucei and could allow chemical genetic screens 
or HCS studies of various cellular processes.
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4 Trypanosoma brucei Protein Kinases as Drug 
Targets 
4.1 Targets that were identified in the screen for further 
study 
The trypanosome kinome possesses several families of protein kinases that are 
considerably different to those found in the human kinome and therefore may 
present opportunities for selective inhibition. The family of NEK protein kinases, 
which contains protein kinases resembling those found in humans, is 
dramatically expanded in T. brucei, potentially hinting at their importance. The 
other family of trypanosome protein kinase that are interesting from a drug 
target validation viewpoint are termed Orphan protein kinases, as they have 
very divergent amino acid sequences such that no orthologues have been 
identified in protein kinase families in other organisms. Trypanosomes also 
possess protein kinases with homology to human protein kinases, such as PDK1, 
that are the focus of drug development programmes - this may present 
opportunities for repurposing existing inhibitors. This chapter discusses the 
validation of NEK, Orphan and PDK1-related protein kinases as drug targets. The 
main focus of the work is a NEK kinase predicted to have an active site amenable 
to rational drug design. 
4.2 Introduction 
4.2.1 NEK Family Protein Kinases 
NEK stands for Never-in-Mitosis Related Protein Kinase. NEK kinases are 
serine/threonine kinases and Trypanosoma brucei is predicted to possess an 
expanded family of this type of protein kinase (Previous Page - Figure 1-7). The 
first discovered NEK protein kinase was NimA, for which the family is named 
(Osmani et al., 1988). It was discovered during a screen for mitotic defective 
mutants of the filamentous fungus, Aspergillus nidulans. Mutants were assessed 
for being blocked-in-mitosis (bim) or never-in-mitosis (nim). The gene from the 
first nim mutant, nimA, was investigated using a regulatable system for further 
analysis. Conditional mutants of the nimA gene could be blocked in the G2 phase 
of the cell cycle at restrictive temperatures. The role of this gene in regulating 
mitosis was further confirmed by overexpression of the gene. Cloning of the 
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cDNA followed by sequencing showed that the protein product possessed the 
characteristic of a protein kinase (Osmani et al., 1988). Subsequently 
homologues were identified in other organisms (hence the use of NEK 
nomenclature), with further characterisations showing NEKs have a diverse range 
of cellular functions. NEKs are a deeply conserved family of protein kinases with 
phylogenetic inferences suggesting that the last common ancestor of eukaryotes 
(which had to be a dividing, ciliated cell) had at least 5 NEKs(Parker et al., 
2007). As some of the mammalian NEKS have been implicated in cancer and 
other diseases their biological roles have been studied, giving insights into how 
they function. The literature on this subject is expanding rapidly and is reviewed 
well in (Quarmby and Mahjoub, 2005; O’regan et al., 2007; Moniz et al., 2011).  
The NEKs that have been currently characterised appear to fall into two 
functional clades; those that regulate mitosis and those that regulate cilium 
development. The nimA homologues were the first to be studied in other 
organisms and Nek2 was the first to be researched in humans. Direct functional 
homology amongst the nimA sequence homologues from different organisms 
appears to be rare. nimA deficiency in Aspergillus cannot be rescued by fin1, 
KIN3 or NEK2 (the nimA sequence homologues in S. pombe, S. cerevisiae or 
mammals respectively) but only by the nim-1 from Neurospora crassa, a related 
fungus (Pu et al., 1995). Following nimA characterisation the main focus of 
research on NEKs was conducted on HsNEK2 due to its roles in mitosis. During 
mitosis HsNEK2 regulates centrosome segregation. It localises to centrosomes 
and phosphorylates centrosomal proteins such cNap-1, Rootletin and -catenin. 
Inhibition of HsNEK2 prevents centrosome segregation, spindle assembly and 
formation of multinucleate cells. It is highly essential for mouse embryogenesis. 
Increased levels and activity of HsNEK2 are detected in a large number cancer 
types and cancer cell lines. HsNEK2 siRNA silencing reduces the proliferation of a 
number of these cell types suggesting HsNEK2 presents a drug target for anti-
cancer therapy (Kokuryo et al., 2007; Moniz et al., 2011). 
In humans three other NEKs have been shown to participate in regulating 
mitosis; interestingly, these operate in a cascade. HsNEK6 and HsNEK7 are 87% 
identical within their kinase domains and do not possess much sequence 
similarity outside this domain. These appear to regulate the mitotic spindle and 
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centrosome splitting and cytokinesis. They are activated by NEK9, which in turn 
is activated by CDK1 and PLK1. The activity of HsNEK7 and HsNEK7 on the kinesin 
Eg5 causes it to accumulate at the centrosomes prior to centrosome separation. 
These are microtubule dependent processes and it appears that several NEKs can 
regulate microtubule dependent events outside of mitosis (Moniz et al., 2011). 
HsNEK3, for example, plays a role in regulating acetylation of microtubules in 
neurons. When expression of an inactive mutant is induced in cultured human 
neurons the cells lose their polarity and have abnormal morphology (Chang et 
al., 2009). 
The other functional clade of NEKs is made up of those that regulate the 
development of cilia and flagella. This was first highlighted by studies 
implicating NEK1 and NEK8 (in mice and zebrafish) disruption in the deregulation 
of primary cilium. This is a sensory organelle and when disrupted by ablation of 
NEK1 and/or NEK8 leads to polycystic kidney disease (Mahjoub et al., 2005).  
Interestingly, NEKs seem to be expanded in ciliated and flagellated organisms 
and their importance to these organisms may be related to regulating the 
formation of these organelles. It is likely that NEKs evolved and diverged early in 
the evolution of eukaryotes (Parker et al., 2007). Chlamydomanas reinhardtii, a 
bi-flagellated, single-celled algae, possesses 11 NEKs. Two NEKs, Fa2p and 
Cnk2p, localise to the flagellum are responsible for regulating the length of its 
flagellum and the size of its cells and localise to the flagellum (Mahjoub et al., 
2004; Bradley and Quarmby, 2005). The family of NEKs is also expanded further 
in the freshwater ciliate Tetrahymena thermophila. This organism is a single cell 
possessing several hundred cilia and it has a complement of 39 NEK kinases. A 
number of these have been localised to distinct subsets of cilia and three have 
been implicated in several different mechanisms of cilia disassembly (Wloga et 
al., 2006).  
In an extreme example the NEK family of protein kinases is expanded in a most 
striking manner in Giardia. The intestinal parasite Giardia lamblia has a huge 
expansion and diversity in its NEKs. In the WB strain 198 proteins have been 
classified as NEKs, though, only 56 of these are predicted to be active. The 198 
proteins make up 71% of its kinome and 3.7% of its proteome. When these 
expanded families of NEK kinases were compared between 3 strains of G. 
lamblia it was apparent that a core of genes were conserved but many were 
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strain specific loss or gains and many were diverged. It is suggested that these 
differences may account for strain specific differences (Manning et al., 2011). 
Characterisation of some Giardia NEKs has been undertaken. Homologues of 
HsNEK1 and HsNEK2 genes were identified in Giardia by sequence similarity and 
termed GlNEK1 and GlNEK2 respectively. These were shown to be active kinases 
in vitro, with activity against Histone H1 and Histone H3, and Histone H1 and 
BSA respectively. As targeted gene knockout or inducible RNAi silencing is not 
feasible Giardia, the two NEK kinases were overexpressed in kinase-dead form in 
order to achieve a dominant negative phenotype. Both led to growth defects but 
it demonstrated that GlNEK1 was involved in regulating cytokinesis, as there was 
a large increase in cells stalled in cytokinesis in the cultures. When localised by 
immunofluorescense microscopy it was shown that the two protein kinases 
localised to areas of intense microtubule remodelling such as the mitotic spindle 
poles and microtubules, and the microtubules of the ventral disc. They also show 
some co-localisation with phosphorylated aurora kinase. Overexpression of 
GlNEK1 and kinase dead GlNEK2 led to a drop in the number of excyzoites that 
could be obtained from cysts formed by the relevant overexpression cell line, 
showing these kinases play some role in excystation, a process that requires 
dramatic remodelling of the cytoskeleton as well as segregation of nuclei into 
daughter cells (Smith et al., 2012). 
In comparison with flagellated parasites only four NEK kinases have been 
identified it the apicomplexan parasites Plasmodium falciparum and P. berghei, 
which have been characterised in some detail. Pfnek-1 is the only one expressed 
in asexual parasites and is an active kinase in vitro. It can phosphorylate Pfmap2 
(MAP kinase 2) in vitro leading to the activation of this kinase (Dorin et al., 
2001). It is essential to the multiplicative erythrocytic stage and is expressed in 
male gametocytes, making it a therapeutic and transmission blocking target 
(Dorin-Semblat et al., 2011). Pfnek-3 is a dual specificity Ser/Thr and Tyr kinase 
has also been shown to phosphorylate and activate Pfmap2 in its activation loop 
in vitro (Lye et al., 2006; Low et al., 2007, 2012).  In P. falciparum nek-2 and 
nek-4 are individually essential for DNA replication prior to meiosis in the zygote 
(Reininger et al., 2009; Tewari et al., 2010). The NEKs of P. falciparum have 
been shown to possess specificities for different generic substrates in vitro 
kinase assays. 
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Trypanosoma brucei has 21 genes predicated to encode NEK kinases compared 
with 15 in humans. NEKs from T. brucei do not form close relationships to the 
NEKs from P. falciparum nor to S. cerevisiae, D. melanogaster or C. elegans in 
phylogenetic analyses (Parsons et al., 2005a). However, some of the NEK kinases 
in the latter organisms do form close relationships, suggesting divergence of 
trypanosomatid NEK kinases from other eukaryotes. Most of the of T. brucei NEKs 
possess the architecture of human NEKs, with a protein kinase domain located at 
the N-terminus or close to it and a C-terminal extension containing other 
domains. Several contain coiled coil domains C-terminal to the active site, 
reminiscent of HsNEK1 an HsNEK2 (Figure 4-1). 
 
Figure 4-1: Depiction of the domain architecture of the predicted NEKs of T. brucei. Protein 
kinase domains are shaded in red, coiled coil regions in pink and PH domains in blue.  
The NEKs of T. brucei have not been investigated in much detail at all, only 
several have had any characterisation and only one investigated in detail (in 
procyclic forms). The first to be identified were NRKA and NRKB, which were 
cloned using degenerate primers for protein kinase domains, in the pre-genomic 
era (Gale and Parsons, 1993). Analysis of the sequence showed that outside the 
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catalytic domains the protein showed very little homology to HsNEK1 and NIMA, 
so the researchers concluded that NRKA and NRKB were not the functional 
homologues of the former; however, no functional characterisation was 
undertaken. The transcription of the genes were analysed by northern blot and it 
was shown to be constitutively expressed in both strains at both stages of the 
life cycle (Gale and Parsons, 1993). The genes were later shown to be 
translationally regulated, even though the mRNAs are constitutively expressed. 
The protein levels and kinase activity were increased in progression from slender 
BSF to stumpy BSF and the highest level of expression took place at this point. 
No work was done to identify the location at which they act in the cell.  
NRKC has had much more characterisation. Pradel et al. (2006) demonstrated 
that NRKC has a high similarity to human NEK 2. It is expressed as a protein in 
procyclic and bloodstream forms. In vitro kinase activity was demonstrated from 
recombinant protein, with the generic substrates /-casein being preferentially 
phosphorylated. Using fluorescent antibodies and C-terminal GFP-conjugate 
TbNRKC demonstrated that it localises to the basal body in PCF forms (a 
microtubule organising centre), and with tyrosinated tubulin. This suggests that 
TbNRKC could have some role in organising microtubules. RNAi of TbNRKC in PCF 
led to an accumulation of cells with 4 basal bodies but was not lethal nor mildly 
deleterious. The overexpression of a kinase-dead mutant protein also led to the 
accumulation of a 4-basal body cell type. However, when active TbNRKC was 
overexpressed this led to a lethal cessation of cell division. Cells showed clusters 
of numerous, non-flagellated basal bodies. This blocked kinetoplast division and 
cytokinesis. The researchers postulate that TbNRKC is responsible for activating 
the dissociation of links between dividing basal bodies (Pradel et al., 2006).  
4.2.2 PDK1 
In mammals, PDK1, or 3-phosphoinositide-dependent protein kinase-1, is 
member of the AGC family of protein kinases. It is a constitutively active protein 
kinase that regulates the activity of a number of other AGC kinase, and as such is 
termed a “master kinase”. It functions in the transduction of extracellular 
stimuli to intracellular signalling pathways. Following stimulation of cells with 
insulin or growth-factor, PI3 kinases (phosphatidylinositol 3-kinases) become 
activated and generate phosphatidylinositol 3,4,5-trisphosphate in the cell 
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membrane. Both PDK1 and PKB can bind phosphoinositides, using C- and N-
terminal PH domains respectively, and this co-localisation allows PDK1 to 
phosphorylate PKB in its activation loop. Other AGC kinases such as PKA, SGK and 
S6K, possess a C-terminal hydrophobic motif that PDK1 can bind to, allowing it 
to activate them by phosphorylation outside of the activation loop. The region in 
PDK1 responsible for this binding is termed the “PIF-Pocket” (Mora et al., 2004; 
Pearce et al., 2010). 
 
Figure 4-2: The mechanisms of PDK1 activation of PKB, SGC and S6K. Both PKB and PDK1 
are localised to the plasma membrane by binding to phosphoinositides using their PH 
domains. PDK1 phosphorylates the activation loop of PKB allowing a hydrophobic pocket 
to accommodate the hydrophobic motif (phosphorylated by another protein kinase) and 
locking PKB in an active conformation. PDK1 can bind SGK and S6K by accommodating 
their phosphorylated hydrophobic motifs into its PIF pocket thus allowing it to 
phosphorylate the activation loop of these two protein kinases. From (Mora et al., 2004). 
 
Increased levels of phosphoinositides in certain cancer cells can drive their 
proliferation through the upregulation of PKB and SGK activity. As PDK1 
integrates this signalling it is being investigated as a target for therapeutic 
inhibition, with a large number of inhibitors being tested against PDK1 (Peifer 
and Alessi, 2008; Raimondi and Falasca, 2011). Due to the potential of there 
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being inhibitors of TbPDK1 in the vast number of compounds developed against 
HsPDK1 this protein kinase was investigated as a target that would be possible 
for inhibitor repurposing.  
4.2.3 Orphan Kinases 
The orphan kinases of T. brucei show no clear homology to any currently 
identified families of protein kinase, despite being readily identifiable as protein 
kinases. They were the most divergent families between the three 
trypanosomatid kinomes defined by Parsons et al. and show poor conservation 
between the three species studied, representing lineage specific gains and losses 
(Parsons et al., 2005a). Due to their increased sequence divergence from any 
protein kinases found in humans they may possess structural differences in the 
active site that can be exploited in the design of selective inhibitors. This 
potentially increases the chemical space within which selective inhibitors could 
be developed for any essential orphan kinases making them possible good drug 
targets. 
4.2.4 Research Aims 
The objectives of the work presented here was to further investigate the validity 
of three protein kinases as potential drug targets. This included genetic 
validation of the protein kinases by RNA interference, generation of recombinant 
protein for chemical validation and molecular modelling to gain information on 
their structure. A protein kinase from the expanded NEK family was analysed in 
detail along with a diverged Orphan protein kinase and a potential homologue of 
PDK1.  
4.3 Results 
4.3.1 Features of NEK12 
After the initial definition of the Trypanosoma brucei kinome, it was possible to 
detect by multiple sequence alignment that one NEK kinase (Tb927.8.7110) 
contained a small gatekeeper residue (J. Mottram, Unpublished). Tb927.8.7110 
(NEK 12.1) has a paralogous gene Tb927.4.5310 (NEK12.2) that is the result of a 
chromosome translocation. The coding sequence of the 1323 nt genes share 87% 
118 
 
1
1
8
 
identity though the UTRs are more diverged at 36% and 24% for the 5’ UTR and 3’ 
UTR respectively (Jackson, 2007). The products of the two genes are also highly 
similar, at 85% identity of the amino acid sequence (Figure 4-4). Both proteins 
are 440 amino acids in length, NEK12.1 is predicted to have a mass of 49.6 kDa 
and NEK 12.2 a mass of 50.2 kDa. The proteins have an N-terminal kinase domain 
followed 48 amino acids later by a C-terminal PH domain. The gatekeeper 
residues of the two active sites are Ala117 in NEK 12.1 and Met117 in NEK 12.2; 
alanine possesses the second smallest side chain of the amino acids (after 
glycine). It was predicted that this would generate a large active site in NEK 
12.1 compared to NEK12.2 and other kinases in Trypanosoma brucei. This was 
further investigated by molecular modelling. Three phosphopeptides 
corresponding to two phosphosites (Ser 195 and Ser 197) in the activation loop of 
NEK12 were detected by Nett et al. 2009. This was assigned to both kinases in 
their analysis but this should not be assigned to one or the other as the sequence 
the peptide covered was identical in each kinase (Nett et al., 2009b). These key 
features are annotated to a schematic representation of NEK 12.1 in Figure 4-3. 
The catalytic lysine was identified as K70, and was considered as a site for 
mutagenesis to creat kinase-dead mutants.
 
Figure 4-3: Schematic representation of NEK 12.1 protein domain architecture with key 
features annotated. This representation is the same for NEK 12.2 with the exception of Met 
117 replacing Ala 117. The scale above the diagram shows the amino acid number. The 
equivalent region of the CDS targeted by RNAi is highlighted in cyan. Ser 195 and Ser 197 
have been detected as phosphorylated by Nett et al. 2009. 
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Figure 4-4: Sequence alignment of NEK 12.1 and NEK 12.2 proteins. The protein kinase and 
PH domain are highlighted by red bars. The position of the gatekeeper residue is annotated 
and differences in amino acid are highlighted in blue, identical residues are indicated by 
dots. 
4.3.2 NEK 12 RNAi 
To assess the relevance of the NEK 12 protein kinases a stem loop RNAi construct 
(pGL2064) was generated and transfected into T. brucei 2T1 BSF cells. Two 
clones (15356/15357) were selected for investigation. The RNAi plasmid was 
generated targeting 555 nt of the coding sequence, which results in cross-
targeting of the two NEK 12 mRNAs leading to a double knockdown. Due to the 
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similarity of the two NEK 12 coding sequences this was unavoidable as the UTRs 
were also unsuitable for RNAi targeting due to their similarity to other UTRs in 
the T. brucei genome. 
Initial assessment of the NEK12 RNAi phenotype was carried out by generating a 
cumulative growth curve of the BSF RNAi phenotype in vitro. Ablation of both 
NEK12 proteins by RNAi generated a severe growth defect after 24 h. After 24 h 
there was a rapid cell death phenotype in the induced cultures and by 96 h no 
viable cells were visible in the medium. This was observed in two biological 
replicates (and three technical replicates) (Figure 4-5a). 
In order to assess the severity of NEK 12 ablation in a more realistic situation in 
vivo RNAi studies were carried out in ICR mice. The 2T1 strain of T. brucei 
generates acute infection dynamics due to lack of density regulation by the 
parasites. Mice were inoculated on Day 0 with 5x104 parasites (clone 15356) and 
24 hours later the test mice were presented with doxycycline laced sugar water. 
Parasitaemia was monitored every 24 h by haemocytometry on blood obtained 
from tail venepuncture. Mice were typically culled if parasitaemia rose above 
109 parasites per ml of blood or after 96 h since inoculation. The parasitaemia of 
control and RNAi induced mice increased at the same rate for 48 h post exposure 
to doxycycline, however between 48 h and 72 h in the induced group the 
parasitaemia decreased to below a detectable level (1x104 per ml blood)(Figure 
4-5b). This demonstrates that depletion of NEK 12 kinases is fatal to BSF 
parasites in culture and in mammalian infections. 
In order to demonstrate that the NEK 12.1 mRNA was being downregulated by 
the NEK 12 RNAi construct a qPCR was performed to assess this. Samples of RNAi 
induced and uninduced cultures were taken at 24 h and used in total RNA 
extractions, which were then used to make cDNA. When these cDNAs were used 
as templates in a qPCR a downregulation of the NEK 12.1 transcript by over 50% 
was detected (Figure 3-7). In order to determine if the ablation of the mRNA was 
causing depletion of the NEK 12.1 protein an allele of NEK 12.1 was 
endogenously tagged with a GFP fusion. 
To achieve this the NEK 12.1 CDS was amplified and cloned into pENt-6-BG (pGL 
1796) to generate an N-terminally tagged GFP-TY-NEK12.1 fusion (Kelly et al., 
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2007). This CDS was linearised with a unique AgeI site and transfected into cell 
line 15356 (containing an RNAi cassette to target the NEK 12 genes) (Kelly et al., 
2007). Two clones were identified by anti-GFP western blot as expressing a 
protein of 79 KDa, the predicted size of the fusion protein. The clone possessing 
the strongest expression (15356B2) was grown for 24 h in the presence or 
absence of NEK 12 RNAi induction and then the cells were harvested for western 
blot analysis. After probing with an anti-GFP antibody and appropriate secondary 
antibody the GFP signal was undetectable in the induced culture demonstrating 
the RNAi was effective at depleting NEK 12.1 protein from the cells (Figure 
4-5c). 
 
122 
 
1
2
2
 
 
Figure 4-5: Growth curves for T. brucei 2T1 BSF RNAi lines (15356/15357) undergoing 
NEK12 double knockdown, panel a. shows the cumulative cell counts (from 
haemocytometry) when RNAi is induced in culture. Error bars indicate the standard 
deviation around the mean of three technical replicates. Cell cultures were maintained 
between 10
5
 and 10
6
 cells per ml. Panel b. shows the levels of parasitaemia in mice infected 
with the RNAi line 15356 under induced (+ Dox, doxycycline) and non-induced conditions. 
Panel c. Western blot against GFP-TY-NEK 12.1 from induced and uninduced cultures of cell 
line 15356B2, the primary antibody was mouse anti-GFP and the secondary HRP-conjugate 
anti-mouse. Mouse anti-EF1 was used to demonstrate equal sample loading. 
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4.3.3  NEK 12 Phenotype – cell cycle analysis 
In order to determine if the depletion of the NEK 12 proteins was causing BSF 
cell death through a cell cycle defect the DNA content of the cells was analysed 
by two different methods. Microscopic characterisation of cells following DAPI 
staining was performed alongside fluorescence activated cell sorting (FACS). In 
DAPI counts the cells are classified into 1N1K, 1N2K and 2N2K categories – any 
other configurations can also be scored. If a cell cycle defect is the direct cause 
of the cell death phenotype this can be expected to appear before the growth 
defect is apparent. The second method, FACS, uses flow cytometry to determine 
the DNA content of cells stained with propidium iodide- this method uses far 
greater numbers of cells than manual counting and removes observer bias. It can 
detect multinucleated cells but cannot differentiate whether a 2N2K cell is 
undergoing cytokinesis or not. 
To perform manual counts slides were prepared from induced and uninduced 
cultures and stained with DAPI. The nucleus:kinetoplast configuration of several 
hundred cells per time point was determined by fluorescence microscopy. At 24 
h, before appearance of a growth defect, RNAi of the NEK 12 genes led to an 
increase in 1N1K cells from 75% to 83% and a reduction in 1N2K cells from18% to 
9% suggesting cells are delaying entry into S-Phase. The number of 2N2K cells is 
slightly decreased and a small rise in other cell types is noted. Between 24 h and 
48 h the number of 1N1K cells drops to 68%, 1N2K to 5% and the 2N2K category 
increases to 11%. Other cell types rise dramatically to 16%.Other cell types did 
not consist of a characteristic phenotype. Many contained multiple nuclei with 
or without kinetoplasts or one nucleus with multiple kinetoplasts. Others 
contained kinetoplasts or nuclei only. In some cells the nucleolus appeared 
enlarged. This may suggest aberrant positioning cytokinesis mechanisms in cells 
depleted of NEK 12 proteins. A clear cell cycle defect is not apparent from this 
analysis. 
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Figure 4-6: Results of DAPI counts showing proportion of cell types in NEK 12 depleted 
cells (line 15356). N=>200 cells per time point. 
When DNA content of the cells was examined using flow cytometry at 24 h a 
slight increase in 1N1K cells and a slight drop in G2/M cells was observed. At 48 
h a larger increase in G1 cells was observed, together with an almost total block 
of S phase and a reduction in G2/M cells. A very slight increase in sub-G1 cells 
was observed, possibly indicating the formation of zoids. The increase in “G1” 
cells may be due to “other” cell types that possess a similar DNA content to 
1N1K cells. Again, a clear cell cycle defect is difficult to interpret from these 
data.  
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Figure 4-7: Histograms showing the DNA content of NEK 12 RNAi induced (black, dashed 
line) and uninduced (grey, filled) cells at 24 h (a) and 48 h (b). Cell line used for analysis was 
15356. FL2-A peak at 200 corresponds to 1N1K (G1) parasites, and at 400 2N2K (G2/M), 
intermediate values correspond to S phase parasites. Panel c. Represents the proportion of 
cells in each phase of the cell cycle as determined by the Dean/Jett/Fox Model using FlowJo 
software. 
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4.3.4  Generation of Recombinant NEK 12 Proteins 
4.3.4.1 Cloning and mutagenesis 
For a cohort of 17 of the smaller NEK (including NEK 12.1) and Orphan kinases 
the entire CDS was cloned into either the pET-32Xa/LIC or the pET-30Xa/LIC 
system from Novagen for protein expression experiments. Another cohort of 21 
plasmids were generated to express truncations of 13 proteins producing only 
the protein kinase domain and regions either side intended to allow correct 
folding and solubility (designed by J. Cowman, University of Edinburgh) (Table 
2-6). The pET-30 Xa/LIC vector encodes a C-terminal 6xHis tag (and S-Tag) to 
allow IMAC purification of the protein; this adds 4.9 kDa to the protein. pET-32 
Xa/LIC adds a thioredoxin (Trx) upstream of this with the aim of increasing the 
solubility of exogenous proteins in the E. coli  expression system and adds 17.2 
kDa to the protein of interest (LaVallie et al., 1993; Hammarström et al., 2006) 
(Figure 4-8). 
 
Figure 4-8: Schematic depicting the construct encoded tags fused to the C-terminus of 
proteins expressed using E. coli in this study. 
After generating pET-32 Xa/LIC expression constructs for full-length active 
NEK12.1 and NEK12.2 these were modified by site directed mutagenesis to 
generate kinase dead mutations of the catalytic lysine to methionine 
(K70M).These were generated to provide negative controls for kinase activity 
assays to ensure protein purifications did not contain co-purifying contaminant 
protein kinases. 
GOI
GOI
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4.3.4.2 Cell lines, media, temperature optimisation 
Various expression conditions were tested in combination for each construct, 
varying the cell line, medium and temperature of expression (Table 4-1), at the 
Edinburgh Protein Production Facility (EPPF). It was apparent that for all the 
expression constructs tested the optimum cell line to use was Rosetta pLysS in 
standard LB broth, with expression being induced with 1 mM IPTG at 15oC. 
Rosetta pLysS contains the pLysS-RARE plasmid to encode for extra copies of rare 
tRNAs of E. coli to increase yields of eukaryotic proteins and to reduce leaky 
expression of exogenous proteins. An example of expression testing is shown in 
Figure 4-9 for the proteins in Table 4-2. Other conditions were tested but data 
are not shown as the conditions were inferior in terms of generating soluble 
protein. NEK 12.1 was expressed at high levels and was detected in coomassie 
stained gels as well as the anti-his western blot Figure 4-9. The bands from these 
gels were excised and analysed by MALDI-MS to ensure the overexpressed protein 
was the intended target protein; this was the case for all 12 tested at EPPF. 
Table 4-1: Variables tested to optimise protein expression,   
Cell Type Medium Temp. 
o
C 
BL21 (DE3) LB+ 1mM IPTG 15 
C41 (DE3) Autoinduction TB 20 
C43 (DE3) LB+ 1% Glucose, 2mM MgCl, 1mM IPTG 30 
Rosetta pLysS  37 
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Figure 4-9: Anti-His Western blot (panel a.) showing the expression levels of various NEK 
and Orphan kinases in the soluble fraction of Rosetta pLysS cells using an overnight 
induction with 1mM IPTG at 15
o
C in LB Broth. Panel b. shows a duplicate SDS-PAGE gel 
stained with Coomassie blue. Descriptions for each lane are presented in Table 4-2. 
Table 4-2: Details of lanes in Figure 4-9. 
Number Name Gene ID Size+Trx Tag Plasmid 
1 NEK 6 Tb927.3.3080 73.1kDa pGL 1990 
2 NEK 7 Tb927.3.3190 73.3 kDa pGL 1991 
3 NEK 12.1 Tb927.8.7110 66.8 kDa pGL 1993 
4 NEK 14 Tb927.8.1670 82.6 kDa pGL 1994 
5 NEK 15 Tb09.160.0450 68.6 kDa pGL 1995 
6 Ladder N/A N/A N/A 
7 NEK 17 Tb927.10.5950 72.1 kDa pGL 1996 
8 NEK 20 Tb11.01.2900 58.8 kDa pGL 1997 
9 NEK 21 Tb11.01.6650 81.6 kDa pGL 1998 
10 NEK 22 Tb927.2.2120 67.8 kDa pGL 1999 
11 Orphan Tb10.61.0100  55.5 kDa pGL 2000 
12 Orphan Tb927.3.3290 69.6 kDa pGL 2001 
13 Orphan Tb11.02.4530 62.3 kDa pGL 2002 
14 His tagged control N/A N/A N/A 
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4.3.4.3 Purification of NEK12 
Various purification strategies were tested at EPPF, University of Edinburgh, to 
purify NEK 12.1. Initial purification using Immobilised Metal Affinity 
Chromatography (IMAC) was then followed by ion exchange chromatography or 
size exclusion chromatography. Various buffers were tested for maintaining NEK 
12.1 stability in solution.  A simple strategy was found to be suitable for 
producing NEK 12.1 for activity assays. Pellets of E. coli Rosetta pLysS expressing 
NEK 12.1 were lysed using BPER (Pearce) in the presence of protease inhibitors, 
the lysates were clarified and TRX-His-NEK 12 was purified using IMAC. Fractions 
containing NEK 12.1 were buffer exchanged to remove imidazole prior to activity 
assays. NEK 12.1 was found to be stable in a buffer containing 300 mM NaCl and 
50 mM sodium phosphate, pH 8. Protein concentrations of around 0.5 mg/ml 
could be obtained from this purification strategy allowing the protein to be used 
in kinase activity assays. Quantities of approximately 10 mg could be extracted 
from 4 litres of bacterial culture, this protocol was further optimised by workers 
at EPPF to allow recombinant NEK 12.1 to be further processed for use in 
crystallization trials. This technique was used with NEK 12.2 but this protein 
expresses at lower levels than NEK 12.1 and is much more unstable in solution 
than NEK 12.1, making it much more difficult to work with.  
4.3.5 Activity assays/inhibitors of NEKs 
Recombinant Trx-His-NEK12.1 and Trx-His-NEK12.2 (purified as described 
previously) were tested in kinase assays using 32P -phosphate radiolabelled ATP 
to label substrates. Preliminary tests suggested that the NEK12.1 exhibited 
kinase activity against -casein but not MBP or histone H1, and displayed an 
ability to autophosphorylate (Figure 4-10a). Following this discovery, kinase dead 
mutants (K70M) of NEK 12.1 and NEK 12.2 were generated and purified alongside 
the wild type protein (using the same conditions) to control for co-purifying, 
contaminating protein kinases in further activity assays. When the four 
purifications were used in kinase assays against -casein (Figure 4-10b) the 
kinase dead mutant purifications did not exhibit any kinase activity. NEK12.2 
exhibited very weak kinase activity against -casein but the protein appears to 
be unstable and this reduction in activity may be due to sub-optimal expression, 
purification or assay conditions. Weak autophosphorylation was detected, though 
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this was not of the same magnitude as the substrate phosphorylation and was 
less intense than in preliminary experiments. In order to test if NEK 12.1 could 
be inhibited by bulky kinase inhibitors, activity assays were conducted in the 
presence of the bumped PP1 analogue 3MB-PP1 (Figure 4-10c). Due to the 
instability of NEK 12.2 this was only performed for NEK 12.1. Activity of NEK 12.1 
was calculated based on band intensity (measured using ImageJ) of 
phosphorylated -casein, and calculated as a percentage of a reaction 
containing only DMSO. Inhibition of NEK 12.1 kinase activity was observed with 
an IC50 calculated to be 0.83 M with a concentration of radiolabelled ATP at 
100 M in the assay (Figure 4-10d). 
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Figure 4-10: Inhibition of NEK12.1 kinase activity with 3-MB-PP1. a. Trx-His NEK 12.1 
purifications were tested for kinase activity against three generic substrates. b. These 
purifications were controlled by the generation of kinase dead mutants (K70M) and Trx-his-
NEK 12.2 was also tested for kinase activity. c. Kinase reactions of NEK 12.1 were incubated 
with increasing concentration of 3-MB-PP1 to determine if NEK 12.1 can be inhibited by a 
bumped kinase inhibitor. d. The IC50 of 3-MB-PP1 was determined as 0.83 M using band 
densitometry. 
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4.3.6  Homology Modelling of NEKs and Virtual Screening 
Garnering structural information on NEK 12 proteins was deemed important as it 
would facilitate attempts at rational inhibitor design and chemoinformatic 
studies to identify potential inhibitors. Despite multiple attempts by 
collaborators at EPPF, no reliable protocol could be developed that yielded NEK 
12.1 crystals that were suitable for X-ray diffraction studies. In lieu of this a 
homology modelling approach was used to generate limited structural 
information on the two NEK 12s. NEK 12 sequences were used to search the 
Protein Data Bank and aligned against several human NEK templates (NEK2: 2JAV, 
2W5H and NEK7: 2WQM) using Molecular Operating Environment software. This 
software was then used to homology model the NEK 12 structure against the 
crystal structure of the templates. Energy minimisation was used to refine the 
models, these were then used to observe differences between the active sites of 
the two proteins. Homology modelling demonstrated a difference in the size of 
the active site in the NEK 12.1, indicating a larger hydrophobic pocket at the 
back of the active site due to the presence of a small alanine gatekeeper residue 
(Figure 4-11). 
The models were then used to try and identify potential inhibitors of the two 
NEK 12s. The pyrrole indolinone ligand in the HsNEK2 structure (PDB ID: 2JAV) 
was superposed onto the models and used to define the binding site of the NEK 
12 models (to define the larger active site of NEK12.1 the ligand was modified by 
the addition of an ethyl group in PyMol to extend into and define the 
hydrophobic pocket for data mining). These ligands were used to define 
sitepoints in the model which allowed the LIDAEUS CAMELSICK 2 library of 4.2 
million compounds to be searched for potential ligands. The top 100,000 
compounds were then further screened using rigid and flexible docking with the 
Autodock and Vina software. These were then ranked in order of predicted 
binding affinity and the top 10 posematched (where rigid and flexible docking 
produced the same binding pose) were selected for further analysis (shown in 
Figure 4-12 and Figure 4-13). Of the top 10 hits for NEK 12.1, 6 were predicted 
to bind in the deep hydrophobic pocket (Figure 4-12). Compounds available from 
Enamine were purchased for use in further studies (as we had previously 
purchased compound libraries from this company). These were tested against T. 
b. brucei 2T1 BSF cells in an alamar blue cell viability assay to determine the 
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IC50 values (Figure 4-12 and Figure 4-13). The .PDB files of the molecular 
models, the .SDF files of the data-mined ligands and the .PSE files of the docking 
output are contained in supplemental data file S2 on the appended CD-ROM. 
 
Figure 4-11: Homology models of NEK 12.1 (a) and NEK 12.2 (b) cross sectioned through the 
active site to show the predicted size of the rear hydrophobic pocket. NEK 12.1 Ala 117 is 
highlighted in green, NEK 12.2 Met 117 is highlighted in yellow. The ligand (Number 6, 
Figure 4-12) in the active site was predicted to dock into the NEK 12.1 active site but not 
NEK 12.2, steric clashes are observed with the Met117 if the ligand is superposed into the 
NEK 12.2 active site. 
 
a.
b.
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Figure 4-12: Structures of compounds predicted to dock into the NEK 12.1 active site 
identified by virtual screening.  Region of the compound predicted to reside in the deep 
hydrophobic pocket are highlighted using blue ovals. IC50s are assigned for those 
compounds purchased from Enamine and tested against BSF parasites. 
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Figure 4-13: Structures of compounds predicted to dock into the NEK 12.2 active site 
identified by virtual screening. IC50s are assigned for compounds tested against BSF 
parasites. 
4.4 Zinc-Finger Containing Orphan Kinase 
4.4.1 Features of ZFO 
Only one Orphan kinase was identified as having a detectable growth defect in 
the kinome-wide RNAi screen. This was the gene Tb09.211.2260, which contains 
a CDS of 3177 bp and encodes a protein with a predicted size of 118.2 kDa (1058 
aa in length). The protein is predicted to contain an N-terminal kinase domain 
with a long C-terminal extension. This extension is predicted to contain motifs 
consistent with a C2H2 zinc-finger binding domain. These are classical zinc 
finger domains where the motif is defined by #-X-C-X(1-5)-C-X3-#-X5-#-X2-H-X(3-
6)-[H/C], X can be any amino acid, and numbers in brackets indicate the number 
of residues. The positions marked # are those that are important for the stable 
fold of the zinc finger. The final position can be either His or Cys (PFAM, 
accessed 2012). Zinc finger domains were first identified as DNA binding motifs 
but have now been shown to bind DNA, RNA , protein or lipid substrates (Klug, 
1999; Gamsjaeger et al., 2007; Kröncke and Klotz, 2009). The amino acid 
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sequence of the putative C2H2 region from ZFK is YTCDACGREFASSGALRRHSCSC 
with the key residues highlighted in yellow. Subsequently we have named it Zinc 
Finger Orphan protein kinase (ZFO).  
A number of post-translation modifications have been detected on ZFO (Figure 
4-14). Phosphoproteomic data show multiple phosphorylation sites, nine in total 
(serines 372, 376, 466, 488, and 492 and threonines 374, 468, 470, and 486), in 
the region between the kinase domain and the zinc finger motif (Nett et al., 
2009b). A peptide from ZFO was detected as being palmitoylated in PCF form 
parasites but the palmitoylation site in the peptide was not defined as it 
contains several serine and one threonine residue (Emmer et al., 2011). 
 
Figure 4-14: Schematic representation of ZFO protein domain architecture with key features 
annotated. The scale above the diagram shows the amino acid number. 
4.4.2 RNAi Analysis 
Two cell lines (STL52/STL55) containing an RNAi plasmid (pTL37) targeting ZFO 
were generated and detected as giving a severe growth defect by alamar blue 
assay. RNAi ablation of ZFO led to a growth defect becoming apparent after 24 h 
induction in culture. Between 24 h and 96 h the phenotype became a 
pronounced cell death defect (Figure 4-15a). The phenotype appeared to 
variable between technical replicates in both biological replicates leading to 
large error margins. This is despite exhibiting consistent alamar blue values, 
suggesting a variable, pleiotropic phenotype occurs when cells are diluted. When 
ZFO was ablated from trypanosomes infecting mice the growth defect led to 
clearance of parasitaemia to below a detectable level by 72 h (Figure 4-15b). 
Knockdown of mRNA was confirmed by qPCR (Figure 3-7) and further confirmed 
by western blotting against the product of an epitope-tagged allele of ZFO 
(Figure 4-15c).  
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In order to further validate the RNAi knockdown of ZFO the gene was epitope 
tagged at the endogenous locus to allow western blotting to examine protein 
levels. This was performed using pHG80, a derivative of pENt-6B-G (Kelly et al., 
2007). This allows the endogenous tagging of a gene to create an N-terminal 
fusion of 3xHA and eGFP. Five hundred nucleotides of the ZFO 5’ UTR and a 500 
nt fragment of the 5’ of the ZFO CDS were cloned into pHG80 between the XbaI 
and BamHI sites, and were fused together using a unique AscI site in a three-way 
ligation. Following confirmatory restriction enzyme digest the plasmid was 
linearised using AscI and transfected into STL55 (containing the ZFO RNAi 
construct). The linearised plasmid inserts into the ZFO locus by homologous 
recombination, placing a ZFO allele under the control of an aldolase 5’ UTR but 
preserving the endogenous 3’ UTR. Five clones were generated from this 
transfection. Only one clone (STL2266) was observed to express a protein 
detectable by western blot using anti-HA antibody. A band was observed at 149 
kDa, the expected sized of the fusion protein. Following RNAi of the ZFO mRNA 
for 24 h the fusion protein was ablated to undetectable levels. 
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Figure 4-15: Growth curves for T. brucei 2T1 BSF RNAi lines (STL52/55) undergoing ZFO 
knockdown, panel a. shows the cumulative cell counts (from haemocytometry) when RNAi 
was induced in culture. Error bars indicate the standard deviation around the mean of three 
technical replicates. Cell cultures were maintained between 10
5
 and 10
6
 cells per ml. Panel 
b. shows the levels of parasitaemia in mice infected with the RNAi line STL55 under induced 
(+ Dox) and controlled conditions Panel c. Western blot against GFP-HA-ZFO from induced 
and uninduced cultures of cell line STL2266, the primary antibody was mouse anti-HA and 
the secondary HRP-conjugate anti-mouse. Mouse anti-EF1 was used to demonstrate equal 
sample loading. 
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4.5 PDK1 
4.5.1 Features of TbPDK1 
A predicted AGC family protein kinase, Tb09.160.3480, was identified by BlastP 
search as having an active site most similar to HsPDK1 (36% identity and 51% 
similarity). The kinome-wide RNAi screen undertaken previously detected a mild 
growth defect for this gene. The gene encoding this protein has a CDS of 1155 nt 
and encodes a 384 aa long protein predicted to have a mass of 43.17 kDa. It is 
predicted to contain a region C-terminal to the protein kinase domain that is 
annotated as a FYVE-Zinc Finger domain. This is similar in architecture to 
HsPDK1 which contains a PH domain C-terminal to the protein kinase domain.  
 
Figure 4-16: Schematic representation of TbPDK1 and HsPDK1 protein domain architecture 
with key features annotated. The scale above the diagram shows the amino acid number. 
4.5.2 RNAi of TbPDK1 
Two RNAi lines were generated to investigate the function of the PDK1 
homologue (15059/15060). RNAi ablation of TbPDK1 in culture led to a slow 
onset phenotype with a slow growth phenotype becoming apparent in the cells 
after 48 h of RNAi induction (Figure 4-17a). Following this, growth became static 
by 120 h. Cells looked abnormal, becoming enlarged and possessing multiple 
flagella. Cells exhibited abnormal nucleus and kinetoplast numbers, though this 
was not formally quantified. When RNAi of TbPDK1 was induced in trypanosomes 
infecting mice the phenotype became more pronounced with parasitaemia being 
undetectable after 72 h of RNAi induction (Figure 4-17b). RNAi knockdown of the 
target mRNA was confirmed by qPCR (Figure 3-7). 
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Figure 4-17: Growth curves for T. brucei 2T1 BSF RNAi lines (15059/15060) undergoing 
TbPDK1 knockdown, panel a. shows the cumulative cell counts (from haemocytometry) 
when RNAi is induced in culture. Error bars indicate the standard deviation around the 
mean of three technical replicates. Cell cultures were maintained between 10
5
 and 10
6
 cells 
per ml. Panel b. shows the levels of parasitaemia in mice infected with the RNAi line 15059 
under induced (+ Dox) and uninduced conditions. 
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4.6 Discussion 
4.6.1 NEK kinases as drug targets 
4.6.1.1 Overview 
In the study of the NEK 12 protein kinases their (combined) essentiality to the 
parasite has been demonstrated by RNA interference studies. Rapid cell death 
phenotypes were observed in culture and replicated in a more biologically 
relevant mouse infection. The knockdown of the target mRNA and protein was 
confirmed by two methods, qPCR and western blotting (of an epitope tagged 
NEK12.1). Abolition of the two NEK 12 protein kinases did not lead to an 
characteristic morphological or cell cycle defect. Cytokinesis appeared to 
continue, though correct segregation of nuclear DNA or kDNA appeared severely 
impaired leading to aberrant NK configurations. The NEK 12 proteins were 
homology modelled and this suggested that the small alanine gatekeeper residue 
of NEK 12.1 allowed the active site to expand, creating a deep hydrophobic 
pocket – a feature considered amenable for engineering specificity in potential 
inhibitory compounds. NEK 12.1 recombinant protein was amenable to 
expression in a bacterial system and could be purified to homogeneity yielding 
stable protein suitable for activity assays. Protein kinase activity assays, 
controlled by appropriate kinase dead mutants, demonstrated the recombinant 
NEK 12.1 was active and had a substrate preference for -casein. These assays 
could be inhibited by the addition of 3-MB-PP1, a protein kinase inhibitor with a 
bulky side group that should only inhibit protein kinases with a large hydrophobic 
back pocket (Bishop et al., 2000a, 2000b). This demonstrates NEK 12.1 is a 
suitable candidate for inhibition with more selective bulky inhibitors, though 
screening to identify the optimum inhibitor is probably required. These findings 
indicate that NEK 12.1 is potentially a very attractive molecule from the 
viewpoint of rational drug design. Some hurdles must be overcome to consider it 
a validated drug target and must be investigated further.  
4.6.1.2 Genetic Validation 
The first hurdle is to determine if NEK 12.1 is an essential kinase. The current 
knockdown construct targets two closely related genes leaving the question; is 
either NEK 12 essential to BSF trypanosomes in an individual knockdown? In order 
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to answer this it was attempted to design RNAi sequence to target the 3’ UTRs of 
each gene individually, as they are more diverged from each other than the 
relative CDS. However, when used in an RNAit query the UTRs were too similar to 
other regions of the trypanosome genome, and would have led to 
downregulation of non-target mRNAs making this strategy impossible.  Other 
strategies to validate these genes included gene knockout, which could have 
been used to show if either gene was not essential i.e. it can be knocked out. 
However, if a gene cannot be knocked out it only suggests essentiality, as the 
failure to stably transfect knockout constructs may be due to transfection 
failure. An inducible knockout system based on Cre-recombinase has been 
developed for use in trypanosomes that could allow inducible knockout of 
essential genes but is not in widespread use due to concerns over Cre toxicity 
(Scahill et al., 2008). Other techniques exist in other parasitic organisms such as 
plasmid shuttling or fusing the gene of interest to an inducible destabilisation 
domain, but these have not been established in T. brucei (Herm-Götz et al., 
2007; Morales et al., 2010). In order to attempt to validate the genes 
individually the technique we have chosen is a re-expression of RNAi refractory 
mutants to complement either wild-type gene that is ablated by double RNAi of 
both NEK 12s.  
4.6.1.3 Re-Expression of RNAi Refractory NEK 12 Mutants 
The data presented only go so far to validate the NEK 12 kinases as drug targets. 
Due to the nature of the double-knockdown achieved with the current RNAi 
system the relevance of each individual NEK 12 is unclear. In order to resolve 
this and define the more clearly the role of each NEK 12 we aimed to perform 
re-expression experiments where a recoded, RNAi refractory gene is expressed 
to complement the depletion of a wild type allele by RNAi. By doing this for NEK 
12.1 and NEK 12.2 the relative contribution to the double RNAi phenotype could 
be determined. For example it may be that both NEK 12s are essential 
individually, one is individually essential, or neither are individually essential. 
The ability to make functional mutants, e.g K70M kinase dead mutants, would 
also allow the validation of whether NEK 12 kinase activity is essential for BSF 
trypanosomes. The precedent for re-expressing RNAi refractory mutants in an 
RNAi background (in T. brucei) was set by Rusconi et al. 2005 by using targeting 
UTRs of genes and reexpressing them under the control of other UTRs (Rusconi 
143 
 
1
4
3
 
et al., 2005). Szöőr et al.2010 used a different approach by recoding the CDS 
(Szöor et al., 2010).  
In order to re-express RNAi refractory mutants of NEK 12.1 and NEK 12.2, and to 
express kinase dead mutants in vivo the expression vector pRM481 was recoded 
to include more user-friendly restriction sites and AttR Gateway Recombination 
sites (Proudfoot and McCulloch, 2005). Gateway sites were included in an 
attempt to make this system a tool suitable for medium-throughput cloning of 
these vectors to facilitate future functional genetic studies and to remove any 
problems associated with conflicting restriction sites. It was also engineered to 
contain a C-terminal 6xHA epitope tag to allow detection of recoded protein 
expression. To generate RNAi refractory NEK 12 genes their amino acid sequence 
were reverse translated, using T. brucei 927 codon bias, and manually assessed 
to ensure no regions of identity to wild-type genes over 20 nt in length. The 
recoded sequence was then used in an RNAit search to ensure no homology to 
the wild-type gene was detected and thus would not be downregulated by the 
NEK 12 RNAi target sequence (Redmond et al., 2003). The synthetic constructs 
were delivered and cloning attempted, though problems with the efficiency and 
accuracy of Gateway reactions have limited the usefulness of this approach so 
far. 
The advantage of re-expressing RNAi refractory mutants is the ability to mutate 
key features of the re-expressed protein to assess the effect in vivo once the 
wild type protein has been degraded. This should allow the importance of NEK 
12 activity to be tested and determine whether the observed phenotype is due 
to the lack of NEK 12 activity or lack of NEK 12 protein. Should NEK 12 form part 
of a multiprotein complex, ablation of NEK 12 may disrupt the complex and lead 
to a more severe phenotype than, for example, replacing NEK 12 with a kinase 
dead mutant. The importance of NEK 12 protein kinase activity to the parasite is 
an important question to answer; all current protein kinase inhibitors target 
catalytically competent protein kinases. Inactive or scaffold proteins related to 
protein kinases may present poor drug targets as novel inhibitors would have to 
be considered, rather than those that target the active site. Some proteins, such 
as Kinase Suppressor of Raf (KSR), have structural features suggestive of a 
protein kinase, though are catalytically inactive (Roy et al., 2002; Clapéron and 
Therrien, 2007). It acts as scaffold for the mammalian MAPK pathway. These may 
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have evolved from protein kinases to become catalytically inactive MAPK 
pathway supports. As such, proteins like KSR may present limited potential as 
drug targets due to their lack of enzymatic activity and the need for potential 
inhibitors to disrupt protein-protein interactions (Brennan et al., 2011). This is 
due to the fact that disrupting protein-protein interactions, which take place 
across a large surface area, may be more difficult than inhibiting a defined 
active site. However, this is being attempted for some CDK:Cyclin interactions 
(Kontopidis et al., 2003; Andrews et al., 2006). By re-expressing kinase active 
and dead mutants of each NEK 12 protein it should be possible to test if kinase 
activity is required for each protein for its function in vivo and if either NEK 12 
is individually essential to T. brucei. In order to fully genetically validate NEK 
12.1 as a drug target then these two requirements must be satisfied. 
4.6.1.4 Chemical Validation 
Should it be the case that NEK 12.1 is an essential, active protein kinase in the 
trypanosome (which is suggested by the kinase activity of the recombinant 
protein) then the next step is to screen candidate protein kinase inhibitors. This 
can be performed using a multitude of techniques. In this study the results of a 
virtual screen have been presented. Virtual screening has the advantage of being 
a “dry” technique; therefore is cheap, fast and relatively simple. The 
disadvantage is that it may not represent the real biological interaction of a 
receptor and ligand and since many different techniques exist, and each may 
produce a different result, standardisation is a problem. However, it is 
considered by some to be good first-pass screening technique to identify 
potential inhibitors or compound types/families for further investigation 
(Schneider, 2010; Scior et al., 2012).  
Ideally the virtual screen of the NEK 12s would have been conducted against a 
structure of NEK 12 determined by X-ray crystallography. In the absence of this, 
a homology model was used. Although homology models can be viewed as poor 
substitutes for real structural data, protein kinases contain many conserved 
amino acids vital for function, allowing good alignments of the query to the 
template. The template used in this model also had an inhibitor in the active 
site, directing residues towards it and increasing rigidity in this region. This 
should increase reliability of the model in this region. An obvious difference was 
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demonstrated between the back hydrophobic pocket of the two enzymes, with 
NEK 12.1 being much larger and canted upwards from the rest of the active site. 
The main deficiency in the models was the modelling of the activation loop. The 
template used to generate the models did not contain information on the 
activation loop due to its high flexibility producing poor X-ray diffraction 
patterns. This led to potentially very poor modelling of this region, however 
none of the ligands are predicted to interact with this area.  
The results of a virtual screen identified a diverse range of compounds predicted 
to bind into the active sites of both enzymes, including compounds with bulky 
ring structures predicted to interact with the rear hydrophobic pocket of NEK 
12.1. Many of the compounds contain a nitro group that is predicted to occupy a 
solvent accessible site. A number of compounds identified from this screen were 
tested for their ability to inhibit the growth of BSF trypanosomes and several of 
those predicted to bind NEK 12.2 gave IC50s in the low micromolar range. 
Compounds predicted to bind in the deep hydrophobic of NEK 12.1 actually had 
higher IC50s. Their ability to inhibit recombinant NEK 12.1 has not yet been 
tested but doing so might yield information on the structure-activity relationship 
(SAR). The reasons for the bulky, predicted NEK 12.1 inhibitors not having much 
effect on the BSF parasites may be due to solubility or cell permeability issues or 
NEK 12.1 just not being essential. As the inhibition profile of these compounds is 
unknown they may well be generating off target effects. However, even if this is 
the case, it may not necessarily rule them out as potential lead compounds – if 
they inhibit a range of trypanosome NEK kinases (but not human kinase) this 
could exploit the concept of polypharmacology making them more toxic to the 
parasite than a very specific inhibitor (Karaman et al., 2008; Ghoreschi et al., 
2009). It is clear that in vitro bulky inhibitors such as 3-MB-PP1 can inhibit NEK 
12.1 and that it has an inhibitory effect on parasite growth with an IC50 of 0.83 
M. Profiling these inhibitors using chemical proteomics in vivo  may provide 
more realistic IC50s for NEK and other kinases – NEK 12.1 and 12.2 were amongst 
7 NEK kinase detected by a recent chemical proteomics screen investigating 
inhibitors of GSK3 and the NDR kinase PK50/PK53 (Urbaniak et al., 2012b). 
Other techniques to search for inhibitors of NEK 12.1 could include using the 
recombinant protein in a surface plasmon resonance screen (SPR) of a fragment 
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library or to use the recombinant protein to develop a high-throughput screen 
(HTS) based on measuring enzyme activity. Fragment screening using techniques 
such as SPR can be used to detect very weak interactions of a ligand with a 
receptor and also use minute quantities of material. It allows the identification 
of fragments from drug-like molecules, which can then be combined to design 
specific and potent inhibitors of the protein of interest (Neumann et al., 2007).  
In order to set up a HTS against large compound libraries the activity assay used 
to measure the protein kinase activity must be re-formatted. It would be 
unsuitable to use a radioactive assay for both practical and safety concerns, and 
a non-radioactive assay such as an ADP/Kinase-Glo assay or IMAP fluorescent 
polarisation assay would be preferable (Tanega et al., 2009; Walker et al., 
2011c). This would require identification of a suitable peptide substrate for NEK 
12.1 (whose in vivo substrate is unknown), which can be carried out by screening 
a peptide library. Some human NEKs such as NEK 6 (Lizcano et al., 2002) and NEK 
2 (Cell Signalling Technologies) have been profiled for substrate preference and 
this may present a logical place to start looking for a NEK 12 peptide substrate. 
4.6.1.5 Biological Role of NEK 12 protein kinases  
Though the importance of the NEK 12 protein kinases to BSF T. brucei was 
demonstrated in this study, the biological role was not well investigated and one 
can only speculate as to their role in the cell. NEKs have been determined to 
play diverse roles in other organisms, though there are recurring themes. It 
appears that NEKs regulate cytoskeletal events, ranging from the development 
of cilia and axons to the control of mitotic spindle segregation. Trypanosomes 
have highly dynamic microtubule-base structures and organelles and accurate 
control of these is crucial to ensuring accurate morphology, motility and cell 
division (Benz et al., 2012; May et al., 2012). 
In the kinome-wide RNAi screen only 3 NEKs were detected as being important to 
BSF parasites after 3 days of RNAi ablation. Data from BSF RIT-Seq analysis 
confirmed our phenotypes for the NEK 12 kinases and NEK 16 (Tb927.10.14420), 
though RIT-Seq showed a stronger phenotype for NEK 16. RIT-Seq also detected 
Tb11.01.2900 (NEK 20) as generating a loss of fitness phenotype after 6 days 
RNAi, which the pTL screen would not detect (Alsford et al., 2011). The chance 
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of false negatives existing in these data is low after assessment of the library, 
therefore it appears that few of the NEKs are individually essential to BSF 
parasites. Several possibilities could explain this. The first is that the NEKs are 
so important to the parasite that it has evolved a battery of genes to enable 
redundancy in the system. If NEKs of T. brucei operate in cascades as seen in 
mammalian NEKS (Belham et al., 2003) then other protein kinases may be able 
to step in and complement the loss of another. As several NEKs are possessed in 
an array (Tb927.10.5930, Tb927.10.5940, Tb927.10.5950) this may suggest that 
the parasite is attempting to increase its gene dose of these protein kinases, 
further hinting at their importance. The role of redundancy in these systems can 
be probed by conducting double RNAi experiments or by attempting a chemical 
genetics approach. This could combine RNAi lines not exhibiting a growth defect 
combined with application of libraries of potential protein kinase inhibitors that 
also do not generate a lethal phenotype. Observation of the cells for synergistic 
effects of RNAi plus inhibitor can be used to identify different protein kinases 
that are not individually essential but together generate a synthetic lethal. This 
approach may start to allow the assembly of signalling pathways in T. brucei. A 
library of non-lethal inhibitor-like molecules should be identified from screens of 
a 30,000 compound library made available by GSK under the Open Lab 
Foundation (http://www.openlabfoundation.org/NEU-CSIC.aspx) and these may 
provide a useful resource in any future synthetic lethal screen. 
An alternative is that the NEKs examined in BSF form really are not essential for 
normal replicative growth in culture. However, if these proteins are involved in 
the complex remodelling events that occur during the other life cycle stages 
then they may show essential functions in these stages. TbMKK1 has been shown 
to be dispensable in BSF parasites but absolutely essential for progressing the 
parasite through the tsetse vector, potentially at the proventricular or 
epimastigote forms (Morand et al., 2012).The NEK kinases of Plasmodium, and 
Giardia have been shown to perform function at various different stages of 
development and it may be that in trypanosomes that NEKs are temporally 
regulated during different stages of the life cycle and thus an RNAi phenotype 
would only be observed in a given stage or during stage transition 
(differentiation). As the 2T1 strain is monomorphic, and any protein kinase 
important to stumpy BSF parasites may not be detected in this screen, a role in 
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slender to stumpy differentiation cannot be excluded from the potential 
functions of NEK kinases. Data from RIT-Seq experiments show that 
Tb927.2.2120 (NEK 22) and Tb927.4.5390 (NRKA) are essential in differentiating 
(BSF-PCF) trypanosomes and that Tb11.01.2900 (NEK 20) and Tb927.8.1690 (NEK 
14) are essential to established procyclic form trypanosomes (Alsford et al., 
2011). These experiments observe only part of the T. brucei lifecycle and 
important roles for NEK kinases are likely to exist in the other developmental 
stages found in the tsetse fly.  
One potential role of NEK kinases that could be investigated is regulating the 
disassembly of the nuclear pore complex (NPC) since various NEKs are involved 
in the regulation of this during mitosis in mammalian (HeLa) cells. HsNEK 6 and 
HsNEK 7 were shown to phosphorylate the nucleoporin Nup98, a protein which is 
predicted to be conserved in trypanosomes (DeGrasse et al., 2009; Laurell et al., 
2011). Performing a blast search of the T. brucei proteome with these two NEK 
sequences returns no clear homologues, with Tb927.3.3190 the top hit in both 
queries, though an RNAi phenotype was not detected for this NEK kinase during 
the pTL screen. The role of NEKs in regulating the flagellum has not been 
investigated in T. brucei though it may be an interesting avenue for 
investigation. The flagellum of kinetoplastids is a complex organelle responsible 
for multiple functions such as motility, attachment and potentially signalling. 
Several protein kinases are known to regulate flagellum length in Leishmania 
promastigotes (Bengs et al., 2005; Erdmann et al., 2006), and cilia formation in 
Tetrahymena and higher eukaryotes (Mahjoub et al., 2005; Wloga et al., 2006). 
More detailed phenotypic analysis of NEK RNAi lines could measure the flagellum 
for any changes in length or morphology.    
An interesting feature of NEK 12.1 and NEK 12.2 is the PH Domain. 7 NEK kinases 
are predicted to possess this domain (Parsons et al., 2005b), which may regulate 
the localisation of this protein kinase or direct it to its substrate (Lemmon et al., 
2002; Lemmon, 2004). This domain was original identified as binding to 
phosphoinositides. However, the majority of PH domains described do not 
independently localise to phospholipids and binding to small GTPases is another 
proposed target of the PH domain (Lemmon, 2004). Identifying where these 
proteins localise could provide information on their function. Also, if the PH 
domains do interact with other proteins then co-immunoprecipitation 
149 
 
1
4
9
 
experiments should be able to detect this, allowing better characterisation of 
their biological role. Localisation experiments to probe the function of NEK 12.1 
were considered. The localisation of the protein within the cell is unknown. 
Defining this could provide some information on its potential function. 
Recombinant NEK 12.1 (cleaved of its Trx and His tag) was used to immunise 
chickens; subsequently the IgY from the yolks of these chicken’s eggs was 
purified. Even after affinity purification of this IgY against recombinant NEK 12.1 
it has proved impossible to generate a clear, specific signal in western blots 
against parasite lysates. If this resource had been available it would have 
allowed a number of localisation experiments to be performed. It may also have 
allowed immunoprecipitation experiments to attempt to identify potential 
interacting proteins of NEK 12.1 - especially as the PH domain found in NEK 12.1 
may facilitate protein-protein interactions. 
Another feature of NEK 12.1, its small gatekeeper residue, may present 
opportunities to probe the function of protein kinase. If a selective inhibitor can 
be found for NEK 12.1 it could allow chemical genetic studies to dissect the 
function of NEK 12.1 over NEK 12.2. This approach has previously been used to 
investigate the function of TbAUK1 (the homologue of Aurora kinase A) in 
procyclic form parasites (Li et al., 2009). The authors suspected a dual role for 
TbAuk1 in mitosis and cytokinesis but could not perform RNAi in synchronous PCF 
cultures and observe both phenotypes clearly. The highly selective Aurora kinase 
inhibitor VX-680 was found to inhibit TbAuk1 in vitro, phenocopying the RNAi 
and overexpression of kinase dead mutant phenotypes. Using this inhibitor on 
synchronised PCF cells allowed the elucidation of TbAuk1s multiple roles in the 
cell cycle. This demonstrates the power of highly selective chemical inhibitors 
over genetic techniques. 
One way specific inhibitors could be used to investigate NEK 12.1 is in trying to 
identify its substrate. Previously, protein kinases with large gatekeepers have 
been engineered to contain smaller gatekeepers – which are compatible with 
bulky inhibitors. This allows specific inhibition of the so called analogue sensitive 
kinase allele (ASKA) (Bishop and Shokat, 1999; Bishop et al., 2000b). Libraries of 
bulky inhibitors have been developed to allow optimum inhibition of the ASKA 
protein kinase. The mutation often introduced is to change the gatekeeper to a 
glycine or an alanine. This approach is being used to study TbPLK (de 
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Graffenried, Unpublished). As NEK 12.1 already contains this arrangement it may 
be able to take advantage of the existing material (compound series) available 
for ASKA studies. 
The IC50 determination of 3-MB-PP1 against NEK 12.1 demonstrates that the 
small, alanine gatekeeper residue of NEK12.1 allows the accommodation of a 
bumped inhibitor. The optimisation of a kinase assay and further characterisation 
of NEK 12.1 would be crucial prior to making finer assessment of inhibitor 
potency. NEK12.1 could be characterised further by identifying the km and vmax, 
optimum ATP and substrate concentrations (processes that would also need to be 
conducted before developing an HTS assay). However, the ability for NEK 12.1 to 
accommodate bulky compounds could allow specific inhibition of NEK 12.1 by 
compounds that are only suitable as research tools. This could allow more 
accurate definition of the phenotype of blocking NEK 12.1 activity. If a specific 
inhibitor existed for research purposes then comparative phosphoproteomics 
could be used to compare inhibitor treated cells (or cell lystates) to untreated 
controls and look for changes in the patterns of phosphorylation, therefore 
identifying NEK 12 substrates or pathways. The large active site also opens the 
possibility of using bumped ATP analogues that allow radiolabelling or 
thiophosphorylation of the substrate followed by affinity purification and mass 
spectrometry to identify the substrate of NEK 12.1 (Johnson and Hunter, 2005; 
Elphick et al., 2007; Chi and Clurman, 2010). 
In terms of in vivo analysis with a bulky inhibitor, the other bulky derivatives of 
PP1 could be screened for effects against the recombinant NEK 12.1 kinase and 
any potent inhibitors tested against the parasite. This may identify inhibitors 
that phenocopy the RNAi of NEK12 or generate a different phenotype due to the 
lack of NEK 12.2 inhibition (assuming that NEK12.1 is the only ePK capable of 
being inhibited by bumped inhibitors). 3-MB-PP1 was tested against 2T1 BSF 
cells, generating an IC50 of 13.7 M. Though perhaps not ideal, relatively high 
concentrations (5 M) of bumped inhibitors including 3-MB-PP1 have been used 
to study calcium-dependent protein kinase 1 mediated egress of T. gondii from 
host cells (Lourido et al., 2010). Screening of the other derivatives of PP1 may 
reveal more potent inhibitors. Also, one other protein kinase (Tb927.10.3340) 
possesses an alanine gatekeeper. When ablated by RNAi this did not generate a 
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detectable phenotype so the effect of bulky inhibitors on the parasite may be 
unclear unless specificity is engineered into other parts of an inhibitor.  
This finding has implications for ongoing work to establish ASKA versions of other 
trypanosome protein kinases such as TbPLK. Mutations made to the gatekeeper 
of PLK reduced its activity and a compensatory mutation was made in the N-
terminal lobe, allowing inhibition of sensitised-TbPLK with 3-MB-PP1 (de 
Graffenried, Unpublished). However, if 3-MB-PP1 also interferes with NEK 12.1 
then it could complicate the findings of any TbPLK ASKA assay. Recently, a new 
way of targeting sensitised protein kinases with the use of an engineered 
cysteine gatekeeper residue was demonstrated. Modifying the gatekeeper to 
cysteine allows it be targeted by electrophilic inhibitors which may present a 
much more specific way of doing these experiments as cysteine gatekeepers are 
particularly rare (Garske et al., 2011). In addition, these inhibitors form a 
covalent bond to the cysteine and therefore irreversible inhibition of the 
engineered protein kinase. 
A word of caution must be said for the gatekeeper residue – point mutation of 
this single amino acid can lead to drug resistance in a given kinase. The most 
pertinent example of this is resistance of the Abl kinase to imatinib, dasatinib 
and nilotinib, caused by mutations of the small threonine gatekeeper (often to 
an isoleucine) (Barouch-Bentov and Sauer, 2011). In the hypothetical situation 
where a NEK 12.1 inhibitor, taking advantage of its small gatekeeper residue, 
entered clinical use then drug resistance would potentially be easily evolved. 
4.6.2 ZFO and PDK1 as Drug Targets. 
The data presented suggest that both ZFO and PDK1 might be genetically 
validated drug targets, though requirement for activity in vivo must be 
confirmed. The Orphan kinases do not fall into any classical families of protein 
kinase, therefore gaining structural data on ZFO would be interesting from a 
drug development and basic research viewpoint. The characterisation of ZFO 
could be very interesting due to the zinc-finger binding region. These are 
stereotypically involved in binding to nucleic acids- trypanosomes regulate gene 
expression post-transciptionally and RNA binding proteins are key to this. Zinc-
finger containing proteins (including protein kinases) have been previously 
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identified as having important roles in T. brucei (Vassella et al., 2001; Kramer et 
al., 2010; Benz et al., 2011; Ouna et al., 2012). Analysis of ZFO should include 
localisation studies, and imunoprecipitation studies of the HA tagged allele in 
order to attempt to identify interacting proteins or nucleic acids. 
PDK1 in mammals is a well-characterised enzyme and is the focus of much 
research. It is unclear whether the protein kinase investigated here is a 
functional homologue of HsPDK1. Trypanosomes are predicted to possess 
numerous conventional and unconventional PI-Kinases and are susceptible to 
inhibitors of PI3Kinases (Bahia et al., 2009; Diaz-Gonzalez et al., 2011). A blast 
search of the trypanosome kinome with HsPKB protein sequence identified a 
protein kinase with similarities to PKB (Tb927.6.2450), including an N-terminal 
PH domain, suggesting there may be enzymes and pathways analogous to some 
of those involving PDK1 in mammals.  The FYVE type zinc finger motif, predicted 
in TbPDK1, is known to bind PI3 and localisation of this protein should also be 
conducted (Kutateladze and Overduin, 2001; Tibbetts et al., 2004). 
In terms of chemical validation an attempt to target TbPDK1 (in vivo) was 
undertaken. In collaboration with Dr Rudi Marquez at the University of Glasgow 
Department of Chemistry, over 30 compounds (based on a “a polysubstituted 
pyridine framework”) developed as potential inhibitors of human PDK1 were 
assayed for activity against T. brucei 427 wt BSF cells using an alamar blue assay. 
Disappointingly, all compounds bar one had an IC50 above 75M; Compound 
“148” had an IC50 of 19.35M (data from N. Kasumu, MSc), which could be due 
to cell permeability issues or the inability of these compounds to fatally inhibit 
protein kinases in T. brucei. 
For two reasons it may be interesting to investigate this PDK1-like protein kinase 
further; it may represent conservation of a key eukaryotic signalling pathway in 
an early branching eukaryote and may also represent a druggable target that has 
had many potential inhibitors synthesised by medicinal chemists attempting to 
target human PDK1. 
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5 DFK – A Negative Regulator of Bloodstream 
Form to Procyclic Form differentiation 
5.1 Introduction 
5.1.1 Trypanosome Differentiation  
Trypanosoma brucei inhabits several very different environments during the 
course of its life cycle within various tissues of the mammalian host and the 
tsetse fly vector. It has to adapt to these environments and also ensure it does 
not kill the host before it can be transmitted to a new one. Early studies clearly 
noted that bloodstream form trypanosomes existed in differing morphological 
characteristics, slender and stumpy, with these strains being described as 
pleiomorphic (Vickerman, 1965; Steverding, 2008). Eventually, many laboratory 
cell lines lost this feature and became monomorphic – incapable of forming 
stumpy forms. This was due to the method of continuous mechanical passage of 
the infection, which selects for parasites with increased replication dynamics 
(Böhringer and Hecker, 1974) (G. Cross, http://tryps.rockefeller.edu/). The 
stumpy form of the parasite has been shown to be central to the transmission 
cycle of T. brucei as it is the form that can most efficiently differentiate from 
bloodstream form to the procyclic form in the tsetse fly. 
The proliferative slender bloodstream form must pre-adapt in order to regulate 
its density and achieve transmission effectively, by forming stumpy bloodstream 
forms. This process occurs in a density-dependent fashion in response to an 
undefined small-molecule(s) termed stumpy induction factor (SIF). Slender to 
stumpy differentiation triggers changes which prepare the parasite for uptake by 
a tsetse fly and also puts the cell into a quiescent state (G0/G1 arrest) (Reuner et 
al., 1997; Vassella et al., 1997). This proposed role for the cell cycle ensures 
only certain cells commit to becoming stumpy and then allows for rapid and 
synchronous differentiation to PCF forms (Ziegelbauer et al., 1990; Matthews 
and Gull, 1994).  
This density-dependent restriction of proliferation ensures control over parasite 
concentrations within the bloodstream. If this is not controlled, as is seen in 
animal infections with monomorphic laboratory strains, the proliferation will 
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increase in an unabated manner that proves fatal to the host. Once cells enter 
the stumpy form there is no return to proliferation unless the parasites undergo 
differentiation to procyclic form. The SIF trigger to form stumpy from slender 
cells has yet to be identified but was thought to activate cyclic nucleotide 
signalling pathways as it could be induced by cAMP analogues. However, it is now 
thought to be probably mediated by breakdown products of cyclic nucleotides, 
as cell permeable cyclic AMP analogues can be used to drive stumpy formation 
(Vassella et al., 1997; Laxman et al., 2006).  
The pre-adaptions to transmission that occur consist of mitochondrial 
remodelling and elaboration to allow for aerobic respiration instead of 
glycosomal glycolysis, due to the main energy source of the procyclic forms 
being proline rather than glucose. Expression of VSG is dysregulated, potentially 
as this is not required for survival after transmission (Amiguet-Vercher et al., 
2004). Uptake of haptoglobin-haemoglobin is reduced due to haptoglobin-
haemoglobin receptor (HpHbR) expression being downregulated, though 
endocytosis levels of several other ligands remain high. The lysosome is also 
repositioned anterior of the nucleus (Vanhollebeke et al., 2010). 
The surface of the trypanosome becomes further modified to contain PAD 
proteins PAD 1 and PAD 2. PAD 1 and PAD 2 are sited in an array of 8 PAD genes. 
PAD 1 is expressed only in stumpy forms with PAD 2 expressed in stumpy forms 
and procyclic forms, and thus PAD 1 expression provides a molecular cytological 
marker of stumpy forms. The genes encode proteins possessing an estimated 14 
transmembrane domains and have homology to carboxylate transporters; when 
expressed in Xenopus oocytes they function as citrate transporters, supporting 
this notion. Depletion of PAD 1 by RNAi blocked the differentiation of BSF to PCF 
by addition of citrate:cis-aconitate (CCA)(Dean et al., 2009).  CCA is probably 
the in vivo trigger for BSF to PCF differentiation; it can be used to differentiate 
BSF to PCF in culture and the efficacy of this increased by exposing parasites to 
cold shock (of 20oC, the approximate temperature experienced by dusk feeding 
tsetse flies) (Czichos et al., 1986; Engstler and Boshart, 2004). Cold shock 
increases the sensitivity to CCA of BSF trypanosomes to physiologically relevant 
levels, and also PAD 2 levels are upregulated by cold shock (Engstler and 
Boshart, 2004; Dean et al., 2009). 
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The differentiation to procyclic forms results in major morphological changes. 
The cells have a visibly different morphology and motility to BSF, the 
mitochondrion is enlarged and branched, and the positioning of the kinetoplast 
moves closer towards the nucleus (away from the posterior of the cell). Cell 
surface glycoproteins are changed, with a family of procyclins replacing the VSG 
coat. Procyclins play a role in protecting the parasites from peptidases in the 
tsetse midgut (Roditi et al., 1989). Two major forms of procyclin exist and are 
termed EP or GPEET, depending on the amino acid repeats they contain (Glu-Pro 
or Gly-Pro-Glu-Glu-Thr respectively) and multiple forms of these major types 
exist (Mowatt and Clayton, 1987; Mowatt et al., 1989). In fly infections the 
expression of procyclins is, to some extent, sequential with GPEET being 
expressed in early infections then transitioning to the various EP procyclin in late 
procyclic forms (with a concomitant reduction in GPEET); procyclins are subject 
to some proteolytic degradation but have a protease-resistant C-terminal domain 
(Acosta-Serrano et al., 2001). In culture the ratio of EP to GPEET can vary 
between different cell lines (Bütikofer et al., 1997). The levels of expression of 
procyclins (particularly GPEET) can further be regulated by the activity of 
mitochondrial enzymes (Vassella et al., 2004).  
Several studies have attempted to quantify the global changes in mRNA levels 
that occur when the BSF parasites differentiate to stumpy and procyclic forms. 
Microarray analysis of a portion of the trypanosome genome (796 genes) 
suggested that around 6% of this cohort was differentially regulated between BSF 
and PCF. Though this study was rapidly superseded by whole transcriptome 
analyses, it did detect changes in transcript levels of some protein kinases 
(Koumandou et al., 2008). Three studies used microarray analysis to try and 
quantify the changes between BSF and PCF and during the differentiation from 
slender to stumpy to procyclic. Various cell lines were used in each experiment, 
differentiation was conducted in different manners and variation between each 
data set was significant. However, all studies at least agreed there was 
significant remodelling of the transcriptome during differentiation with 14-20% 
of genes being differentially regulated (Jensen et al., 2009; Kabani et al., 2009; 
Queiroz et al., 2009). Of relevance to this study, the previous works all detected 
differences in protein kinase and phosphatase transcripts. Characterisation by 
RNA-Seq of the BSF and PCF transcriptome showed around 6% of transcripts were 
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differentially regulated two-fold or more, and was broadly in agreement with 
other studies (Siegel et al., 2010). Also broadly in agreement with this is the 
comparison of BSF and PCF proteomes by stable isotope labelling in culture 
(SILAC) followed by sensitive LC-MS/MS, showing 10% of the proteome being 
differentially regulated, but at much greater fold change (up to 5-fold)(Urbaniak 
et al., 2012a). Both triggering and effecting the differentiation process in 
trypanosomes requires signalling, and reversible phosphorylation has been 
implicated and well studied in this process. 
5.1.2 Reversible phosphorylation during trypanosome 
differentiation 
Differential phosphorylation of tyrosine and differential tyrosine kinase activity 
has been demonstrated in the various developmental stages of trypanosomes, 
though without assignation of functional relevance (Parsons et al., 1991, 1993). 
The first functional implication of a protein kinase in differentiation came from 
analysis of a protein kinase in the AGC family. Initially investigated for its 
unusual domain architecture – a PX domain followed by a FYVE zinc finger then 
the protein kinase domain. When the gene was knocked out of monomorphic BSF 
trypanosomes (MiTat 1.4) no growth defect was evident. When it was knocked 
out of pleomorphic AnTat 1.1 BSF cells they began to develop growth retardation 
after around 50 hours in culture (after obtaining cells from infected mice and 
pre-culturing them in methylcellulose containing medium). Growth then began 
to plateau after 4 days. It was observed that the cells were differentiating to 
stumpy forms, even though cell density was being controlled to prevent this. 
Differentiation was confirmed by assaying for NAD diaphorase activity (detecting 
the increase in mitochondrial activity), with about 90% of the cells being 
diaphorase positive and in the G1/G0 phase of the cell cycle. The knockout 
parasites exhibited equal virulence to unmodified parasites when used to infect 
both immunocompetent and immunosuppressed mice and could also be 
transmitted through tsetse flies which could then re-infect mice. The increased 
sensitivity to parasite density indicates that ZFK has a dampening effect on the 
activity of SIF (Vassella et al., 2001). 
The second protein kinase to be implicated in the slender to stumpy 
differentiation was TbMAPK5 (Domenicali Pfister et al., 2006a). MAPKs or 
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mitogen activated protein kinases are CMGC family kinases and can be further 
subdivided by the central amino acid in the activation loop TXY motif. TbMAPK5 
has a TDY motif, distinguishing itself from MAPKs in higher eukaryotes; 
phylogenetic analysis has also placed it outside of known MAPK classes. When 
knocked out of monomorphic BSF cells no growth defect was observed (as for 
ZFK) but when in vitro differentiation to PCF was conducted the knockout had a 
50% lower efficiency. When the knockout was conducted in pleiomorphic BSF and 
the cells used to infect mice a growth defect was observed. Peak parasitaemias 
were lower in the knockout cell lines, though waves of parasitaemia were still 
observed. In order to control for the effect of the mouse immune response (in 
case MAPK5 knockouts were more susceptible to it) the lines were used to infect 
immunosuppressed mice. Compared with the wild type the knockout lines did 
not increase their maximal parasitaemia, suggesting they were more sensitive to 
cell density and that this was limiting their growth. Parasites containing an add 
back partially restored their virulence, but when an add back TbMAPK5 with the 
TDY motif mutated to ADF (making it inactivatable, and therefore dead or much 
reduced in kinase activity) was added, the phenotype was much more 
pronounced. Microscopic analysis showed the cells were forming morphologically 
stumpy forms at much lower densities (and was confirmed by diaphorase 
staining). This was replicated in culture by allowing cells to grow in 
unconditioned medium or media mixed to contain various percentages of 
conditioned medium, revealing that TbMAPK5 knockout cells showed a much 
higher sensitivity to SIF.  
The result of these two studies demonstrated a role for ZFK and MAPK5 in 
controlling the responsiveness of trypanosomes to SIF by repressing them from 
differentiating to slender from stumpy cells at low densities. Recently, another 
protein kinase was implicated in this process (Barquilla et al., 2012). TbTORC4, a 
complex containing the TbTOR4 kinase (a PIKK (phosphatidyl inositol 3' kinase-
related kinases, atypical protein kinase group)) was found to negatively regulate 
stumpy formation in monomorphic trypanosomes. Transient or continuous RNAi 
of TbTOR4 led to irreversible differentiation to a G0/G1 arrested state. TbTOR4 
RNAi induced cells became diaphorase positive, indicating increased 
mitochondrial oxidative capacity, became resistant to mild acid and developed a 
shortening of the flagellum with a rounded posterior, consistent with stumpy 
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form trypanosomes. Transcript profiling was conducted for a set of 10 genes 
known to be selectively upregulated in stumpy forms and for the majority of 
these the change in TbTor4 RNAi cells vs. parental cells was the same as stumpy 
vs. slender cells, suggesting the cells had developed a transcriptome similar to 
stumpy forms. RNA polymerase 1 was shown to delocalise from the expression 
site body to all over the nucleus, again consistent with a stumpy phenotype. 
The transcripts upregulated in TbTOR4 RNAi lines included PAD 1 and PAD 2, 
which corresponded to an increase in the expression of PAD1 protein by western 
blot. This protein was presumably being trafficked to the cell membrane as the 
RNAi lines became hypersensitive to physiologically relevant levels of cis-
aconitate, with approximately 20% of cells gaining EP procyclin after exposure to 
0.01 mM or 0.1 mM cis-aconitate. Taken together, this suggests that TbTOR4 
depletion is required for pre-adapting the parasites to allow effective 
transmission. The study sought to assess what signalling pathways might be 
regulating TbTOR4 expression by treating the cells with hydrolysable and non-
hydrolyzable cAMP analogues and AMP analogues. AMP and hydrolysable cAMP 
analogues induced the downregulation of TbTOR4 expresssion, though non-
hydrolysable analogues of cAMP did not. The authors conclude that AMP levels, 
or specifically a high ratio of AMP to ATP (thus indicating reduced cellular 
energy), inactivate TbTOR4 to trigger differentiation of slender to stumpy forms. 
The authors also suggest that TbMAPK5 and ZFK also participate in the same 
complex signalling pathway, and that as ZFK is an AGC kinase (which is a well-
known TOR substrates in other organisms) it may be acting as a downstream 
effector of TbTOR4. Research in other organisms has linked TOR kinase functions 
to nutrient sensing and TbTOR4 may represent a trypanosome specific variation 
on this process (Howell and Manning, 2011). This may be supported by the fact 
that inhibition of glucose transport into BSF cells, and thus nutrient stressing 
them, can induce a partial differentiation to PCF forms (Haanstra et al., 2011).  
The next stage of differentiation, from stumpy to PCF, is a process that also had 
a MAP kinases implicated in its progression (Müller et al., 2002a). When TbMAPK2 
was knocked out of monomorphic bloodstream form parasites no difference in 
the rate of growth or morphology was observed. When the BSF cells were 
induced to differentiate to PCF cells by the addition of cis-aconitate they 
appeared to do so (by morphology) but subsequently became growth arrested. 
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Specificity of the phenotype was confirmed by TbMAPK2 add back at an 
exogenous locus. Examination of the phenotype in more detail showed that the 
cells were experiencing a delay in the differentiation process. This was assessed 
by the expression of PCF markers such as EP procyclin (early) and CAP5.5 (a late 
procyclic marker), which were both delayed to the same extent, suggesting 
differentiation proceeded at a normal pace but cells were delayed in their 
licensing for differentiation. After differentiation cells were shown to go through 
approximately one cell division but then became growth arrested thereafter, and 
also exhibited abnormal nucleus:kinetoplast conformations. The re-expression of 
TbMAPK2 with a non-activatable AEF (instead of TEY) motif in the activation loop 
generated the same phenotype, suggesting that TbMAPK2 is also dependent on 
upstream MAPKKs for activation. Despite many attempts the gene could not be 
knocked out of established PCF cell lines, further indicating that it plays an 
essential role in the proliferation of PCF parasites. 
As protein kinase activity is clearly important to the differentiation process it is 
reasonable to assume that protein phosphatase (enzymes that dephosphorylate a 
substrate) activity is also involved at some stage. T. brucei possesses 78 proteins 
containing a protein phosphatase domain (Brenchley et al., 2007). Whilst 
searching for genes likely to be involved in stumpy BSF differentiation 
competence Szöőr et al. (2006) identified a gene with similarity to a mammalian 
protein tyrosine phosphatase (PTP) that they investigated further (Szöor et al., 
2006). Named TbPTP1, it was found to be upregulated in stumpy forms at a 
transcript level, but that protein levels remained constant throughout slender, 
stumpy and PCF stages. It was found to predominantly associate with the 
cytoskeletal fraction of differentially detergent-fractionated BSF cells. Analysis 
of the amino acid sequence showed that TbPTP1 contained 9 out of 10 PTP-
specific conserved residues and motifs compared with human PTP, and possessed 
a trypanosome specific motif replacing the missing conserved motif. Other 
trypanosome specific motifs also led the authors to place TbPTP1 in a 
trypanosome specific PTP family. TbPTP1 was shown to be a functional tyrosine-
specific protein phosphatase in vitro and did not exhibit activity against Ser/Thr-
phosphorylated substrates, phospholipids, nucleotides or inorganic 
phosphocompounds. The recombinant enzyme could be inhibited with tyrosine 
phosphatase specific inhibitors. Most interestingly was that when TbPTP1 was 
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depleted by RNA interference between 2-12% of cells, of a monomorphic stock, 
spontaneously differentiated to PCF cells at 37 oC in HMI-9 medium. The cells 
stained positively with anti-EP, anti-GPEET and anti-CAP5.5 antibodies, and 
exhibited PCF characteristic repositioning of the kinetoplast. Although the RNAi 
phenotype was unstable (due to the use of pZJM system), an inhibitor of 
mammalian PTP1B, BZ3, could induce the same phenotype as TbPTP1 RNAi when 
applied at 150 M. BZ3 was also shown to inhibit the recombinant TbPTP1. The 
specificity of BZ3 for TbPTP1 was further demonstrated by inducibly expressing a 
dominant-negative, substrate trapping mutant (D199A) and treating the cells 
with BZ3, compared with the uninduced control the substrate trapping mutant 
and BZ3 treatment led to an increase in the proportion of cells differentiating to 
PCF. This demonstrated that BZ3 was not inhibiting a downstream target of 
TbPTP1. 
The authors then used BZ3 to investigate the role of TbPTP1 in the 
differentiation in pleiomorphic cells. When applied to slender parasites 
extracted from infected mice, BZ3 induced a very similar differentiation 
phenotype as seen when applied to monomorphic BSF cells, i.e. 7% 
differentiation after 24 h. When BZ3 was applied to stumpy enriched populations 
extracted from mice the phenotype was strikingly similar to that induced by the 
addition of cis-aconitate. Both these experiments were conducted at 37 oC in 
HMI-9, and cells expressed EP procyclin, CAP5.5 and repositioned the kinetoplast 
to procyclic type morphology. The authors account for the differentiation of 
monomorphic and slender pleiomorphic cells when TbPTP1 is inhibited by 
inferring there is a population of Stumpy* cells that respond to TbPTP1 
inhibition. Stumpy* cells are considered slender in morphology but have the 
functionality of a stumpy in terms of their ability to differentiate (Tasker et al., 
2000; Matthews et al., 2004). 
The ability to generate substrate trapping mutants of TbPTP1 allowed further 
investigation of its biological role (Szöor et al., 2010). By conducting a pulldown 
using resin-chelated TbPTP1-D199A a protein of 39 kDa was found to interact. 
This was confirmed using reciprocal pulldown and the protein was named 
TbPIP39 (TbPTP1-interacting protein, 39 kDA). The authors identified a potential 
phosphorylation site (Tyr 278) and used FGR kinase (human Gardner-Rashid feline 
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sarcoma viral (v-fgr) oncogene homologue protein kinase) to phosphorylate this 
residue (confirmed by generating a T278F mutant). Phosphorylated TbPIP39 
could then be dephosphorylated by TbPTP1 but not by an inactive mutant of 
TbPTP1 in vitro, indicating that it was also a potential substrate of TbPTP1 as 
well as an interacting partner. This tyrosine residue was also deduced to be 
important for the activity of TbPIP39, since while phosphorylated the protein 
exhibited greater phosphatase activity than when not. When the two 
phosphatases were combined to dephosphorylate a third substrate a synergistic 
effect was observed and determined to be due to TbPIP39 increasing the activity 
of TbPTP1. This activity could be abolished by the addition of CCA. TbPIP39 was 
shown to localise to glycosomes and that it was only expressed as a protein in 
stumpy or PCF cells. By testing cell lysates with an antibody against 
phosphorylated TbPIP39 Y278 it was shown that under cis-aconitate or BZ3 
treatment phosphorylation of this residue was enhanced. Expression of TbPIP39 
was also upregulated by cold shock. These factors led the authors to predict that 
TbPIP39 was involved in regulating the stumpy to PCF differentiation process in 
some manner. To test the hypothesis of TbPIP39 being involved in the stumpy-
PCF differentiation it was ablated by RNAi and differentiation induced by 
addition of cis-aconitate. At physiologically relevant levels of CCA the 
differentiation process was reduced in RNAi induced cultures, implicating 
TbPIP39 as being an effector of stumpy to PCF differentiation. Re-expressing a 
wild-type but recoded TbPIP39 allele (which was therefore refractory to RNAi) 
restored the ability to differentiate at 0.1 M cis-aconitate. Expression of 
mutants that were incapable of entering the glycosomes could not compensate 
the differentiation defect, nor could expression of a catalytically dead mutant. 
Taken together the results of Szöőr et al. (2006, 2011) demonstrate that a 
phosphatase cascade is responsible for triggering effective BSF to PCF 
differentiation. 
The differentiation process could provide a novel mechanism of therapeutically 
targeting the parasite. Using an inhibitor to induce differentiation to stumpy or 
PCF cells in the bloodstream of the host would eventually prove fatal to the 
parasite. If parasites could be efficiently stimulated to enter stumpy G0/G1 
arrest, using an inhibitor of TbMAPK5 for example, they would eventually perish 
due to their inability to re-enter proliferation. Aberrant differentiation to PCF 
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forms would also be fatal to the parasite, as the expression of procyclin could 
make them susceptible to complement mediated lysis and also provides a static 
immunological target (due to loss of VSG expression and switching) (Ferrante and 
Allison, 1983). However, this would necessitate any inhibitor to cause 100% 
switching of parasites to a stumpy or procyclic form to be effective. 
5.1.3 Research Aims 
As reversible protein phosphorylation is clearly implicated in trypanosome 
differentiation it was evident that the pTL library provided a resource for 
investigating this process further. The 2T1 strain of trypanosome is considered to 
be monomorphic so it was reasoned that stumpy formation would be difficult to 
investigate. However, the 2T1 cell line can differentiate asynchronously to PCF 
using cis-aconitate stimulation. Two possible roles can be envisioned for protein 
kinases involved in regulating BSF-PCF differentiation; negative and positive 
regulation of differentiation. The first scenario is that RNAi of a protein kinase 
results in the spontaneous induction of BSF to PCF differentiation, akin to the 
TbPTP1 RNAi phenotype. The second is that RNAi of a protein kinase will not 
generate an obvious phenotype in BSF cells but when they are induced with cis-
aconitate are not able to progress to PCF cells. The first scenario was the easiest 
to test during our initial RNAi screen, and was carried out by observing cell 
morphology during RNAi, and/or testing for procyclin expression. The second 
scenario could not be tested due to time and labour constraints. 
Following identification of any such protein kinase involved in regulation of BSF-
PCF differentiation studies would be undertaken to attempt to determine the 
function of the gene including characterisation of the phenotype, localisation of 
the protein, attempts at functional genetics and analysis of recombinant 
protein. 
5.2 Results 
5.2.1 Identification and Features of DFK 
Whilst undertaking the kinome-wide RNAi screen an RNAi cell line, targeting the 
gene Tb11.01.5650, was observed to exhibit a morphological defect under 
tetracycline induction where the BSF parasites exhibited an elongated shape and 
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began to move in an uncharacteristic manner. Because of the interesting 
phenotype this cell line was investigated further. Based on the phenotype of the 
RNAi mutant this protein kinase was eventually termed DFK for Differentiation 
Kinase, the reasons for this are described below. This phenotype was not 
observed in any of the other protein kinase RNAi lines. 
Tb11.01.5650 was detected in the bioinformatic classification of the kinome as a 
STE11 like kinase (Parsons et al., 2005b). The CDS of the gene is 3588 nt in 
length and this encodes a 1195 amino acid peptide – a protein with a predicted 
mass of 131 kDa. The DFK protein is predicted to have a kinase domain in the 
very C-terminal region with most of the protein being N-terminal to the kinase 
domain (Figure 5-1). This region is predicted to contain multiple transmembrane 
domains (Table 5-1). However, different prediction algorithms gave differing 
numbers of TM domains, and predicted them in different positions of the 
sequence (Figure 5-2).  DFK has been detected in the flagellar membrane 
proteome, suggesting it is present in the flagellar or cell membrane (Oberholzer 
et al., 2011). Other domains were detected using PFAM analysis. These were a 
HAMP domain and a TPR2 domain – which had significant E-Values and are also 
present in the T. cruzi orthologue (TcCLB.511727.210) – which was originally 
identified by Parsons et al. 2005. HAMP stands for “Present in Hisitidine Kinases, 
Adenylate Cyclases, Methyl Accepting Proteins and Phosphatases” and is a linker 
domain that crosses the plasma membrane (Parkinson, 2010). TPR domains 
(Tertatricopeptide-like Repeats) are found in a huge diversity of proteins and are 
thought to mediate protein-protein interactions (Allan and Ratajczak, 2011; 
Zeytuni and Zarivach, 2012). To our knowledge the protein has not been 
detected as being post-translationally modified (TriTrypDB). 
 
Figure 5-1: Schematic representation of the DFK protein: TM domains are highlighted 
corresponding to those predicted by the TMHMM algorithm. HAMP, TPR and protein kinase 
domain determined by PFAM domain search. Scale above indicates amino acid position. 
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Table 5-1: List of the transmembrane prediction algorithms used to assess the potential TM 
domains in DFK. 
Algorithm Reference Number of TM Domains 
TMHMM http://www.cbs.dtu.dk/services/TMHMM/ 3 
HHMTOP www.enzim.hu/hmmtop/ 3 
TM-PRED www.ch.embnet.org/software/TMPRED_form.html 5 
SOSUI http://bp.nuap.nagoya-u.ac.jp/sosui/ 2 
PRED-TMR http://athina.biol.uoa.gr/PRED-TMR/ 4 
 
 
Figure 5-2: Diagram of  the position of predicted TM domains of DFK from five different 
prediction algorithms (blue), which are all in the region N-terminal to the protein kinase 
domain (red). The top sequence shows other domains detected in PFAM analysis using CLC 
genomics – the left cyan bar represents a HAMP domain and the right a TPR repeat. 
5.2.2 RNAi Results 
RNAi ablation of DFK mRNA in BSF trypanosomes in HMI-11 at 37oC did not 
generate a growth phenotype detectable by the alamar blue assay. However, 
when viewed under a microscope at 72 hours post-induction the morphology of 
an obvious proportion of the cells was clearly not consistent with BSF 
trypanosomes, with the cells appearing to look and move like procyclic form 
trypanosomes. Using two bioreplicates (cell lines STL201/202) a cumulative 
growth curve was performed over several days, showing that the cells developed 
a slow-growth phenotype by 72 h that should have been detectable by the 
alamar blue screen. The growth defect became apparent at 48 h post-induction 
and this became more severe over the course of a 6 day experiment (Figure 5-3). 
The morphological phenotype was termed PCF-like prior to further confirmation. 
DFK RNAi cell lines were used to infect mice and RNAi was induced in the test 
mice by the addition of doxycycline to drinking water. Due to the weakness of 
the growth defect, RNAi induction was performed at the same time as infection 
in order to increase the chances of detecting the weak phenotype. Parasitaemia 
was unaffected in the test mice despite multiple attempts and varying the level 
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of inoculum and timing of RNAi induction (Figure 5-3b).  Targeting DFK by RNAi in 
culture caused a 60 % depletion of the mRNA after 24 h (as determined by qPCR 
of DFK mRNA levels) (Figure 3-7). Western blotting against a tagged allele 
showed an almost total depletion of the tagged allele by 24 h (Figure 5-7), 
showing that the RNAi of DFK was effective. 
 
Figure 5-3: Growth curves of DFK RNAi cell lines (plus/minus induction). a. In culture RNAi 
using cell lines STL201/STL202 (two bioreplicates) with mean values plotted and 1 standard 
deviation error bars (3 technical replicates). b. Parasitaemia of infected mice using STL201, 
two mice (3 and 4) were given Doxycycline laced water to induce RNAi as soon as they were 
infected. The limit of detection of parasitaemia was 10
4
 parasites per ml of blood. 
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5.2.3 Evidence of Differentiation 
As it appeared that the ablation of DFK RNAi was inducing a PCF-like morphology 
the expression of procyclic-specific markers was tested. Procyclic cells express 
EP procyclin so the DFK RNAi cell lines were tested for expression of this cell 
surface glycoprotein using a monoclonal anti-EP procyclin antibody conjugated 
to FITC. This allowed simple labelling protocols for both FACS (fluorescence 
activated cell sorting) and IFA (immunofluorescense analysis) applications. 
In order to assess whether DFK RNAi cell lines expressed EP procyclin and thus to 
quantify the proportion of cells differentiating to PCF-like cells in the RNAi a 
FACS assay was performed. Cells were fixed, washed and were labelled with 
FITC-conjugated anti-EP procyclin before being assayed by flow cytometry using 
a FACSCalibur system. Control samples consisting of BSF 2T1 cells, PCF 927 cells 
and a mix of BSF and PCF parasites were used to get baseline data on a negative 
control, positive control and mixed sample respectively. The curves generated by 
these controls were used to set bifurcation gates to define the EP procyclin 
positive and negative parasites in the test samples (Figure 5-4). Samples were 
taken of cell lines in which DFK RNAi had been induced for 24 h, 48 h and 72 h 
timepoints and assayed (Figure 5-5). The results showed that 0.18% of events 
were EP procyclin positive in the 2T1 parental cell line, which indicates a level 
of background labelling in the assay. This increased to 0.35% in the uninduced 
DFK RNAi lines. In the induced DFK RNAi samples at 24 h, 1.85% of cells were EP 
procyclin positive, at 48h 5.04% were positive and at 72 h 16.7% were positive. 
For each sample 100,000 events were collected, gated to exclude debris and 
separated by bifurcation gate into EP positive and negative populations. The 
counts were evaluated by Chi square analysis for trend using Prism Graphpad 
which determined the increase in EP positive cells to be highly significant.  
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Figure 5-4: FACS curves for control samples showing the fluorescence of BSF (a.), PCF (c.) 
and mixed cells (b.) when labelled with a FITC-conjugated anti-EP procyclin monoclonal 
antibody, results are combined in panel d. The mixed BSF/PCF sample (b.) was used to 
define the bifurcation gate to separate PCF from BSF in further experiments. N=100,000 
cells per experiment. 
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Figure 5-5: FACS curves for DFK RNAi (Cell line STL201) samples at 37
o
C in HMI-11 showing 
the fluorescence of RNAi induced cells when labelled with a FITC-conjugated anti-EP 
procyclin monoclonal antibody. This marker was used to determine differentiation to PCF. 
Uninduced control a. compared to induced samples at 24 hour intervals until 72 h (b.-d.) 
with panel d showing 17% PCF cells in the culture. Combined results are shown in panel e. 
Bifurcation gate set from Figure 5-4b.  N=100,000 cells per experiment. 
Cells that had been analysed by FACS were further stained with DAPI and 
observed under a fluorescence microscope to assess the morphology of the 
differentiated cells. It was observed that a number of the EP procyclin positive 
cells were undergoing kinetoplast repositioning to exhibit a procyclic morphology 
(Figure 5-6a/b). Other cells were clearly abnormal in their morphology and 
nucleus/kinetoplast configuration though no attempts to quantify a specific 
defect have yet been made. The defect may be specific to DFK RNAi or may be 
due to 2T1 cells not having the ability to proliferate effectively as PCF cells. 
Images collected using an IN-Cell Analyser 2 supported the FACS data as 
approximately 20% of cells were EP procyclin positive in a test of cultures where 
RNAi was induced for 96 h (E. Kalkman, Scottish Bioscreening Facility). 
Repositioning of the kinetoplast was also observed in these samples as well as 
undefined morphological and nucleus-kinetoplast positioning defects (Figure 
5-6c). Although no quantitative analysis of this data has yet been performed it 
should be possible to write an algorithm using IN-Cell Explorer software to 
measure nucleo-kinetoplast distances in the induced and uninduced samples. 
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Figure 5-6: a. An example of an apparently morphologically correct PCF after differentiation 
from BSF induced by RNAi of DFK for 72 h (a. IFA, b. DIC) Green: FITC conjugated anti-EP 
procyclin, Blue: DAPI. Panel c. Shows a representative, merged image from the IN-Cell 2000 
of DFK RNAi after 96 h of induction. Green: FITC conjugated anti-EP procyclin, Blue: DAPI, 
Red: Cellmask Red cytoplasmic stain. In panel a. solid arrow denotes kinetoplast 
repositioning from the typical posterior location in a BSF parasite (approximate location 
indicated with dashed arrow). 
In order to assess if the differentiation process was occurring when RNAi of DFK 
was induced in a mouse infection, terminal bleeds were taken from control and 
test mice, and the buffy coat separated from whole blood. This was washed with 
PBS and labelled with the anti-EP procyclin antibody prior to analysis by IFA and 
10m
a.
10mb.
c.
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FACS but no evidence of differentiated PCF parasites could be detected these 
isolates. 
5.2.4 Localisation of DFK 
5.2.4.1 Epitope Tagging and Crude Cell Fractionation 
An allele of DFK was endogenously tagged with a C-terminal 12Myc epitope using 
the pNAT BSD x12Myc (pGL2178) vector(Alsford and Horn, 2008). The final 3’ 1kb 
of the CDS (minus the stop codon) of the DFK gene was cloned into this vector 
between the HindIII and XbaI sites of the vector (pGL2203). The plasmid was 
linearised with an insert unique PstI site and transfected. This tagging technique 
inserts the 3’ of the CDS fused to the 12Myc epitope tag followed by a stop 
codon into the endogenous DFK locus. The 3’ UTR is replaced with an actin UTR 
in this strategy. The plasmid was transfected into cells carrying the DFK RNAi 
cassette (pTL129, STL403). Eight blasticidin resistant clones were screened for 
expression of Myc by western blot. Three were found to express high levels of a 
Myc-tagged protein close to the predicted size of DFK-12Myc and two (clones 
1/2) were selected for further analysis (designated STL2378/2379) (Figure 5-7a). 
To provide further evidence that it was DFK that had been tagged and that DFK 
RNAi was effective an RNAi induction was performed. After 24 h induction, the 
signal on an anti-Myc western blot was almost totally ablated from both cell 
lines (Figure 5-7b).   
As DFK was observed in the flagellar membrane proteome (Oberholzer et al., 
2011) and has multiple transmembrane domains a crude cell fractionation was 
performed to give a low resolution indication of where DFK localises (Figure 
5-7c). DFK12Myc expressing BSF parasites were lysed using a hypotonic TrisHCl 
buffer or a Triton X-100 containing buffer to differentially fractionate the cells. 
DFK-12Myc was detected in a soluble fraction of the cell following lysis in a 
Triton X-100 detergent-containing buffer and an insoluble pellet from a 
hypotonic cell lysis, suggesting a membrane location. It was not detected in 
fractions corresponding to the cytosol or cytoskeleton in either detergent or 
hypotonic lysis. The anti-Myc signal obtained on the western blot against the 
insoluble pellet from hypotonic lysis was dramatically reduced. To test for the 
presence of Oligopeptidase B (OPB), which should localise to the cytosolic 
171 
 
1
7
1
 
fractions, sheep anti-OPB serum was used as a control (Burleigh et al., 1997; 
Morty et al., 2001; Munday et al., 2011). The KMX-1 antibody was used to probe 
for -tubulin, which should be found in the cytoskeletal fraction. -tubulin was 
also detected in the cytoskeletal and cytosol containing fraction of the 
hypotonic lysis sample. This is at odds with previous work but does not affect the 
interpretation that DFK is a membrane associated protein.  This effect may be 
due to fragmentation of the cytoskeleton by the sonication used during lysis, 
allowing some -tubulin to enter solution.  Attempts were made to use the 
Pierce M-PER kit, which is designed to purify integral membrane proteins, to 
purify DFK-12Myc. However, the volumes of reagents used are quite high and 
appear to require very large numbers of parasite cells to generate concentrated 
protein extracts. Optimisation of this procedure was not sufficiently advanced to 
obtain membrane extracts of sufficient concentration to provide a signal strong 
enough for western blotting experiments. 
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Figure 5-7: Panel a. Western blot to screen parasite clones transfected with pGL2203 to 
endogenously tag DFK with C-terminal 12Myc. Panel b. shows the results of a western blot 
against cell lysates from the selected clones STL 2378/2379 which express a DFK-12Myc 
fusion protein. EF1- provides a loading control. Panel c. is the result of a western blot 
against crude sub-cellular fractionations of STL2378. OPB is used as a control for a 
cytosolic protein and -tubulin a control for a cytoskeletal protein. 
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5.2.4.2 Immunofluorescence Analysis of DFK-12Myc Tagged Cell Lines 
In order to gain further insights into the localisation of DFK, the DFK-12Myc cell 
lines were subjected to immunofluorescense analysis (IFA). Cells were dried onto 
multiwell slides coated in poly-l-lysine and fixed with 4% formaldehyde PBS v/v. 
Some samples were treated with 0.1% Triton X-100 PBS v/v to increase 
membrane permeabilisation for comparison. Samples were blocked with 1% BSA 
PBS w/v. Following labelling with mouse anti-Myc (4A6, Millipore), anti-mouse 
AlexaFluor-594 and DAPI, cells were observed under an epifluorescence 
microscope. Control samples were included to determine if the secondary 
antibody binding was specific, and that the primary antibody did not bind to 
cells not expressing the Myc epitope tag. Cells not exposed to detergent stained 
brightly and evenly over the whole cell membrane, including the flagellum. 
Those that had been permeabilised exhibited a weaker and more punctuate 
fluorescence pattern, occasionally with brighter staining in an area that could 
represent the flagellar pocket. All the cells in the sample appeared to be equally 
labelled. Cells that did not express DFK-12Myc did not label with the primary 
antibody. Cells not treated with the primary antibody did not bind the 
fluorescently labelled secondary antibody. These data are consistent with DFK 
exhibiting a cell membrane localisation. 
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Figure 5-8: Immunofluorescence localisation of DFK-12Myc in cell line STL2379, using 2T1 
cells as a negative control. Prior to immunolabelling cells were permeabilized using Triton 
X-100 or left intact before incubation with anti-Myc antibody and anti-mouse Alexa Fluor 594 
conjugate visualised using appropriate filters (red). DNA was stained using DAPI (blue). 
Reference images were taken using DIC, allowing fluorescence and DIC to be merged. White 
scale bar equals 10 m.  
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5.2.4.3 Immuno-Electron Microscopy for Localisation of DFK-12Myc 
In an attempt to get an even finer resolution view of the location of the DFK-
12Myc protein attempts were made to perform transmission electron microscopy 
on immunogold labelled sections of fixed parasites. As the 12Myc epitope tag 
was fused to the C-terminus of the DFK protein, directly adjacent to the protein 
kinase domain, it was hoped that this analysis would show which side of the cell 
membrane the protein kinase of DFK domain resides.  
In the DFK-12Myc expressing cell line, STL2378, immunogold staining was 
detected on the cytosolic side of the flagellar membrane, the cell membrane 
and on the flagellum (Figure 5-9a-d). Staining was sometimes observed in the 
nuclei of the cells but, as this also occurred in 2T1 control samples, can be 
regarded as non-specific. Other non-specific staining was occasionally seen away 
from cells (Figure 5-9e,-f). Immunolabelling was weak in comparison to IFA 
analysis, but was consistent with previous findings and specific between test and 
control immuno-EM samples. Parasites were fixed with 2% formaldehyde/0.2% 
glutaraldehyde PBS to increase epitope preservation though this fixative 
appeared to be quite poor in many of the cells, leaving some artefacts (irregular, 
often round, less electron dense areas in the cytoplasm of cells). Despite this, 
the analysis is consistent with DFK localising to the cell membrane, with the 
protein kinase domain most likely to be intracellular. 
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Figure 5-9: Transmission immune-electron micrographs from cell line STL2378 treated with 
mouse anti-Myc IgG and anti-mouse immunogold (10 nm) spheres. Immunogold labelling is 
highlighted by arrowheads. Panel a. shows immunogold labelling of the flagellum (inside 
the flagellar pocket) and internal membrane of the flagellar pocket. Panels b. and c. show 
intraflagellar membrane labelling. Panel d. shows labelling on the internal face of the cell 
membrane under the microtubule corset. Panel e. and f. depict some of the non-specific 
labelling seen in 2T1 cell control samples.  
a. b.
c. d.
e. f.
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5.2.4.4 Immunoprecipitation of DFK-12Myc 
As the anti-Myc antibody was clearly effective at detecting the epitope-tagged 
DFK protein attempts were made to immunoprecipitate DFK-12Myc from cell 
lysates. This was done with the aim of detecting interacting partners of DFK and 
so may provide information on how DFK effects its repression of the 
differentiation process. Immunoprecipitation (IP) was attempted with DynaBead 
technology (Life Technologies) and the Pierce c-Myc IP kit. The results of an IP 
conducted using the Pierce Kit (and its standard protocol) is presented in Figure 
5-10. A large number (5x108) of cells were used to increase the chance of 
detecting weakly interacting proteins. A control immunoprecipitation was also 
performed using T. brucei 2T1 cells that do not express a Myc tagged protein. 
Elution fractions from DFK-12Myc samples and 2T1 samples contained proteins 
visible using Coomassie stained SDS-PAGE analysis (Figure 5-10a). Samples of 
total cell lysates, unbound, wash and elution fractions were taken for western 
blot to detect DFK-12Myc (Figure 5-10b). This showed that DFK-12Myc was 
expressed in the STL2378 cell line used in this assay and that it was capable of 
being immunoprecipitated, though a substantial amount remained in the 
unbound fraction. The western blot contains bands corresponding to the heavy 
and light chains of the co-eluted mouse anti-Myc IgG and also bands 
corresponding to breakdown products of DFK, despite the inclusion of protease 
inhibitors in the lysis buffers.  
The IP elutions from tagged cell lines and 2T1 controls suggested a lot of non-
specific binding was occurring with the agarose resin of the kit (Figure 5-10a). 
However, despite either unequal loading or elution in this example, it appeared 
that a band of DFK-12Myc was visible on a coomassie stained SDS-PAGE gel. 
Further to this initial test, a repeat of this experiment was performed with the 
eluates being sent to The University of Dundee for mass spectrometry analysis to 
investigate DFK for phosphorylation sites. This analysis did not detect any 
phosphopeptides corresponding to DFK (M Urbaniak, Unpublished).  
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Figure 5-10: Immunoprecipitation of DFK-12Myc. Cell lysates from STL2378 (containing 
DFK-12Myc) and a T. brucei 2T1 negative control were incubated with anti-Myc antibody 
conjugated agarose beads (Pierce) and eluted by boiling in SDS-PAGE buffer. In panel a. the 
comparison to a control pulldown of T. b. brucei 2T1 lysate shows high levels of non-
specific binding. A band potentially corresponding to DFK-12Myc is visible between 150 kDa 
and 250 kDa (Arrow), however loading is visibly not equal. Panel b. confirms 
immunoprecipitation of DFK-12myc by western blot using mouse anti-Myc IgG and anti-
mouse HRP IgG, heavy and light chains from anti-Myc IgG liberated from agarose beads are 
visible (Arrow heads). 
5.2.4.5 Transcriptomic analysis of DFK RNAi cell lines 
The natural differentiation from BSF to PCF is associated with dramatic 
remodelling of the transcriptome and proteome (Jensen et al., 2009; Kabani et 
al., 2009; Queiroz et al., 2009; Kolev et al., 2010; Urbaniak et al., 2012a). We 
had determined that DFK RNAi was inducing EP procyclin expression,  
morphological changes and (unquantified) kinetoplast repositioning but had yet 
to detect other biological changes associated with differentiation. We therefore 
sought to analyse the process in an untargeted manner. The aim was to 
determine if the differentiation was representative of the natural differentiation 
process or was only the restructuring of the cell and its surface, without the 
commensurate changes in gene expression and metabolism etc. In order to do 
this we initially chose a transcriptomic analysis to identify global changes in RNA 
levels, in order to try and identify the gene expression signature of BSF-PCF 
differentiation. 
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Total RNA from DFK RNAi cell lines (STL201/STL202) was extracted from RNAi 
induced (48h) and uninduced cultures (2 bioreplicates), purified and prepared 
for RNA-seq at Glasgow Polyomics Facility. There it was prepared, and mRNA 
amplified using oligo-dT and multiplexed. This was then sequenced using an 
Illumina Genome Analyzer IIx.  This generated paired-end reads (4 million per 
sample, with an average size of 110 bases), with an average insert size of 200 
bases. GC content was 49% for all libraries. The read quality was controlled by 
trimming on mean quality score >Phred 20 (equating to <1% error rate). They 
were also checked for adapter or primer contamination. Non-redundant read 
data was aligned to the T. b. brucei 927 reference genome from TriTrypDB 
version 4.0 using Bowtie (0.12.7), and analysed for differential gene expression 
using Cufflinks (1.3.0). Cufflinks determined differentially regulated genes by 
calculating an uncorrected p-value for the fold change in reads for a gene and a 
q-value (a corrected p-value using a false discovery rate of 0.05). If the p-value 
is less than the q-value the gene is considered significantly differentially 
regulated. This analysis was performed by Dr Nick Dickens at the Wellcome Trust 
Centre for Molecular Parasitology.   
The analysis of DFK RNAi lines identified a total of 479 significantly differentially 
regulated genes, of these 191 were identified individually in either of the 
bioreplicates. The remaining 288 were identified in both bioreplicates. Of the 
479 genes identified as differentially regulated 242 were downregulated and 237 
upregulated. These were compared to genes previously identified as 
differentially regulated in differentiating trypanosomes or PCF trypanosomes by 
microarray or RNA-seq (obtained from Jensen et al. 2010 and Siegal et al. 2010) 
using the search strategy functions of TriTrypDB. The genes used for 
differentiation time points came from those identified in Kabani et al. 2009 and 
Quieroz et al. 2009. Using the default settings of TriTrypDB the results of genes 
significantly up- or downregulated were pooled and then compared to the results 
of the DFK RNAi transcriptome. For early time points (representative of 
stumpy/early PCF) the reference samples were set to BSF form and compared to 
high density BSF, 0, 1 h and 1.5 h post CCA induced differentiation. For later 
time points this was set to compare BSF to 6 h-72 h post CCA induction of 
differentiation. The data comparing BSF to established PCF came from studies by 
Siegel et al. (2010) and Jensen et al. (2009) combined. The comparisons are 
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presented in Table 5-2, but overall when all the differentially regulated genes 
were tallied up from previous studies, 415 of the 479 genes detected in DFK RNAi 
induced cells were present in these studies. The full list is presented as an Excel 
Spreadsheet in supplemental file S3 on the appended CD-ROM. In order to 
determine if this was more than can be expected by chance a Chi-Squared test 
was performed against a list of 500 genes that should represent a random 
distribution over the genome. This showed that the genes found to be 
differentially regulated in DFK RNAi cell lines are significantly more likely to be 
found in other transcriptomes of differentiating trypanosomes than a random 
sample of genes. This is supportive of a true BSF-PCF differentiation process 
occurring after ablation of DFK. 
Genes for certain processes were identified and exemplified (Table 5-3), based 
on previous findings in other transcriptomic analyses of differentiation (Jensen 
et al., 2009; Kabani et al., 2009; Queiroz et al., 2009). As the expression of EP 
procyclin had already been detected by IFA it was reassuring to find the 
transcripts for EP1, 2, 3 were all upregulated as well as for GPEET2. These 
transcripts were hugely upregulated; for EP2 the levels rose from 2.6 reads per 
sample to over 67 reads per sample – a fold change of 25.38. For GPEET2 a 45-
fold increase was detected. If this is reflected at protein level assaying by FACS 
to detect GPEET expression may show an even higher proportion of 
differentiated cells than using EP procyclin as a marker for differentiation. 
Transcripts for VSG related genes were downregulated, whereas transcripts for 
TbPAD1 and TbPAD2 were upregulated. Evidence for mitochondrial development 
is supported by the increase in transcripts for cytochrome oxidase IV, VIII and X 
and putative NADH-cytochrome b5 reductases. There were changes in the levels 
of transcript for the RNA binding proteins, some of which are known to either be 
differentially regulated in the procyclic form or essential to them in RNAi 
analyses(Wurst et al., 2009). Taken together, these data suggest the formation of 
mature PCF parasites following DFK RNAi. 
The differentiation phenotype (determined by expression of EP procyclin) 
following DFK ablation by RNAi only manifests in 5% of parasites at 48 h and 17% 
of parasites at 72 h therefore the changes detected in the DFK RNAi 
transcriptomes probably only represent the transcripts exhibiting the largest 
amount of change. Changes in low abundance transcripts may be masked by 
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transcript from the other 95-83% of cells not undergoing differentiation, 
assuming their transcriptome is not undergoing changes to which the cells are 
not responding. The fold change of the differentially regulated transcripts in the 
5-17% of differentiating cells is therefore likely to be much higher than that 
detected by RNA-seq analysis. In this experiment, differentiation was quantified 
by expression of EP procyclin on the cell surface. It may be that the changes in 
mRNA levels are detectable to a greater extent than protein levels due to the 
time taken to synthesise EP procyclin and traffic it to the cell surface. 
Table 5-2: Overview of genes detected as differentially regulated (up or down) in DFK RNAi 
cells and the existing data available in TriTrypDB. Following this is the output of the Chi-
Squared test performed using Prism Graphpad. 
 Number of Genes 
Life cycle stage Differentiation early Differentiation late BSF vs PCF 
 UP DOWN UP DOWN UP DOWN 
TriTrypDB 610 517 650 551 2199 3156 
Shared with DFK RNAi (479) 41 62 77 102 180 226 
 
Chi-square       
Chi-square, df 281.9, 1     
P value < 0.0001     
P value summary ***     
One- or two-sided Two-sided     
Statistically significant? (alpha<0.05) Yes     
        
Strength of association       
        
        
        
        
Difference between proportions       
Fraction of top, bottom row in left column 0.8664, 0.3400     
Difference between fractions 0.5264     
95% confidence interval of difference 0.4649 to 0.5879     
        
Data analyzed Diff Reg Not Diff Reg Total 
DFK 415 64 479 
Random 170 330 500 
Total 585 394 979 
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Table 5-3: Selected transcripts identified as differentially regulated in DFK RNAi induced cells (48h), supporting the differentiation to PCF phenotype. Those 
marked with a * are fold changes for samples where no transcript was detected in the uninduced culture, to perform the fold change calculations read numbers 
were set to 1. The column labelled Transcriptome describes whether the transcript was detected in both bioreplicates (Common) or in only one of the cell lines 
(STL 201/202). 
 
Category Transcriptome Gene ID Gene Product Fold Change 
RNA Binding Common Tb11.01.3940 RNA-binding protein, putative (RBP9) -4.70 
Common Tb11.01.2580 pumillio/PUF RNA binding protein 11 (PUF11) -2.64 
Common Tb927.6.3480 RNA-binding protein, putative (DRBD5) -1.98 
Common Tb11.01.3915 RNA-binding protein, putative (RBP5) 4.99 
Common Tb927.7.5930 Protein Associated with Differentiation (TbPAD1) 2.22 
Surface Modification Common Tb927.7.5940 Protein Associated with Differentiation (TbPAD2) 3.70 
Common Tb927.6.520 EP3-2 procyclin,PARP A-beta,surface protein EP3-
3 procyclin precursor,procyclic form specific 
polypeptide A-beta precursor 
20.54 
Common Tb927.10.10260 EP1 procyclin (EP1) 20.21 
Common Tb927.10.10250 EP2 procyclin (EP2) 25.38 
Common Tb927.6.510 GPEET2 procyclin precursor,PARP A-
alpha,procyclin A-alpha,procyclic form specific 
polypeptide A-alpha precursor 
45.05 
Common Tb927.6.480 EP3-2 procyclin,PARP A-beta,surface protein EP3-
2,surface protein EP3-2 procyclin 
precursor,procyclic form specific polypeptide A-beta 
precursor 
20* 
Common Tb927.6.450 EP3-2 procyclin,PARP,procyclin PARP A,procyclin 
B1- alpha,procyclic acidic repetitive protein 
A.beta,procyclic form specific polypeptide B1-alpha 
precursor 
15* 
Common Tb927.10.11220 procyclic form surface glycoprotein (PSSA-2) 2.80 
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Common Tb927.8.7300 variant surface glycoprotein (VSG)-related, putative -3.48 
Common Tb927.8.7320 variant surface glycoprotein (VSG)-related, putative -3.58 
Common Tb927.3.1470 variant surface glycoprotein (VSG)-related, putative -3.15 
Common Tb927.3.1520 variant surface glycoprotein (VSG)-related, putative -3.15 
Common Tb927.1.5170 variant surface glycoprotein (VSG)-related, putative -3.97 
Common Tb11.02.1566 variant surface glycoprotein (VSG)-related, putative -3.41 
Common Tb927.5.130 variant surface glycoprotein (VSG)-related, putative -3.42 
Common Tb927.3.1510 variant surface glycoprotein (VSG)-related, putative -2.98 
Common Tb927.3.1500 variant surface glycoprotein (VSG)-related, putative -3.32 
201-only Tb927.1.700 phosphoglycerate kinase (PGKC) -2.57 
Glycolysis Common Tb927.1.3830 glucose-6-phosphate isomerase, glycosomal (PGI) -2.61 
Common Tb927.3.3270 ATP-dependent phosphofructokinase (TbPFK) -3.53 
Common Tb927.10.5620 fructose-bisphosphate aldolase, glycosomal (ALD) -2.93 
Common Tb927.10.14140 pyruvate kinase 1 (PYK1) -3.58 
Common Tb927.1.4100 cytochrome oxidase subunit IV (COXIV) 2.08 
Respiration Common Tb927.4.4620 cytochrome oxidase subunit VIII (COXVIII) 4.13 
Common Tb927.8.1890 cytochrome c1, heme protein, mitochondrial 
precursor 
2.09 
Common Tb11.02.1230 NADH-cytochrome b5 reductase, putative (B5R) 2.84 
Common Tb11.01.7190 NADH-cytochrome b5 reductase, putative (B5R) 2.15 
Common Tb11.01.4702 cytochrome oxidase subunit X (COXX) 3.40 
202-only Tb11.01.3780 cytochrome oxidase assembly protein, putative 2.94 
202-only Tb927.3.680 cytochrome P450, putative 2.00 
202-only Tb927.7.2700 NADH-cytochrome b5 reductase, putative (B5R) 1.91 
201-only Tb927.10.7090 alternative oxidase (AOX) -2.31 
     
 
  
184 
 
1
8
4
 
5.3 Discussion 
The roles of protein kinases and phosphatases in the various stages of 
trypanosome development and differentiation are becoming more apparent and 
increasingly more defined. Several protein kinases (ZFK, MAPK5) have been 
shown to repress the differentiation of slender to stumpy forms at parasitaemia 
densities which would too low (Vassella et al., 2001; Domenicali Pfister et al., 
2006b). TOR4 has been shown to retain slender BSF in that state and depletion of 
TOR4 leads to irreversible commitment to stumpy forms (Barquilla et al., 2012). 
Once in this form, TbPTP1 and TbPIP39 combine to hold the parasite in G0 arrest 
until the addition of CCA inactivates TbPTP1 allowing TbPIP39 to trigger stumpy 
to PCF differentiation following its entry into glycosomes in its phosphorylated, 
active form(Szöor et al., 2006, 2010). Following this differentiation event 
TbMAPK2 is essential in driving the proliferation of PCF parasites(Müller et al., 
2002a). In this study we implicate another protein kinase as a negative regulator 
the differentiation process. RNAi knockdown of DFK led to spontaneous 
differentiation of 17% of a monomorphic BSF population to PCF parasites. This 
phenotype is reminiscent of the RNAi of TbPTP1 in monomorphic cells or the 
inhibition of TbPTP1 using BZ3 suggesting DFK may act somewhere in the same 
pathway (Szöor et al., 2006). In order to probe the function of DFK a number of 
approaches were taken to determine the localisation of the protein and the 
process of DFK RNAi induced differentiation. These approaches suggested DFK is 
an integral cell membrane protein, and that once it is removed from BSF cells by 
RNAi the differentiation process reflects the natural BSF-PCF differentiation 
process. Thus it appears the DFK acts as a negative regulator of BSF-PCF 
differentiation.  
5.3.1  Confirming the DFK Phenotype 
The DFK RNAi phenotype was detected by visual observation of RNAi induced 
cultures during the pTL screen of the trypanosome kinome for potential drug 
targets. Having observed a visible morphological phenotype apparently 
consistent with PCF parasites the cell line was assessed further in order to 
determine if these cells had other markers that have been used to define the 
PCF stage. Several results are suggestive of this and some appear to strongly 
confirm it.  
185 
 
1
8
5
 
When RNAi of DFK was induced a growth defect in cultured parasites was 
detected by haemocytometry. The growth defect was more severe than the one 
exhibited by NEK 16 (Figure 3-5) and should have been detectable by the alamar 
blue assay. After 72 h induction of DFK RNAi there were fewer cells than in the 
comparable NEK 16 sample (which did generate a detectable alamar blue 
phenotype). The smaller number of DFK RNAi induced cells were therefore 
reducing resazurin to resorufin at the same rate as the DFK RNAi uninduced 
samples.  Thus they generated the same fluorescence levels, giving an alamar 
blue assay ratio of >0.9 and so not placing DFK in the loss of fitness group. One 
explanation for this could be that despite there being reduced cell numbers in 
the alamar blue assay, these cells were more metabolically active (as may be 
expected if the cells were developing their mitochondrion, as occurs in stumpy 
or PCF parasites). Conversely, the NEK 16 RNAi may lead to a decrease in the 
ability to reduce resazurin but only generate a small growth defect.  
It was observed that 10% of the cells exhibited the morphology of PCF parasites 
and were tested for other markers of this life cycle stage. The cells were tested 
for the presence of EP procyclin – which is usually a marker for late procyclic 
form cells(Acosta-Serrano et al., 2001). This was visible on individual cells using 
IFA analysis and was an amenable phenotype for assessment using a FACS assay. 
Analysis of EP procyclin expression in RNAi induced cultures showed that 17% 
were EP procyclin positive by 72 h. This was confirmed by initial experiments 
using an IN-Cell 2000, which showed 20% of cells were EP procyclin positive. 
Although cells expressing EP procyclin were also observed to reposition their 
kinetoplast this remains to be thoroughly quantified and further experiments are 
necessary to confirm the morphological changes in the RNAi induced parasites. 
5.3.1.1 Testing for Mitochondrial Development Using Respiratory Inhibitors 
In an effort to determine whether the PCF-like cells were developing a fully 
functional mitochondrion as would be expected for PCF trypanosomes, an 
approach was attempted to use respiratory inhibitors to enrich or reduce for PCF 
cells in the population. BSF trypanosomes possess only one terminal alternative 
oxidase (TAO) in the mitochondrion which does not contain cytochrome oxidase 
(COX). Upon differentiation to the PCF form the cytochrome oxidase system is 
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expressed and respiration mostly occurs through the COX system, though TAO is 
still functional - TAO can be selectively inhibited with SHAM (salicylhydroxamic 
acid) and COX with KCN (potassium cyanide)(reviewed in (Chaudhuri et al., 
2006)). In order to infer whether this was happening in the DFK RNAi induced 
cell lines they were treated with KCN and SHAM. KCN treatment was expected to 
block the development of the PCF-like cells if they were developing a complex 
mitochondrion containing COX – which would be stronger evidence of a true BSF 
to PCF differentiation. Using the previously published protocol of Le Febvre and 
Hill, DFK RNAi induced and uninduced cultures (and T. brucei 927 PCF controls) 
were exposed to varying concentrations of respiratory inhibitors (KCN: 100 M, 
SHAM: 250 M)(Le Febvre and Hill, 1986). It appeared that the KCN treatment 
had only a very slight effect on established PCF parasites or the DFK RNAi 
induced cultures at any concentration. SHAM had a toxic effect on all samples, it 
proved slightly more toxic to DFK RNAi induced cells due to their inherent 
growth defect. At the end of the initial test experiment too few cells remained 
to perform follow up experiments. The 2T1 cell line did not respond to the 
compounds in the same manner as previous studies(Le Febvre and Hill, 1986). 
Perhaps a more simple approach should have been undertaken to look for visible 
increases in the size of the mitochondrion after labelling with a dye such as 
MitoTracker or TMRM – which would have allowed qualitative analysis by 
microscopy and quantification of any change in fluorescence in a FACS assay, 
along with the expression of EP procyclin, to analyse the population of DFK RNAi 
induced cultures. The NADH diaphorase assay could also have been used to 
determine the phenotype of mitochondrial development (Vickerman, 1965). 
These experiments were superseded by the transcriptomic data showing increase 
in expression levels of several cytochrome oxidase subunits, though it would be 
interesting to know if they are expressed in a functioning mitochondrion. 
5.3.1.2 Transcriptomic Analysis 
Although the observable changes in the cells suggested a PCF phenotype the 
opportunity to perform a transcriptomic analysis of the population presented a 
chance to explore this in more detail. The transcriptomic data appear to show 
that the populations of cells undergoing DFK RNAi generated an expression 
profile that is very suggestive of a differentiation to a PCF cell. Though the 
number of genes detected as being differentially regulated in DFK RNAi lines is 
187 
 
1
8
7
 
much smaller than those detected in other studies comparing efficient, 
synchronous differentiation there are signatures that are distinctive of stumpy 
and PCF trypanosomes. This may be explained by the fact that only 5% of the 
cells appear to differentiate at 48 h, the time of RNA extraction, so there may 
be a population of stumpy* cells and a population of cells undergoing stumpy to 
PCF differentiation. As there was a limit to the amount of samples that could be 
analysed (due to cost, time and ability to multiplex the assay) a timepoint was 
chosen that was expected to observe cells going through the differentiation 
process, rather than being at the end of it. Whether this readjustment of the 
transcriptome is represented in all the cells in the population is undetermined. 
One would expect that as only a small proportion of cells in the population 
differentiate after DFK RNAi that the transcriptome remodelling is only occurring 
in these cells, and this may lead to masking of changes in these cells by the 
majority of unchanged cells. It would be difficult to expect large changes in the 
transcriptome of a cell to not lead to phenotypic changes in the cell. Because 
the process of differentiation post-DFK ablation is partial and also asynchronous 
this presumably dampens the signal coming from differential gene expression (in 
the differentiating cells), and could explain the low number of genes detected 
compared to other studies that examined either synchronous or stable 
populations. However, the detection of key markers (Table 5-3) is enough to give 
a good idea that the differentiation phenotype is real, especially when combined 
with other evidence such as detection of EP procyclin protein expression.  
Tellingly, the transcripts for PAD1 and PAD2 were detected as upregulated; a 
result which has since been confirmed for the case of PAD2 by qPCR (M. Saldivia, 
Unpublished). Though PAD2 can be upregulated very rapidly by cold shock, PAD1 
is a specific marker for stumpy form trypanosomes and the expression of this 
could suggest the DFK RNAi lines are progressing thorough a stumpy or stumpy* 
phase during the differentiation to PCF. However, whether this is expressed or 
trafficked to the surface of the cell requires further investigation by western 
blot or IFA for confirmation. PAD1 is upregulated at mRNA level in PCF versus BSF 
cells even though the protein is only detectable in stumpy forms(Dean et al., 
2009).  VSG and VSG-related transcripts are downregulated in DFK RNAi lines, 
and this has also been confirmed by qPCR (for VSG 221) (M Saldivia, 
Unpublished). This suggests that RNAi of DFK is triggering the formation of 
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stumpy-like cells which proceed to PCF cells in the absence of a stimulus such as 
cis-aconitate. 
During the natural slender-stumpy-PCF differentiation process the DFK transcript 
is detected in two expression profiling studies to be downregulated (Figure 5-11, 
TriTrypDB). Two other studies did not show the same magnitude of 
downregulation though there was a slight downward trend. The study by Kabani 
et al. 2009 used 5 bioreplicates, strengthening the reliability of the data from 
this study. This suggests that DFK is important for keeping BSF forms in that 
lifecycle stage but is less important or not required for the PCF stage, and its 
expression is reduced once it has served its purpose in the BSF. DFK was not 
detected in several recent proteomic experiments that compare BSF to PCF 
stages (Gunasekera et al., 2012; Urbaniak et al., 2012a), which if it had would 
possibly offer more robust evidence for this idea.  
 
Figure 5-11: Transcript expression profiling of DFK from a. Quieroz et al. 2009, b. Kabani et 
al. 2009 c. Jensen et al. 2009 and Siegel et al. 2010.The graphs in a. and b. show the level of 
DFK transcript in slender BSF parasites and over the synchronous differentiation of stumpy 
form parasites to PCF parasites. Panel a. used cells derived from axenic cultures whilst b. 
and c. used stumpy forms derived from animal infections. Study d. used established 
cultures of BSF and PCF forms. Adapted from TriTrypDB.  
In overview, the transcriptome of DFK RNAi mutants shows clear signs of 
differentiation – but it probably does not provide information on the mechanisms 
Time hTime h
a. b.
c. d.
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causing that differentiation. Changes in the transcriptome in this instance 
probably occur as a response to changes in other pathways/process after 
ablation of DFK. It is difficult to see how this analysis assists in determining the 
pathways that DFK is mediating, though it does give a clearer picture of the 
nature of the phenotype. RNAi of DFK does not just lead to induction of 
procyclin expression but of a wide range of processes and consequences for the 
cells, culminating in an inefficient and fatal differentiation. Ultimately, whether 
this is due to ablation of DFK activity or simply by removal of a protein or 
disruption of a protein complex remains to be seen in future experiments. 
5.3.2 Localisation and Topology of DFK 
The location of a protein kinase can give clues to the function it performs. The 
case for DFK being located in the cell membrane appears quite strong. Prior to 
this work, DFK had been detected in a study examining the proteome of the 
flagellum – which had sought to resolve flagellar membrane proteins from 
flagellar matrix proteins. Oberholzer et al. detected DFK in the membrane 
fraction of the flagellum, and as it is predicted to have multiple TM domains, 
this would appear to be a sensible localisation(Oberholzer et al., 2011). Their 
study did not confirm the localisation of DFK by another method, and even goes 
as far to suggest that DFK is a receptor kinase. This is an interesting concept but 
no exploration of this suggestion has yet been published. In the present study, 
we determined that DFK localised to a membranous fraction of cell lysates. This 
was a simple fractionation so it could not be determined whether the protein 
was in a cell membrane or an organellar membrane fraction. However, when the 
epitope tagged version of DFK was localised by microscopy it appeared to reside 
over the entire cell membrane, including the flagellar membrane.  
Different TM domain prediction algorithms produced varying results for the 
number of TM domains in DFK. One would expect a “receptor kinase” to possess 
an intracellular kinase domain to perform phosphorylation of the next protein in 
a signalling cascade or of an effector protein. The 12Myc epitope tag is located 
at the C-terminus of the protein, effectively fused to the kinase domain. The IFA 
staining pattern on cells with a non-permeabilised cell membrane would suggest 
the epitope tag, and thus the kinase domain, is extracellular – if correct this may 
be considered an unconventional arrangement. However, when these samples 
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were prepared for microscopy they were first dried onto poly-L-Lysine treated 
multi-well slides to adhere them. This probably compromised the cell 
membrane, thereby allowing antibodies to permeate through the cell 
membrane. It is therefore difficult to assess from these data whether the 
protein kinase domain is intra- or extracellular. Certainly when the membrane is 
permeabilised using Triton X-100 the signal from anti-Myc IFA decreases and 
becomes more punctuate, suggesting that DFK-12Myc is being stripped away with 
the membrane. Further analysis by immunoelectron microscopy does point to a 
cell membrane localisation of DFK, and immunogold labelling consistently 
appears on the internal face of the cell membrane in the DFK-12Myc cell line, 
suggesting that the epitope tagged protein kinase domain of DFK-12Myc is 
intracellular. Though the amount of staining is weak, possibly due to the age of 
the anti-mouse immunogold reagent, it is consistent – and is consistent with 
other data on the localisation of DFK. Repeats of this experiment with optimised 
reagents may provide a clearer picture of the localisation of DFK. 
Further IFA analysis could assess the localisation of the DFK kinase domain 
further by treating cells with a protease to remove proteins on the cell surface. 
If the DFK-12Myc signal is ablated it would confirm an extracellular localisation 
of the kinase domain, if not it would confirm an intracellular localisation. 
Further optimisation of the immune-EM procedure would probably be the ideal 
way of determining the localisation of the protein kinase domain, and this 
combined with deletion mutants with epitope tags following the various 
predicted TM domains could potentially be used to determine the topology of 
DFK in the cell membrane. The current problems with the immune-EM analysis 
are probably due to the age of the anti-mouse immunogold, which appeared to 
be heavily precipitated, leading to a low concentration of the reagent in the 
supernatant – unfortunately this could not be redressed due to time constraints 
and limited access to the Integrated Microscopy Facility.  
5.3.3 Functional Role of DFK 
Currently, in T. brucei, there are no defined protein kinase signalling pathways – 
although a protein phosphatase cascade has been described – coincidentally 
acting in the BSF-PCF differentiation process. DFK appears to be a candidate ripe 
for investigation due to the striking phenotype exhibited after its depletion.  
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DFK is predicted to contain a protein kinase domain most similar to a STE11 
family kinase, also known as a MAPKKK. Using the example of the yeast mating 
pheromone response, these typically sit at the top of a MAPK signalling cascade; 
after being activated by STE20 (MAPKKKK). MAPKKKs, such as STE11, will 
typically phosphorylate a MAPKK, such as STE7, which will then go on to activate 
a MAPK such as Kss1 or Fus3. MAPK signalling components are usually organised 
together at the plasma membrane by means of a scaffold protein, such as STE5 
or Pbs2 in yeast or KSR, IQGAP or -arrestin in mammalian cells (Qi and Elion, 
2005; Brown and Sacks, 2009; Good et al., 2011). As signalling cascades in T. 
brucei are completely undefined, no scaffold proteins supporting signalling 
components are known either. The future experiments to perform SILAC-labelled 
quantitative MS/MS on DFK-12Myc IP samples may provide information on 
whether other potential MAPK pathway proteins associate with DFK and whether 
this type of signalling complex exists. No other protein kinase demonstrated this 
phenotype during RNAi, though this does not rule out other MAPKKs and MAPKs 
being involved in this process until the efficacy of knockdown has been 
performed for all cell lines. The possibility of functional redundancy further 
along in the pathway (which is evident in well characterised yeast MAPK 
pathways (Wang et al., 2011)) exists and this may explain why the DFK RNAi 
phenotype was not observed for any other protein kinase RNAi. 
If DFK is a MAPKKK it would be atypical as it is an integral membrane protein. 
The architecture of the protein domains is very reminiscent of a transmembrane 
receptor kinase. It possesses multiple transmembrane domains, although the 
topology of the protein is still unclear despite the current analysis. Since the 
determination of structures of a large number of membrane proteins it is clear 
that they possess more topological diversity than first assumed, i.e. the length 
and angle of the transmembrane helix across the membrane can vary 
significantly. Predicting topology by bioinformatic methods should also be done 
with caution(Von Heijne, 2006). One of the predicted transmembrane regions is 
detected by PFAM analysis as a HAMP domain. These were originally defined in 
prokaryotes and  are common to a multitude of prokaryotic transmembrane 
receptor histidine kinase and chemotaxis receptors (reviewed in (Parkinson, 
2010)). They are usually confined to regions near the cytoplasmic side of the 
membrane and consist of a sequence approximately 50 amino acids in length 
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forming two amphipathic helices connected by a linker region. When 
extracellular receptor domains are bound by their ligand, conformational 
changes occurring in this region can be transmitted via a TM domain to the HAMP 
domain which can either tighten or loosen. This change can induce kinase-on/off 
states in the relevant domain of the protein. Many of the chemoreceptors and 
sensor kinases possessing these domains operate as homodimers in the cell 
membrane. Another interesting feature detected by PFAM search are the TPR2 
repeats which represent a motif that allows protein-protein interaction. It could 
be speculated that this assists other proteins to complex with DFK or even allows 
dimerisation of DFK to occur. This conjecture is totally untested but aspects of 
the DFK protein architecture do at least hint of these possibilities.  
Searching for DFK in OrthoMCL shows that it is confined to kinetoplastids. TbDFK 
is predicted to have both a syntenic and non-syntenic orthologue in Leishmania 
braziliensis, L. infantum, L. major, L. mexicana and L. tarentolae; however, only 
the syntenic orthologues provide the best sequence orthologues. The two 
orthologues in T. cruzi (as predicted by OrthoMCL) appear to align poorly to the 
T. brucei DFK sequence and the closest match at the level of protein sequence is 
the gene TcCLB.511727.210. There is a syntenic orthologue in T. b. gambiense. 
Trypanosoma congolense does not contain an orthologue of DFK and T. vivax is 
predicted to contain two gene fragments with orthology to DFK – though this may 
be a sequencing or assembly error in this genome. Performing a tblastn search of 
the T. evansi and T. equiperdum genome detect a gene identical to the T. brucei 
927 DFK gene in each (D. Barry, Unpublished). Thus DFK appears to be present in 
organisms that do not, or in the case of T. evansi, cannot form procyclic forms 
(Brun et al., 1998).  
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Table 5-4: Sequence orthologues of TbDFK from published genomes. * denotes syntenic 
orthologue. 
Species Gene ID 
T. b. brucei 927 Tb11.01.5650* 
T. b. brucei 427 Tb427tmp.1.5650* 
T.b. gambiense Tbg972.11.15700* 
T. vivax TvY486_0044340,TvY486_0044360 
T. cruzi Tc00.1047053511727.210 
L. major LmjF.32.0810* 
L. infantum LinJ.32.0860* 
L. braziliensis LbrM.32.0900* 
L. mexicana LmxM.31.0810* 
L. tarentolae LtaP32.0880* 
 
5.3.3.1 Testing for Effects of pCPT-cAMP and BZ3 on DFK RNAi lines 
In order to try and determine at which stage in the differentiation process DFK 
operates at, attempts were made to modulate other parts of the pathway using 
small molecules. An attempt to enrich an uninduced population of the DFK RNAi 
line for stumpy* parasites using a cyclic-AMP analogue was made, as it was 
expected that if DFK was operating to induce stumpy-PCF differentiation then an 
increase in EP procyclin positive cells would be observed if stumpy* parasites 
were increased. If DFK was involved in mediating slender to stumpy 
differentiation and the PCF differentiation was an artefact of this then enriching 
for stumpy* parasites with cAMP-analogues might not have an effect on the 
proportion differentiating to PCF. Due to the ability of cAMP breakdown products 
to increase the proportion of stumpy form cells in the population it was 
attempted to test the effect 8-(4-chlorophenylthio)-cAMP (pCPT-cAMP), a cell 
permeable cAMP analogue on DFK RNAi cell lines(Vassella et al., 1997). This was 
expected to increase the proportion of stumpy* cells in the monomorphic 2T1 
cell line. The aim of performing this was to then induce RNAi of DFK and observe 
any increase in the efficiency of differentiation following ablation of DFK, 
similar to RNAi of TbPTP1 after pCPT-cAMP treatment(Szöor et al., 2006). Trial 
treatments of DFK RNAi lines with 100, 500 and 1000 M appeared to be highly 
toxic to 2T1 derived cell lines- after an overnight incubation with this compound 
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the cells looked enlarged and unhealthy. RNAi of DFK was not attempted. This 
would be an interesting experiment to pursue under optimised conditions. 
Attempts were also made to test what, if any, effect BZ3 had on the proportion 
of cells differentiating during DFK RNAi. This was done to determine if inhibition 
of TbPTP1 and removal of DFK generated additive or synergistic effects on the 
number of cells differentiating from BSF to PCF. Unfortunately both BZ3 also 
proved toxic to 2T1 cells at the concentrations used successfully in other studies 
(Szöor et al., 2006). Optimisation of these experiments could allow potentially 
informative data to be generated, otherwise RNAi vectors could be made to 
target multiple genes (e.g. DFK+TbPTP1) in an effort to circumvent the problems 
of inhibitor toxicity. Other proteins involved in aspects of differentiation, such as 
TOR4, do not yet have specific inhibitors developed or identified for use as 
research tools and double RNAi of these genes may be the only way to study 
their interactions. 
5.3.4 Summary and Future Direction 
DFK appears to be a repressor of differentiation in BSF cells to prevent them 
becoming PCF cells under inappropriate conditions. The pathway it participates 
in is as yet undetermined. DFK RNAi to 17% of cells differentiating to PCF as 
determined by expression of EP procyclin. Also, stumpy form specific transcripts 
were detected. However, detection of these at protein level would be required 
to determine the presence of stumpy cells categorically. It is likely that, due to 
the proportion of cells differentiating, DFK acts in procyclic cells as a molecular 
brake – similar to TbPTP1 (Figure 5-12). DFK protein has multiple transmembrane 
domains and features reminiscent of prokaryotic receptor kinases- further 
investigations should attempt to determine if DFK acts as a receptor, possibly 
entering a kinase-off conformation after encountering a stimulus. Interestingly, 
TbPIP39 triggers differentiation when entering the glycosomes in an 
(phosphorylated) active mode, whatever its substrate is must be phosphorylated 
by an as yet undetermined protein kinase: could the substrate of DFK also be 
trafficked to the glycosomes where it represses differentiation until 
dephosphorylated by TbPIP39? Removal of DFK by RNAi could simulate this 
situation and is one line of conjecture for the function of this protein kinase. 
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Clearly, much work remains to be undertaken before these answers will become 
apparent.  
 
Figure 5-12: Schematic representing the known regulators of BSF to PCF differentiation. 
Known interactions are connected by arrows. 
In order to advance the understanding of DFK’s role in the differentiation 
process a number of lines of investigation can be taken. The search for a specific 
inhibitor of DFK is one such enquiry that is currently ongoing. As the spontaneous 
differentiation under RNAi was only observed for DFK it was reasoned that a 
specific inhibitor will also induce this phenotype (if DFK kinase activity alone is 
negatively regulating differentiation). A high-content screen has been developed 
to apply protein kinase focused inhibitor libraries to BSF trypanosomes and 
assess for EP procyclin expression after 72h (Figure 5-6c). Several compound 
libraries have been obtained from Roche, GSK and SULSA totalling over 6000 
compounds, with the screen being conducted at the Scottish Bioscreening 
Facility – based at the University of Glasgow. Should a protein kinase inhibitor-
like molecule be found to induce BSF-PCF differentiation it is probable that DFK 
would be the target, though further confirmation of this would be required to 
validate it fully – perhaps by in vitro assays and chemical genetic studies of DFK. 
Should an inhibitor of DFK be identified it would potentially allow for 
phosphoproteomic experiments to determine downstream phosphorylation 
events dependent on the presence of active DFK. Also, any inhibitors identified 
may provide a starting point for optimisation of drug-like compounds for use 
against DFK in a therapeutic manner. Trypanosomes expressing procyclin are 
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susceptible to complement mediated lysis by the alternative pathway and thus 
any differentiation of parasites by DFK inhibition would lead to their 
killing(Ferrante and Allison, 1983). This would explain why no EP-procyclin 
expressing parasites were detected in the mouse infections after DFK RNAi 
induction.  
Work to completely genetically validate DFK as playing a role in this pathway 
must be undertaken. Re-expression of recoded, RNAi refractory mutants has 
been attempted but the generation of the expression constructs using Gateway 
cloning has proved problematic. A restriction enzyme adapted vector, containing 
an active, recoded DFK gene, for performing these experiments is being 
synthesised. This will then be mutated at the catalytic lysine (K950M) to 
generate a kinase dead mutant. By using these two mutants in a DFK RNAi 
background it should be possible to determine the importance of DFK activity, 
and not simply presence of the protein, for repression of differentiation. Ideally 
this would have been undertaken before HCS screens for DFK inhibitors to 
confirm that DFK is an active protein kinase in vivo. If a potential DFK inhibitor 
is found during the HCS screen then this re-expression technique could be used 
to validate the inhibitor:target using chemical genetics to mutate residues 
important for inhibitor binding (and not for enzyme function) and observe for 
resistance to the inhibitor. Overexpression of a kinase dead, kinase domain might 
be another way of testing this, if a dominant negative phenotype can be 
achieved by the level of overexpression. 
DFK presents an interesting opportunity to study trypanosomal signalling in the 
differentiation process due to its potential to interact with known modulators of 
trypanosome differentiation. It may be possible for this protein kinase to 
integrate environmental signals into signalling pathways allowing trypanosomes 
to respond to environmental changes and this would be a key hypothesis to 
investigate in the future. Also, it could be considered a novel drug target and as 
protein kinases are known to be druggable then the potential for specific 
inhibition of DFK must also be investigated further in order to further new 
opportunities for developing potential treatments of a widespread human and 
animal pathogen.  
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6 Concluding Remarks 
RNA interference was discovered in trypanosomes in 1998 and since then the 
development and application of heritable, inducible RNAi systems has greatly 
facilitated the study of gene function in these parasites. As these technologies 
evolved they improved in terms of finesse (i.e. use of endogenous promoters 
instead of the T7 promoter), efficiency and reliability (i.e. using tagged loci). 
The development of the pTL system for rapidly generating stem-loop RNAi 
constructs has allowed the generation of several hundred RNAi plasmids, 
including a library to target the complement of the trypanosome kinome. The 
pTL system was based on an existing system for use in BSF parasites allowing 
efficient transfection into a single rRNA spacer locus, thus generating reliable 
RNAi performance. The speed and reliability of this system should facilitate the 
investigation of other gene families in T. brucei. In this study the system was 
used to interrogate the kinome of T. brucei for protein kinases that were 
important for the growth and replication of the clinically relevant bloodstream 
form parasite in order to identify potential drug targets. Several of the protein 
kinases identified as being essential to BSF parasites were further investigated as 
potential drug targets. In future studies the pTL and STL libraries could be 
applied to answer various biological questions. As protein kinases are implicated 
in regulating almost all cellular processes at some level the ability to test the 
effect of each T. brucei protein kinase individually on any given process makes 
these libraries a powerful resource.  
Protein kinases have been investigated prodigiously as drug targets in the field of 
oncology and the application of this strategy to infectious disease is conceptually 
uncomplicated, as one intends only to stop a rapidly proliferating cell type. 
Candidate approaches have identified T. brucei protein kinases as drug targets 
but due to the high failure rates of drug development programmes the need to 
provide a large number of validated targets into pipelines means that genetic 
validation techniques must become more rapid. The pTL screen has partially 
genetically validated 53 protein kinases as drug targets and now defines where 
future validation efforts should be directed. This scope can be further refined by 
choosing protein kinases that might be amenable to work with, such as those 
that do not require co-factors such as cyclins or calmodulin for activity, or those 
that are likely to require activation by upstream kinases (e.g. MAPKs). This 
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would attempt to stack the odds in favour of progressing a target protein kinase 
some way through the drug development pipeline by increasing the likelihood of 
generating an in vitro activity assay successfully. 
In particular this study targeted several families of protein kinase, the NEK and 
Orphan families, which displayed features predicted to make them attractive 
drug targets (if they were essential to the parasite). These families were among 
the first to be tested in the RNAi screen and a concurrent effort to express 
recombinant protein for a number of these was also performed. Those protein 
kinases which were essential to the parasite and also could be expressed 
recombinantly were prioritised for further assessment as drug targets. NEK 12.1 
and NEK 12.2 were shown to be essential to the parasite under double-
knockdown conditions. Further experiments are needed to assess whether these 
proteins are individually essential to the parasite but if NEK 12.1 activity can be 
fully genetically validated as individually essential then it could be further 
pursued as a drug target due to the ability to express it as an active recombinant 
protein that can be used in biochemical assays. With optimisation of the format, 
an HTS assay could be developed. The structural features NEK 12.1 is predicted 
to contain suggest it may be amenable for rational design of selective inhibitors. 
In theory this raises the possibility that these could be developed into 
therapeutic inhibitors. However, any selective inhibitor identified could 
potentially be used as a research tool to investigate the role of NEK 12.1 in 
trypanosome biology.  
The characterisation of signalling pathways in T. brucei lags behind that of other 
model organisms. The signalling processes surrounding BSF to PCF differentiation 
represents those best characterised in the parasite. Identification of DFK as a 
negative regulator of this process adds a new facet of differentiation for 
investigation. Integration of the pTL library with assays to determine the 
phosphorylation status of other protein kinases and phosphatases may be able to 
determine the signalling events that precede differentiation. An effort to 
identify phosphosites on signalling or effector proteins and generate specific 
antibodies against these could then be used in systematic profiling of the library 
to identify those protein kinases that have an effect on that given residue. 
Clearly, this is a serious undertaking, mainly in the need to identify and 
understand the important phosphosites in members of a signalling cascade. 
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Therefore other processes maybe less complicated to investigate due to the 
ability to use reporter assays. Some biological processes may be more amenable 
to the application of reporter assays than others, but the ability to generate 
reporter cell lines is relatively straightforward. The majority of STL cell lines are 
compatible with any construct using a blasticidin or puromycin selectable 
markers allowing proteins to be tagged with fluorescent proteins or epitope tags. 
This flexibility will allow the generation of cell lines compatible with techniques 
to allow phenotypic screens to identify the effect of a kinase RNAi on a tagged 
protein or process. This has already been used in this laboratory for several 
proteins demonstrating the utility of such a library, and that it can be applied to 
more complicated questions than the identification of protein kinases required 
for cell viability.  
RNAi of certain protein kinases can produce very defined phenotypes; for 
example, differentiation to PCF under DFK ablation, which was identified in the 
initial pTL screen. These specific or characteristic phenotypes present 
opportunities to develop assays to identify inhibitors that phenocopy the RNAi of 
these protein kinases. High-Content Screens are under development to identify 
inhibitors that phenocopy the DFK-RNAi-induced differentiation, and it is 
expected that these assays could be applied to other processes. Inhibitors that 
phenocopy a given RNAi are likely to target the same protein or pathway 
involved in that process and could be used in further studies investigating that 
process. These investigations could lead to new research tools, lead compounds 
for drug development, and will contribute to the understanding of trypanosome 
biology.  
The protein kinase complement of T. brucei represents a richness of signalling 
interactions that have barely been investigated by the standards of some other 
eukaryotes. Cell signalling by reversible phosphorylation has been well studied in 
many other model organisms, where the ready availability of appropriate 
reagents provides the ability to investigate and understand pathways. A number 
of protein kinases have been investigated individually in T. brucei but these 
studies represent islands of data, with little interconnectivity. Given the 
tractability of T. brucei  as a model organism the development or reagents and 
assays compatible with the pTL/STL libraries will make it possible possible to 
start to piece together the effect of protein kinases on signalling pathways and 
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other biological processes in this. This will contribute to our understanding of 
the basic biology of an early branching eukaryote that is also an important 
human and animal pathogen. By studying these processes we will generate 
opportunities for translational science to investigate new therapeutic avenues 
with the potential to positively impact on this neglected tropical disease. 
201 
 
2
0
1
 
List of References 
Acosta-Serrano, A., Vassella, E., Liniger, M., Kunz Renggli, C., Brun, R., Roditi, I., 
and Englund, P.T. (2001). The surface coat of procyclic Trypanosoma brucei: 
programmed expression and proteolytic cleavage of procyclin in the tsetse fly. 
Proceedings of the National Academy of Sciences of the United States of America 
98, 1513–1518. 
Adams, J.A. (2001). Kinetic and catalytic mechanisms of protein kinases. 
Chemical Reviews 101, 2271–2290. 
Alibu, V.P., Storm, L., Haile, S., Clayton, C., and Horn, D. (2005). A doubly 
inducible system for RNA interference and rapid RNAi plasmid construction in 
Trypanosoma brucei. Molecular and Biochemical Parasitology 139, 75–82. 
Allan, R.K., and Ratajczak, T. (2011). Versatile TPR domains accommodate 
different modes of target protein recognition and function. Cell Stress & 
Chaperones 16, 353–367. 
Alsford, S., Eckert, S., Baker, N., Glover, L., Sanchez-Flores, A., Leung, K.F., 
Turner, D.J., Field, M.C., Berriman, M., and Horn, D. (2012). High-throughput 
decoding of antitrypanosomal drug efficacy and resistance. Nature 482, 232–236. 
Alsford, S., and Horn, D. (2008). Single-locus targeting constructs for reliable 
regulated RNAi and transgene expression in Trypanosoma brucei. Molecular and 
Biochemical Parasitology 161, 76–79. 
Alsford, S., Kawahara, T., Glover, L., and Horn, D. (2005). Tagging a T. brucei 
RRNA locus improves stable transfection efficiency and circumvents inducible 
expression position effects. Molecular and Biochemical Parasitology 144, 142–
148. 
Alsford, S., Turner, D.J., Obado, S.O., Sanchez-Flores, A., Glover, L., Berriman, 
M., Hertz-Fowler, C., and Horn, D. (2011). High-throughput phenotyping using 
parallel sequencing of RNA interference targets in the African trypanosome. 
Genome Research 21, 915–924. 
Amiguet-Vercher, A., Pérez-Morga, D., Pays, A., Poelvoorde, P., Van Xong, H., 
Tebabi, P., Vanhamme, L., and Pays, E. (2004). Loss of the mono-allelic control of 
the VSG expression sites during the development of Trypanosoma brucei in the 
bloodstream. Molecular Microbiology 51, 1577–1588. 
Andrews, M.J.I., Kontopidis, G., McInnes, C., Plater, A., Innes, L., Cowan, A., 
Jewsbury, P., and Fischer, P.M. (2006). REPLACE: a strategy for iterative design 
of cyclin-binding groove inhibitors. Chembiochem : a European Journal of 
Chemical Biology 7, 1909–1915. 
Atayde, V.D., Tschudi, C., and Ullu, E. (2011). The emerging world of small 
silencing RNAs in protozoan parasites. Trends in Parasitology 27, 321–327. 
202 
 
2
0
2
 
Atayde, V.D., Ullu, E., and Kolev, N.G. (2012). A single-cloning-step procedure for 
the generation of RNAi plasmids producing long stem-loop RNA. Molecular and 
Biochemical Parasitology 184, 55–58. 
Bahia, D., Oliveira, L.M., Lima, F.M., Oliveira, P., Da Silveira, J.F., Mortara, R.A., 
Ruiz, J.C., and Silveira, J.F. Da (2009). The TryPIKinome of five human 
pathogenic trypanosomatids: Trypanosoma brucei, Trypanosoma cruzi, 
Leishmania major, Leishmania braziliensis and Leishmania infantum - New tools 
for designing specific inhibitors. Biochemical and Biophysical Research 
Communications 390, 963–970. 
Baker, N., Alsford, S., and Horn, D. (2011). Genome-wide RNAi screens in African 
trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter 
AAT6. Molecular and Biochemical Parasitology 176, 55–57. 
Bangs, J.D. (2011). Replication of the ERES:Golgi junction in bloodstream-form 
African trypanosomes. Molecular Microbiology 82, 1433–1443. 
Barnes, R., Shi, H., Kolev, N., Tschudi, C., and Ullu, E. (2012). Comparative 
Genomics Reveals Two Novel RNAi Factors in Trypanosoma brucei and Provides 
Insight into the Core Machinery. PLoS Pathogens 8, e1002678. 
Barouch-Bentov, R., and Sauer, K. (2011). Mechanisms of drug resistance in 
kinases. Expert Opinion on Investigational Drugs 20, 153–208. 
Barquilla, A., Crespo, J.L., and Navarro, M. (2008). Rapamycin inhibits 
trypanosome cell growth by preventing TOR complex 2 formation. Proceedings of 
the National Academy of Sciences of the United States of America 105, 14579–
14584. 
Barquilla, A., Saldivia, M., Diaz, R., Bart, J.-M., Vidal, I., Calvo, E., Hall, M.N., and 
Navarro, M. (2012). Third target of rapamycin complex negatively regulates 
development of quiescence in Trypanosoma brucei. Proceedings of the National 
Academy of Sciences of the United States of America. 
Barry, J.D., Hall, J.P.J., and Plenderleith, L. (2012). Genome hyperevolution and 
the success of a parasite. Annals of the New York Academy of Sciences 1267, 
11–17. 
Barry, J.D., Marcello, L., Morrison, L.J., Read, a F., Lythgoe, K., Jones, N., 
Carrington, M., Blandin, G., Böhme, U., Caler, E., et al. (2005). What the genome 
sequence is revealing about trypanosome antigenic variation. Biochemical Society 
Transactions 33, 986–989. 
Belham, C., Roig, J., Caldwell, J.A., Aoyama, Y., Kemp, B.E., Comb, M., and 
Avruch, J. (2003). A mitotic cascade of NIMA family kinases. Nercc1/Nek9 
activates the Nek6 and Nek7 kinases. The Journal of Biological Chemistry 278, 
34897–34909. 
Bengs, F., Scholz, A., Kuhn, D., and Wiese, M. (2005). LmxMPK9, a mitogen-
activated protein kinase homologue affects flagellar length in Leishmania 
mexicana. Molecular Microbiology 55, 1606–1615. 
203 
 
2
0
3
 
Benz, C., Clucas, C., Mottram, J.C., and Hammarton, T.C. (2012). Cytokinesis in 
bloodstream stage Trypanosoma brucei requires a family of katanins and spastin. 
PloS One 7, e30367. 
Benz, C., Mulindwa, J., Ouna, B., and Clayton, C. (2011). The Trypanosoma 
brucei zinc finger protein ZC3H18 is involved in differentiation. Molecular and 
Biochemical Parasitology 2–5. 
Berriman, M., Ghedin, E., Hertz-Fowler, C., Blandin, G., Renauld, H., 
Bartholomeu, D.C., Lennard, N.J., Caler, E., Hamlin, N.E., Haas, B., et al. (2005). 
The genome of the African trypanosome Trypanosoma brucei. Science (New York, 
N.Y.) 309, 416–422. 
Biebinger, S., Rettenmaier, S., Flaspohler, J., Hartmann, C., Peña-Diaz, J., Wirtz, 
L.E., Hotz, H.R., Barry, J.D., and Clayton, C. (1996). The PARP promoter of 
Trypanosoma brucei is developmentally regulated in a chromosomal context. 
Nucleic Acids Research 24, 1202–1211. 
Biebinger, S., Wirtz, L.E., Lorenz, P., and Clayton, C. (1997). Vectors for inducible 
expression of toxic gene products in bloodstream and procyclic Trypanosoma 
brucei. Molecular and Biochemical Parasitology 85, 99–112. 
Bishop, a, Buzko, O., Heyeck-Dumas, S., Jung, I., Kraybill, B., Liu, Y., Shah, K., 
Ulrich, S., Witucki, L., Yang, F., et al. (2000a). Unnatural ligands for engineered 
proteins: new tools for chemical genetics. Annual Review of Biophysics and 
Biomolecular Structure 29, 577–606. 
Bishop, a C., Ubersax, J. a, Petsch, D.T., Matheos, D.P., Gray, N.S., Blethrow, J., 
Shimizu, E., Tsien, J.Z., Schultz, P.G., Rose, M.D., et al. (2000b). A chemical 
switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395–401. 
Bishop, A.C., and Shokat, K.M. (1999). Acquisition of inhibitor-sensitive protein 
kinases through protein design. Pharmacology & Therapeutics 82, 337–346. 
Boran, A.D.W., and Iyengar, R. (2010). Systems approaches to polypharmacology 
and drug discovery. Current Opinion in Drug Discovery & Development 13, 297–
309. 
Bradley, B.A., and Quarmby, L.M. (2005). A NIMA-related kinase, Cnk2p, 
regulates both flagellar length and cell size in Chlamydomonas. Journal of Cell 
Science 118, 3317–3326. 
Brenchley, R., Tariq, H., McElhinney, H., Szöor, B., Huxley-Jones, J., Stevens, R., 
Matthews, K., and Tabernero, L. (2007). The TriTryp phosphatome: analysis of the 
protein phosphatase catalytic domains. BMC Genomics 8, 434. 
Brennan, D.F., Dar, A.C., Hertz, N.T., Chao, W.C.H., Burlingame, A.L., Shokat, 
K.M., and Barford, D. (2011). A Raf-induced allosteric transition of KSR stimulates 
phosphorylation of MEK. Nature 472, 366–369. 
Brennand, A., Gualdrón-López, M., Coppens, I., Rigden, D.J., Ginger, M.L., and 
Michels, P. a M. (2011). Autophagy in parasitic protists: unique features and drug 
targets. Molecular and Biochemical Parasitology 177, 83–99. 
204 
 
2
0
4
 
Brognard, J., and Hunter, T. (2011). Protein kinase signaling networks in cancer. 
Current Opinion in Genetics & Development 21, 4–11. 
Brown, M.D., and Sacks, D.B. (2009). Protein scaffolds in MAP kinase signalling. 
Cellular Signalling 21, 462–469. 
Brumlik, M.J., Pandeswara, S., Ludwig, S.M., Murthy, K., and Curiel, T.J. (2011). 
Parasite mitogen-activated protein kinases as drug discovery targets to treat 
human protozoan pathogens. Journal of Signal Transduction 2011, 971968. 
Brun, R., Blum, J., Chappuis, F., and Burri, C. (2010). Human African 
trypanosomiasis. Lancet 375, 148–159. 
Brun, R., Hecker, H., and Lun, Z.R. (1998). Trypanosoma evansi and T. 
equiperdum: distribution, biology, treatment and phylogenetic relationship (a 
review). Veterinary Parasitology 79, 95–107. 
Burleigh, B.A., Caler, E. V, Webster, P., and Andrews, N.W. (1997). A cytosolic 
serine endopeptidase from Trypanosoma cruzi is required for the generation of 
Ca2+ signaling in mammalian cells. The Journal of Cell Biology 136, 609–620. 
Burnett, G., and Kennedy, E.P. (1954). The enzymatic phosphorylation of proteins. 
The Journal of Biological Chemistry 211, 969–980. 
Burri, C., and Brun, R. (2003). Eflornithine for the treatment of human African 
trypanosomiasis. Parasitology Research 90 Supp 1, S49–52. 
Böhringer, S., and Hecker, H. (1974). Quantitative ultrastructural differences 
between strains of the Tryponasoma brucei subgroup during transformation in 
blood. The Journal of Protozoology 21, 694–698. 
Bütikofer, P., Ruepp, S., Boschung, M., and Roditi, I. (1997). “GPEET” procyclin is 
the major surface protein of procyclic culture forms of Trypanosoma brucei brucei 
strain 427. The Biochemical Journal 326 ( Pt 2, 415–423. 
Bütikofer, P., Vassella, E., Ruepp, S., Boschung, M., Civenni, G., Seebeck, T., 
Hemphill, a, Mookherjee, N., Pearson, T.W., and Roditi, I. (1999). Phosphorylation 
of a major GPI-anchored surface protein of Trypanosoma brucei during transport 
to the plasma membrane. Journal of Cell Science 112 ( Pt 1, 1785–1795. 
Chang, J., Baloh, R.H., and Milbrandt, J. (2009). The NIMA-family kinase Nek3 
regulates microtubule acetylation in neurons. Journal of Cell Science 122, 2274–
2282. 
Chaudhuri, M., Ott, R.D., and Hill, G.C. (2006). Trypanosome alternative oxidase: 
from molecule to function. Trends in Parasitology 22, 484–491. 
Chi, Y., and Clurman, B.E. (2010). Mass spectrometry-based identification of 
protein kinase substrates utilizing engineered kinases and thiophosphate labeling. 
Current Protocols in Chemical Biology 2, 1–19. 
Clapéron, A., and Therrien, M. (2007). KSR and CNK: two scaffolds regulating 
RAS-mediated RAF activation. Oncogene 26, 3143–3158. 
205 
 
2
0
5
 
Cleghorn, L. a T., Woodland, A., Collie, I.T., Torrie, L.S., Norcross, N., Luksch, T., 
Mpamhanga, C., Walker, R.G., Mottram, J.C., Brenk, R., et al. (2011). 
Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. 
ChemMedChem 6, 2214–2224. 
Cohen, P. (2002). The origins of protein phosphorylation. Nature Cell Biology 4, 
E127–30. 
Coley, A.F., Dodson, H.C., Morris, M.T., and Morris, J.C. (2011). Glycolysis in the 
african trypanosome: targeting enzymes and their subcellular compartments for 
therapeutic development. Molecular Biology International 2011, 123702. 
Cong, F., Cheung, A.K., and Huang, S.-M.A. (2012). Chemical genetics-based 
target identification in drug discovery. Annual Review of Pharmacology and 
Toxicology 52, 57–78. 
Conrad, C., and Gerlich, D.W. (2010). Automated microscopy for high-content 
RNAi screening. The Journal of Cell Biology 188, 453–461. 
Cuny, G.D. (2009). Kinase inhibitors as potential therapeutics for acute and 
chronic neurodegenerative conditions. Current Pharmaceutical Design 15, 3919–
3939. 
Czichos, J., Nonnengaesser, C., and Overath, P. (1986). Trypanosoma brucei: cis-
aconitate and temperature reduction as triggers of synchronous transformation of 
bloodstream to procyclic trypomastigotes in vitro. Experimental Parasitology 62, 
283–291. 
Dean, S., Marchetti, R., Kirk, K., and Matthews, K.R. (2009). A surface transporter 
family conveys the trypanosome differentiation signal. Nature 459, 213–217. 
DeGrasse, J. a, DuBois, K.N., Devos, D., Siegel, T.N., Sali, A., Field, M.C., Rout, 
M.P., and Chait, B.T. (2009). Evidence for a shared nuclear pore complex 
architecture that is conserved from the last common eukaryotic ancestor. 
Molecular & Cellular Proteomics : MCP 8, 2119–2130. 
Deininger, M.W., and Druker, B.J. (2003). Specific targeted therapy of chronic 
myelogenous leukemia with imatinib. 55, 401–423. 
Diaz-Gonzalez, R., Kuhlmann, F.M., Galan-Rodriguez, C., Madeira da Silva, L., 
Saldivia, M., Karver, C.E., Rodriguez, A., Beverley, S.M., Navarro, M., and 
Pollastri, M.P. (2011). The Susceptibility of Trypanosomatid Pathogens to 
PI3/mTOR Kinase Inhibitors Affords a New Opportunity for Drug Repurposing. 
PLoS Neglected Tropical Diseases 5, e1297. 
Doerig, C., Billker, O., Pratt, D., and Endicott, J. (2005). Protein kinases as targets 
for antimalarial intervention: Kinomics, structure-based design, transmission-
blockade, and targeting host cell enzymes. Biochimica Et Biophysica Acta 1754, 
132–150. 
Domenicali Pfister, D., Burkard, G., Morand, S., Renggli, C.K., Roditi, I., and 
Vassella, E. (2006a). A Mitogen-activated protein kinase controls differentiation of 
bloodstream forms of Trypanosoma brucei. Eukaryotic Cell 5, 1126–1135. 
206 
 
2
0
6
 
Domenicali Pfister, D., Burkard, G., Morand, S., Renggli, C.K., Roditi, I., and 
Vassella, E. (2006b). A Mitogen-activated protein kinase controls differentiation of 
bloodstream forms of Trypanosoma brucei. Eukaryotic Cell 5, 1126–1135. 
Dorin, D., Le Roch, K., Sallicandro, P., Alano, P., Parzy, D., Poullet, P., Meijer, L., 
and Doerig, C. (2001). Pfnek-1, a NIMA-related kinase from the human malaria 
parasite Plasmodium falciparum Biochemical properties and possible involvement 
in MAPK regulation. European Journal of Biochemistry / FEBS 268, 2600–2608. 
Dorin-Semblat, D., Schmitt, S., Semblat, J.-P., Sicard, A., Reininger, L., Goldring, 
D., Patterson, S., Quashie, N., Chakrabarti, D., Meijer, L., et al. (2011). 
Plasmodium falciparum NIMA-related kinase Pfnek-1: sex specificity and 
assessment of essentiality for the erythrocytic asexual cycle. Microbiology 
(Reading, England) 157, 2785–2794. 
Drew, M.E., Morris, J.C., Wang, Z., Wells, L., Sanchez, M., Landfear, S.M., and 
Englund, P.T. (2003). The adenosine analog tubercidin inhibits glycolysis in 
Trypanosoma brucei as revealed by an RNA interference library. The Journal of 
Biological Chemistry 278, 46596–46600. 
Druker, B.J. (2004). Imatinib as a paradigm of targeted therapies. Advances in 
Cancer Research 91, 1–30. 
Dumon-Seignovert, L., Cariot, G., and Vuillard, L. (2004). The toxicity of 
recombinant proteins in Escherichia coli: a comparison of overexpression in 
BL21(DE3), C41(DE3), and C43(DE3). Protein Expression and Purification 37, 
203–206. 
Durand-Dubief, M., Kohl, L., and Bastin, P. (2003). Efficiency and specificity of 
RNA interference generated by intra- and intermolecular double stranded RNA in 
Trypanosoma brucei. Molecular and Biochemical Parasitology 129, 11–21. 
Duszenko, M., Ginger, M.L., Brennand, A., Gualdrón-López, M., Colombo, M.I., 
Coombs, G.H., Coppens, I., Jayabalasingham, B., Langsley, G., Lisboa de Castro, 
S., et al. (2011). Autophagy in protists. Autophagy 7, 127–158. 
D’Elia, M. a, Pereira, M.P., and Brown, E.D. (2009). Are essential genes really 
essential? Trends in Microbiology 17, 433–438. 
Ellis, J., Sarkar, M., Hendriks, E., and Matthews, K. (2004). A novel ERK-like, 
CRK-like protein kinase that modulates growth in Trypanosoma brucei via an 
autoregulatory C-terminal extension. Molecular Microbiology 53, 1487–1499. 
Elphick, L.M., Lee, S.E., Gouverneur, V., and Mann, D.J. (2007). Using chemical 
genetics and ATP analogues to dissect protein kinase function. ACS Chemical 
Biology 2, 299–314. 
Emmer, B.T., Nakayasu, E.S., Souther, C., Choi, H., Sobreira, T.J.P., Epting, C.L., 
Nesvizhskii, A.I., Almeida, I.C., and Engman, D.M. (2011). Global analysis of 
protein palmitoylation in African trypanosomes. Eukaryotic Cell 10, 455–463. 
207 
 
2
0
7
 
Engstler, M., and Boshart, M. (2004). Cold shock and regulation of surface protein 
trafficking convey sensitization to inducers of stage differentiation in Trypanosoma 
brucei. Genes & Development 18, 2798–2811. 
Engstler, M., Pfohl, T., Herminghaus, S., Boshart, M., Wiegertjes, G., Heddergott, 
N., and Overath, P. (2007). Hydrodynamic flow-mediated protein sorting on the 
cell surface of trypanosomes. Cell 131, 505–515. 
Erdmann, M., Scholz, A., Melzer, I.M., Schmetz, C., and Wiese, M. (2006). 
Interacting protein kinases involved in the regulation of flagellar length. Molecular 
Biology of the Cell 17, 2035–2045. 
Farr, H., and Gull, K. (2012). Cytokinesis in trypanosomes. Cytoskeleton 
(Hoboken, N.J.) 000,. 
Le Febvre, R.B., and Hill, G.C. (1986). Effects on Trypanosoma brucei 
differentiating bloodstream trypomastigotes and established procyclic 
trypomastigotes when grown in the presence of respiratory inhibitors. The Journal 
of Parasitology 72, 481–483. 
Fedorov, O., Müller, S., and Knapp, S. (2010). The (un)targeted cancer kinome. 
Nature Chemical Biology 6, 166–169. 
Ferrante, A., and Allison, A.C. (1983). Alternative pathway activation of 
complement by African trypanosomes lacking a glycoprotein coat. Parasite 
Immunology 5, 491–498. 
Field, M.C., Allen, C.L., Dhir, V., Goulding, D., Hall, B.S., Morgan, G.W., Veazey, 
P., and Engstler, M. (2004). New approaches to the microscopic imaging of 
Trypanosoma brucei. Microscopy and Microanalysis : the Official Journal of 
Microscopy Society of America, Microbeam Analysis Society, Microscopical 
Society of Canada 10, 621–636. 
Fire, A., Xu, S.Q., Montgomery, M.K.K., Kostas, S.A.A., Driver, S.E.E., and Mello, 
C.C.C. (1998). Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature 391, 806–811. 
Fischer, E.H., Graves, D.J., Crittenden, E.R.S., and Krebs, E.G. (1959). Structure 
of the site phosphorylated in the phosphorylase b to a reaction. The Journal of 
Biological Chemistry 234, 1698–1704. 
Fischer, E.H., and Krebs, E.G. (1955). Conversion of phosphorylase b to 
phosphorylase a in muscle extracts. The Journal of Biological Chemistry 216, 
121–132. 
Flaspohler, J. a, Jensen, B.C., Saveria, T., Kifer, C.T., and Parsons, M. (2010). A 
novel protein kinase localized to lipid droplets is required for droplet biogenesis in 
trypanosomes. Eukaryotic Cell 9, 1702–1710. 
Fragoso, C.M., Schumann Burkard, G., Oberle, M., Renggli, C.K., Hilzinger, K., 
and Roditi, I. (2009). PSSA-2, a membrane-spanning phosphoprotein of 
Trypanosoma brucei, is required for efficient maturation of infection. PloS One 4, 
e7074. 
208 
 
2
0
8
 
Frearson, J.A., Wyatt, P.G., Gilbert, I.H., and Fairlamb, A.H. (2007). Target 
assessment for antiparasitic drug discovery. 23, 589–595. 
Fu, C., Wehr, D.R., Edwards, J., and Hauge, B. (2008). Rapid one-step 
recombinational cloning. Nucleic Acids Research 36, e54. 
Gale, M., and Parsons, M. (1993). A Trypanosoma brucei gene family encoding 
protein kinases with catalytic domains structurally related to Nek1 and NIMA. 
Molecular and Biochemical Parasitology 59, 111–121. 
Gamsjaeger, R., Liew, C.K., Loughlin, F.E., Crossley, M., and Mackay, J.P. 
(2007). Sticky fingers: zinc-fingers as protein-recognition motifs. Trends in 
Biochemical Sciences 32, 63–70. 
Garske, A.L., Peters, U., Cortesi, A.T., Perez, J.L., and Shokat, K.M. (2011). 
Chemical genetic strategy for targeting protein kinases based on covalent 
complementarity. Proceedings of the National Academy of Sciences of the United 
States of America 108, 15046–15052. 
Ghoreschi, K., Laurence, A., and O’Shea, J.J. (2009). Selectivity and therapeutic 
inhibition of kinases: to be or not to be? Nature Immunology 10, 356–360. 
Giaever, G., Chu, A.M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., 
Lucau-Danila, A., Anderson, K., André, B., et al. (2002). Functional profiling of the 
Saccharomyces cerevisiae genome. Nature 418, 387–391. 
Glover, L., and Horn, D. (2009). Site-specific DNA double-strand breaks greatly 
increase stable transformation efficiency in Trypanosoma brucei. Molecular and 
Biochemical Parasitology 166, 194–197. 
Gomes, F.C., Ali, N.O.M., Brown, E., Walker, R.G., Grant, K.M., and Mottram, J.C. 
(2010). Recombinant Leishmania mexicana CRK3:CYCA has protein kinase 
activity in the absence of phosphorylation on the T-loop residue Thr178. Molecular 
and Biochemical Parasitology 171, 89–96. 
Good, M.C., Zalatan, J.G., and Lim, W. a. (2011). Scaffold Proteins: Hubs for 
Controlling the Flow of Cellular Information. Science 332, 680–686. 
De Graffenried, C.L., Ho, H.H., and Warren, G. (2008). Polo-like kinase is required 
for Golgi and bilobe biogenesis in Trypanosoma brucei. 181, 431–438. 
Grant, K.M., Dunion, M.H., Yardley, V., Skaltsounis, A., Marko, D., Eisenbrand, G., 
Croft, S.L., Meijer, L., and Mottram, J.C. (2004). Inhibitors of Leishmania mexicana 
CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial 
activity. Antimicrobial Agents and Chemotherapy 48, 3033–3042. 
Gualdrón-López, M., Brennand, A., Hannaert, V., Quiñones, W., Cáceres, A.J., 
Bringaud, F., Concepción, J.L., and Michels, P. a M. (2012). When, how and why 
glycolysis became compartmentalised in the Kinetoplastea. A new look at an 
ancient organelle. International Journal for Parasitology 42, 1–20. 
Gunasekera, K., Wüthrich, D., Braga-Lagache, S., Heller, M., and Ochsenreiter, T. 
(2012). Proteome remodelling during development from blood to insect-form 
209 
 
2
0
9
 
Trypanosoma brucei quantified by SILAC and mass spectrometry. BMC Genomics 
13, 556. 
Günzl, A. (2010). The pre-mRNA splicing machinery of trypanosomes: complex or 
simplified? Eukaryotic Cell 9, 1159–1170. 
Güttinger, A., Schwab, C., Morand, S., Roditi, I., and Vassella, E. (2007). A 
mitogen-activated protein kinase of Trypanosoma brucei confers resistance to 
temperature stress. Molecular and Biochemical Parasitology 153, 203–206. 
Haanstra, J.R., Kerkhoven, E.J., Van Tuijl, A., Blits, M., Wurst, M., Van Nuland, R., 
Albert, M.-A., Michels, P. a M., Bouwman, J., Clayton, C., et al. (2011). A domino 
effect in drug action: from metabolic assault towards parasite differentiation. 
Molecular Microbiology 79, 94–108. 
Hammarström, M., Woestenenk, E. a, Hellgren, N., Härd, T., and Berglund, H. 
(2006). Effect of N-terminal solubility enhancing fusion proteins on yield of purified 
target protein. Journal of Structural and Functional Genomics 7, 1–14. 
Hammarton, T.C., Kramer, S., Tetley, L., Boshart, M., and Mottram, J.C. (2007). 
Trypanosoma brucei Polo-like kinase is essential for basal body duplication, kDNA 
segregation and cytokinesis. Molecular Microbiology 65, 1229–1248. 
Hanks, S.K. (2003). Genomic analysis of the eukaryotic protein kinase 
superfamily: a perspective. Genome Biology 4, 111. 
Hanks, S.K., and Hunter, T. (1995). Protein kinases 6. The eukaryotic protein 
kinase superfamily: kinase (catalytic) domain structure and classification. FASEB 
Journal : Official Publication of the Federation of American Societies for 
Experimental Biology 9, 576–596. 
Hanks, S.K., Quinn, a M., and Hunter, T. (1988). The protein kinase family: 
conserved features and deduced phylogeny of the catalytic domains. Science 
(New York, N.Y.) 241, 42–52. 
Hann, M.M., and Oprea, T.I. (2004). Pursuing the leadlikeness concept in 
pharmaceutical research. Current Opinion in Chemical Biology 8, 255–263. 
Hassan, P., Fergusson, D., Grant, K.M., and Mottram, J.C. (2001). The CRK3 
protein kinase is essential for cell cycle progression of Leishmania mexicana. 
Molecular and Biochemical Parasitology 113, 189–198. 
Von Heijne, G. (2006). Membrane-protein topology. Nature Reviews. Molecular 
Cell Biology 7, 909–918. 
Helliwell, C.A., Wesley, S. V, Wielopolska, A.J., and Waterhouse, P.M. (2002). 
High-throughput vectors for efficient gene silencing in plants. Functional Plant 
Biology 29, 1217–1225. 
Helms, M.J., Ambit, A., Appleton, P., Tetley, L., Coombs, G.H., and Mottram, J.C. 
(2006). Bloodstream form Trypanosoma brucei depend upon multiple 
metacaspases associated with RAB11-positive endosomes. Journal of Cell 
Science 119, 1105–1117. 
210 
 
2
1
0
 
Herm-Götz, A., Agop-Nersesian, C., Münter, S., Grimley, J.S., Wandless, T.J., 
Frischknecht, F., and Meissner, M. (2007). Rapid control of protein level in the 
apicomplexan Toxoplasma gondii. Nature Methods 4, 1003–1005. 
Hirumi, H. Hirumi, K. (1989). Continuous cultivation of Trypanosoma brucei blood 
stream forms in a medium containing a low concentration of serum protein without 
feeder cell layers. The Journal of Parasitology 75, 985–989. 
Hopkins, A.L. (2008). Network pharmacology: the next paradigm in drug discovery. 
Nature Chemical Biology 4, 682–690. 
Howell, J.J., and Manning, B.D. (2011). mTOR couples cellular nutrient sensing to 
organismal metabolic homeostasis. Trends in Endocrinology and Metabolism: 
TEM 22, 94–102. 
Hua, S.B., and Wang, C.C. (1994). Differential accumulation of a protein kinase 
homolog in Trypanosoma brucei. Journal of Cellular Biochemistry 54, 20–31. 
Hua, S.B., and Wang, C.C. (1997). Interferon-gamma activation of a mitogen-
activated protein kinase, KFR1, in the bloodstream form of Trypanosoma brucei. 
The Journal of Biological Chemistry 272, 10797–10803. 
Ikeda, K. (2012). Polo-like kinase is necessary for flagellum inheritance in 
Trypanosoma brucei. Journal of Cell Science. 
Ivens, A.C., Peacock, C.S., Worthey, E.A., Murphy, L., Aggarwal, G., Berriman, 
M., Sisk, E., Rajandream, M.-A., Adlem, E., Aert, R., et al. (2005). The genome of 
the kinetoplastid parasite, Leishmania major. Science (New York, N.Y.) 309, 436–
442. 
Jackson, A.P. (2007). Evolutionary consequences of a large duplication event in 
Trypanosoma brucei: chromosomes 4 and 8 are partial duplicons. BMC Genomics 
8, 432. 
Jackson, D.G., Owen, M.J., and Voorheis, H.P. (1985). A new method for the rapid 
purification of both the membrane-bound and released forms of the variant surface 
glycoprotein from Trypanosoma brucei. The Biochemical Journal 230, 195–202. 
Jamonneau, V., Ilboudo, H., Kaboré, J., Kaba, D., Koffi, M., Solano, P., Garcia, A., 
Courtin, D., Laveissière, C., Lingue, K., et al. (2012). Untreated Human Infections 
by Trypanosoma brucei gambiense Are Not 100% Fatal. PLoS Neglected Tropical 
Diseases 6, e1691. 
Jensen, B.C., Kifer, C.T., and Parsons, M. (2011). Trypanosoma brucei: Two 
mitogen activated protein kinase kinases are dispensable for growth and virulence 
of the bloodstream form. Experimental Parasitology 1–6. 
Jensen, B.C., Sivam, D., Kifer, C.T., Myler, P.J., and Parsons, M. (2009). 
Widespread variation in transcript abundance within and across developmental 
stages of Trypanosoma brucei. BMC Genomics 10, 482. 
Jetton, N., Rothberg, K.G., Hubbard, J.G., Wise, J., Li, Y., Ball, H.L., and Ruben, 
L. (2009). The cell cycle as a therapeutic target against Trypanosoma brucei: 
211 
 
2
1
1
 
Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream 
forms. Molecular Microbiology 72, 442–458. 
Johnson, S.A., and Hunter, T. (2005). Kinomics: methods for deciphering the 
kinome. Nature Methods 2, 17–25. 
Kabani, S., Fenn, K., Ross, A., Ivens, A., Smith, T.K., Ghazal, P., and Matthews, 
K. (2009). Genome-wide expression profiling of in vivo-derived bloodstream 
parasite stages and dynamic analysis of mRNA alterations during synchronous 
differentiation in Trypanosoma brucei. BMC Genomics 10, 427. 
Kalidas, S., Li, Q., and Phillips, M. a (2011). A Gateway® compatible vector for 
gene silencing in bloodstream form Trypanosoma brucei. Molecular and 
Biochemical Parasitology 178, 51–55. 
Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, 
B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., et al. (2008). A quantitative 
analysis of kinase inhibitor selectivity. Nature Biotechnology 26, 127–132. 
Kelly, S., Reed, J., Kramer, S., Ellis, L., Webb, H., Sunter, J., Salje, J., Marinsek, 
N., Gull, K., Wickstead, B., et al. (2007). Functional genomics in Trypanosoma 
brucei: a collection of vectors for the expression of tagged proteins from 
endogenous and ectopic gene loci. Molecular and Biochemical Parasitology 154, 
103–109. 
Klug, a (1999). Zinc finger peptides for the regulation of gene expression. Journal 
of Molecular Biology 293, 215–218. 
Knight, Z. a, Lin, H., and Shokat, K.M. (2010). Targeting the cancer kinome 
through polypharmacology. Nature Reviews. Cancer 10, 130–137. 
Knight, Z. a, and Shokat, K.M. (2005). Features of selective kinase inhibitors. 
Chemistry & Biology 12, 621–637. 
Knighton, D.R., Zheng, J.H., Ten Eyck, L.F., Ashford, V.A., Xuong, N.H., Taylor, 
S.S., and Sowadski, J.M. (1991). Crystal structure of the catalytic subunit of cyclic 
adenosine monophosphate-dependent protein kinase. Science (New York, N.Y.) 
253, 407–414. 
Kokuryo, T., Senga, T., Yokoyama, Y., Nagino, M., Nimura, Y., and Hamaguchi, 
M. (2007). Nek2 as an effective target for inhibition of tumorigenic growth and 
peritoneal dissemination of cholangiocarcinoma. Cancer Research 67, 9637–
9642. 
Kolev, N.G., Franklin, J.B., Carmi, S., Shi, H., Michaeli, S., and Tschudi, C. (2010). 
The Transcriptome of the Human Pathogen Trypanosoma brucei at Single-
Nucleotide Resolution. PLoS Pathogens 6, e1001090. 
Kolev, N.G., Tschudi, C., and Ullu, E. (2011). RNA interference in protozoan 
parasites: achievements and challenges. Eukaryotic Cell 10, 1156–1163. 
Kontopidis, G., Andrews, M.J.I., McInnes, C., Cowan, A., Powers, H., Innes, L., 
Plater, A., Griffiths, G., Paterson, D., Zheleva, D.I., et al. (2003). Insights into 
212 
 
2
1
2
 
cyclin groove recognition: complex crystal structures and inhibitor design through 
ligand exchange. Structure (London, England : 1993) 11, 1537–1546. 
Korfel, A., and Thiel, E. (2007). Targeted therapy and blood-brain barrier. Recent 
Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les 
Recherches Sur Le Cancer 176, 123–133. 
Koumandou, V.L., Natesan, S.K. a, Sergeenko, T., and Field, M.C. (2008). The 
trypanosome transcriptome is remodelled during differentiation but displays limited 
responsiveness within life stages. BMC Genomics 9, 298. 
Kramer, S., Kimblin, N.C., and Carrington, M. (2010). Genome-wide in silico 
screen for CCCH-type zinc finger proteins of Trypanosoma brucei, Trypanosoma 
cruzi and Leishmania major. BMC Genomics 11, 283. 
Krebs, E.G., and Fischer, E.H. (1956). The phosphorylase b to a converting 
enzyme of rabbit skeletal muscle. Biochimica Et Biophysica Acta 20, 150–157. 
Kröncke, K.-D., and Klotz, L.-O. (2009). Zinc fingers as biologic redox switches? 
Antioxidants & Redox Signaling 11, 1015–1027. 
Kutateladze, T., and Overduin, M. (2001). Structural mechanism of endosome 
docking by the FYVE domain. Science (New York, N.Y.) 291, 1793–1796. 
Lambrecht, F.L. (1985). Trypanosomes and Hominid Evolution. BioScience 35, 
640–646. 
Laurell, E., Beck, K., Krupina, K., Theerthagiri, G., Bodenmiller, B., Horvath, P., 
Aebersold, R., Antonin, W., and Kutay, U. (2011). Phosphorylation of Nup98 by 
multiple kinases is crucial for NPC disassembly during mitotic entry. Cell 144, 
539–550. 
LaVallie, E.R., DiBlasio, E.A., Kovacic, S., Grant, K.L., Schendel, P.F., and 
McCoy, J.M. (1993). A thioredoxin gene fusion expression system that 
circumvents inclusion body formation in the E. coli cytoplasm. Bio/technology 
(Nature Publishing Company) 11, 187–193. 
Laxman, S., Riechers, A., Sadilek, M., Schwede, F., and Beavo, J. a (2006). 
Hydrolysis products of cAMP analogs cause transformation of Trypanosoma 
brucei from slender to stumpy-like forms. Proceedings of the National Academy of 
Sciences of the United States of America 103, 19194–19199. 
Lemmon, M. (2004). Pleckstrin homology domains: not just for phosphoinositides. 
Biochemical Society Transactions 32, 707. 
Lemmon, M. a, Ferguson, K.M., and Abrams, C.S. (2002). Pleckstrin homology 
domains and the cytoskeleton. FEBS Letters 513, 71–76. 
Li, Z. (2012). Regulation of the cell division cycle in Trypanosoma brucei. 
Eukaryotic Cell. 
Li, Z., Gourguechon, S., and Wang, C.C. (2007a). Tousled-like kinase in a 
microbial eukaryote regulates spindle assembly and S-phase progression by 
213 
 
2
1
3
 
interacting with Aurora kinase and chromatin assembly factors. Journal of Cell 
Science 120, 3883–3894. 
Li, Z., Gourguechon, S., and Wang, C.C. (2007b). Tousled-like kinase in a 
microbial eukaryote regulates spindle assembly and S-phase progression by 
interacting with Aurora kinase and chromatin assembly factors. Journal of Cell 
Science 120, 3883–3894. 
Li, Z., Umeyama, T., and Wang, C.C. Polo-like kinase guides cytokinesis in 
Trypanosoma brucei through an indirect means. Eukaryotic Cell 9, 705–716. 
Li, Z., Umeyama, T., and Wang, C.C. (2008). The chromosomal passenger 
complex and a mitotic kinesin interact with the Tousled-like kinase in 
trypanosomes to regulate mitosis and cytokinesis. PloS One 3, e3814. 
Li, Z., Umeyama, T., and Wang, C.C. (2009). The Aurora Kinase in Trypanosoma 
brucei plays distinctive roles in metaphase-anaphase transition and cytokinetic 
initiation. PLoS Pathogens 5, e1000575. 
Li, Z., and Wang, C.C. (2006). Changing roles of aurora-B kinase in two life cycle 
stages of Trypanosoma brucei. Eukaryotic Cell 5, 1026–1035. 
Liu, B.Y., Liu, Y.N., Motyka, S.A., Agbo, E.E.C., and Englund, P.T. (2005). 
Fellowship of the rings: the replication of kinetoplast DNA. 21, 363–369. 
Liu, Y., and Gray, N.S. (2006). Rational design of inhibitors that bind to inactive 
kinase conformations. Nature Chemical Biology 2, 358–364. 
Lizcano, J.M., Deak, M., Morrice, N., Kieloch, A., Hastie, C.J., Dong, L., 
Schutkowski, M., Reimer, U., and Alessi, D.R. (2002). Molecular basis for the 
substrate specificity of NIMA-related kinase-6 (NEK6). Evidence that NEK6 does 
not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and 
serum- and glucocorticoid-induced protein kinase in vivo. The Journal of Biological 
Chemistry 277, 27839–27849. 
Lourido, S., Shuman, J., Zhang, C., Shokat, K.M., Hui, R., and Sibley, L.D. (2010). 
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in 
Toxoplasma. Nature 465, 359–362. 
Low, H., Chua, C.S., and Sim, T.-S. (2012). Plasmodium falciparum possesses a 
unique dual-specificity serine/threonine and tyrosine kinase, Pfnek3. Cellular and 
Molecular Life Sciences : CMLS 69, 1523–1535. 
Low, H., Lye, Y.M., and Sim, T.-S. (2007). Pfnek3 functions as an atypical MAPKK 
in Plasmodium falciparum. Biochemical and Biophysical Research 
Communications 361, 439–444. 
Lye, Y.M., Chan, M., and Sim, T.-S. (2006). Pfnek3: an atypical activator of a MAP 
kinase in Plasmodium falciparum. FEBS Letters 580, 6083–6092. 
Ma, J., Benz, C., Grimaldi, R., Stockdale, C., Wyatt, P., Frearson, J., and 
Hammarton, T.C. (2010). Nuclear DBF-2-related kinases are essential regulators 
214 
 
2
1
4
 
of cytokinesis in bloodstream stage Trypanosoma brucei. The Journal of Biological 
Chemistry 285, 15356–15368. 
Mackey, Z.B., Koupparis, K., Nishino, M., and McKerrow, J.H. (2011). High-
throughput analysis of an RNAi library identifies novel kinase targets in 
Trypanosoma brucei. Chemical Biology & Drug Design 78, 454–463. 
Mahjoub, M.R., Qasim Rasi, M., and Quarmby, L.M. (2004). A NIMA-related 
kinase, Fa2p, localizes to a novel site in the proximal cilia of Chlamydomonas and 
mouse kidney cells. Molecular Biology of the Cell 15, 5172–5186. 
Mahjoub, M.R., Trapp, M.L., and Quarmby, L.M. (2005). NIMA-related kinases 
defective in murine models of polycystic kidney diseases localize to primary cilia 
and centrosomes. Journal of the American Society of Nephrology : JASN 16, 
3485–3489. 
Malvy, D., and Chappuis, F. (2011). Sleeping sickness. Clinical Microbiology and 
Infection : the Official Publication of the European Society of Clinical Microbiology 
and Infectious Diseases 17, 986–995. 
Manning, G., Plowman, G.D., Hunter, T., and Sudarsanam, S. (2002a). Evolution 
of protein kinase signaling from yeast to man. Trends in Biochemical Sciences 27, 
514–520. 
Manning, G., Reiner, D.S., Lauwaet, T., Dacre, M., Smith, A., Zhai, Y., Svard, S., 
and Gillin, F.D. (2011). The minimal kinome of Giardia lamblia illuminates early 
kinase evolution and unique parasite biology. Genome Biology 12, R66. 
Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002b). 
The protein kinase complement of the human genome. 298, 1912–+. 
Matthews, K.R. (2005). The developmental cell biology of Trypanosoma brucei. 
Journal of Cell Science 118, 283–290. 
Matthews, K.R., Ellis, J.R., and Paterou, A. (2004). Molecular regulation of the life 
cycle of African trypanosomes. Trends in Parasitology 20, 40–47. 
Matthews, K.R., and Gull, K. (1994). Evidence for an interplay between cell cycle 
progression and the initiation of differentiation between life cycle forms of African 
trypanosomes. The Journal of Cell Biology 125, 1147–1156. 
May, S.F., Peacock, L., Almeida Costa, C.I.C., Gibson, W.C., Tetley, L., Robinson, 
D.R., and Hammarton, T.C. (2012). The Trypanosoma brucei AIR9-like protein is 
cytoskeleton-associated and is required for nucleus positioning and accurate 
cleavage furrow placement. Molecular Microbiology. 
Mercer, L., Bowling, T., Perales, J., Freeman, J., Nguyen, T., Bacchi, C., Yarlett, 
N., Don, R., Jacobs, R., and Nare, B. (2011). 2,4-Diaminopyrimidines as Potent 
Inhibitors of Trypanosoma brucei and Identification of Molecular Targets by a 
Chemical Proteomics Approach. PLoS Neglected Tropical Diseases 5, e956. 
215 
 
2
1
5
 
Michels, P. a M., Bringaud, F., Herman, M., and Hannaert, V. (2006). Metabolic 
functions of glycosomes in trypanosomatids. Biochimica Et Biophysica Acta 1763, 
1463–1477. 
Moniz, L., Dutt, P., Haider, N., and Stambolic, V. (2011). Nek family of kinases in 
cell cycle, checkpoint control and cancer. Cell Division 6, 18. 
Monnerat, S., Clucas, C., Brown, E., Mottram, J.C., and Hammarton, T.C. (2009). 
Searching for novel cell cycle regulators in Trypanosoma brucei with an RNA 
interference screen. BMC Research Notes 2, 46. 
Mora, A., Komander, D., Van Aalten, D.M.F., and Alessi, D.R. (2004). PDK1, the 
master regulator of AGC kinase signal transduction. Seminars in Cell & 
Developmental Biology 15, 161–170. 
Morales, M. a, Watanabe, R., Dacher, M., Chafey, P., Osorio y Fortéa, J., Scott, D. 
a, Beverley, S.M., Ommen, G., Clos, J., Hem, S., et al. (2010). Phosphoproteome 
dynamics reveal heat-shock protein complexes specific to the Leishmania 
donovani infectious stage. Proceedings of the National Academy of Sciences of 
the United States of America 107, 8381–8386. 
Morand, S., Renggli, C.K., Roditi, I., and Vassella, E. (2012). MAP kinase kinase 1 
(MKK1) is essential for transmission of Trypanosoma brucei by Glossina 
morsitans. Molecular and Biochemical Parasitology 1, 1–4. 
Morris, J.C., Wang, Z., Drew, M.E., and Englund, P.T. (2002). Glycolysis 
modulates trypanosome glycoprotein expression as revealed by an RNAi library. 
The EMBO Journal 21, 4429–4438. 
Morty, R.E., Lonsdale-Eccles, J.D., Mentele, R., Auerswald, E.A., and Coetzer, 
T.H. (2001). Trypanosome-derived oligopeptidase B is released into the plasma of 
infected rodents, where it persists and retains full catalytic activity. Infection and 
Immunity 69, 2757–2761. 
Mowatt, M.R., and Clayton, C.E. (1987). Developmental regulation of a novel 
repetitive protein of Trypanosoma brucei. Molecular and Cellular Biology 7, 2838–
2844. 
Mowatt, M.R., Wisdom, G.S., and Clayton, C.E. (1989). Variation of tandem 
repeats in the developmentally regulated procyclic acidic repetitive proteins of 
Trypanosoma brucei. Molecular and Cellular Biology 9, 1332–1335. 
Munday, J.C., McLuskey, K., Brown, E., Coombs, G.H., and Mottram, J.C. (2011). 
Oligopeptidase B deficient mutants of Leishmania major. Molecular and 
Biochemical Parasitology 175, 49–57. 
Mäser, P., Wittlin, S., Rottmann, M., Wenzler, T., Kaiser, M., and Brun, R. (2012). 
Antiparasitic agents: new drugs on the horizon. Current Opinion in Pharmacology 
1–5. 
Müller, I.B., Domenicali-Pfister, D., Roditi, I., and Vassella, E. (2002a). Stage-
specific requirement of a mitogen-activated protein kinase by Trypanosoma brucei. 
Molecular Biology of the Cell 13, 3787–3799. 
216 
 
2
1
6
 
Müller, I.B., Domenicali-Pfister, D., Roditi, I., and Vassella, E. (2002b). Stage-
specific requirement of a mitogen-activated protein kinase by Trypanosoma brucei. 
Molecular Biology of the Cell 13, 3787–3799. 
Nakano, H., Kobayashi, E., Takahashi, I., Tamaoki, T., Kuzuu, Y., and Iba, H. 
(1987). Staurosporine inhibits tyrosine-specific protein kinase activity of Rous 
sarcoma virus transforming protein p60. The Journal of Antibiotics 40, 706–708. 
Naula, C., Parsons, M., and Mottram, J.C. (2005). Protein kinases as drug targets 
in trypanosomes and Leishmania. Biochimica Et Biophysica Acta 1754, 151–159. 
Nett, I.R.E., Davidson, L., Lamont, D., and Ferguson, M.A.J. (2009a). Identification 
and specific localization of tyrosine-phosphorylated proteins in Trypanosoma 
brucei. Eukaryotic Cell 8, 617–626. 
Nett, I.R.E., Martin, D.M.A., Miranda-Saavedra, D., Lamont, D., Barber, J.D., 
Mehlert, A., and Ferguson, M.A.J. (2009b). The phosphoproteome of bloodstream 
form Trypanosoma brucei, causative agent of African sleeping sickness. Molecular 
& Cellular Proteomics : MCP 8, 1527–1538. 
Neumann, T., Junker, H.-D., Schmidt, K., and Sekul, R. (2007). SPR-based 
fragment screening: advantages and applications. Current Topics in Medicinal 
Chemistry 7, 1630–1642. 
Ngô, H., Tschudi, C., Gull, K., and Ullu, E. (1998). Double-stranded RNA induces 
mRNA degradation in Trypanosoma brucei. Proceedings of the National Academy 
of Sciences of the United States of America 95, 14687–14692. 
Novy, R., and Yaeger, K. (1996). Ligation independent cloning: efficient directional 
cloning of PCR products. InNovations 6–8. 
Oberholzer, M., Langousis, G., Nguyen, H.T., Saada, E. a, Shimogawa, M.M., 
Jonsson, Z.O., Nguyen, S.M., Wohlschlelgel, J. a, and Hill, K.L. (2011). 
Independent analysis of the flagellum surface and matrix proteomes provides 
insight into flagellum signaling in mammalian-infectious Trypanosoma brucei. 
Molecular & Cellular Proteomics : MCP. 
Ochiana, S.O., Pandarinath, V., Wang, Z., Kapoor, R., Ondrechen, M.J., Ruben, 
L., and Pollastri, M.P. (2012). The human Aurora kinase inhibitor danusertib is a 
lead compound for anti-trypanosomal drug discovery via target repurposing. 
European Journal of Medicinal Chemistry. 
Ojo, K.K., Arakaki, T.L., Napuli, A.J., Inampudi, K.K., Keyloun, K.R., Zhang, L., 
Hol, W.G.J., Verlinde, C.L.M.J., Merritt, E. a, and Van Voorhis, W.C. (2010). 
Structure determination of glycogen synthase kinase-3 from Leishmania major and 
comparative inhibitor structure-activity relationships with Trypanosoma brucei 
GSK-3. Molecular and Biochemical Parasitology 1–11. 
Ojo, K.K., Gillespie, J.R., Riechers, A.J., Napuli, A.J., Verlinde, C.L.M.J.C., 
Buckner, F.S., Gelb, M.H., Domostoj, M.M., Wells, S.J., Scheer, A., et al. (2008). 
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis 
therapy. Antimicrobial Agents and Chemotherapy 52, 3710–3717. 
217 
 
2
1
7
 
Osmani, S. a, Pu, R.T., and Morris, N.R. (1988). Mitotic induction and 
maintenance by overexpression of a G2-specific gene that encodes a potential 
protein kinase. Cell 53, 237–244. 
Osolodkin, D.I., Zakharevich, N. V, Palyulin, V.A., Danilenko, V.N., and Zefirov, 
N.S. (2011). Bioinformatic analysis of glycogen synthase kinase 3: human versus 
parasite kinases. Parasitology 1–11. 
Ouna, B.A., Stewart, M., Helbig, C., and Clayton, C. (2012). The Trypanosoma 
brucei CCCH zinc finger proteins ZC3H12 and ZC3H13. Molecular and 
Biochemical Parasitology 1–5. 
O’regan, L., Blot, J., and Fry, A.M. (2007). Mitotic regulation by NIMA-related 
kinases. Cell Division 2, 25. 
Palenchar, J.B., and Bellofatto, V. (2006). Gene transcription in trypanosomes. 
Molecular and Biochemical Parasitology 146, 135–141. 
Parker, J.D.K., Bradley, B.A., Mooers, A.O., and Quarmby, L.M. (2007). 
Phylogenetic analysis of the Neks reveals early diversification of ciliary-cell cycle 
kinases. PloS One 2, e1076. 
Parkinson, J.S. (2010). Signaling mechanisms of HAMP domains in 
chemoreceptors and sensor kinases. Annual Review of Microbiology 64, 101–122. 
Parsons, M., Valentine, M., and Carter, V. (1993). Protein kinases in divergent 
eukaryotes: identification of protein kinase activities regulated during trypanosome 
development. Proceedings of the National Academy of Sciences of the United 
States of America 90, 2656–2660. 
Parsons, M., Valentine, M., Deans, J., Schieven, G.L., and Ledbetter, J. a (1991). 
Distinct patterns of tyrosine phosphorylation during the life cycle of Trypanosoma 
brucei. Molecular and Biochemical Parasitology 45, 241–248. 
Parsons, M., Worthey, E.A., Ward, P.N., and Mottram, J.C. (2005a). Comparative 
analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, 
Trypanosoma brucei and Trypanosoma cruzi. 6, (15 September 2005). 
Parsons, M., Worthey, E.A., Ward, P.N., and Mottram, J.C. (2005b). Comparative 
analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, 
Trypanosoma brucei and Trypanosoma cruzi. 6, (15 September 2005). 
Peacock, L., Ferris, V., Bailey, M., and Gibson, W. (2009). Intraclonal mating 
occurs during tsetse transmission of Trypanosoma brucei. Parasites & Vectors 2, 
43. 
Peacock, L., Ferris, V., Sharma, R., Sunter, J., Bailey, M., Carrington, M., and 
Gibson, W. (2011). Identification of the meiotic life cycle stage of Trypanosoma 
brucei in the tsetse fly. Proceedings of the National Academy of Sciences of the 
United States of America 1–6. 
Pearce, L.R., Komander, D., and Alessi, D.R. (2010). The nuts and bolts of AGC 
protein kinases. Nature Reviews. Molecular Cell Biology 11, 9–22. 
218 
 
2
1
8
 
Peifer, C., and Alessi, D.R. (2008). Small-molecule inhibitors of PDK1. 
ChemMedChem 3, 1810–1838. 
Pradel, L.C., Bonhivers, M., Landrein, N., and Robinson, D.R. (2006). NIMA-
related kinase TbNRKC is involved in basal body separation in Trypanosoma 
brucei. Journal of Cell Science 119, 1852–1863. 
Preußer, C., Jaé, N., and Bindereif, A. (2012). mRNA splicing in trypanosomes. 
International Journal of Medical Microbiology : IJMM 302, 221–224. 
Proto, W.R., Castanys-Munoz, E., Black, A., Tetley, L., Moss, C.X., Juliano, L., 
Coombs, G.H., and Mottram, J.C. (2011). Trypanosoma brucei metacaspase 4 is a 
pseudopeptidase and a virulence factor. The Journal of Biological Chemistry 286, 
39914–39925. 
Proudfoot, C., and McCulloch, R. (2005). Distinct roles for two RAD51-related 
genes in Trypanosoma brucei antigenic variation. Nucleic Acids Research 33, 
6906–6919. 
Pu, R.T., Xu, G., Wu, L., Vierula, J., O’Donnell, K., Ye, X.S., and Osmani, S.A. 
(1995). Isolation of a functional homolog of the cell cycle-specific NIMA protein 
kinase of Aspergillus nidulans and functional analysis of conserved residues. The 
Journal of Biological Chemistry 270, 18110–18116. 
Qi, M., and Elion, E. a (2005). MAP kinase pathways. Journal of Cell Science 118, 
3569–3572. 
Quarmby, L.M., and Mahjoub, M.R. (2005). Caught Nek-ing: cilia and centrioles. 
Journal of Cell Science 118, 5161–5169. 
Queiroz, R., Benz, C., Fellenberg, K., Hoheisel, J.D., and Clayton, C. (2009). 
Transcriptome analysis of differentiating trypanosomes reveals the existence of 
multiple post-transcriptional regulons. BMC Genomics 10, 495. 
Raimondi, C., and Falasca, M. (2011). Targeting PDK1 in cancer. Current 
Medicinal Chemistry 18, 2763–2769. 
Redmond, S., Vadivelu, J., and Field, M.C. (2003). RNAit: an automated web-
based tool for the selection of RNAi targets in Trypanosoma brucei. Molecular and 
Biochemical Parasitology 128, 115–118. 
Reininger, L., Tewari, R., Fennell, C., Holland, Z., Goldring, D., Ranford-
Cartwright, L., Billker, O., and Doerig, C. (2009). An essential role for the 
Plasmodium Nek-2 Nima-related protein kinase in the sexual development of 
malaria parasites. The Journal of Biological Chemistry 284, 20858–20868. 
Reuner, B., Vassella, E., Yutzy, B., and Boshart, M. (1997). Cell density triggers 
slender to stumpy differentiation of Trypanosoma brucei bloodstream forms in 
culture. Molecular and Biochemical Parasitology 90, 269–280. 
Roditi, I., Schwarz, H., Pearson, T.W., Beecroft, R.P., Liu, M.K., Richardson, J.P., 
Bühring, H.J., Pleiss, J., Bülow, R., and Williams, R.O. (1989). Procyclin gene 
219 
 
2
1
9
 
expression and loss of the variant surface glycoprotein during differentiation of 
Trypanosoma brucei. The Journal of Cell Biology 108, 737–746. 
Rokosz, L.L., Beasley, J.R., Carroll, C.D., Lin, T., Zhao, J., Appell, K.C., and 
Webb, M.L. (2008). Kinase inhibitors as drugs for chronic inflammatory and 
immunological diseases: progress and challenges. Expert Opinion on Therapeutic 
Targets 12, 883–903. 
Roper, J.R., Guther, M.L.S., Milne, K.G., and Ferguson, M. a J. (2002). Galactose 
metabolism is essential for the African sleeping sickness parasite Trypanosoma 
brucei. Proceedings of the National Academy of Sciences of the United States of 
America 99, 5884–5889. 
Rotureau, B., Subota, I., and Bastin, P. (2011). Molecular bases of cytoskeleton 
plasticity during the Trypanosoma brucei parasite cycle. Cellular Microbiology 13, 
705–716. 
Rotureau, B., Subota, I., Buisson, J., and Bastin, P. (2012). A new asymmetric 
division contributes to the continuous production of infective trypanosomes in the 
tsetse fly. Development (Cambridge, England) 1850, 1842–1850. 
Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D., and Therrien, M. 
(2002). KSR is a scaffold required for activation of the ERK/MAPK module. Genes 
& Development 16, 427–438. 
Rudenko, G. (2010). Epigenetics and transcriptional control in African 
trypanosomes. Essays in Biochemistry 48, 201–219. 
Rudenko, G. (2011). African trypanosomes: the genome and adaptations for 
immune evasion. Essays in Biochemistry 51, 47–62. 
Rusconi, F., Durand-Dubief, M., and Bastin, P. (2005). Functional 
complementation of RNA interference mutants in trypanosomes. BMC 
Biotechnology 5, 6. 
Räz, B., Iten, M., Grether-Bühler, Y., Kaminsky, R., and Brun, R. (1997). The 
Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. 
rhodesiense and T.b. gambiense) in vitro. Acta Tropica 68, 139–147. 
Scahill, M.D., Pastar, I., and Cross, G.A. (2008). CRE recombinase-based 
positive-negative selection systems for genetic manipulation in Trypanosoma 
brucei. Molecular and Biochemical Parasitology 157, 73–82. 
Schnaufer, A., Domingo, G.J., and Stuart, K. (2002). Natural and induced 
dyskinetoplastic trypanosomatids: how to live without mitochondrial DNA. 
International Journal for Parasitology 32, 1071–1084. 
Schneider, G. (2010). Virtual screening: an endless staircase? Nature Reviews. 
Drug Discovery 9, 273–276. 
Schumann Burkard, G., Jutzi, P., and Roditi, I. (2011). Genome-wide RNAi 
screens in bloodstream form trypanosomes identify drug transporters. Molecular 
and Biochemical Parasitology 175, 91–94. 
220 
 
2
2
0
 
Schwede, A., and Carrington, M. (2010). Bloodstream form Trypanosome plasma 
membrane proteins: antigenic variation and invariant antigens. Parasitology 137, 
2029–2039. 
Scior, T., Bender, A., Tresadern, G., Medina-Franco, J.L., Martínez-Mayorga, K., 
Langer, T., Cuanalo-Contreras, K., and Agrafiotis, D.K. (2012). Recognizing 
Pitfalls in Virtual Screening: A Critical Review. Journal of Chemical Information 
and Modeling. 
Seeliger, D., and De Groot, B.L. (2010). Ligand docking and binding site analysis 
with PyMOL and Autodock/Vina. Journal of Computer-Aided Molecular Design 24, 
417–422. 
Service, M. (2004). Medical Entomology for Students (Cambridge: Cambridge 
University Press). 
Shi, H., Djikeng, A., Mark, T., Wirtz, E., Tschudi, C., and Ullu, E. (2000). Genetic 
interference in Trypanosoma brucei by heritable and inducible double-stranded 
RNA. RNA (New York, N.Y.) 6, 1069–1076. 
Shi, H., Tschudi, C., and Ullu, E. (2006). An unusual Dicer-like1 protein fuels the 
RNA interference pathway in Trypanosoma brucei. RNA (New York, N.Y.) 12, 
2063–2072. 
Siegel, T.N., Hekstra, D.R., Wang, X., Dewell, S., and Cross, G. a M. (2010). 
Genome-wide analysis of mRNA abundance in two life-cycle stages of 
Trypanosoma brucei and identification of splicing and polyadenylation sites. 
Nucleic Acids Research 38, 4946–4957. 
Simarro, P.P., Franco, J., Diarra, a, Postigo, J. a R., and Jannin, J. (2012). Update 
on field use of the available drugs for the chemotherapy of human African 
trypanosomiasis. Parasitology 139, 842–846. 
Simpson, L., Aphasizhev, R., Gao, G., and Kang, X. (2004). Mitochondrial proteins 
and complexes in Leishmania and Trypanosoma involved in U-insertion/deletion 
RNA editing. RNA (New York, N.Y.) 10, 159–170. 
Smith, A.J., Lauwaet, T., Davids, B.J., and Gillin, F.D. (2012). Giardia lamblia 
Nek1 and Nek2 kinases affect mitosis and excystation. International Journal for 
Parasitology 42, 411–419. 
Steverding, D. (2008). The history of African trypanosomiasis. Parasites & Vectors 
1, 3. 
Steverding, D. (2010). The development of drugs for treatment of sleeping 
sickness: a historical review. Parasites & Vectors 3, 15. 
Subramaniam, C., Veazey, P., Redmond, S., Hayes-Sinclair, J., Chambers, E., 
Carrington, M., Gull, K., Matthews, K., Horn, D., and Field, M.C. (2006). 
Chromosome-wide analysis of gene function by RNA interference in the african 
trypanosome. Eukaryotic Cell 5, 1539–1549. 
221 
 
2
2
1
 
Sun, L., and Wang, C.C. (2011). The Structural Basis of Localizing Polo-Like 
Kinase to the Flagellum Attachment Zone in Trypanosoma brucei. PloS One 6, 
e27303. 
Szöor, B., Ruberto, I., Burchmore, R., and Matthews, K.R. (2010). A novel 
phosphatase cascade regulates differentiation in Trypanosoma brucei via a 
glycosomal signaling pathway. Genes & Development 24, 1306–1316. 
Szöor, B., Wilson, J., McElhinney, H., Tabernero, L., and Matthews, K.R. (2006). 
Protein tyrosine phosphatase TbPTP1: A molecular switch controlling life cycle 
differentiation in trypanosomes. The Journal of Cell Biology 175, 293–303. 
Tanega, C., Shen, M., Mott, B.T., Thomas, C.J., MacArthur, R., Inglese, J., and 
Auld, D.S. (2009). Comparison of bioluminescent kinase assays using substrate 
depletion and product formation. Assay and Drug Development Technologies 7, 
606–614. 
Tasker, M., Wilson, J., Sarkar, M., Hendriks, E., and Matthews, K. (2000). A novel 
selection regime for differentiation defects demonstrates an essential role for the 
stumpy form in the life cycle of the African trypanosome. Molecular Biology of the 
Cell 11, 1905–1917. 
Taylor, P., Blackburn, E., Sheng, Y.G., Harding, S., Hsin, K.-Y., Kan, D., Shave, 
S., and Walkinshaw, M.D. (2008). Ligand discovery and virtual screening using the 
program LIDAEUS. British Journal of Pharmacology 153 Suppl , S55–67. 
Tewari, R., Straschil, U., Bateman, A., Böhme, U., Cherevach, I., Gong, P., Pain, 
A., and Billker, O. (2010). The systematic functional analysis of Plasmodium 
protein kinases identifies essential regulators of mosquito transmission. Cell Host 
& Microbe 8, 377–387. 
Tibbetts, M.D., Shiozaki, E.N., Gu, L., McDonald, E.R., El-Deiry, W.S., and Shi, Y. 
(2004). Crystal structure of a FYVE-type zinc finger domain from the caspase 
regulator CARP2. Structure (London, England : 1993) 12, 2257–2263. 
Torkamani, A., and Schork, N.J. (2008). Prediction of cancer driver mutations in 
protein kinases. Cancer Research 68, 1675–1682. 
Torreele, E., Bourdin Trunz, B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., Bray, 
M. a., and Pécoul, B. (2010). Fexinidazole – A New Oral Nitroimidazole Drug 
Candidate Entering Clinical Development for the Treatment of Sleeping Sickness. 
PLoS Neglected Tropical Diseases 4, e923. 
Tu, X., and Wang, C.C. (2004). The involvement of two cdc2-related kinases 
(CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-
specific phenotypes caused by CRK3 depletion. The Journal of Biological 
Chemistry 279, 20519–20528. 
Tu, X., and Wang, C.C. (2005). Pairwise knockdowns of cdc2-related kinases 
(CRKs) in Trypanosoma brucei identified the CRKs for G1/S and G2/M transitions 
and demonstrated distinctive cytokinetic regulations between two developmental 
stages of the organism. Eukaryotic Cell 4, 755–764. 
222 
 
2
2
2
 
Ullu, E., Matthews, K.R., and Tschudi, C. (1993). Temporal order of RNA-
processing reactions in trypanosomes: rapid trans splicing precedes 
polyadenylation of newly synthesized tubulin transcripts. Molecular and Cellular 
Biology 13, 720–725. 
Umeyama, T., and Wang, C.C. (2008). Polo-like kinase is expressed in S/G2/M 
phase and associated with the flagellum attachment zone in both procyclic and 
bloodstream forms of Trypanosoma brucei. Eukaryotic Cell 7, 1582–1590. 
Urbaniak, M.D. (2009). Casein kinase 1 isoform 2 is essential for bloodstream 
form Trypanosoma brucei. Molecular and Biochemical Parasitology 166, 183–185. 
Urbaniak, M.D., Guther, M.L.S., and Ferguson, M. a J. (2012a). Comparative 
SILAC Proteomic Analysis of Trypanosoma brucei Bloodstream and Procyclic 
Lifecycle Stages. PloS One 7, e36619. 
Urbaniak, M.D., Mathieson, T., Bantscheff, M., Eberhard, D., Grimaldi, R., 
Miranda-Saavedra, D., Wyatt, P., Ferguson, M. a J., Frearson, J., and Drewes, G. 
(2012b). Chemical Proteomic Analysis Reveals the Drugability of the Kinome of 
Trypanosoma brucei. ACS Chemical Biology. 
Vanhollebeke, B., Uzureau, P., Monteyne, D., Pérez-Morga, D., and Pays, E. 
(2010). Cellular and molecular remodeling of the endocytic pathway during 
differentiation of Trypanosoma brucei bloodstream forms. Eukaryotic Cell 9, 1272–
1282. 
Vassella, E., Krämer, R., Turner, C.M., Wankell, M., Modes, C., Van den Bogaard, 
M., and Boshart, M. (2001). Deletion of a novel protein kinase with PX and FYVE-
related domains increases the rate of differentiation of Trypanosoma brucei. 
Molecular Microbiology 41, 33–46. 
Vassella, E., Probst, M., Schneider, A., Studer, E., Renggli, C.K., and Roditi, I. 
(2004). Expression of a major surface protein of Trypanosoma brucei insect forms 
is controlled by the activity of mitochondrial enzymes. Molecular Biology of the Cell 
15, 3986–3993. 
Vassella, E., Reuner, B., Yutzy, B., and Boshart, M. (1997). Differentiation of 
African trypanosomes is controlled by a density sensing mechanism which signals 
cell cycle arrest via the cAMP pathway. Journal of Cell Science 110 ( Pt 2, 2661–
2671. 
Vickerman, K. (1965). Polymorphism and mitochondrial activity in sleeping 
sickness trypanosomes. Nature 208, 762–766. 
Vickerman, K. (1985). Developmental cycles and biology of pathogenic 
trypanosomes. British Medical Bulletin 41, 105–114. 
Walker, G., Dorrell, R.G., Schlacht, A., and Dacks, J.B. (2011a). Eukaryotic 
systematics: a user’s guide for cell biologists and parasitologists. Parasitology 138, 
1638–1663. 
Walker, R.G., Thomson, G., Malone, K., Nowicki, M.W., Brown, E., Blake, D.G., 
Turner, N.J., Walkinshaw, M.D., Grant, K.M., and Mottram, J.C. (2011b). High 
223 
 
2
2
3
 
throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 
cyclin-dependent kinase. PLoS Neglected Tropical Diseases 5, e1033. 
Walker, R.G., Thomson, G., Malone, K., Nowicki, M.W., Brown, E., Blake, D.G., 
Turner, N.J., Walkinshaw, M.D., Grant, K.M., and Mottram, J.C. (2011c). High 
throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 
cyclin-dependent kinase. PLoS Neglected Tropical Diseases 5, e1033. 
Wang, C.C. (1997). Validating targets for antiparasite chemotherapy. Parasitology 
114 Suppl, S31–44. 
Wang, X., Sheff, M. a, Simpson, D.M., and Elion, E. a (2011). Ste11p MEKK 
signals through HOG, mating, calcineurin and PKC pathways to regulate the FKS2 
gene. BMC Molecular Biology 12, 51. 
Wang, Z., Morris, J.C., Drew, M.E., and Englund, P.T. (2000). Inhibition of 
Trypanosoma brucei gene expression by RNA interference using an integratable 
vector with opposing T7 promoters. The Journal of Biological Chemistry 275, 
40174–40179. 
Wheeler, R.J., Gull, K., and Gluenz, E. (2012). Detailed interrogation of 
trypanosome cell biology via differential organelle staining and automated image 
analysis. BMC Biology 10, 1. 
Wirtz, E., Leal, S., Ochatt, C., and Cross, G.A. (1999). A tightly regulated inducible 
expression system for conditional gene knock-outs and dominant-negative 
genetics in Trypanosoma brucei. Molecular and Biochemical Parasitology 99, 89–
101. 
Wloga, D., Camba, A., Rogowski, K., Manning, G., Jerka-Dziadosz, M., and 
Gaertig, J. (2006). Members of the NIMA-related kinase family promote 
disassembly of cilia by multiple mechanisms. Molecular Biology of the Cell 17, 
2799–2810. 
Wurst, M., Robles, A., Po, J., Luu, V.-D., Brems, S., Marentije, M., Stoitsova, S., 
Quijada, L., Hoheisel, J., Stewart, M., et al. (2009). An RNAi screen of the RRM-
domain proteins of Trypanosoma brucei. Molecular and Biochemical Parasitology 
163, 61–65. 
Wyatt, P.G., Gilbert, I.H., Read, K.D., and Fairlamb, A.H. (2011). Target validation: 
linking target and chemical properties to desired product profile. Current Topics in 
Medicinal Chemistry 11, 1275–1283. 
Zeytuni, N., and Zarivach, R. (2012). Structural and functional discussion of the 
tetra-trico-peptide repeat, a protein interaction module. Structure (London, 
England : 1993) 20, 397–405. 
Zhang, J., Yang, P.L., and Gray, N.S. (2009). Targeting cancer with small 
molecule kinase inhibitors. Nature Reviews. Cancer 9, 28–39. 
Zhao, Z., Lindsay, M.E., Roy Chowdhury, A., Robinson, D.R., and Englund, P.T. 
(2008). p166, a link between the trypanosome mitochondrial DNA and flagellum, 
mediates genome segregation. The EMBO Journal 27, 143–154. 
224 
 
2
2
4
 
Ziegelbauer, K., Quinten, M., Schwarz, H., Pearson, T.W., and Overath, P. (1990). 
Synchronous differentiation of Trypanosoma brucei from bloodstream to procyclic 
forms in vitro. European Journal of Biochemistry / FEBS 192, 373–378.  
 
